---
document_datetime: 2025-05-14 11:20:20
document_pages: 186
document_pathfilename: www.ema.europa.eu/en/documents/assessment-report/welireg-epar-public-assessment-report_en.pdf
document_name: welireg-epar-public-assessment-report_en.pdf
version: success
processing_time: 179.9428755
conversion_datetime: 2025-12-27 20:17:34.741212
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
<!-- image -->

12 December 2024 EMA/18425/2025 Committee for Medicinal Products for Human Use (CHMP)

## Assessment report

## Welireg

International non-proprietary name: belzutifan

Procedure No. EMEA/H/C/005636/0000

## Note

Assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted.

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Table of contents

| 1. Background information on the procedure..............................................                                 | 8                                                                                                         |
|--------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------|
| 1.1. Submission of the dossier ...................................................................................       | 8                                                                                                         |
| 1.2. Legal basis, dossier content.................................................................................       | 8                                                                                                         |
| 1.3. Information on Paediatric requirements.................................................................             | 8                                                                                                         |
| 1.4. Information relating to orphan market exclusivity...................................................                | 8                                                                                                         |
| 1.4.1. Orphan designation                                                                                                | ......................................................................................... 8               |
| 1.4.2. Similarity                                                                                                        | ....................................................................................................... 9 |
| 1.5. Applicant's request for consideration.....................................................................          | 9                                                                                                         |
| 1.5.1. Conditional marketing authorisation...................................................................            | 9                                                                                                         |
| 1.5.2. New active Substance status.............................................................................          | 9                                                                                                         |
| 1.6. Scientific advice.................................................................................................  | 9                                                                                                         |
| 1.7. Steps taken for the assessment of the product......................................................10               |                                                                                                           |
| 2. Scientific discussion..............................................................................                   | 11                                                                                                        |
| 2.1. Problem statement............................................................................................11     |                                                                                                           |
| 2.1.1. Disease or condition                                                                                              | .......................................................................................11                 |
| 2.1.2. Epidemiology.................................................................................................12   |                                                                                                           |
| 2.1.3. Aetiology and pathogenesis .............................................................................12        |                                                                                                           |
| 2.1.4. Clinical presentation, diagnosis and stage/prognosis............................................13                |                                                                                                           |
| 2.1.5. Management                                                                                                        | .................................................................................................14       |
| 2.2. About the product.............................................................................................17    |                                                                                                           |
| 2.3. Type of Application and aspects on development                                                                      | ...................................................19                                                     |
| 2.4. Quality aspects.................................................................................................20  |                                                                                                           |
| 2.4.1. Introduction                                                                                                      | ..................................................................................................20      |
| 2.4.2. Active substance............................................................................................20    |                                                                                                           |
| 2.4.3. Finished medicinal product                                                                                        | ..............................................................................23                          |
| 2.4.4. Discussion on chemical, and pharmaceutical aspects                                                                | ...........................................26                                                             |
| 2.4.5. Conclusions on the chemical, pharmaceutical and biological aspects                                                | ......................26                                                                                  |
| 2.4.6. Recommendations for future quality development...............................................26                   |                                                                                                           |
| 2.5. Non-clinical aspects...........................................................................................27   |                                                                                                           |
| 2.5.1. Introduction                                                                                                      | ..................................................................................................27      |
| 2.5.2. Pharmacology................................................................................................27    |                                                                                                           |
| 2.5.3. Pharmacokinetics                                                                                                  | ...........................................................................................33             |
| 2.5.4. Toxicology.....................................................................................................36 |                                                                                                           |
| 2.5.5. Ecotoxicity/environmental risk assessment                                                                         | ........................................................42                                                |
| 2.5.6. Discussion on non-clinical aspects                                                                                | ....................................................................43                                    |
| 2.5.7. Conclusion on the non-clinical aspects...............................................................47           |                                                                                                           |
| 2.6. Clinical aspects.................................................................................................48 |                                                                                                           |
| 2.6.1. Introduction                                                                                                      | ..................................................................................................48      |

<div style=\"page-break-after: always\"></div>

| 2.6.2. Clinical pharmacology .....................................................................................50    |                                                                                                       |
|-------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------|
| 2.6.3. Discussion on clinical pharmacology..................................................................75          |                                                                                                       |
| 2.6.4. Conclusions on clinical pharmacology................................................................81           |                                                                                                       |
| 2.6.5. Clinical efficacy                                                                                                | ..............................................................................................81      |
| 2.6.6. Discussion on clinical efficacy.........................................................................137      |                                                                                                       |
| 2.6.7. Conclusions on the clinical efficacy..................................................................149        |                                                                                                       |
| 2.6.8. Clinical safety                                                                                                  | ..............................................................................................149     |
| 2.6.9. Discussion on clinical safety...........................................................................167      |                                                                                                       |
| 2.6.10. Conclusions on the clinical safety..................................................................170         |                                                                                                       |
| 2.7. Risk Management Plan.....................................................................................171       |                                                                                                       |
| 3.4.4 Risk minimisation measures............................................................................172         |                                                                                                       |
| 2.7.1. Conclusion on the RMP..................................................................................173       |                                                                                                       |
| 2.8. Pharmacovigilance                                                                                                  | ..........................................................................................173         |
| 2.8.1. Pharmacovigilance system.............................................................................173         |                                                                                                       |
| 2.8.2. Periodic Safety Update Reports submission requirements...................................173                     |                                                                                                       |
| 2.9. Product information.........................................................................................174    |                                                                                                       |
| 2.9.1. User consultation                                                                                                | .........................................................................................174          |
| 2.9.2. Additional monitoring....................................................................................174     |                                                                                                       |
| 3. Benefit-Risk Balance ...........................................................................                     | 174                                                                                                   |
| 3.1. Therapeutic Context........................................................................................174     |                                                                                                       |
| 3.1.1. Disease or condition                                                                                             | .....................................................................................174              |
| 3.1.2. Available therapies and unmet medical need....................................................174                |                                                                                                       |
| 3.1.3. Main clinical studies......................................................................................175   |                                                                                                       |
| 3.2. Favourable effects...........................................................................................175   |                                                                                                       |
| 3.3. Uncertainties and limitations about favourable effects                                                             | ..........................................176                                                         |
| 3.4. Unfavourable effects                                                                                               | .......................................................................................177            |
| 3.5. Uncertainties and limitations about unfavourable effects.......................................178                 |                                                                                                       |
| 3.6. Effects Table                                                                                                      | ..................................................................................................178 |
| 3.7. Benefit-risk assessment and discussion..............................................................180            |                                                                                                       |
| 3.7.1. Importance of favourable and unfavourable effects                                                                | ...........................................180                                                        |
| 3.7.2. Balance of benefits and risks..........................................................................181       |                                                                                                       |
| 3.7.3. Additional considerations on the benefit-risk balance.........................................182                |                                                                                                       |
| 3.8. Conclusions....................................................................................................183 |                                                                                                       |
| Recommendations...................................................................................                      | 183                                                                                                   |

<div style=\"page-break-after: always\"></div>

## List of abbreviations

1L, 2L, 3L

first-line, second-line, third-line

ADR

adverse drug reaction

AE

adverse event

APaT

all patients as treated

API

active pharmaceutical ingredient

ARNT

aryl hydrocarbon receptor nuclear translocator

AUC

area under the concentration-time curve

AUC0-24

AUC from time 0 to 24 hours

AUC0-inf

AUC from time 0 to infinity

AUCss

AUC at steady-state

AUC0-tau

AUC from time 0 to end of the dosing interval

BCS

Biopharmaceutical Classification System

BICR

blinded independent central review

BID

twice a day

BMI

body mass index

BOR

best overall response

ccRCC

clear cell renal cell carcinoma

CHMP

Committee for Medicinal Products for Human Use

CI

confidence interval

CKD

chronic kidney disease

Cmax

maximum concentration

Cmin

minimum concentration

CNS

central nervous system

CR

complete response

CRSD

cumulative running safety dataset

CSF

cerebrospinal fluid

CTLA

cytotoxic T-lymphocyte-associated antigen

CYP

cytochrome P450 enzyme

CV

coefficient of variation

DCR

disease control rate

<div style=\"page-break-after: always\"></div>

| DDI           | drug-drug interaction                                                                                  |
|---------------|--------------------------------------------------------------------------------------------------------|
| DFS           | disease-free survival                                                                                  |
| DOR           | duration of response                                                                                   |
| ECOG (PS)     | Eastern Cooperative Oncology Group (performance status)                                                |
| EM            | extensive metaboliser                                                                                  |
| EMA           | European Medicine Agency                                                                               |
| EORTC QLQ-C30 | European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 items |
| EPO           | erythropoietin                                                                                         |
| E-R           | exposure-response                                                                                      |
| ESA           | erythropoietin-stimulating agent                                                                       |
| ESMO          | European Society for Medical Oncology                                                                  |
| ESRD          | end-stage renal disease                                                                                |
| FAS           | full analysis set                                                                                      |
| FFP           | fit-for-purpose formulation (oral compressed tablet)                                                   |
| FISH          | fluorescence in situ hybridization                                                                     |
| FKSI-DRS      | Functional Assessment of Cancer Therapy - Kidney Symptom Index-disease-related symptoms                |
| GLP           | Good Laboratory Practice                                                                               |
| GM            | geometric mean                                                                                         |
| HA            | health authority                                                                                       |
| HB            | haemangioblastoma                                                                                      |
| HIF           | hypoxia-inducible factor                                                                               |
| HR            | hazard ratio                                                                                           |
| HV            | healthy volunteers                                                                                     |
| IA1           | interim analysis 1                                                                                     |
| IA2           | interim analysis 2                                                                                     |
| ICI           | immune checkpoint inhibitor                                                                            |
| IM            | intermediate metabolizer                                                                               |
| IMDC          | International Metastatic RCC Database Consortium                                                       |
| IND           | Investigational New Drug application                                                                   |
| IRC           | Independent Review Committee                                                                           |

<div style=\"page-break-after: always\"></div>

| ITT      | intention to treat                                        |
|----------|-----------------------------------------------------------|
| KM       | Kaplan-Meier                                              |
| KPS      | Karnofsky Performance Status                              |
| LC-MS/MS | liquid chromatography-mass spectrometry/mass spectrometry |
| LGR      | linear growth rate                                        |
| MAA      | marketing authorization application                       |
| MPA      | Medical Products Agency (Sweden)                          |
| MTD      | maximum tolerated dose                                    |
| NCCN     | National Comprehensive Cancer Network                     |
| NCI      | National Cancer Institute                                 |
| NHS      | natural history study                                     |
| NSS      | nephron-sparing surgery                                   |
| OD       | orphan drug                                               |
| ODD      | orphan drug designation                                   |
| ORR      | objective response rate                                   |
| OS       | overall survival                                          |
| PBPK     | physiologically based pharmacokinetic(s)                  |
| PD       | disease progression                                       |
| PD-1/L1  | programmed cell death 1/-ligand 1                         |
| PFS      | progression-free survival                                 |
| PIP      | paediatric investigation plan                             |
| PK       | pharmacokinetic(s)                                        |
| PM       | poor metaboliser                                          |
| pop-PK   | population pharmacokinetic(s)                             |
| PPGL     | pheochromocytoma/paraganglioma                            |
| PRO      | patient-reported outcomes                                 |
| pVHL     | VHL protein                                               |
| QD       | once daily                                                |
| RCC      | renal cell carcinoma                                      |
| RECIST   | Response Evaluation Criteria in Solid Tumors              |
| RP2D     | recommended Phase 2 dose                                  |

<div style=\"page-break-after: always\"></div>

| SA         | scientific advice                                               |
|------------|-----------------------------------------------------------------|
| SAE        | serious adverse event                                           |
| SD         | stable disease                                                  |
| SOC        | standard of care                                                |
| SOD        | sum of Diameter                                                 |
| TKI        | tyrosine kinase inhibitor                                       |
| T max      | time of maximum concentration                                   |
| TTR        | time to response                                                |
| TTS        | time to surgery                                                 |
| UGT        | 5'-uridine diphosphate glucuronosyltransferase                  |
| US         | United States                                                   |
| VEGF       | vascular endothelial growth factor                              |
| VEGFR      | vascular endothelial growth factor receptor                     |
| VHL        | von Hippel-Lindau                                               |
| VHL-CNS HB | VHL disease-associated central nervous system haemangioblastoma |
| VHL-pNET   | VHL disease-associated pancreatic neuroendocrine tumour         |
| VHL-RCC    | VHL disease-associated RCC                                      |
| WONCBP     | woman of non-childbearing potential                             |

<div style=\"page-break-after: always\"></div>

## 1. Background information on the procedure

## 1.1. Submission of the dossier

The applicant Merck Sharp &amp; Dohme B.V. submitted on 23 November 2023 an application for marketing authorisation to the European Medicines Agency (EMA) for Welireg, through the centralised procedure falling within the Article 3(1) and point 3 of Annex of Regulation (EC) No 726/2004. The eligibility to the centralised procedure was agreed upon by the EMA/CHMP on 30 April 2020.

The applicant applied for the following indications:

## Renal cell carcinoma (RCC)

Welireg is indicated for the treatment of adult patients with advanced renal cell carcinoma that progressed following immune checkpoint and anti-angiogenic therapies.

von Hippel-Lindau (VHL) disease-associated tumours

Welireg is indicated for the treatment of adult patients with von Hippel-Lindau disease who require therapy for associated renal cell carcinoma (RCC), central nervous system (CNS) haemangioblastomas, or pancreatic neuroendocrine tumours (pNET), and for whom localised procedures are unsuitable or undesirable.

## 1.2. Legal basis, dossier content

## The legal basis for this application refers to:

Article 8.3 of Directive 2001/83/EC - complete and independent application

The application submitted is composed of administrative information, complete quality data, non-clinical and clinical data based on applicants' own tests and studies and/or bibliographic literature substituting/supporting certain test(s) or study(ies).

## 1.3. Information on paediatric requirements

Pursuant to Article 7 of Regulation (EC) No 1901/2006, the application included EMA decisions on the granting of product-specific waivers: P/0239/202 for treatment of VHL disease (except VHL disease-associated RCC) and treatment of neuroendocrine tumours except neuroblastoma).

## 1.4. Information relating to orphan market exclusivity

## 1.4.1. Orphan designation

Welireg (3-(((1S,2S,3R)-2,3-difluoro-1-hydroxy-7-(methylsulfonyl)-2,3-dihydro-1H-inden-4-yl)oxy)-5fluorobenzonitrile) was designated as an orphan medicinal product EU/3/20/2324 on 21 Aug 2020 in the following condition: treatment of von Hippel-Lindau disease. On 13 Nov 2023, however, the orphan designation status was withdrawn upon request from the applicant.

<div style=\"page-break-after: always\"></div>

## 1.4.2. Similarity

Pursuant to Article 8 of Regulation (EC) No. 141/2000 and Article 3 of Commission Regulation (EC) No 847/2000, the applicant did not submit a critical report addressing the possible similarity with authorised orphan medicinal products because there is no authorised orphan medicinal product for a condition related to the proposed indication.

## 1.5. Applicant's request for consideration

## 1.5.1. Conditional marketing authorisation

The applicant applied initially for a full marketing authorisation, but during the assessment, in response to CHMP concerns on the comprehensiveness of the data, requested consideration of its application for a conditional marketing authorisation in accordance with Article 14-a of Regulation (EC) No 726/2004.

## 1.5.2. New active substance status

The applicant requested the active substance belzutifan contained in the above medicinal product to be considered as a new active substance, as the applicant claims that it is not a constituent of a medicinal product previously authorised within the European Union.

## 1.6. Scientific advice

The applicant received the following scientific advice on the development relevant for the indication subject to the present application:

| Date            | Reference                     | SAWP co-ordinators                                 |
|-----------------|-------------------------------|----------------------------------------------------|
| 28 March 2019   | EMEA/H/SA/4045/1/2019/SME/III | Dr Martin Mengel, Dr Olli Tenhunen                 |
| 23 July 2020    | EMEA/H/SA/4045/2/2020/III     | Prof. Dieter Deforce, Dr Serena Marchetti          |
| 15 October 2020 | EMEA/H/SA/4045/3/2020/I       | Prof. Fernando de Andrés Trelles, Dr Olli Tenhunen |
| 22 July 2021    | EMA/SA/0000063878             | Adriana Andrić, Dr Serena Marchetti                |

The scientific advice pertained to the following quality, non-clinical, and clinical aspects:

## Quality:

- The appropriateness of proposed regulatory starting material for the drug substance.

Non-clinical:

- Non-clinical development to support a MAA for the treatment of advanced renal cell carcinoma following immunotherapy and vascular endothelial growth factor (VEGF)-targeted and von-Hippel Lindau diseaseassociated renal cell carcinoma, respectively.
- To support a MAA for the treatment of von Hippel-Lindau disease, need for a carcinogenicity study.

<div style=\"page-break-after: always\"></div>

Multidisciplinary non-clinical and clinical:

- Assessment of clinical drug-drug interactions.

Clinical:

- Phase 3 study design to support a MAA in advanced renal cell carcinoma, in particular dose and dose regimen, patient population, comparator, primary and secondary endpoints, stratification factors, overall clinical development to support a MAA, safety database, evaluation of effects on cardiac repolarization, food-effect study, pharmacokinetic sampling plan, as well as population PK analysis plan and assessment of pharmacokinetics in patients with impaired hepatic and renal function.
- Regarding the von-Hippel Lindau disease-associated renal cell carcinoma indication; clinical pharmacology programme, characterization of food effects of the final product, design of a phase 2 study design as pivotal evidence for a MAA, primary clinical efficacy dataset to support a full MAA, demonstration of clinical benefit and supportive evidence, overall safety database.
- To support a MAA for the treatment of von Hippel-Lindau disease, adequacy of the overall clinical development plan, use of a natural history study data as an external control.

## 1.7. Steps taken for the assessment of the product

The Rapporteur and Co-Rapporteur appointed by the CHMP were:

Rapporteur: Peter Mol  Co-Rapporteur:  Elita Poplavska

| The application was received by the EMA on                                                                                                                                  | 23 November 2023   |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------|
| The procedure started on                                                                                                                                                    | 28 December 2023   |
| The CHMP Rapporteur's first assessment report was circulated to all CHMP and PRAC members on                                                                                | 18 March 2024      |
| The CHMP Co-Rapporteur's first assessment report was circulated to all CHMP and PRAC members on                                                                             | 29 March 2024      |
| The PRAC Rapporteur's first assessment report was circulated to all CHMP and PRAC members on                                                                                | 02 April 2024      |
| The CHMP agreed on the consolidated list of questions to be sent to the applicant during the meeting on                                                                     | 25 April 2024      |
| The applicant submitted the responses to the CHMP consolidated list of questions on                                                                                         | 16 July 2024       |
| The following GCP GLP inspection(s) were requested by the CHMP and their outcome taken into consideration as part of the quality/safety/efficacy assessment of the product: |                    |

<div style=\"page-break-after: always\"></div>

| - GCP inspections at two investigator sites, located in Chile and Spain and at the Sponsor site in the United States were conducted between 1 April 2024 and 30 April 2024. The outcome of the inspection carried out was issued on   | 11 July 2024      |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------|
| The CHMP Rapporteurs circulated the CHMP and PRAC Rapporteurs joint assessment report on the responses to the List of Questions to all CHMP and PRAC members on                                                                       | 27 August 2024    |
| The CHMP agreed on a list of outstanding issues <in writing and/or in an oral explanation> to be sent to the applicant on                                                                                                             | 19 September 2024 |
| The applicant submitted the responses to the CHMP list of outstanding issues on                                                                                                                                                       | 08 November 2024  |
| The CHMP Rapporteurs circulated the CHMP and PRAC Rapporteurs joint assessment report on the responses to the list of outstanding issues to all CHMP and PRAC members on                                                              | 26 November 2024  |
| The outstanding issues were addressed by the applicant during an oral explanation before the CHMP during the meeting on                                                                                                               | 10 December 2024  |
| The CHMP, in the light of the overall data submitted and the scientific discussion within the Committee, issued a positive opinion for granting a marketing authorisation to Welireg on                                               | 12 December 2024  |
| Furthermore, the CHMP adopted a report on new active substance (NAS) status of the active substance contained in the medicinal product                                                                                                | 12 December 2024  |

## 2. Scientific discussion

## 2.1. Problem statement

## 2.1.1. Disease or condition

The applicant proposes the following indication:

## Renal cell carcinoma (RCC)

Welireg is indicated for the treatment of adult patients with advanced renal cell carcinoma that progressed following immune checkpoint and anti-angiogenic therapies.

## von Hippel-Lindau (VHL) disease-associated tumours

Welireg is indicated for the treatment of adult patients with von Hippel-Lindau disease who require therapy for associated renal cell carcinoma (RCC), central nervous system (CNS) haemangioblastomas, or pancreatic neuroendocrine tumours (pNET), and for whom localised procedures are unsuitable or undesirable.

<div style=\"page-break-after: always\"></div>

The adopted indications are:

## Renal cell carcinoma (RCC)

Welireg is indicated as monotherapy for the treatment of adult patients with advanced clear cell renal cell carcinoma that progressed following two or more lines of therapy that included a PD-(L)1 inhibitor and at least two VEGF-targeted therapies.

von Hippel-Lindau (VHL) disease-associated tumours

Welireg is indicated as monotherapy for the treatment of adult patients with von Hippel-Lindau disease who require therapy for associated, localised renal cell carcinoma (RCC), central nervous system (CNS) haemangioblastomas, or pancreatic neuroendocrine tumours (pNET), and for whom localised procedures are unsuitable.

## 2.1.2. Epidemiology

## Advanced RCC

RCC accounts for 85% of all adult kidney cancers, representing the 11 th  most common cancer in men and the 16 th  most common cancer in women worldwide (NCCN Guidelines; Sung et al. CA Cancer J Clin. 2021). In 2020, GLOBOCAN reported an estimated 431,288 newly diagnosed cases of RCC and an estimated 179,368 deaths worldwide per year (Sung et al. CA Cancer J Clin. 2021).

## VHL Disease

VHL disease is a rare hereditary syndrome caused by germline mutations of the von Hippel-Lindau tumour suppressor gene located on chromosome 3p25, which is transmitted in an autosomal dominant fashion. This disorder occurs in about one in 36,000 livebirths (Lonser 2003). Tumour development in this setting is due to inactivation or loss of the remaining wild-type allele in a susceptible cell (Maher 1997).

Affected individuals are at lifelong risk for the development of tumours and fluid-filled sacs (cysts) in several organs, including the kidneys, brain and spinal cord, pancreas, and retina. Tumours may be either benign (noncancerous) or malignant and can initially appear during young adulthood; however, the signs and symptoms of VHL disease can occur throughout life with near complete penetrance by 70 years of age. Tumours are often found in multiple organs in a simultaneous, multicentric fashion, and affected patients are at risk for the development of recurrent tumours throughout their life.

## 2.1.3. Aetiology and pathogenesis

## Advanced RCC and VHL Disease

Under normal conditions, oxygen-dependent post-translational modifications on HIF-2 α allow the VHL protein to recognize and target HIF-2 α for rapid degradation. Hypoxia and lack of functional VHL protein results in stabilization of HIF-2 α, and its aberrant accumulation in the nucleus where HIF-2 α binds HIF-1 β. Consequently, HIF-2 α translocates into the nucleus and regulates expression genes, associated with cellular proliferation, angiogenesis, and tumour growth (Albiges et al. Ann Oncol. 2023).

In sporadic clear cell RCC (ccRCC), over 90% of tumours have either somatic VHL gene alterations or epigenetic silencing of the VHL gene, leading to defective VHL protein function. Patients with VHL disease have a germline mutation or deletion of the VHL gene also leading to defective VHL protein function.

<div style=\"page-break-after: always\"></div>

## 2.1.4. Clinical presentation, diagnosis and stage/prognosis

## Advanced RCC

Approximately one third of patients with RCC present with unresectable disease or metastases at diagnosis, and between 20% to 30% of patients with localized tumours will eventually relapse after nephrectomy (NCCN Guidelines). The 5-year survival rate for patients with advanced RCC was approximately 14% (SEER*Stat [Internet]. NCI. 2021. Cancer stat facts: kidney and renal pelvis cancer; [about 16 screens]. Available from: https://seer.cancer.gov/statfacts/html/kidrp.html).

## VHL Disease

Patients affected with VHL disease are at risk to develop renal cysts and ccRCC, haemangioblastoma (HB) of the brain and spinal cord, pancreatic cysts and pancreatic neuro-endocrine tumours (pNETs), retinal angiomas, pheochromocytomas, inner ear endolymphatic sac tumours, and epididymal and broad ligament cystadenomas. Mean age at VHL tumour diagnosis is 26 years (range: 1 to 70 years). The ages of onset of different manifestations are summarized in Table 1 (Binderup et al. Dan Med J. 2013).

Table 1: Age of Onset of VHL Disease Manifestations

| Manifestation                | Approximate age of onset, average (years) a   | Approximate age of onset, range (years) b   |
|------------------------------|-----------------------------------------------|---------------------------------------------|
| RCC                          | 40-45                                         | 20 to 69                                    |
| CNS haemangioblastomas       | CNS haemangioblastomas                        | CNS haemangioblastomas                      |
| Cerebellar haemangioblastoma | 29-30                                         | 13 to 61                                    |
| Spinal haemangioblastoma     | 33-34                                         | 8 to 60                                     |
| Brainstem haemangioblastoma  | 25-38                                         | 16 to 60                                    |
| Cerebral haemangioblastoma   | 29                                            | N/A                                         |
| Retinal haemangioblastoma    | 25-37                                         | 9 to 84                                     |
| pNET                         | 32-38                                         | 16 to 68                                    |
| Renal cyst                   | 34-39                                         | 12 to 64                                    |
| Epididymal cystadenoma       | 24                                            | 10 to 37                                    |
| Pancreatic cysts             | 29-37                                         | 12 to 63                                    |
| Pheochromocytoma             | 20-29                                         | 5 to 62                                     |
| Endolymphatic sac tumour     | 22-40                                         | 11 to 63                                    |

Abbreviations: CNS=central nervous system; N/A=not applicable; pNET=pancreatic neuroendocrine tumour; RCC=renal cell carcinoma; VHL=von Hippel-Lindau.

a  Age of onset: This is a review based on studies that have reported: the number of patients with VHL disease/VHL mutation carriers with the specific VHL manifestation, the average age at diagnosis of the specific manifestation, and how the diagnosis of VHL was made. The ages given were rounded up to the nearest whole year. The published studies were of varying sizes. For each manifestation, the table gives data from the 3 studies with the largest number of patients. Average age of onset: The lowest to the highest reported average ages at diagnosis in the 3 included.

b  Range: The lowest - the highest age at diagnosis of the manifestation in the 3 studies used for the calculation. This range does not account for the extreme limits reported in smaller studies.

Criteria for clinical diagnosis of VHL disease have been well established. For an individual with a family history of VHL disease, clinical diagnosis of VHL disease is established when the individual presents with a single characteristic VHL-related manifestation, for instance, retinal or cerebellar HB or RCC. In the absence of a

<div style=\"page-break-after: always\"></div>

family history of VHL disease, clinical diagnosis requires: 1) 2 or more retinal or cerebellar HB; or 2) an HB and a visceral tumour excluding epididymal and renal cysts, which are common in the general population. For the diagnosis of VHL disease based on germline alterations of the VHL gene, Sanger sequencing of the coding region with deletion/duplication analysis is the standard testing method for analysing the VHL gene, which results in a 95% to 100% detection rate. Other genetic testing methods used for detecting partial and complete gene deletions/duplications include FISH, Southern blotting, next-generation sequencing, and multiplex ligation-dependent probe amplification.

While it is rare to find all VHL manifestations in one patient, more than one tumour type often coexist. The importance of multiple tumour types is reflected in the clinical diagnostic criteria requiring at least two tumours, at least one of which must be an HB in CNS or retina, if no family history of VHL exists. In addition, genotype-phenotype correlations have been made in which the majority of patients with truncating mutations or deletions can be classified as Type 1 VHL disease and have a clinical phenotype of ccRCC and HB. Type 2 VHL disease and all its subtypes (2A, 2B, and 2C) are associated with missense mutations and pheochromocytomas. More specifically, the clinical phenotype for Type 2A consists of HB and pheochromocytomas; for Type 2B, they consist of ccRCC, HB, and pheochromocytomas, and for Type 2C, pheochromocytomas alone.

## 2.1.5. Management

## Current Therapies for Advanced RCC and Unmet Need

ICIs have become standard treatment options for RCC and have greatly improved disease outcome. Initially, anti-PD-1/L1 therapies were approved as subsequent lines of care after treatment with a VEGF-targeting agent. Anti-PD-1/L1 therapies are now approved in the adjuvant setting (as monotherapy) and in the 1L setting in combination with VEGF-targeting agents or with anti-CTLA-4 checkpoint inhibitors. NCCN and ESMO practice guidelines (Powles et al. Ann Oncol. 2021) recommend three combination regimens of PD-1/L1 inhibitors and VEGF-targeting agents as 1L treatments, irrespective of IMDC risk category: pembrolizumab and axitinib (based on pivotal study KEYNOTE-426; EMA approval: Keytruda II/69 EPAR); cabozantinib and nivolumab (CheckMate 9ER; Opdivo II/92 EPAR); and lenvatinib and pembrolizumab (CLEAR/KEYNOTE-581; Keytruda II/104 EPAR). Additional preferred 1L treatment options for poor and intermediate risk RCC include cabozantinib (CaboSun; Cabometyx II/3 EPAR) and the combination of nivolumab and ipilimumab (CheckMate 214; Opdivo WS/1278 EPAR).

Although significant advances have changed the treatment paradigm for patients with advanced RCC, there continues to be a need for evidence-based options for the optimal management of pre-treated patients, particularly after immunotherapy and anti-angiogenic therapies. Current NCCN Guidelines identify no preferred regimen for treatment of patients with ccRCC who have received prior ICI therapy. Figure 1 shows the ESMO recommendations for the systemic 1L and 2L treatment of ccRCC (Powles et al. Ann Oncol. 2021).

<div style=\"page-break-after: always\"></div>

Figure 1: Systemic First- and Second-line Treatment of ccRCC

<!-- image -->

Purple: general categories or stratification; blue: systemic anticancer therapy.

Abbreviations: ccRCC = clear cell renal cell cancer; EMA = European Medicines Agency; ESMO-MCBS = European Society for Medical Oncology-Magnitude of Clinical Benefit Scale; FDA = Food and Drug Administration; IMDC = International Metastatic RCC Database Consortium; MCBS = ESMO-Magnitude of Clinical Scale; VEGFR = vascular endothelial growth factor receptor.

a  ESMO-MCBS v1.1 score for new therapy/indication approved by the EMA or FDA. The score has been calculated by the ESMO-MCBS Working Group and validated by the ESMO Guidelines Committee (https://www.esmo.org/guidelines/esmomcbs/scale-evaluation-forms-v1.0-v1.1/scale-evaluation-forms-v1.1).

b  FDA approved; not currently EMA approved.

<div style=\"page-break-after: always\"></div>

Figure 2 shows the 2023 EAU Guidelines recommendations for later-line therapy.

Figure 2: EAU Guidelines Recommendations for Later-Line Therapy

<!-- image -->

Abbreviations: IO = immunotherapy; TKI = tyrosine kinase inhibitors; VEGF = vascular endothelial growth factor.

1b = based on one randomised controlled phase III trial.

2b = subgroup analysis of a randomised controlled phase III trial.

4 = expert opinion.

For 2L treatment following a 1L combination of IO + TKI, the ESMO and EAU guidelines thus both recommend a(ny) VEGF-targeted therapy that has not been given in 1L. Of note, both nivolumab and cabozantinib that are recommended after a prior TKI in Figure 2 have demonstrated an OS benefit over everolimus (Opdivo II/8 EPAR; Cabometyx SmPC).

There have been no Phase 3 clinical studies conducted in patients with advanced RCC following treatment with anti-PD-1/L1 and anti-angiogenic therapies, as combination or sequentially. One Phase 3 study (CONTACT-03) was conducted in patients with advanced RCC following treatment with ICIs. CONTACT-03 evaluated the use of cabozantinib in combination with atezolizumab, but it did not meet the primary endpoints of PFS and OS (Pal et al. Lancet. 2023). Therefore, there remains an unmet need to improve treatment outcomes for patients who received prior PD-1/L1 and VEGF-targeted therapies.

## Current Therapies for VHL Disease and Unmet Need

The goals of current clinical management or treatment options for VHL disease-associated tumours are to prevent the development of distant metastasis and/or limit locoregional morbidity, while preserving normal organ function as much as possible. Management often involves extensive lifelong surveillance and multiple local procedures to the kidneys, brain, and/or spinal cord, pancreas, adrenal glands, and retina. However, surgery is not curative; it provides local palliation and does not address the multifocal nature of the disease. In addition, multiple surgeries in the same and/or different organs in these patients through their lives are associated with significant morbidity and mortality, including long-term complications and/or organ function loss.

The decision whether a specific VHL patient requires immediate surgery or local therapy is a clinical decision made by the treating physicians together with the patient after considering multiple factors. These multifactorial considerations include: 1) tumour-specific features, such as tumour size, tumour location, and tumour-growth kinetics; and 2) patient characteristics, such as number of prior surgeries/procedures, current organ function, pre-existing comorbidities, and patient's preference.

<div style=\"page-break-after: always\"></div>

For patients with VHL-RCC, the purpose of surgical removal of tumours is to prevent metastatic disease while preserving organ function as much as possible. In general, if the RCC tumour is &lt;3 cm in diameter, active surveillance is recommended, as the risk of metastases is very low. If tumour size is between 3-4 cm, active surveillance may still be performed and a need for surgery may not be deemed immediate in the following scenarios: 1) the tumour is relatively slow growing; 2) the lesion is comprised of a complex cyst with a solid component and the size of the solid component is &lt;3 cm; 3) the patient has had multiple partial nephrectomies or has a centrally located tumour in a solitary kidney in that maximally preserving renal function and/or delaying dialysis is of great clinical importance; 4) the patient has significant comorbidities, which renders surgery of low feasibility; or 5) the patient's preference of a nonsurgical approach.

For patients with VHL-CNS HB, the mainstay of therapy is surgical resection judiciously performed for symptomatic tumours. Asymptomatic tumours that are imminent to cause CSF obstruction should be treated promptly.

For patients with VHL-pNET, tumour size and tumour growth kinetics are referenced by the VHL Alliance consensus for the management of pNET to minimize the risk of metastasis. Surgical intervention is recommended for those tumours with diameters ≥3 cm in the pancreatic body and ≥2 cm in the head.

In the EU, there is no systemic therapeutic option approved for treating VHL disease-associated tumours for which localized procedures (such as surgery, radiation, or ablation) are unsuitable or undesirable. While these procedures temporarily address individual tumours, they are not curative and new tumours continue to occur. There is, therefore, an unmet need for systemic treatment options that would reduce the size and/or reduce the growth rate of VHL tumours and/or delay or obviate the need for surgery, for select patients with VHL disease-associated neoplasms, including RCC, CNS HB, and pNET.

## 2.2. About the product

Mechanism of action: Belzutifan is an inhibitor of hypoxia-inducible factor 2 alpha (HIF-2 α) HIF-2 α is a transcription factor that plays a role in oxygen sensing by regulating genes that promote adaptation to hypoxia. Under normal oxygen levels, HIF-2 α is targeted for ubiquitin-proteasomal degradation by the VHL protein. Lack of functional VHL protein results in stabilisation and accumulation of HIF-2 α. Upon stabilisation, HIF-2 α translocates into the nucleus and interacts with hypoxia-inducible factor 1 beta (HIF-1 β) to form a transcriptional complex that regulates expression of downstream genes, including genes associated with cellular proliferation, angiogenesis, and tumour growth. Belzutifan binds to HIF-2 α, and in conditions of impairment of VHL protein function, belzutifan blocks the HIF-2 α -HIF-1 β interaction, leading to reduced transcription and expression of HIF-2 α target genes. In vivo , belzutifan demonstrated anti-tumour activity in mouse xenograft models of VHL-deficient RCC, while no (statistically significant) activity was observed in VHL-proficient tumours (Albiges et al, New England Journal of Medicine 2024).

Pharmacological classification: Pharmacotherapeutic group: Antineoplastic agent, other antineoplastic agents. ATC code: L01XX74.

## Claimed indications:

## Renal cell carcinoma (RCC)

Welireg is indicated for the treatment of adult patients with advanced renal cell carcinoma that progressed following immune checkpoint and anti-angiogenic therapies.

<div style=\"page-break-after: always\"></div>

## von Hippel-Lindau (VHL) disease-associated tumours

Welireg is indicated for the treatment of adult patients with von Hippel-Lindau disease who require therapy for associated renal cell carcinoma (RCC), central nervous system (CNS) haemangioblastomas, or pancreatic neuroendocrine tumours (pNET), and for whom localised procedures are unsuitable or undesirable.

## Approved indications

## Renal cell carcinoma (RCC)

Welireg is indicated as monotherapy for the treatment of adult patients with advanced clear cell renal cell carcinoma that progressed following two or more lines of therapy that included a PD-(L)1 inhibitor and at least two VEGF-targeted therapies.

## von Hippel-Lindau (VHL) disease-associated tumours

Welireg is indicated as monotherapy for the treatment of adult patients with von Hippel-Lindau disease who require therapy for associated, localised renal cell carcinoma (RCC), central nervous system (CNS) haemangioblastomas, or pancreatic neuroendocrine tumours (pNET), and for whom localised procedures are unsuitable.

Therapy must be initiated and supervised by specialist physicians experienced in the treatment of cancer.

Proposed posology: The recommended dose of Welireg is 120 mg (three 40 mg tablets) administered orally once daily.

Treatment should continue until disease progression or unacceptable toxicity occurs.

## Missed dose

If a dose of Welireg is missed, it can be taken as soon as possible on the same day. The regular daily dose should be resumed the next day. Extra tablets should not be taken to make up for the missed dose.

If vomiting occurs any time after taking Welireg, another dose should not be taken. The next dose should be taken the next day.

## Dose modifications

Dose modifications for Welireg for adverse reactions are summarised in Table 2.

Table 2: Recommended Dose Modifications

| Adverse reactions         | Severity*                                                                                                    | Dose modification                                                                                                                                                           |
|---------------------------|--------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Anaemia (see section 4.4) | Grade 3 (haemoglobin < 8 g/dL; < 4.9 mmol/L; < 80 g/L; transfusion indicated)                                | • Withhold until resolved to ≤ Grade 2 • Resume at the same or reduced dose (reduce by 40 mg); consider discontinuing depending on the severity and persistence of anaemia  |
| Anaemia (see section 4.4) | Grade 4 (life-threatening consequences or urgent intervention indicated)                                     | • Withhold until resolved to ≤ Grade 2 • Resume at a reduced dose (reduce by 40 mg) or permanently discontinue upon recurrence of Grade 4                                   |
| Hypoxia (see section 4.4) | Grade 3 asymptomatic (decreased oxygen saturation at rest (e.g., pulse oximeter < 88% or Pa O 2 ≤ 55 mm Hg)) | • Option to continue or withhold until resolved to ≤ Grade 2 • Resume at reduced dose (reduce by 40 mg) or discontinue depending on the severity and persistence of hypoxia |
| Hypoxia (see section 4.4) | Grade 3 symptomatic (decreased                                                                               | • Withhold until resolved to ≤ Grade 2 • Resume at reduced dose (reduce by 40 mg) or                                                                                        |

<div style=\"page-break-after: always\"></div>

| Adverse reactions                         | Severity*                                                                                                  | Dose modification                                                                                                                                                                                    |
|-------------------------------------------|------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                           | oxygen saturation at rest (e.g., pulse oximeter < 88% or Pa O 2 ≤ 55 mm Hg))                               | discontinue depending on the severity and persistence of hypoxia                                                                                                                                     |
|                                           | Grade 4 (life-threatening airway compromise; urgent intervention needed (e.g., tracheotomy or intubation)) | • Permanently discontinue                                                                                                                                                                            |
| Other adverse reactions (see section 4.8) | Grade 3                                                                                                    | • Withhold dosing until resolved to ≤ Grade 2 • Consider resuming at a reduced dose (reduce by 40 mg) depending on the severity and persistence • Permanently discontinue upon recurrence of Grade 3 |
| Other adverse reactions (see section 4.8) | Grade 4                                                                                                    | • Permanently discontinue                                                                                                                                                                            |

## 2.3. Type of application and aspects on development

Regulatory status outside the EU: Welireg has been approved the US, Great Britain and several other countries for VHL-RCC, CNS HB, or pNETs in certain patients. The global registration status of Welireg is evolving, as applications are under regulatory agency review worldwide. Notably, on 14-Dec-2023 the FDA approved  Welireg also for the treatment of advanced RCC ' Welireg is indicated for the treatment of adult patients with advanced renal cell carcinoma (RCC) following a programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor and a vascular endothelial growth factor tyrosine kinase inhibitor (VEGF-TKI). '.

Development programme: The belzutifan clinical development programme consists of several Phase 1 and Phase 2 studies, and a single Phase 3 study, see Table 16 For a more up-to-date list, see the website ClinicalTrials.gov.

The applicant requested consideration of its application for a Conditional Marketing Authorisation in accordance with Article 14-a of the above-mentioned Regulation, based on the following criteria:

- The benefit-risk balance is positive.
- It is likely that the applicant will be able to provide comprehensive data. The overall clinical programme of belzutifan is extensive, including two independent single arm trials (Studies 004 and 015) with corresponding NHS and/or ECA in patients with VHL disease. Study 004 has a median duration of follow-up of 49.7 months and Study 015 a median duration of follow-up of 14.9 months, and additional longer-term safety and efficacy data can be provided for both studies. Study 015 is still enrolling; so far information from 23 patients has been provided, but additional data will be available with further follow-up.
- Unmet medical needs will be addressed, as the affected individuals are at lifelong risk for the development of tumours in several organs, including the kidneys, brain and spinal cord, pancreas, and retina. The goals of current clinical management or treatment options for VHL disease-associated neoplasms are to prevent the development of distant metastasis and/or limit locoregional morbidity, while preserving normal organ function as much as possible. Management often involves extensive lifelong surveillance and multiple local procedures/ surgeries to the kidneys, brain, and/or spinal cord, pancreas, adrenal glands, and retina. However, local procedure / surgery is not curative; it provides local palliation and does not address the recurrent and multifocal nature of the disease. In addition, multiple surgeries in the same and/or different organs in these patients through their lives are associated with significant morbidity and mortality, including long-term complications and / or organ

<div style=\"page-break-after: always\"></div>

- function loss. Belzutifan targets the underlying pathophysiological driver of VHL-associated tumours.
- The benefits to public health of the immediate availability outweigh the risks inherent in the fact that additional data are still required. The benefits of the immediate availability outweigh the risks since the safety profile has been shown to be manageable and the immediate availability would allow treatment of VHL patients who do not have any other systemic or local therapeutic option currently available in Europe.

## 2.4. Quality aspects

## 2.4.1. Introduction

The finished product is presented as a film-coated tablet for oral administration containing 40 mg of belzutifan as active substance.

Other ingredients are:

Tablet core: hypromellose acetate succinate, cellulose microcrystalline (E460), mannitol (E421), croscarmellose sodium (E468), silica, colloidal anhydrous (E551), magnesium stearate (E470b).

Film-coating: polyvinyl alcohol (E1203), titanium dioxide (E171), macrogol (E1521), talc (E553b), indigo carmine aluminium lake (E132).

The product is available in aluminium/aluminium blisters in an outer carton.

## 2.4.2. Active substance

## General information

The chemical name of belzutifan is 3-{[(1 S ,2 S ,3 R )-2,3-difluoro-1-hydroxy-7-(methanesulfonyl)-2,3-dihydro1 H -inden-4-yl]oxy}-5-fluorobenzonitrile corresponding to the molecular formula C17H12F3NO4S. It has a relative molecular mass of 383.84 and the following structure, as depicted in Figure 3 .

Figure 3: Active Substance Structure

<!-- image -->

<div style=\"page-break-after: always\"></div>

The chemical structure of belzutifan was elucidated by a combination of  1 H and  13 C NMR (also used to demonstrate correct isoform), MS, and UV. The solid-state properties of the active substance were measured by DSC and XRPD.

The belzutifan is a is a white to light brown powder. Belzutifan is non-hygroscopic, has low solubility in aqueous solution and high in vitro permeability; it is classified as is a BCS Class II compound.

Belzutifan exhibits stereoisomerism due to the presence of three chiral centres. Enantiomeric purity is controlled routinely by chiral HPLC. Three stereoisomeric impurities are controlled to. Chiral purity is controlled in the active substance specification

Polymorphism has been observed for belzutifan. Upon request of the CHMP, polymorph screen experiments were conducted and only one crystalline form of belzutifan was observed - form A.

## Manufacture, characterisation and process controls

Belzutifan is synthesised using well-defined starting materials with acceptable specifications.

The active substance intermediates and the active substance are all manufactured by the same manufacturer.

The proposed manufacturing process contains 8 chemical transformation steps (stated as 6 manufacturing steps), 5 isolated and 3 non-isolated intermediates. The three stereogenic centres of belzutifan are introduced under GMP. Upon request from the CHMP, the process flow diagram has been supplemented with the non-isolated intermediates.

The proposed starting material is acceptable as the starting material as it is synthesized from a chemical commodity, incorporates a major structural fragment in the active substance and there are multiple chemical transformation steps in line with ICH Q11. The starting material is adequately controlled by its specification.

Adequate in-process controls (IPCs) are applied during the synthesis. The specifications and control methods for intermediate products, starting materials and reagents have been presented and are considered adequate.

The manufacturing process has been developed using a combination of conventional univariate studies and elements of QbD such as risk assessment, design of experiment (DOE) and multivariate studies. A risk assessment was performed to determine the impact on the critical quality attributes (CQAs) of the active substance across the six process steps. Active substance CQAs included identity, assay, impurity content, chiral purity, residual solvents and water content. The risk assessment concluded that existing controls are sufficient to meet the CQAs limits. Two critical process parameters (CPPs) have been identified in the belzutifan active substance manufacturing process. The active substance manufacturing process has been described in sufficient detail, and the provided ranges for several process parameters  are justified by the DoE, one factor or multiple factors at a time experimental work. Based on these studies, proven acceptable ranges (PARs) have been defined for the charges of reagents and solvents used and operating conditions and linked to the CPPs and IPCs. The available development data, the proposed control strategy and batch analysis data from commercial scale batches fully support the proposed PARs.

The characterisation of the active substance and its impurities are in accordance with the EU guideline on chemistry of new active substances.

<div style=\"page-break-after: always\"></div>

Potential and actual impurities, residual solvents and elemental impurities were well discussed with regards to their origin and characterised, including when applicable spike and purge studies. Of note, option 3 of ICH M7 is proposed for both therapeutic indications. This could be acceptable for RCC only; however, ICH S9 is not applicable for VHL indication. Upon request of the CHMP, additional spiking studies were performed, concluding that an impurity content in the active substance dry cake is below the TTC limit of 12.5 ppm but above the 30% level, applicable for Option 3. Purge data on crystallisation impurity removal have also been provided; however, its efficiency has not been sufficiently demonstrated as the impurity is present above the 30% of the TTC; hence, additional control for the named impurity was requested according to Option 1 and its limit was tightened in the active substance specification.

For the mutagenic impurities' discussion, the QSAR and AMES reports are provided. The identities (i.e. chemical name and compound structure) of a number of impurities are provided and the results are considered sufficient.

The development of the manufacturing process is considered adequate. The commercial manufacturing process for the active substance was developed in parallel with the clinical development programme. Changes introduced have been presented in sufficient detail and have been justified. The quality of the active substance used in the various phases of the development is considered to be comparable with that produced by the proposed commercial process.

The active substance is packaged in material which complies with Commission Regulation (EU) 10/2011, as amended .

## Specification

The active substance specification includes tests for: appearance, identity (FTIR, HPLC), assay (HPLC), impurities (specified, individual unspecified impurities and total impurities), chiral purity (HPLC), residual solvents (GC) and water content (KF).

The active substance specifications are based on the active substance CQAs.

In general, the inclusion of the selected tests and the acceptance criteria in the proposed active substance specification are acceptable in line with ICH Q6A.

Concerning the control of impurities, impurities present at higher level than the qualification threshold according to ICH Q3A were qualified by toxicological and clinical studies and appropriate specifications have been set.

The omission of a microbial enumeration test in the active substance specification has been sufficiently justified by water activity results over the re-test period. Since the active substance is dissolved in acetone in the spray drying process, input polymorphic form and particle size are not expected to impact the finished product performance and hence their omission is justified.

The analytical methods used have been adequately described and non-compendial methods appropriately validated in accordance with the ICH guidelines. During the procedure, the analytical method validation for an impurity ,in line with ICH Q2, has been provided.

Satisfactory information regarding the reference standards used for assay and impurities testing has been presented.

<div style=\"page-break-after: always\"></div>

Batch analytical data have been provided on multiple batches at different development stages. Batch data of three consecutive commercial scale batches of the active substance, manufactured by the proposed manufacturer using the proposed manufacturing method, are provided. The results are within the specifications and consistent from batch to batch.

## Stability

Stability data from three consecutive full-scale batches of active substance from the proposed manufacturer stored in the intended commercial package for up to 36 months under long term conditions (25ºC / 60% RH) and for up to 6 months under accelerated conditions (40ºC / 75% RH) according to the ICH guidelines were provided.

The parameters tested are the same as for release, with the exception that identity, chiral purity and physical form (which is not part of the release specifications) are tested only at initial and 36 months, under long terms conditions and at 6 months under accelerated. The analytical methods used were the same as for release and were stability indicating.

All tested parameters were within the specifications. No trends were observed at both storage conditions. The chiral purity and polymorphism results remained stable, up to 36 months of storage.

Photostability testing following the ICH guideline Q1B was performed.

Results on stress conditions: thermal, acidic, basic (caustic), oxidative, and free radical stressed solutions were also provided The stability indicating nature of the assay and related substances method was demonstrated and supported by conclusive mass balance.

The stability results indicate that the active substance manufactured by the proposed supplier is sufficiently stable. The stability results justify the proposed retest period, with no special storage conditions, when stored in the proposed container.

## 2.4.3. Finished medicinal product

## Description of the product and Pharmaceutical development

Belzutifan 40 mg tablets are blue, oval shaped, debossed with markings '177' on one side and film-coated for immediate release. The core tablet dimensions are 8.20 mm x 13.36 mm.

Sufficient details on the description and composition of the finished product have been provided. The excipients are well known and widely used in oral pharmaceutical preparations.

All excipients are well known pharmaceutical ingredients, and their quality is compliant with Ph. Eur. standards, with the exception of indigo carmine aluminium lake. There are no novel excipients used in the finished product formulation. The list of excipients is included in section 6.1 of the SmPC and in Section 1.1.1. of this report.

The pharmaceutical development of the finished product contains QbD elements. In line with ICH Q8, a quality target product profile (QTTP), critical quality attributes (CQAs) and critical material attributes (CMAs) have been identified. The QTTP is given in Table 6 .

<div style=\"page-break-after: always\"></div>

Table 3: Quality Target Product Profile

| Clinical andProductQualityAttributes            | Target                                                                                                                                     |
|-------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------|
| Dose/Dose Frequency                             | Maximum dose of 200 mg /Once Daily (QD)                                                                                                    |
| Route of Administration                         | Oral                                                                                                                                       |
| Appearance                                      | Tablet conforming to size, shape, color and debossing.                                                                                     |
| Assay                                           | Will comply with the relevant acceptance criteria                                                                                          |
| Uniformity of Dosage Units (Content Uniformity) | Will comply with the relevant pharmacopeial acceptance criteria                                                                            |
| Identity                                        | Positive for active substance                                                                                                              |
| Dissolution Profile                             | Completerelease<60minutes tomeet immediaterelease criteria                                                                                 |
| Phase form Control                              | Control moisture during manufacturing and packaging operations with required environmental controls. Appropriate packaging configurations. |
| Impurities andDegradationProducts               | Controlled below ICH Q3B (R2) identification threshold or qualified levels                                                                 |
| Microbiological quality                         | Productfreefrom microbial contamination                                                                                                    |
| Shelf life                                      | Minimum of 24 months in suitable packaging                                                                                                 |

An adequate and detailed risk assessment in line with ICH Q8 (R2) has been provided for the active substance, excipients and formulation parameters in which the material attributes are linked to the finished product CQAs and the observed risks were used to set adequate material controls and to steer the formulation development towards an optimised and robust formulation.

The QC dissolution development has been adequately described and justified. Sink conditions have been demonstrated. The discriminatory power of the QC dissolution method was demonstrated.  During development, the method was slightly optimised to reduce analytical variability. MO1 was raised with regards to tightening the dissolution specification, however, it was demonstrated that the proposed specification is adequate. Additionally, in response to MO1, it was confirmed that the dissolution data generated before and after the optimisation of the method was performed in line with Ph. Eur. requirements and hence acceptable.

The development of the manufacturing process was guided by prior experience, risk analysis and elements of QbD by design of experiments execution for the spray drying and roller compaction process development. Where applicable the results of the development studies support process parameter settings (target and ranges) and in-process control acceptance criteria as laid down in the manufacturing process description. No design space is claimed. The manufacturing process development has been adequately described.

The primary packaging is aluminium/aluminium blisters with push through lidding. The material complies with Ph. Eur. and EC requirements. The choice of the container closure system has been validated by stability data and is adequate for the intended use of the product.

## Manufacture of the product and process controls

The finished product is manufactured by one manufacturer MSD International GmbH, Ireland.

The manufacturing process consists of nine main steps The process is considered to be a standard manufacturing process.

<div style=\"page-break-after: always\"></div>

The manufacturing process has been described in sufficient detail, including material introduction steps, justified process parameter settings or ranges by development data and in-process controls for the critical steps. No design space is claimed for any of the process parameters. The claimed holding time is acceptable.

Relevant steps of the manufacturing process have been validated by a number of studies. It has been demonstrated that the manufacturing process is capable of producing the finished product of intended quality in a reproducible manner.

## Product specification

The finished product release specifications include appropriate tests for this kind of dosage form: description (visual), identification (NIR, HPLC, UV), assay (HPLC), degradation products (HPLC), uniformity of dosage units (HPLC), dissolution (HPLC), and microbial limits (Ph. Eur.).

The finished product release and shelf life specifications are now considered acceptable following the revisions requested by CHMP: the identity tests and uniformity of dosage units test have been included in the shelf life specification, the dimensions of the film-coated tablets have been added to the description acceptance criteria, the identity test by HPLC retention time has been defined numerically, the uniformity of dosage units limits acceptance criteria is in line with Ph. Eur. 2.9.40.

The finished product is released on the market based on the above release specifications, through traditional final product release testing.

The potential presence of elemental impurities in the finished product has been assessed following a riskbased approach in line with the ICH Q3D Guideline for Elemental Impurities. Batch analysis data using a validated ICP-MS method was provided, demonstrating that each relevant elemental impurity was not detected above 30% of the respective PDE. Based on the risk assessment and the presented batch data it can be concluded that it is not necessary to include any elemental impurity controls in the finished product specification. The information on the control of elemental impurities is satisfactory.

A risk assessment concerning the potential presence of nitrosamine impurities in the finished product has been performed (as requested to address MO2) considering all suspected and actual root causes in line with the 'Questions and answers for marketing authorisation holders/applicants on the CHMP Opinion for the Article 5(3) of Regulation (EC) No 726/2004 referral on nitrosamine impurities in human medicinal products' (EMA/409815/2020) and the 'Assessment report- Procedure under Article 5(3) of Regulation EC (No) 726/2004- Nitrosamine impurities in human medicinal products' (EMA/369136/2020). Based on the information provided, it is accepted that there is no risk of nitrosamine impurities in the active substance or the related finished product. Therefore, no specific control measures are deemed necessary.

The analytical methods used have been adequately described and appropriately validated in accordance with the ICH guidelines. Satisfactory information regarding the reference standards used for assay and impurities testing has been presented.

Batch analysis results are provided confirming the consistency of the manufacturing process and its ability to manufacture to the intended product specification.

<div style=\"page-break-after: always\"></div>

## Stability of the product

Stability data from production scaled batches) stored under long terms conditions and under accelerated conditions) according to the ICH guidelines were provided. The batches were packed in the primary packaging proposed for marketing.  The following parameters were investigated: assay, degradation products, description, dissolution, and microbiological quality. In addition, the following informational tests were performed: moisture content, water activity, hardness, and crystallinity by XRPD.

For the long term and 6 months accelerated data no clear trends were seen in any of the tested parameters. All parameters were well within the specification limit.

In addition, samples were exposed to light as defined in the ICH Guideline on Photostability Testing of New Drug Substances and Products. It is concluded that the film-coated tablets are photo stable and do not require to be protected from light.

The proposed hold time of the bulk of film-coated tablets in has been sufficiently justified with data.

Based on available stability data, the proposed shelf-life of 4 years without special storage conditions as stated in the SmPC (section 6.3 and 6.4) are acceptable.

## Post approval change management protocols

Two post-approval change management protocols (PACMP) were submitted.

## Adventitious agents

No excipients derived from animal or human origin have been used.

## 2.4.4. Discussion on chemical, and pharmaceutical aspects

Information on development, manufacture and control of the active substance and finished product has been presented in a satisfactory manner. During the procedure two major objections have been raised and pertaining to the dissolution limits (MO1) and the nitrosamine risk assessment (MO2). Both MOs were adequately addressed by provision of additional information and appropriate justifications. The results of tests carried out indicate consistency and uniformity of important product quality characteristics, and these in turn lead to the conclusion that the product should have a satisfactory and uniform performance in clinical use.

## 2.4.5. Conclusions on the chemical, pharmaceutical and biological aspects

The quality of this product is considered to be acceptable when used in accordance with the conditions defined in the SmPC. Physicochemical and biological aspects relevant to the uniform clinical performance of the product have been investigated and are controlled in a satisfactory way.

## 2.4.6. Recommendations for future quality development

Not applicable.

<div style=\"page-break-after: always\"></div>

## 2.5. Non-clinical aspects

## 2.5.1. Introduction

Belzutifan is a small molecule developed as an inhibitor of HIF-2 α.

The primary pharmacodynamics of belzutifan were evaluated using in vitro and in vivo assays while the secondary pharmacology was tested in two screening panels to assess its selectivity and potential for off target. Potential effects of belzutifan on critical organ systems were also evaluated in several safety pharmacology studies conducted as stand-alone experiments or as components of the 28-day or 13-week repeat-dose GLP toxicity studies.

Pharmacokinetics of belzutifan were determined in plasma, urine, and tissue homogenate samples from nonclinical species, as well as in vitro studies utilizing human biomaterials, using LC-MS/MS methods. Validated methods were used for the analysis of samples from GLP studies.

## 2.5.2. Pharmacology

## 2.5.2.1. Primary pharmacodynamic studies

## In Vitro

With a scintillation proximity assay, the potency of belzutifan to bind to the PAS-B domain was investigated by determining its ability to displace a radiolabelled probe. The obtained IC50 values ranged from &lt;0.005 μ M to 0.015 μ M. The glucuronide metabolite PT3317 (M16) is not pharmacologically active (IC50 of &gt;100 μ M), although only one batch was tested.

Figure 4: dose Response Curves of SPA Results of Different PT2977 Lots and the Displacement of Radioactive Probe as a Function of MK-6482 (Belzutifan) Concentration

SPAResultsforPT2977

<!-- image -->

<div style=\"page-break-after: always\"></div>

<!-- image -->

IC50=half-maximal inhibitory concentration; µM=micromolar; SPA=scintillation proximity assay. In this figure MK-6482 is labelled as PT2977. The average displacement of a radiolabelled probe by several batches of MK6482 in the SPA assay is plotted. The IC50 values obtained from these data ranged from &lt;0.005 to 0.015 μM. [PT2977] refers to the concentration of MK-6482.

The potency, selectivity, mechanism of action and downstream consequences of HIF-2 α inhibition by belzutifan were assessed in cellular experiments.

Inhibition of HIF-2 α -driven HRE-dependent luciferase activity was investigated in the 786-O ccRCC cell line, a VHL-mutant cell line with constitutively active HIF-2 α and non-functional HIF-1 α. An HRE-regulated luciferase gene was transfected into the cells and a stable clone was isolated. Belzutifan treatment reduced luciferase activity in a dose-dependent manner, and the IC50 was calculated to be 0.015 µM.

Additionally, belzutifan potently inhibited transcription of the HIF-2 α target genes cyclin D1 (CCND1), plasminogen activator inhibitor type 1 gene (SERPINE1), VEGFA, and glucose transporter solute carrier family 2 member 1 (SLC2A1) in 786-O cells, as determined by reverse transcriptase-quantitative polymerase chain reaction (RT-qPCR).

The mRNA levels for a number of HIF-2 α target genes. were reduced in a dose-dependent fashion in cells treated with belzutifan, and data for CCND1 and SLC2A1 are shown in the Figure 5.

Figure 5: HIF-2α Target Genes mRNA Level Reduction In A Dose-Dependent Fashion

<!-- image -->

Cellular selectivity was demonstrated by the ability of belzutifan to inhibit HIF-2 α hypoxia-driven gene transcription in Hep3B cells, while in the same experiment having no effect on genes regulated by HIF-1 α.

<div style=\"page-break-after: always\"></div>

The mechanism of action of belzutifan was evaluated in 786-O and Hep3B cells by examining its effect on HIF-2 α hetero-dimerization with ARNT.

Specificity of belzutifan and its mechanism of action in hypoxic conditions were tested.

Under conditions of oxygen deprivation, both HIF-1 α and HIF-2 α proteins are stabilized in Hep3B hepatoma cells, resulting in the activation of hypoxia-response genes. Treatment of Hep3B cells with belzutifan reduced the levels of hypoxia-induced mRNA of erythropoietin (EPO) and SERPINE1 (see figures below), both known HIF-2 α target genes. The treatment had no effect on the expression of phosphoglycerate kinase 1 (PGK1) and pyruvate dehydrogenase kinase 1, both of which are regulated specifically by HIF-1 α.

Figure 6: Levels of Hypoxia-Induced mRNA of Erythropoietin (EPO) and SERPINE1in Hep3B Cells Treated With Belzutifan

Wr

<!-- image -->

In vivo

The anti-tumour activity of belzutifan was evaluated in a VHL-deficient tumour xenograft model derived from the human ccRCC cell line 786-O implanted in SCID/Beige mice. Mice with established tumours were treated orally with vehicle or belzutifan twice daily at doses of 0.3, 1, or 3 mg/kg for 28 days. Treatment with belzutifan resulted in tumour regression at all three doses tested (see figure and table below):

<div style=\"page-break-after: always\"></div>

Figure 7: Anti-Tumour Activity of Belzutifan

<!-- image -->

b.i.d.=twice daily; SCID=severe combined immunodeficiency; SEM=standard error of the mean; TGI=tumour growth inhibition.

Shown is the decrease in tumour volume in SCID/Beige mice, with established sub-cutaneous 786-O tumours, that were treated orally with twice-daily administration of MK-6482 for 28 days.

Table 4: Belzutifan Results in Tumour Regression at all Three Doses Tested

| Treatment     | Tumour Weight (mg) a   | (1-T/C)% b   | P -value c   |
|---------------|------------------------|--------------|--------------|
| Vehicle       | 35.8 ± 5.21            | -            | -            |
| 0.3 mg/kg BID | 4.1 ± 1.22             | 89           | <0.0001      |
| 1 mg/kg BID   | 1.3 ± 0.13             | 96           | <0.0001      |
| 3 mg/kg BID   | 1.0 ± 0.04             | 97           | <0.0001      |

BID=twice daily; C=control; mg/kg=milligram per kilogram; SEM=standard error of the mean; T=treated.

- a Mean ± SEM.
- b 1-(MK-6482-treated)/(Vehicle control group)
- c P -value based on comparison to the vehicle group.

Belzutifan was also administered orally at 0.3, 1, and 3 mg/kg BID for 3 days to SCID/Beige mice bearing 786-O ccRCC xenografts (Study PD008). Plasma and tumour tissue samples were collected 12 hours after the last dose was given. Human VEGFa protein, derived from the tumours, was detected by ELISA in the circulation of tumour-bearing mice treated with vehicle, but was essentially undetectable in animals treated with belzutifan, with the exception of one sample in the 0.3 mg/kg dose group (table below). Gene expression analyses of the tumours showed a dose-dependent decrease in expression of the HIF-2 α target genes ( CCND1 , SERPINE1 , VEGFA , and SLC2A1 ) in tumour-bearing mice treated with belzutifan (figure 10 below).

<div style=\"page-break-after: always\"></div>

Table 5: Plasma Levels of Human VEGFa at 12 Hours After the Last Dose of MK-6482

| Treatment Group   | Dose      |   Animal Number | Plasma human VEGFa concentration (pg/mL)   |
|-------------------|-----------|-----------------|--------------------------------------------|
| Vehicle           | NA        |               1 | 121.145                                    |
| Vehicle           | NA        |               2 | 90.544                                     |
| Vehicle           | NA        |               3 | 17.808                                     |
| MK-6482           | 0.3 mg/kg |               4 | 7.102 a                                    |
| MK-6482           | 0.3 mg/kg |               5 | 0.000 a                                    |
| MK-6482           | 0.3 mg/kg |               6 | 0.000 a                                    |
| MK-6482           | 1 mg/kg   |               7 | 0.000                                      |
| MK-6482           | 1 mg/kg   |               8 | 0.000                                      |
| MK-6482           | 1 mg/kg   |               9 | 0.000                                      |
| MK-6482           | 3 mg/kg   |              10 | 0.000                                      |
| MK-6482           | 3 mg/kg   |              11 | 0.000                                      |
| MK-6482           | 3 mg/kg   |              12 | 0.000                                      |

mg/kg=milligram per kilogram; NA=not applicable; pg/mL=picogram per millilitre; VEGFa=vascular endothelial growth factor A protein.

d Below the lower limit of quantitation for the assay.

Source: Nonclinical Study Report PD008

The anti-tumour activity of belzutifan was also evaluated in a mouse xenograft model (CTG-0824) derived from a patient with ccRCC. Tumour fragments that had been passaged in nu/nu immunocompromised mice were implanted subcutaneously (Nonclinical Study Report PD007). Treatment with belzutifan at 3 mg/kg twice daily for 28 days resulted in 89% tumour growth inhibition relative to treatment with vehicle (see figure below).

Figure 8 Tumour Growth Curves of a Patient-Derived Clear Cell Renal Cell Carcinoma Xenograft Model (CTG-0824) Treated With MK-6482 or Vehicle

<!-- image -->

b.i.d.=twice daily; ccRCC=clear cell renal cell carcinoma; mg/kg=milligram per kilogram; SEM=standard error of the mean. In this figure MK-6482 is labelled as PT2977. Shown is the decrease in tumour volume in nu/nu mice with established subcutaneous patient-derived ccRCC tumours treated orally with twice-daily administration of MK-6482 at 3 mg/kg for 28 days.

<div style=\"page-break-after: always\"></div>

## 2.5.2.2. Secondary pharmacodynamic studies

Belzutifan was tested in two screening panels in order to assess its selectivity and potential for off-target activity. Belzutifan was tested in a safety panel that consists of 76 receptors and 8 ion channels, and no activity was detected across this panel of assays (up to 12.5 µM). Belzutifan was also tested in a panel that consists of 40 protein kinases and 2 protein phosphatases, and no inhibition was detected at a concentration of 10 µM.

## 2.5.2.3. Safety pharmacology programme

To assess potential effects on critical organ systems, safety pharmacology studies have been conducted as stand-alone experiments or as components of the SD rat or dog 28-day and dog 13-week repeat-dose GLP toxicity studies. The potential effect on the cardiac IKr channel was assessed with an in vitro non-GLP and a GLP hERG assay. The SD rat 28-day GLP toxicity study included an FOB evaluation for an assessment of effects on the central nervous system and plethysmography measurements for an assessment of the respiratory system. Potential in vivo effects on ECGs and blood pressure were assessed in the dog 28-day and 13-week GLP toxicity studies.

The IC50 for the inhibitory effect of belzutifan on hERG potassium current could not be calculated as the highest concentration tested (50 µM) resulted in only 16.3% inhibition. The IC50 was considered to be &gt;50 µM. This concentration of belzutifan is &gt; 26-fold the maximum free plasma concentration (1.95 µM) corresponding to steady state Cmax for 120 mg QD dosing in cancer patients as calculated using pop-PK analysis. In addition, no effects on ECG parameters, QTc interval or blood pressure measurements were observed in the dog 28-day or 13-week GLP toxicity studies. No drug-related effects were observed in the in vivo assessments of respiratory function (plethysmography measurements) and central nervous system (FOB).

Table 6: Summary of Safety Pharmacology Studies

| Study ID/ GLP         | Study type                | Test system          | Concentration/ dose/ route   | Major results                                                                                                                                                            |
|-----------------------|---------------------------|----------------------|------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| TT #14-7857 (Non-GLP) | hERG Assay                | HEK293               | 1, 10 µM / In vitro          | Mean %hERG inhibition at 1 µM was 3.0% and at 10 µM was 7.6%                                                                                                             |
| TT #16-7824 (GLP)     | hERG Assay                | HEK293               | 0, 10, 50 µM / In vitro      | Belzutifan inhibited hERG current by 16.3% at 50 µM. The IC 50 for the inhibitory effect of belzutifan on hERG potassium current was estimated to be greater than 50 µM. |
| TT #16-7821 (GLP)     | Cardiovasc ular function  | Dog / Beagle         | 0, 1, 5, 30 mg/kg/day        | No abnormalities at cardiovascular endpoints                                                                                                                             |
| TT #16-7820 (GLP)     | Respiratory and Neurobeha | Rat / Crl:CD(SD) IGS | 0, 6, 20, 200 mg/kg/day      | No abnormalities at respiratory and FOB evaluations                                                                                                                      |

<div style=\"page-break-after: always\"></div>

|                                                                                                                                                              | vioral Function                                                                                                                                              |                                                                                                                                                              |                                                                                                                                                              |                                                                                                                                                              |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------|
| TT #18-7808 (GLP)                                                                                                                                            | Cardiovasc ular function                                                                                                                                     | Dog / Beagle                                                                                                                                                 | 0, 1, 5, 30 mg/kg/day                                                                                                                                        | Except for a lower mean diastolic pressure value at 30 mg/kg in males, there were no abnormalities at cardiovascular endpoints.                              |
| GLP=Good Laboratory Practices; HEK293=Human Embryonic Kidney Cells; hERG=Human ether-à- go-go related gene; mg/kg/day=milligram/kilogram/day; µM=micromolar; | GLP=Good Laboratory Practices; HEK293=Human Embryonic Kidney Cells; hERG=Human ether-à- go-go related gene; mg/kg/day=milligram/kilogram/day; µM=micromolar; | GLP=Good Laboratory Practices; HEK293=Human Embryonic Kidney Cells; hERG=Human ether-à- go-go related gene; mg/kg/day=milligram/kilogram/day; µM=micromolar; | GLP=Good Laboratory Practices; HEK293=Human Embryonic Kidney Cells; hERG=Human ether-à- go-go related gene; mg/kg/day=milligram/kilogram/day; µM=micromolar; | GLP=Good Laboratory Practices; HEK293=Human Embryonic Kidney Cells; hERG=Human ether-à- go-go related gene; mg/kg/day=milligram/kilogram/day; µM=micromolar; |

## 2.5.2.4. Pharmacodynamic drug interactions

No pharmacodynamic drug interaction studies were conducted.

## 2.5.3. Pharmacokinetics

The applicant provided a comprehensive package of non-clinical pharmacokinetic studies in mice, rats, dogs and monkeys. Most studies were performed in rats and dogs (the toxicological species). Validation reports for the applied analytical methods were also included in the package.

## Analytical methods

Bioanalytical LC-MS/MS methods were validated for belzutifan in plasma of dogs, rats and rabbits. These are the species used in the toxicity studies. Samples were first extracted by liquid-liquid extraction, then analysed by LC-MS/MS. In rat and rabbit plasma a dynamic range of 12.5 to 5,000 ng/mL for belzutifan and 2.50 to 1,000 ng/mL for the metabolite was validated. In dogs, belzutifan was validated in a range of 20.0 20000 ng/milk The metabolite PT3317 was validated in the range from 5.0 - 5000 ng/mL.

No GLP statements were included in the validation reports, quality statements only state that the validation was performed according to guidelines and industry whitepapers and internal SOPs.

## Absorption

Pharmacokinetics of belzutifan after a single-dose administration has been studied in mice, rats, dogs and monkeys. Furthermore, the main (not major) metabolite PT3317 was also studied in rats, dogs and monkeys. Additionally, different formulations of belzutifan were used and in dogs also tablets were administered. It should be noted that a spray-dried formulation of belzutifan was used in additional rodent toxicokinetic studies (studies TT #21-1033 and TT#21-1023). The exposure of rats to this formulation was up to 18-fold higher compared to other formulations used in the same study (TT#21-1023). In mice, this comparison was not made.

Overall, absorption of belzutifan was rapid across species (&lt;1 hr - approx. 5 hrs) but large differences were observed in bioavailability. Oral bioavailability was low in rats (18%), moderate in dogs and monkeys (33 and 53%, respectively) and high in mice (approx. 100%). In humans, an absolute bioavailability was not determined. Belzutifan exhibited a low plasma clearance in dogs and monkeys (CL=1.35 and 3.7 mL/min/kg, respectively) and moderate plasma clearance in mice and rats (CL=21.05 and 36.2 mL/min/kg, respectively). Clearance in dogs is therefore comparable to the clearance in humans (1.4 mL/min/kg). Volume of distribution (Vd) in humans was 1.7 L/kg, which also corresponds closely to the value in dogs (1.8 L/kg)

<div style=\"page-break-after: always\"></div>

The half-life of belzutifan was moderate in rats (approx. 1-5 hours depending on the formulation), in mice (approx. 3 hours) and monkeys (6-10 hours) and long in dogs (ranging from approx. 17 hours to up to approx. 40 hours after single PO dosing). Human half-life was measured at approx. 14 hours, which is slightly longer than in rats, but shorter than in dogs.

Across species, the Cmax and AUC0-inf appear to increase in a less-than-dose proportional manner.

## Distribution

The distribution of belzutifan has been studied in SD rats. No substantial sex differences or substantial differences between nonpigmented and pigmented animals were observed. Higher belzutifan binding to uveal tract of Long Evans rats was observed comparing to SD rats - 5430 ng-eq/g and 1870 ng-eq/g respectively 0.5h after a single oral 10 mg/kg dose. Belzutifan concentration in eye lens, uveal tract and eye decreased over time. At 4 hours, the difference disappeared with values of 1380 ng-eq/g in male LE rats and 1440 ngeq/g male SD rats at 4h. No phototoxicity was observed (see Toxicology section). Highest concentrations of belzutifan were observed in the gastro-intestinal tract and the excretory organs. In rats, belzutifan also moderately distributed to the testes and the brain. The belzutifan brain to plasma concentration ratio after a single dose of 30 mg/kg ranged 0.14 to 0.25 for the samples collected from 4 to 24 hr. In a separate study, rat brain tissue was also collected following a single oral dose administration of belzutifan at 10 mg/kg. The belzutifan brain to plasma concentration ratio, measured by LC-MS/MS, ranged from 0.36 to 0.53 for the samples collected at 4 and 24 hr in this study. The testes to plasma concentration ratios after a single PO administration of 30 mg/kg to rats were 0.59, 0.47 and 0.66 at 4, 12 and 24 hours respectively.

In vitro studies showed that the unbound fraction of belzutifan in humans is higher (55%) than in all the tested pre-clinical animal species (39-48%). For the metabolite PT3317 the unbound fraction in humans is substantially higher (approx. 50%) compared to rats (approx. 18%) and dogs (approx. 15%)

Belzutifan is roughly equally distributed between red blood cells and plasma with the blood to plasma ratio ranging from 0.86 to 1.06 across species (0.88 in human).

Placental transfer and excretion in milk were not studied.

## Metabolism

The in vitro metabolism of belzutifan was evaluated at 1 µM in liver microsomes and at 3 µM in hepatocytes from mouse, rat, dog, monkey, and human. The metabolic turnover of belzutifan was found to be low in all species. Given the low turnover observed in hepatocyte suspensions, a follow up study was conducted in the hepatopac co-culture system with a longer incubation time to maximize turnover. The major metabolites observed in vitro were hydroxylation to M9 and glucuronidation to PT3317.

Table 7: Metabolites Detected in Hepatocyte Suspension

| Metabolite                                                | Rat   | Dog   | Human   |
|-----------------------------------------------------------|-------|-------|---------|
| MK6482                                                    | +     | +     | +       |
| M8 (Oxidative defluorination and glutathione conjugation) | +     |       |         |
| M9 (Oxidation)                                            | +     |       | +       |
| M16(PT3317,Directglucuronide)                             | +     | +     | +       |
| M20 (Oxidativedefluorination)                             | +     | +     | +       |

+ = detected by mass spectrometry; - = Not detected.

All metabolites were detected by LC-MS/MS only, due to low metabolic turnover across species.

<div style=\"page-break-after: always\"></div>

Table 8: Metabolites Detected in HEPATOPAC CO-cultures

| Metabolite                    | Rat   | Dog   | Human   |
|-------------------------------|-------|-------|---------|
| MK6482                        | +     |       | +       |
| M9 (Oxidation)                | +     |       |         |
| M16(PT3317,Directglucuronide) | +     | 十     | +       |
| M24a                          | +     |       | +       |
| M25a                          | +     |       | +       |

M24 and M25 were identified by mass spectrometry and radiometric detection. The mass is consistent with a dual cysteine conjugate.Based on the fact that the HEPATOPAC?assay media is supplemented with cysteine and the absence of this analyte in hepatocyte suspensions, this is suspected to be an artifact of the assay.

In vivo , belzutifan was studied extensively in rats. One study was performed in healthy human participants. In rats, parent belzutifan was abundant in plasma, followed by metabolite M2 (23.7%) and M9 (7.5%). In humans belzutifan was the major drug-related component in plasma (73% of total radioactivity in the 0-48 hr time period).  None of the metabolites in plasma were greater than 10% of drug-related exposure based on the radiometric peak area, however PT3317 which circulates at approximately 9%, has been characterized as a major human metabolite.

The PK of PT3317 was measured as part of GLP rat and dog safety studies. In the 13 week GLP rat safety PT3317 exposures were low day 91 AUC0-24 hr at the highest tested dose of 100 mg/kg BID was 0.09 µg·hr/mL, &lt;0.02X the mean human AUC0-24 hr of 6.5µg·hr/mL. In a 13-week GLP tox study PT3317 exposures in dog plasma were 11.7 µg·hr/mL (approx. 1.8-fold higher than total clinical exposures, and approx. 0.6-fold of unbound exposures), and as such, the safety of PT3317 in dogs was adequately characterized in this study. PT3317 exposures in rat GLP safety studies were well below human levels (&lt;0.02-fold). PT3317 does not have activity against HIF-2 α is unlikely to be a perpetrator of drug interactions

Belzutifan is metabolized via UGT2B17 to form the glucuronic acid metabolite M16 (PT3317) and via CYP2C19 and to a lesser extent CYP3A4 to form oxidative metabolites such as M9.

The presented metabolism studies identify no specific risks with regard to interspecies differences or unique human metabolites

## Excretion

Excretion of belzutifan was mainly studied in rats and some have been performed in dogs and monkeys. Overall, the urinary excretion of the parent compound belzutifan was low in dogs (0.3% to 0.8% of the P.O. dose) and monkeys (0.09% of the P.O. dose). In rats, the urinary excretion of the parent compound belzutifan was not reported, but between 9.72-19.5% of total radioactivity after a PO dose of 30 mg/kg was recovered from urine indicating a low urinary excretion overall. In humans belzutifan is also mainly metabolized and metabolites are excreted in both urine and feces. 32% of the dose was excreted in urine as metabolite PT3317, and M9 which is primarily excreted in the feces and accounted for 42% of the dose.

In rats, about 85% of radioactivity was detected in bile. Only 1.5% was detected in feces and approx. 10% in the urine. No substantial gender differences were observed. Recovery of radioactivity was high (93.9-96.2%).

<div style=\"page-break-after: always\"></div>

## 2.5.4. Toxicology

## 2.5.4.1. Single dose toxicity

No single dose toxicity studies were conducted as acute toxicity was evaluated in the repeat dose toxicity studies in rats and dogs.

## 2.5.4.2. Repeat dose toxicity

Belzutifan was tested in two forms: Form A and FORM B. Form A was tested in SD rats and dogs, and Form B was tested in WH rats and mice.

Repeat- dose toxicity studies and findings are presented in the table below.

Table 9: Repeat-dose toxicity studies:

| Study details Species Duration + recovery                                                    | No:Sex/ Group                                   | Dose (mg/kg/ day)   | Exposure   | Exposure                                                                | Major findings & NOAEL                                                                                                                                                                                                                                                                                                            |
|----------------------------------------------------------------------------------------------|-------------------------------------------------|---------------------|------------|-------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| (weeks)                                                                                      |                                                 |                     |            |                                                                         |                                                                                                                                                                                                                                                                                                                                   |
|                                                                                              |                                                 |                     | C max (mM) | AUC 0-24hr (hr*mg/mL) (Times human exposure adjusted for free fraction) |                                                                                                                                                                                                                                                                                                                                   |
| TT #22-9012 b GLP Mouse/CByB6F 1/Tg rasH2 Oral (gavage) Dosing: 28 Days Test article: form B | Main: 10F/10M TK: Control - 3F/3M, TA - 18F/18M | 0                   |            |                                                                         | ≥30: ↓ RBC counts (-15%), HGB (-20%), HCT (-20%) d ≥60: ↓ RBC counts (-20%), HGB (-24%), HCT (-24%) d , ↓ testes weight ≥ 150: ↓ RBC counts (-23%), HGB (-27%), HCT (-26%) d , minimal seminiferous tubule degeneration 600: RBC counts (-30%), HGB (- 34%), HCT (-33%) d , ↓ Reti in M, ↑ heart (in M&F) and liver weight (in F) |
| TT #22-9012 b GLP Mouse/CByB6F 1/Tg rasH2 Oral (gavage) Dosing: 28 Days Test article: form B | Main: 10F/10M TK: Control - 3F/3M, TA - 18F/18M | 30                  | 9.65 (SW2) | 102 (4.05x) (SW2)                                                       | ≥30: ↓ RBC counts (-15%), HGB (-20%), HCT (-20%) d ≥60: ↓ RBC counts (-20%), HGB (-24%), HCT (-24%) d , ↓ testes weight ≥ 150: ↓ RBC counts (-23%), HGB (-27%), HCT (-26%) d , minimal seminiferous tubule degeneration 600: RBC counts (-30%), HGB (- 34%), HCT (-33%) d , ↓ Reti in M, ↑ heart (in M&F) and liver weight (in F) |
| TT #22-9012 b GLP Mouse/CByB6F 1/Tg rasH2 Oral (gavage) Dosing: 28 Days Test article: form B | Main: 10F/10M TK: Control - 3F/3M, TA - 18F/18M | 60                  | 17.4 (SW2) | 186 (7.22x) (SW2)                                                       | ≥30: ↓ RBC counts (-15%), HGB (-20%), HCT (-20%) d ≥60: ↓ RBC counts (-20%), HGB (-24%), HCT (-24%) d , ↓ testes weight ≥ 150: ↓ RBC counts (-23%), HGB (-27%), HCT (-26%) d , minimal seminiferous tubule degeneration 600: RBC counts (-30%), HGB (- 34%), HCT (-33%) d , ↓ Reti in M, ↑ heart (in M&F) and liver weight (in F) |
| TT #22-9012 b GLP Mouse/CByB6F 1/Tg rasH2 Oral (gavage) Dosing: 28 Days Test article: form B | Main: 10F/10M TK: Control - 3F/3M, TA - 18F/18M | 150                 | 27.3 (SW2) | 250 (9.71x) (SW2)                                                       | ≥30: ↓ RBC counts (-15%), HGB (-20%), HCT (-20%) d ≥60: ↓ RBC counts (-20%), HGB (-24%), HCT (-24%) d , ↓ testes weight ≥ 150: ↓ RBC counts (-23%), HGB (-27%), HCT (-26%) d , minimal seminiferous tubule degeneration 600: RBC counts (-30%), HGB (- 34%), HCT (-33%) d , ↓ Reti in M, ↑ heart (in M&F) and liver weight (in F) |
| TT #22-9012 b GLP Mouse/CByB6F 1/Tg rasH2 Oral (gavage) Dosing: 28 Days Test article: form B | Main: 10F/10M TK: Control - 3F/3M, TA - 18F/18M | 600                 | 38.2 (SW2) | 573 (22.3x) (SW2)                                                       | ≥30: ↓ RBC counts (-15%), HGB (-20%), HCT (-20%) d ≥60: ↓ RBC counts (-20%), HGB (-24%), HCT (-24%) d , ↓ testes weight ≥ 150: ↓ RBC counts (-23%), HGB (-27%), HCT (-26%) d , minimal seminiferous tubule degeneration 600: RBC counts (-30%), HGB (- 34%), HCT (-33%) d , ↓ Reti in M, ↑ heart (in M&F) and liver weight (in F) |
| TT #167820 GLP Rat/SD                                                                        | Main: 10 F/10M TK: Control                      | 0                   | (SD1)      | (SD1)                                                                   | ≥6: ↓ RBC counts (-13%), HGB (- 10%), HCT (-13%), ↓ Reti (-9%) in M; ↓ RBC counts (-4%), HGB (-                                                                                                                                                                                                                                   |
| TT #167820 GLP Rat/SD                                                                        | Main: 10 F/10M TK: Control                      |                     | (SD28)     | (SD28)                                                                  | ≥6: ↓ RBC counts (-13%), HGB (- 10%), HCT (-13%), ↓ Reti (-9%) in M; ↓ RBC counts (-4%), HGB (-                                                                                                                                                                                                                                   |

<div style=\"page-break-after: always\"></div>

| Oral (gavage) Dosing: 28 days (BID) Recovery: 28 or 90 Days Test article:   | - 3F/3M, TA - 9F/9M 28 Day Recovery:5F /5M 90 Day          | 6 (3 BID)     | SD1- F: 0.480 M: 0.362   | SD1- F: 2.76 M:3.02          | 6%), HCT (-5%), ↓ Reti (-9%) in F without correlating changes in bone marrow histopathology. ≥20: ↓ RBC counts (-20%), HGB (- 23%), HCT (-26%) in M; ↓ RBC counts (-10%), HGB (-11%), HCT (-12%), ↓ Reti (-16%) in F Minimal hypospermatogenesis, germ cell degeneration and multinucleated giant cells; mild to moderate epididymal oligospermia; reduced testes and epididymis weight (irreversible) ≥200: ↓ RBC counts (-30%), HGB (-32%), HCT (-34%), ↓ Reti (- 7%) in M; ↓ RBC counts (-21%), HGB (-24%), HCT (-24%), ↓ Reti (-37%) in F Mild to moderate hypospermatogenesis, germ cell degeneration and multinucleated giant cells; marked epididymal   |
|-----------------------------------------------------------------------------|------------------------------------------------------------|---------------|--------------------------|------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Oral (gavage) Dosing: 28 days (BID) Recovery: 28 or 90 Days Test article:   | - 3F/3M, TA - 9F/9M 28 Day Recovery:5F /5M 90 Day          | 6 (3 BID)     | SD28- F: 0.513 M: 0.549  | SD28- F: 3.20 M:4.42 (0.15x) | 6%), HCT (-5%), ↓ Reti (-9%) in F without correlating changes in bone marrow histopathology. ≥20: ↓ RBC counts (-20%), HGB (- 23%), HCT (-26%) in M; ↓ RBC counts (-10%), HGB (-11%), HCT (-12%), ↓ Reti (-16%) in F Minimal hypospermatogenesis, germ cell degeneration and multinucleated giant cells; mild to moderate epididymal oligospermia; reduced testes and epididymis weight (irreversible) ≥200: ↓ RBC counts (-30%), HGB (-32%), HCT (-34%), ↓ Reti (- 7%) in M; ↓ RBC counts (-21%), HGB (-24%), HCT (-24%), ↓ Reti (-37%) in F Mild to moderate hypospermatogenesis, germ cell degeneration and multinucleated giant cells; marked epididymal   |
| Oral (gavage) Dosing: 28 days (BID) Recovery: 28 or 90 Days Test article:   | - 3F/3M, TA - 9F/9M 28 Day Recovery:5F /5M 90 Day          | 20 (10 BID)   | SD1- F: 0.850 M:0.77 3   | SD1- F: 8.22 M:10.0          | 6%), HCT (-5%), ↓ Reti (-9%) in F without correlating changes in bone marrow histopathology. ≥20: ↓ RBC counts (-20%), HGB (- 23%), HCT (-26%) in M; ↓ RBC counts (-10%), HGB (-11%), HCT (-12%), ↓ Reti (-16%) in F Minimal hypospermatogenesis, germ cell degeneration and multinucleated giant cells; mild to moderate epididymal oligospermia; reduced testes and epididymis weight (irreversible) ≥200: ↓ RBC counts (-30%), HGB (-32%), HCT (-34%), ↓ Reti (- 7%) in M; ↓ RBC counts (-21%), HGB (-24%), HCT (-24%), ↓ Reti (-37%) in F Mild to moderate hypospermatogenesis, germ cell degeneration and multinucleated giant cells; marked epididymal   |
| Oral (gavage) Dosing: 28 days (BID) Recovery: 28 or 90 Days Test article:   | - 3F/3M, TA - 9F/9M 28 Day Recovery:5F /5M 90 Day          | 20 (10 BID)   | SD28- F: 1.12 M: 1.12    | SD28- F: 8.40 M:9.44 (0.35x) | 6%), HCT (-5%), ↓ Reti (-9%) in F without correlating changes in bone marrow histopathology. ≥20: ↓ RBC counts (-20%), HGB (- 23%), HCT (-26%) in M; ↓ RBC counts (-10%), HGB (-11%), HCT (-12%), ↓ Reti (-16%) in F Minimal hypospermatogenesis, germ cell degeneration and multinucleated giant cells; mild to moderate epididymal oligospermia; reduced testes and epididymis weight (irreversible) ≥200: ↓ RBC counts (-30%), HGB (-32%), HCT (-34%), ↓ Reti (- 7%) in M; ↓ RBC counts (-21%), HGB (-24%), HCT (-24%), ↓ Reti (-37%) in F Mild to moderate hypospermatogenesis, germ cell degeneration and multinucleated giant cells; marked epididymal   |
| Oral (gavage) Dosing: 28 days (BID) Recovery: 28 or 90 Days Test article:   | - 3F/3M, TA - 9F/9M 28 Day Recovery:5F /5M 90 Day          | 200 (100 BID) | SD1- F: 2.30 M: 2.53     | SD1- F: 32.0 M:35.0          | 6%), HCT (-5%), ↓ Reti (-9%) in F without correlating changes in bone marrow histopathology. ≥20: ↓ RBC counts (-20%), HGB (- 23%), HCT (-26%) in M; ↓ RBC counts (-10%), HGB (-11%), HCT (-12%), ↓ Reti (-16%) in F Minimal hypospermatogenesis, germ cell degeneration and multinucleated giant cells; mild to moderate epididymal oligospermia; reduced testes and epididymis weight (irreversible) ≥200: ↓ RBC counts (-30%), HGB (-32%), HCT (-34%), ↓ Reti (- 7%) in M; ↓ RBC counts (-21%), HGB (-24%), HCT (-24%), ↓ Reti (-37%) in F Mild to moderate hypospermatogenesis, germ cell degeneration and multinucleated giant cells; marked epididymal   |
| Oral (gavage) Dosing: 28 days (BID) Recovery: 28 or 90 Days Test article:   | - 3F/3M, TA - 9F/9M 28 Day Recovery:5F /5M 90 Day          | 200 (100 BID) | SD28- F: 3.48 M:3.31     | SD28- F: 34.6 M:36.0 (1.41x) | 6%), HCT (-5%), ↓ Reti (-9%) in F without correlating changes in bone marrow histopathology. ≥20: ↓ RBC counts (-20%), HGB (- 23%), HCT (-26%) in M; ↓ RBC counts (-10%), HGB (-11%), HCT (-12%), ↓ Reti (-16%) in F Minimal hypospermatogenesis, germ cell degeneration and multinucleated giant cells; mild to moderate epididymal oligospermia; reduced testes and epididymis weight (irreversible) ≥200: ↓ RBC counts (-30%), HGB (-32%), HCT (-34%), ↓ Reti (- 7%) in M; ↓ RBC counts (-21%), HGB (-24%), HCT (-24%), ↓ Reti (-37%) in F Mild to moderate hypospermatogenesis, germ cell degeneration and multinucleated giant cells; marked epididymal   |
| TT #18-7809 GLP Rat/SD Oral (gavage)                                        | Main : 15F/15M (0, 6, 20, 200 MKD), 15M (2 MKD) TK : 3F/3M | 0             | (SD1)                    | (SD1)                        | ≥2 : ↓ RBC count (-8%) d , HGB (- 8% in M), HCT (-10% in M), minimal testicular tubular degeneration (fully reversible) Decreased testes and epididymides weight. ≥ 6: ↓ RBC count (-10%), HGB (- 11%), HCT (-11%), Reti (-7%) d , testicular tubule degeneration, ↓ testes and epididymis weight (irreversible) ≥ 20: ↓ RBC count (-13%), HGB (- 17%), HCT (-17%), Reti (-14%) d                                                                                                                                                                                                                                                                              |
| TT #18-7809 GLP Rat/SD Oral (gavage)                                        | Main : 15F/15M (0, 6, 20, 200 MKD), 15M (2 MKD) TK : 3F/3M | 0             | (SD91)                   | - (SD91)                     | ≥2 : ↓ RBC count (-8%) d , HGB (- 8% in M), HCT (-10% in M), minimal testicular tubular degeneration (fully reversible) Decreased testes and epididymides weight. ≥ 6: ↓ RBC count (-10%), HGB (- 11%), HCT (-11%), Reti (-7%) d , testicular tubule degeneration, ↓ testes and epididymis weight (irreversible) ≥ 20: ↓ RBC count (-13%), HGB (- 17%), HCT (-17%), Reti (-14%) d                                                                                                                                                                                                                                                                              |
| TT #18-7809 GLP Rat/SD Oral (gavage)                                        | Main : 15F/15M (0, 6, 20, 200 MKD), 15M (2 MKD) TK : 3F/3M | 2             | (SD1) F: NA M: 0.120     | (SD1) F: NA M: 0.816         | ≥2 : ↓ RBC count (-8%) d , HGB (- 8% in M), HCT (-10% in M), minimal testicular tubular degeneration (fully reversible) Decreased testes and epididymides weight. ≥ 6: ↓ RBC count (-10%), HGB (- 11%), HCT (-11%), Reti (-7%) d , testicular tubule degeneration, ↓ testes and epididymis weight (irreversible) ≥ 20: ↓ RBC count (-13%), HGB (- 17%), HCT (-17%), Reti (-14%) d                                                                                                                                                                                                                                                                              |
| Dosing: 13 Weeks Recovery: 28 Days or 26 Week Test article: Form A          | (Control), 0F/9M (2MKD), 9F/9M (6, 20, 200 MKD)            |               |                          |                              | ≥2 : ↓ RBC count (-8%) d , HGB (- 8% in M), HCT (-10% in M), minimal testicular tubular degeneration (fully reversible) Decreased testes and epididymides weight. ≥ 6: ↓ RBC count (-10%), HGB (- 11%), HCT (-11%), Reti (-7%) d , testicular tubule degeneration, ↓ testes and epididymis weight (irreversible) ≥ 20: ↓ RBC count (-13%), HGB (- 17%), HCT (-17%), Reti (-14%) d                                                                                                                                                                                                                                                                              |
| Dosing: 13 Weeks Recovery: 28 Days or 26 Week Test article: Form A          | (Control), 0F/9M (2MKD), 9F/9M (6, 20, 200 MKD)            |               | (SD91) F: NA M: 0.211    | (SD91) F: NA M: 1.64 (0.07x) | ≥2 : ↓ RBC count (-8%) d , HGB (- 8% in M), HCT (-10% in M), minimal testicular tubular degeneration (fully reversible) Decreased testes and epididymides weight. ≥ 6: ↓ RBC count (-10%), HGB (- 11%), HCT (-11%), Reti (-7%) d , testicular tubule degeneration, ↓ testes and epididymis weight (irreversible) ≥ 20: ↓ RBC count (-13%), HGB (- 17%), HCT (-17%), Reti (-14%) d                                                                                                                                                                                                                                                                              |
| Dosing: 13 Weeks Recovery: 28 Days or 26 Week Test article: Form A          | (Control), 0F/9M (2MKD), 9F/9M (6, 20, 200 MKD)            | 6             | (SD1) F: 0.298 M: 0.316  | (SD1) F: 2.32 M: 2.56        | ≥2 : ↓ RBC count (-8%) d , HGB (- 8% in M), HCT (-10% in M), minimal testicular tubular degeneration (fully reversible) Decreased testes and epididymides weight. ≥ 6: ↓ RBC count (-10%), HGB (- 11%), HCT (-11%), Reti (-7%) d , testicular tubule degeneration, ↓ testes and epididymis weight (irreversible) ≥ 20: ↓ RBC count (-13%), HGB (- 17%), HCT (-17%), Reti (-14%) d                                                                                                                                                                                                                                                                              |

<div style=\"page-break-after: always\"></div>

|                                                        | MKD), 0F/5M (2MKD) 26 Week Recovery: 5M (0, 2, 6, 20, 200   |     | (SD91) F: 0.511 M: 0.397   | (SD91) F: 2.96 M: 3.36   | ≥200: ↓ RBC count (-21%), HGB (-24%), HCT (-24%), Reti (- 25%) d                                                                                                                                                                                                                                   |
|--------------------------------------------------------|-------------------------------------------------------------|-----|----------------------------|--------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                                        | MKD), 0F/5M (2MKD) 26 Week Recovery: 5M (0, 2, 6, 20, 200   |  20 | (SD1) F: 0.665 M: 0.822    | (SD1) F: 6.72 M: 8.22    | ≥200: ↓ RBC count (-21%), HGB (-24%), HCT (-24%), Reti (- 25%) d                                                                                                                                                                                                                                   |
|                                                        | MKD), 0F/5M (2MKD) 26 Week Recovery: 5M (0, 2, 6, 20, 200   |  20 | (SD91) F: 0.893 M: 0.917   | (SD91) F: 7.76 M: 8.4    | ≥200: ↓ RBC count (-21%), HGB (-24%), HCT (-24%), Reti (- 25%) d                                                                                                                                                                                                                                   |
|                                                        | MKD), 0F/5M (2MKD) 26 Week Recovery: 5M (0, 2, 6, 20, 200   | 200 | (SD1) F: 1.27 M: 1.47      | (SD1) F: 19.6 M: 21.6    | ≥200: ↓ RBC count (-21%), HGB (-24%), HCT (-24%), Reti (- 25%) d                                                                                                                                                                                                                                   |
|                                                        | MKD), 0F/5M (2MKD) 26 Week Recovery: 5M (0, 2, 6, 20, 200   | 200 | (SD91) F: 1.54 M: 1.20     | (SD91) F: 19.86 M: 15.7  | ≥200: ↓ RBC count (-21%), HGB (-24%), HCT (-24%), Reti (- 25%) d                                                                                                                                                                                                                                   |
| TT #22-9011 c GLP Rat/WH Oral (gavage) Dosing: 91 Days | Main: 10F/10M TK : 6F/6M                                    |   0 | (SD91)                     | (SD91)                   | ≥ 30: ↓ RBC count (-13%), HGB (-16%), HCT (-15%) d and reti (- 20% in M), minimal to marked degeneration of seminiferous tubules, ↓ testes weight ≥ 100:RBC count ( -24%), HGB (- 30%), HCT (-29%) and reti (- 24%) d , ↑ heart weight 300: RBC count (-34%), HGB (- 40%), HCT (- 38%) and reti (- |
| TT #22-9011 c GLP Rat/WH Oral (gavage) Dosing: 91 Days | Main: 10F/10M TK : 6F/6M                                    |  30 | 10.6 (SD91)                | 66.3 (SD91)              | ≥ 30: ↓ RBC count (-13%), HGB (-16%), HCT (-15%) d and reti (- 20% in M), minimal to marked degeneration of seminiferous tubules, ↓ testes weight ≥ 100:RBC count ( -24%), HGB (- 30%), HCT (-29%) and reti (- 24%) d , ↑ heart weight 300: RBC count (-34%), HGB (- 40%), HCT (- 38%) and reti (- |
| TT #22-9011 c GLP Rat/WH Oral (gavage) Dosing: 91 Days | Main: 10F/10M TK : 6F/6M                                    | 100 | 27.8 (SD91)                | 215 (SD91)               | ≥ 30: ↓ RBC count (-13%), HGB (-16%), HCT (-15%) d and reti (- 20% in M), minimal to marked degeneration of seminiferous tubules, ↓ testes weight ≥ 100:RBC count ( -24%), HGB (- 30%), HCT (-29%) and reti (- 24%) d , ↑ heart weight 300: RBC count (-34%), HGB (- 40%), HCT (- 38%) and reti (- |
| TT #22-9011 c GLP Rat/WH Oral (gavage) Dosing: 91 Days | Main: 10F/10M TK : 6F/6M                                    | 300 | 39.6 (SD91)                | 466 (SD91)               | ≥ 30: ↓ RBC count (-13%), HGB (-16%), HCT (-15%) d and reti (- 20% in M), minimal to marked degeneration of seminiferous tubules, ↓ testes weight ≥ 100:RBC count ( -24%), HGB (- 30%), HCT (-29%) and reti (- 24%) d , ↑ heart weight 300: RBC count (-34%), HGB (- 40%), HCT (- 38%) and reti (- |
| TT #16-7821 GLP Dog/Beagle Oral (gavage) Dosing: 28    | Main: 3F/3M Recovery (28 Days): 2F/2M Recovery (90 Days):   |   0 | - (SD1)                    | (SD1) (SD28)             | ≥1 : No belzutifan effects on EPO levels. No belzutifan-related gross findings, organ weight changes or microscopic findings in the testes                                                                                                                                                         |
| TT #16-7821 GLP Dog/Beagle Oral (gavage) Dosing: 28    | Main: 3F/3M Recovery (28 Days): 2F/2M Recovery (90 Days):   |   0 | (SD28)                     |                          | ≥1 : No belzutifan effects on EPO levels. No belzutifan-related gross findings, organ weight changes or microscopic findings in the testes                                                                                                                                                         |
| TT #16-7821 GLP Dog/Beagle Oral (gavage) Dosing: 28    | Main: 3F/3M Recovery (28 Days): 2F/2M Recovery (90 Days):   |   1 | (SD1) F: 0.525 M: 0.501    | (SD1) F: 5.81 M: 5.30    | ≥1 : No belzutifan effects on EPO levels. No belzutifan-related gross findings, organ weight changes or microscopic findings in the testes                                                                                                                                                         |

<div style=\"page-break-after: always\"></div>

| Days or 90 Days Test article: Form A                                                             |                             |    | (SD28) F: 0.651 M:                                | (SD28) F: 7.84 M:6.89 (0.25x)                | or epididymides in the terminal, 28- or 90-day recovery phase animals Dose-dependent progressive significant decreases (up to -36% relative to concurrent control mean value on Day 29) in RBC mass, HGB, HCT and reticulocytes correlated with minimal to moderate femoral and minimal to mild sternal bone marrow haematopoietic hypocellularity (reversible during recovery)   |
|--------------------------------------------------------------------------------------------------|-----------------------------|----|---------------------------------------------------|----------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Days or 90 Days Test article: Form A                                                             |                             | 5  | 0.574 (SD1) F: 1.18 M: 1.03 (SD28) F: 1.34 M:1.53 | (SD1) F: 17.3 M: 14.8 (SD28) F: 18.2 M: 21.3 | or epididymides in the terminal, 28- or 90-day recovery phase animals Dose-dependent progressive significant decreases (up to -36% relative to concurrent control mean value on Day 29) in RBC mass, HGB, HCT and reticulocytes correlated with minimal to moderate femoral and minimal to mild sternal bone marrow haematopoietic hypocellularity (reversible during recovery)   |
| Days or 90 Days Test article: Form A                                                             |                             | 30 | (SD1) F: 2.70 M: 2.27 (SD28)                      | (SD1) F: 41.3 M: 32.0 (SD28)                 | or epididymides in the terminal, 28- or 90-day recovery phase animals Dose-dependent progressive significant decreases (up to -36% relative to concurrent control mean value on Day 29) in RBC mass, HGB, HCT and reticulocytes correlated with minimal to moderate femoral and minimal to mild sternal bone marrow haematopoietic hypocellularity (reversible during recovery)   |
| TT #18-7808 GLP Dog/Beagle Oral (gavage) Dosing: 13 Weeks Recovery: 28 Days Test article: Form A | Main: 4F/4M Recovery: 2M/2F | 0  | (SD1) (SD91)                                      | - (SD1) - (SD91)                             | ≥1 : ↓ RBC count (-40%), HGB (- 38%), HCT (-37%), and Reti (- 57% at wk5 d ; -44% in F at wk13) reversible No effects on testes and epididymis ≥5 : ↓ RBC count (-45%), HGB (- 43%), HCT (-42%), Reti (-77.5% at wk5 d ;-24% in F at wk13) 30 : ↓ RBC count (-49%), HGB (- 47%), HCT (-48%), Reti (-81% at wk5 d ;-22% in F at wk13)                                              |
| TT #18-7808 GLP Dog/Beagle Oral (gavage) Dosing: 13 Weeks Recovery: 28 Days Test article: Form A | Main: 4F/4M Recovery: 2M/2F | 0  | M: 0.375 (SD91) F: 0.556 M:                       | (SD91) F: 7.13 M: 6.75 (0.24x)               | ≥1 : ↓ RBC count (-40%), HGB (- 38%), HCT (-37%), and Reti (- 57% at wk5 d ; -44% in F at wk13) reversible No effects on testes and epididymis ≥5 : ↓ RBC count (-45%), HGB (- 43%), HCT (-42%), Reti (-77.5% at wk5 d ;-24% in F at wk13) 30 : ↓ RBC count (-49%), HGB (- 47%), HCT (-48%), Reti (-81% at wk5 d ;-22% in F at wk13)                                              |
| TT #18-7808 GLP Dog/Beagle Oral (gavage) Dosing: 13 Weeks Recovery: 28 Days Test article: Form A | Main: 4F/4M Recovery: 2M/2F | 5  | 0.572 (SD1) F: 1.01 M: 0.783                      | (SD1) F: 12.4 M: 9.87                        | ≥1 : ↓ RBC count (-40%), HGB (- 38%), HCT (-37%), and Reti (- 57% at wk5 d ; -44% in F at wk13) reversible No effects on testes and epididymis ≥5 : ↓ RBC count (-45%), HGB (- 43%), HCT (-42%), Reti (-77.5% at wk5 d ;-24% in F at wk13) 30 : ↓ RBC count (-49%), HGB (- 47%), HCT (-48%), Reti (-81% at wk5 d ;-22% in F at wk13)                                              |
| TT #18-7808 GLP Dog/Beagle Oral (gavage) Dosing: 13 Weeks Recovery: 28 Days Test article: Form A | Main: 4F/4M Recovery: 2M/2F |    | (SD91)                                            | (SD91)                                       | ≥1 : ↓ RBC count (-40%), HGB (- 38%), HCT (-37%), and Reti (- 57% at wk5 d ; -44% in F at wk13) reversible No effects on testes and epididymis ≥5 : ↓ RBC count (-45%), HGB (- 43%), HCT (-42%), Reti (-77.5% at wk5 d ;-24% in F at wk13) 30 : ↓ RBC count (-49%), HGB (- 47%), HCT (-48%), Reti (-81% at wk5 d ;-22% in F at wk13)                                              |
| TT #18-7808 GLP Dog/Beagle Oral (gavage) Dosing: 13 Weeks Recovery: 28 Days Test article: Form A | Main: 4F/4M Recovery: 2M/2F | 30 | (SD1) F: 3.24 M: 1.22 (SD91) F: 2.12              | (SD1) F: 31.8 M: 14.5 (SD91) F: 30.2         | ≥1 : ↓ RBC count (-40%), HGB (- 38%), HCT (-37%), and Reti (- 57% at wk5 d ; -44% in F at wk13) reversible No effects on testes and epididymis ≥5 : ↓ RBC count (-45%), HGB (- 43%), HCT (-42%), Reti (-77.5% at wk5 d ;-24% in F at wk13) 30 : ↓ RBC count (-49%), HGB (- 47%), HCT (-48%), Reti (-81% at wk5 d ;-22% in F at wk13)                                              |
| TT #18-7808 GLP Dog/Beagle Oral (gavage) Dosing: 13 Weeks Recovery: 28 Days Test article: Form A | Main: 4F/4M Recovery: 2M/2F |    | M: 1.94                                           | M: 29.0 (1.02x)                              | ≥1 : ↓ RBC count (-40%), HGB (- 38%), HCT (-37%), and Reti (- 57% at wk5 d ; -44% in F at wk13) reversible No effects on testes and epididymis ≥5 : ↓ RBC count (-45%), HGB (- 43%), HCT (-42%), Reti (-77.5% at wk5 d ;-24% in F at wk13) 30 : ↓ RBC count (-49%), HGB (- 47%), HCT (-48%), Reti (-81% at wk5 d ;-22% in F at wk13)                                              |

<div style=\"page-break-after: always\"></div>

F=female; GLP=Good Laboratory Practice; M=male; MKD=mg/kg/day; NA=not applicable; SD=Study Day; SW=study week; TA=test article; TK=toxicokinetic

- A    NOAEL bolded
- B    NOAEL = &lt;60 mg/kg/day (males), &gt;600 mg/kg/day (females)
- C    NOAEL = &lt;30 mg/kg/day (males), &gt;300 mg/kg/day (females)
- D    The mean percentage of the reduction in RBC mass or reticulocyte in males and females unless otherwise mentioned.

## 2.5.4.3. Genotoxicity

In vitro studies with Ames-test, micronucleus screening in TK6-cells and in human lymphocytes were conducted testing belzutifan for genotoxicity. These in vitro studies were negative. A 2-day in vivo genotoxicity study was conducted in SD rats testing belzutifan Form A at doses up to 200 mg/kg/day, with a one-day dose-range finding phase (3 animals/sex/group), and a one-day main test phase (5 animals/sex/group). This in vivo study was negative with a maximum exposure of around 1-fold human AUC.

## 2.5.4.4. Carcinogenicity

Belzutifan was administered once daily by oral gavage for 26 weeks to CByB6F1/Tg rasH2 hemizygous mice at 0, 10, 75, and 600 mg/kg/day. No belzutifan-related effects on mortality were observed. Belzutifan-related decreases in mean body weight or mean body weight gain at 75 mg/kg/day and 600 mg/kg/day and increased incidences of hunched posture, decreased activity, erected fur, and/or thin appearance in males at 600 mg/kg/day were noted. Belzutifan-related nonneoplastic finding consisting of epithelial necrosis in the Harderian gland was observed in animals at 600 mg/kg/day and could be attributed to the antemortem findings in body weight and clinical signs observed in the animals. The Harderian gland is a rodent-specific tissue and does not have a human equivalent and thus this change is not considered to be toxicologically meaningful. No belzutifan-related neoplastic findings were observed at any dose level and no carcinogenic risk was identified in the study.

## 2.5.4.5. Reproductive and developmental toxicity

No dedicated fertility and early embryonic development toxicity studies were conducted. Reproductive organs of mice, rats, and dogs were assessed in the repeat dose toxicity studies. In mice, reduced testes weight and seminiferous tubule degeneration were observed at the mid doses, with an exposure multiple of around 10fold human AUC. In SD rats, mild to moderate irreversible degenerative changes in testes and epididymides were observed at the mid and high dose, with an exposure multiple of 0.13 to 0.7-fold human AUC, but reversible at the low dose. In WH rats, marked seminiferous tubule degeneration and moderate reduced sperm were seen at the low dose, with an exposure multiple of 2.63-fold human AUC. However, in dogs, no changes were noted in testes and epididymides at doses of up to 1-fold human exposure.

In a non-GLP, preliminary embryo-fetal development (EFD) study, pregnant female rats were orally administered with belzutifan at doses of 6, 60, or 200 mg/kg/day from GD6 through GD17. There was an observed reduction in body weight gain and gravid uterine weight in the pregnant rats dosed 60 mg/kg and higher. secondary to post-implantation loss and/or reduced fetal body weights observed at these dose levels. A belzutifan-related decrease in red cell mass parameters was observed at doses of 60 mg/kg and higher. At doses of 60 mg/kg onwards, there was a dose-related increase in post-implantation loss and in the mean number of resorptions per litter. As a result, the average litter size was decreased as were the number of live

<div style=\"page-break-after: always\"></div>

fetuses, with 100% embryo-foetal lethality in the high-dose group. A drug-related decrease in fetal body weight was apparent from 6 mg/kg onwards. This decrease correlated with developmental delays observed by reduced ossification of sacrocaudal vertebrae compared to (historical) controls. At 60 mg/kg, an increase incidence of domed head and incomplete ossification of sternebrae were also observed. At doses of 6 mg/kg onwards, a dose-related increase in incidence of rib malformations were observed, exceeding the historical control range at a dose of 60 mg/kg. It should be noted that foetuses at the high-dose group could not have been examined due to 100% embryo-fetal lethality. No visceral abnormalities were noted at any dose. Based on the adverse foetal effects at 6 mg/kg and higher, the developmental NOAEL could not be determined. The lowest dose tested corresponded to maternal AUC0-24hr of 2.60 measured at GD7, which is below the exposure at the MRHD (~0.10x EM).

In the tolerability study in nonpregnant rabbits, belzutifan was dosed at 3, 30, 100 mg/kg/day or 100 mg/kg b.i.d. for 8 days. There were no belzutifan-related clinical observations, effects on mean body weight, body weight gain, or food consumption. Consistent with the pharmacological action of belzutifan on HIF-2 α inhibition, very slight to marked decreases in reticulocyte counts at &gt;3 mg/kg/day were observed, resulting in very slight decreases in red cell mass parameters at &gt;30 mg/kg/day. No further rabbit studies were conducted based on the identified risk in the rat embryo-fetal development study,

## 2.5.4.6. Toxicokinetic data

Toxicokinetic data after repeat-dose administration showed a slight accumulation of belzutifan after repeatdose administration of up to 91 days in both dogs and rats. In female rats the exposure (AUC0-24h) accumulation was 1.28-, 1.15- and 1.01-fold between day 1 and day 91 for the 6, 20 and 200 mg/kg doses respectively. For males the accumulation was 1.31-, 1.02- and 0.73-fold. In dogs the sex-combined AUC accumulated 1.49-, 1.65- and 1.28-fold for the 1, 5 and 30 mg/kg dose groups between day 1 and day 91.

In rats different formulations of belzutifan were compared in a single-administration study not a repeat-dose. The formulation used had a big impact on the AUC that was reached, with AUC values of up to 7.5-fold difference between the lowest and highest AUC for a 100 mg/kg dose and up to 21.7-fold difference for the 300 mg/kg dose.

Single-dose pharmacokinetic analysis already revealed a similar pharmacokinetic profile across animal species. especially between dogs and humans. It was observed that unbound fractions in plasma of belzutifan in humans were higher than in dogs and rats (55% versus 39% and 45% respectively), however, plasma binding was only moderate in all species. Especially in dogs (probably the most reflective animal for humans based on pharmaco- and toxicokinetics) margins of exposure are very low, ranging from 0.34 to 1.44 after repeat dosing for up to 13 weeks.

For rats the margins of exposure were higher, ranging from 0.08-22.6.

## 2.5.4.7. Local tolerance

No specific local tolerance studies were conducted. Taking into account the intended route of administration (oral) and the lack of signs of irritation in the repeated dose toxicity studies, the conduct of additional studies is not considered necessary.

The applicant conducted two additional studies to assess the ocular and dermal irritation potential of belzutifan. Based on these studies, Belzutifan was classified as non-irritating (data not shown).

<div style=\"page-break-after: always\"></div>

## 2.5.4.8. Other toxicity studies

No studies on antigenicity, immunotoxicity and dependence were deemed necessary. One major metabolite was qualified in the 3-month dog study. The AUC of that metabolite in dogs based on free fraction was 0.5 times human exposure. The amount in humans of the metabolite was below 10% which is the amount needed for qualification according to ICH M3.

A number of impurities were qualified by using QSARs, Ames tests and two animal studies.

Administration of 200 mg/kg/day belzutifan resulted in no skin reactions indicative of phototoxicity.

## 2.5.5. Ecotoxicity/environmental risk assessment

## Table 10: Summary of Main Study Results

| Substance (INN/Invented Name): Belzutifan CAS-number (if available): 1672668-24-4                                                                      | Substance (INN/Invented Name): Belzutifan CAS-number (if available): 1672668-24-4                            | Substance (INN/Invented Name): Belzutifan CAS-number (if available): 1672668-24-4                                                                                                           | Substance (INN/Invented Name): Belzutifan CAS-number (if available): 1672668-24-4   | Substance (INN/Invented Name): Belzutifan CAS-number (if available): 1672668-24-4   | Substance (INN/Invented Name): Belzutifan CAS-number (if available): 1672668-24-4   |
|--------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------|
| PBT screening                                                                                                                                          | PBT screening                                                                                                | Result                                                                                                                                                                                      | Conclusion                                                                          |                                                                                     |                                                                                     |
| Bioaccumulation potential- log K ow                                                                                                                    | OECD107                                                                                                      | pH 5 = 1.08 pH 7 = 1.11 pH 9 = 1.07                                                                                                                                                         | Potential PBT: N                                                                    |                                                                                     |                                                                                     |
| PBT-assessment                                                                                                                                         | PBT-assessment                                                                                               | PBT-assessment                                                                                                                                                                              | PBT-assessment                                                                      | PBT-assessment                                                                      | PBT-assessment                                                                      |
| Parameter                                                                                                                                              | Result relevant for conclusion                                                                               |                                                                                                                                                                                             | Conclusion                                                                          |                                                                                     |                                                                                     |
| Bioaccumulation                                                                                                                                        | log K ow                                                                                                     | pH 5 = 1.08 pH 7 = 1.11 pH 9 = 1.07                                                                                                                                                         | not B                                                                               |                                                                                     |                                                                                     |
| Persistence                                                                                                                                            | DT50 water DT50 sediment DT50 system Values are derived from the OECD 308 and have been recalculated to 12°C | 30.6 - 64.8 days 154.9 - 266.58 days 138 - 237 days                                                                                                                                         | vP                                                                                  |                                                                                     |                                                                                     |
| Toxicity                                                                                                                                               | NOEC (Daphnia)                                                                                               | 0.1 mg/L                                                                                                                                                                                    | not T                                                                               |                                                                                     |                                                                                     |
| PBT-statement :                                                                                                                                        | Belzutifan is considered to be not PBT, nor vPvB                                                             | Belzutifan is considered to be not PBT, nor vPvB                                                                                                                                            | Belzutifan is considered to be not PBT, nor vPvB                                    | Belzutifan is considered to be not PBT, nor vPvB                                    | Belzutifan is considered to be not PBT, nor vPvB                                    |
| Phase I                                                                                                                                                | Phase I                                                                                                      | Phase I                                                                                                                                                                                     | Phase I                                                                             | Phase I                                                                             | Phase I                                                                             |
| Calculation                                                                                                                                            | Value                                                                                                        | Unit                                                                                                                                                                                        | Conclusion                                                                          |                                                                                     |                                                                                     |
| PEC sw , default                                                                                                                                       | 0.60                                                                                                         | µg/L                                                                                                                                                                                        | ≥ 0.01 threshold: Y                                                                 |                                                                                     |                                                                                     |
| Other concerns (e.g. chemical class)                                                                                                                   |                                                                                                              |                                                                                                                                                                                             | N                                                                                   |                                                                                     |                                                                                     |
| Phase II Physical-chemical properties and fate                                                                                                         | Phase II Physical-chemical properties and fate                                                               | Phase II Physical-chemical properties and fate                                                                                                                                              | Phase II Physical-chemical properties and fate                                      | Phase II Physical-chemical properties and fate                                      | Phase II Physical-chemical properties and fate                                      |
| Study type                                                                                                                                             | Test protocol                                                                                                | Results                                                                                                                                                                                     | Remarks                                                                             |                                                                                     |                                                                                     |
| Adsorption-Desorption Soil 1 = silt loam Soil 2 = sandy loam Soil 3 = clay Soil 4 = loamy sand Sludge 1 = activated sludge Sludge 2 = activated sludge | OECD 106                                                                                                     | K oc, soil 1 = 223 L/kg oc K oc, soil 2 = 190 L/kg oc K oc, soil 3 = 293 L/kg oc K oc, soil 4 = 335 L/kg oc K oc, sludge 1 = 4.8 L/kg oc K oc, sludge 2 = 12.8 L/kg oc                      | Geometric mean 254 L/kg sludge: 7.8 L/kg                                            |                                                                                     |                                                                                     |
| Aerobic and Anaerobic Transformation in Aquatic Sediment systems Sediment 1 = Silt loam Sediment 2 = Sand                                              | OECD 308                                                                                                     | DT 50, water = 14.3 / 30.4 d DT 50, sediment = 125 / 91.3 d DT 50, whole system = 64.6 / 111 d shifting to sediment = 67-73% CO 2 = 1.85 - 4.49% NER = >10% Transformation products >10% Y, | DT 50 s for 20°C 1 / 2 at day 62 at day 100 at day 100                              |                                                                                     |                                                                                     |

<div style=\"page-break-after: always\"></div>

|                                                   |                          | TP1 = 16.1 %, DT50 43.9 d TP2 = 39.7%   | TP1 = 16.1 %, DT50 43.9 d TP2 = 39.7%   | TP1 = 16.1 %, DT50 43.9 d TP2 = 39.7%   | TP1: 3-([1S,2S,3R)- 2,3-difluoro-1- hydroxy-7- (methanesulfonyl)- 2,3-dihydro-1H- inden-4-yl]oxy)-5- fluorobenzamide TP2: 3-([1S,2S,3R)- 2,3-difluoro-1- hydroxy-7- (methanesulfonyl)- 2,3-dihydro-1H- inden-4-yl]oxyl0-5- flurobenzoic acid   |
|---------------------------------------------------|--------------------------|-----------------------------------------|-----------------------------------------|-----------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Phase IIa Effect studies                          | Phase IIa Effect studies | Phase IIa Effect studies                | Phase IIa Effect studies                | Phase IIa Effect studies                | Phase IIa Effect studies                                                                                                                                                                                                                       |
| Study type                                        | Test protocol            | Result                                  | Value                                   | Unit                                    | Remarks                                                                                                                                                                                                                                        |
| Algae, Growth Inhibition Test/ R. subcapitata     | OECD 201                 | NOEC EC 10                              | ≥10 >10                                 | mg/L mg/L                               | growth rate growth rate                                                                                                                                                                                                                        |
| Daphnia magna , Reproduction Test                 | OECD 211                 | NOEC EC 10                              | 0.1 3.9                                 | mg/L mg/L                               | length reproduction                                                                                                                                                                                                                            |
| Fish, Early Life Stage Toxicity Test/ P. promelas | OECD 210                 | NOEC                                    | 0.52                                    | mg/L                                    | live, normal larvae at hatch                                                                                                                                                                                                                   |
| Activated Sludge, Respiration Inhibition Test     | OECD 209                 | EC 10                                   | >1000                                   | mg/L                                    | respiration                                                                                                                                                                                                                                    |
| Phase IIb Studies                                 | Phase IIb Studies        | Phase IIb Studies                       | Phase IIb Studies                       | Phase IIb Studies                       | Phase IIb Studies                                                                                                                                                                                                                              |
| Sediment dwelling organism/ C. riparius           | OECD 218                 | NOEC                                    | ≥3696                                   | mg/kg dw                                | Emergence, development rate, normalised to 10% OC.                                                                                                                                                                                             |
| Biodegradation in sludge                          | OECD 314B                | DT50 DT90                               | 18.1 60.3                               | day day                                 | primary degradation                                                                                                                                                                                                                            |

## 2.5.6. Discussion on non-clinical aspects

## Pharmacodynamics

Primary pharmacodynamics were studied in several in vitro and in vivo studies. Under normal conditions, oxygen-dependent post-translational modifications on HIF-2 α allow tumour suppressor von Hippel-Lindau protein (pVHL) to recognize and target HIF-2 α for rapid degradation. Hypoxic signalling in tumour cells or lack of functional pVHL results in stabilization of HIF-2 α and accumulation of HIF-2 α in the nucleus, where it binds ARNT (HIF-1 β) to form a transcriptional complex that induces expression of downstream genes, including genes involved in oncogenesis. Belzutifan is a small molecule developed as an inhibitor of HIF-2 and should disrupt the hetero-dimerization of HIF-2 α with ARNT in cells in conditions of impaired VHL protein function (germline mutation in VHL disease and somatic mutation in advanced RCC) or hypoxia, leading to reduced transcription and expression of HIF-2 α target genes. The mode of action is supported by in vitro studies demonstrating high binding affinity to the PAS-B domain of HIF-2 α, with IC50 values between 0.005 μ M to 0.015 μ M. Notably, many high concentrations were tested in the scintillation proximity assay, which obviously displace a very high percentage of the radiolabelled probe. Although this experiment demonstrates the potency of belzutifan, a more informative and specific IC50 could have been determined if belzutifan concentrations were selected close to the concentration that results in 50% displacement. In cell lines exposed to hypoxic conditions and in VHL-deficient human renal cell carcinoma (RCC) cells, belzutifan blocked the HIF-2 α -ARNT interaction, leading to reduced transcription and significant dose-dependent reduced expression of HIF-2 α target genes ( CCND1, SERPINE1, VEGFa, SLC2A1 and EPO ) that would normally promote tumour cell survival. In contrast, HIF-1 α target genes were not affected.

<div style=\"page-break-after: always\"></div>

Belzutifan binding to HIF-2 α of mice, rats and dogs was not investigated. Although it would have been preferable since from the repeated dose toxicity studies, dogs and rats are relevant test species which presented pharmacologically-related adverse effects of HIF-2 α inhibition on red blood cell mass parameters.

In vivo , effects of belzutifan on tumour growth were presented in different xenograft models. In xenograft models derived from VHL-deficient RCC cell lines, belzutifan treatment for three days reduced VEGFA levels in plasma and expression levels of HIF-2 α target genes ( CCND1, SERPINE1, SLC2A1 and VEGFa ), at the highest tested concentrations, although these effects may be transient when belzutifan treatment is not continued. In line with in vitro data, significant decreases in mRNA levels of HIF-2 α target genes ( CCND1, SERPINE1, VEGFA and SCL2A1 ) in the tumour tissues were observed at clinically relevant exposures of belzutifan.

In VHLdeficient ccRCC xenograft mice treated for 28 days, belzutifan treatment (≥0.3 mg/kg) resulted in a nearly complete regression of established tumours. Notably, belzutifan showed a variable potency on tumour growth inhibition depending on the xenograft model exploited. 38% and 47% higher TGI was observed in Champions TumorGraft™ model and 786-O cell xenograft model respectively comparing to UMRC2 cell based ccRCC xenograft model. In general, tumour growth inhibition was observed in response to belzutifan in all xenograft models assessed in non-clinical studies designed by the applicant, thus despite the fact that a precise mechanism behind differences in response at the moment is now known, the effect on tumour growth has been demonstrated.

In a mouse xenograft model with implanted tumour fragments derived from a patient with ccRCC, belzutifan treatment (at 3 mg/kg) significantly decreased the tumour volume following 28-day treatment. Overall, the proof of concept of belzutifan has been sufficiently demonstrated. The presented in vivo results are considered relevant for patients with VHL that exhibit RCC tumours and for the ccRCC patients who exhibit VHL deficiency or hypoxic tumours. Based on the mode of action, the data on VHL-deficient ccRCC can most likely also be extrapolated to other VHL-related tumours.

Regarding secondary pharmacodynamics, the selectivity of belzutifan (up to 12.5 µM) was evaluated in a binding screen consisting of 76 receptors and 8 ion channels. Belzutifan (at 10 µM) was also tested in a panel consisting of 40 protein kinases and 2 protein phosphatases. No notable effects of belzutifan were observed for the tested targets.

Safety pharmacology studies included evaluation of respiratory and neurobehavioral measures (functional observation battery) in SD rats (n=10/sex/group) over a 28-day repeated-dosing period at belzutifan doses 6, 20 and 200 mg/kg/day. Respiratory parameters were analysed only in female rats while neurobehavioral parameters only in males. The applicant has provided pharmacokinetic data for male and female rats to confirm that differences in belzutifan exposure were not detected between the sexes, doses and study days 1 and 28. No significant differences between the sexes and doses were observed in AUC0-12hr and Cmax. Additionally, over a 28-day period, no significant accumulation of belzutifan was observed, allowing comparison of pharmacokinetic data obtained on day 1 and day 28. Taking into account these observations, the reduction of animals in non-clinical studies is supported in line with 3R principles and the use of one sex animals for the analysis of respiratory and neurobehavioral parameters in study TT #16 7820 is considered justified. No belzutifan-related abnormalities at cardiovascular, neurological, or respiratory endpoints were observed in dogs and rats, respectively (in repeat-dose toxicity studies), nor any concerns regarding hERG inhibition (IC50 &gt; 50 µM in vitro ).

## Pharmacokinetics

Bioanalytical LC-MS/MS methods were fully validated for belzutifan in plasma of dogs, rats and rabbits. These are the species used in the toxicity studies. No GLP statements were included in the validation study reports,

<div style=\"page-break-after: always\"></div>

however, the validation of the analytical methods appears to be adequate. Belzutifan PK parameters have been analysed also as a part of toxicokinetics in GLP compliant mice, rat and dog repeated-dose toxicology studies. GLP compliant method validation for belzutifan detection in mice, rat and dog plasma have been provided as a part of repeated-dose toxicity reports and is considered suitable for the proposed purpose.

Based on the overall PK parameters measured after single dose administration of belzutifan and their similarity to human parameters, rats and dogs are appropriate species for toxicological assessment. Across species, the Cmax and AUC0-inf appear to increase in a less-than-dose proportional manner, which appear to be more evident at the higher doses. Clearance in dogs is comparable to the clearance in humans (1.4 mL/min/kg). Volume of distribution (Vd) in humans was 1.7 L/kg, which also corresponds closely to the value in dogs (1.8 L/kg) The half-life of belzutifan was moderate in rats and long in dogs. Human half-life was measured at approx. 14 hours, which was slightly shorter than in dogs (17-40 hours) but longer than in rats (1-5 hours). Bioavailability was moderate in dogs and low in rats, probably due to first-pass metabolism. Absolute bioavailability in humans was not assessed. The spray dried formulation increased dissolution and bioavailability in rats and substantially increased the AUC (up to 18-times).

Distribution studies showed distribution of belzutifan to mostly excretory organs and the GI tract in rats. No gender differences were observed and no melanin binding was evident. Distribution across the placenta and to milk was not assessed. Unbound fractions in plasma were highest in humans (approx. 7-16% higher than dogs and rats). Metabolism studies, both in vitro and in vivo , revealed no human unique metabolites nor any major or pharmacologically active metabolites (PT3317/M16 was 9%).  Excretion was mainly via bile and urine as metabolites. Renal and faecal clearance of parent belzutifan was low across animal species. It can be concluded that especially dogs and to a lesser extent rats exhibit a similar pharmacokinetic profile of belzutifan compared to humans and are therefore appropriate for toxicological assessment of belzutifan.

## Toxicology

## Repeat dose toxicity

Repeat-dose oral toxicity studies in rats and dogs for up to 3 months duration revealed anaemia at all doses including at exposure levels lower than the human exposure levels. Although the anaemia was reversible, and most probably due to exaggerated pharmacology a NOEL could not be derived. Nevertheless, this is relevant to humans and has been reflected in SmPC section 5.3.

The seminiferous tubule degeneration was observed at ≥6 mg/kg/day (0.13 -fold human AUC) in SD rats but not in dogs with 10 times higher exposure (30 mg/kg/day, 1-fold human AUC). Therefore, the observed adverse effects on male reproductive organs are possibly not pharmacology related. However, the testicular findings in rat and mouse studies are consistent with those in HIF-2 α knock-out mice, indicating a role of HIF-2 α pathway in the process of spermatogenesis in rodents as shown in a publication by Gruber et al, 2010. The reason that the testicular findings were not seen in dogs may very well be due to the low exposures in the dog studies of maximal about 1.5 times the intended human exposure. In mice, the effects were not seen at ca. 4 times human exposure, but started at ca. 7 times human exposure. Therefore, the dog studies are not very suitable for discussion on the human relevance. Male reproductive organ toxicity observed in the rats are reflected in section 5.3 of the SmPC.

## Genotoxicity and carcinogenicity

Belzutifan was not genotoxic in in vitro bacterial mutagenesis and micronucleus assays, and an in vivo rat micronucleus assay at 1.7-fold human exposure. The TK data from the repeat dose toxicity studies in SD rats

<div style=\"page-break-after: always\"></div>

receiving 200 mg/kg/day revealed that the exposure multiple of belzutifan (Form A) would be around 1-fold human AUC.

Initially the applicant did not perform the necessary carcinogenicity studies while this product is not an ICH S9 case. A 26-week carcinogenicity study in rasH2 transgenic mice and a 104-week carcinogenicity study in WH rats have been initiated in April 2023. The applicant justified in depth why the results of the 2-year carcinogenicity study in rats would not be required for this MAA, and presented the results of the 6-month Tg. rasH2 mouse carcinogenicity study with belzutifan at doses up to 600 mg/kg/day.

The results indicate no belzutifan-related neoplastic findings at any dose level and no carcinogenic risk were identified in the study.

Based on the evidence submitted it is considered that the carcinogenicity risk associated with belzutifan appears very low. Belzutifan doesn't appears to be genotoxic. the Inhibition of HIF-2 α is not associated with carcinogenicity, belzutifan does not show off-target activity, did not induce proliferative changes or potential endocrine/hormonal perturbations, or immunosuppression in repeat-dose toxicity studies and also in clinical studies there is no evidence that suggests endocrine/hormonal perturbations, immune suppression, or induction of neoplastic changes in patients. The risk on carcinogenicity of belzutifan is low enough to concur with the submission of the 2-year carcinogenicity study in rats post-approval by April 2026. (REC)

## Reproductive toxicity

No dedicated fertility and early embryonic development toxicity studies were conducted. Reproductive organs of mice, rats, and dogs were assessed in the repeat dose toxicity studies. No effects were noted in the female reproductive organs in all studies. However, published data on animal and human genetics indicated that HIF-2 α has a functional role in the uterus during embryo implantation and establishment of pregnancy in mice, and that similar HIF-2 α -mediated mechanisms may be involved in human pregnancy. HIF-2 α inhibition by exposure to belzutifan has the potential to interfere with embryo implantation, leading to impairment of female fertility. Belzutifan may cause embryo-foetal harm, including foetal loss, in humans. The pregnancy status of women of childbearing potential should be verified prior to initiating treatment with belzutifan. Women of childbearing potential have to use highly effective contraceptive methods during treatment with belzutifan and for at least 1 week after the last dose due to the potential risk to the foetus (see sections 4.4, 4.5, 4.6 and 5.3 of the SmPC).

Male reproductive organ toxicity observed in the rats is reflected in the SmPC where it states in 5.3 that irreversible testicular atrophy/degeneration and oligospermia was observed in the 3-month repeat-dose toxicity study in rats, at exposures lower than the human exposure at the recommended dose of 120 mg daily.

In a non-GLP, preliminary embryofetal development (EFD) study, pregnant female rats were orally administered with belzutifan at doses of 6, 60, or 200 mg/kg/day from GD6 through GD17. At doses of 60 mg/kg onwards, there was a dose-related increase in post-implantation loss and in the mean number of resorptions per litter, with 100% embryo-fetal lethality in the high-dose group. A drug-related decrease in fetal body weight and increase in rib malformations was apparent from 6 mg/kg onwards. Therefore, the developmental NOAEL could not be determined. The lowest dose tested corresponded to maternal AUC0-24hr of 2.60 measured at GD7, which is below the exposure at the MRHD (~0.10x EM). The observed embryofetal toxicity may be related to the mechanism of action of belzutifan. Therefore, these findings are considered clinically relevant. As belzutifan showed teratogenic and embryotoxic potential in the pEFD rat study, a confirmatory study in a second species (rabbit) was not performed and is not required in accordance with ICH S5 (R3). The proposed VHL indication does not concern an advanced cancer population and concerns a

<div style=\"page-break-after: always\"></div>

population with a disease that is not immediately life threatening. Therefore, a contraindication in pregnancy for patients with VHL disease-associated tumours is included in section 4.3 and a warning in section 4.6 of the SmPC in line with Appendix 2 of the Guideline on risk assessment of medicinal products on human reproduction and lactation from data to labelling (EMEA/CHMP/203927/2005). In addition, embryo-foetal toxicity was included as an Important potential risk in the RMP.

## Impurities

A special qualification 13-week toxicity study in rats (TT #22 9010) was performed to evaluate 'belzutifan with a new impurity profile'. There appears to be only one impurity in the test-sample named 'Individual Unspecified Amide Impurity', which has given a specification limit of ≤0.10%, so below the identification limit. However in this rat-study, it was apparently concentrated up to 5.9%.. According to the applicant, this Individual Unspecified Amide Impurity is a potential new impurity expected to be present after a post marketing process change, which has not been implemented yet. Therefore, the applicant only needs to qualify this impurity when this process change will be implemented.

## Environmental risk assessment

Phase I screening showed that the PECsurfacewater value met the action limit of 0.01 µg/L. Therefore, Phase IITier A assessment was carried out. The PNEC was calculated using appropriate assessment factors. PEC/PNEC ratios in each compartment were less than 1 and it is therefore agreed that the drug substance is unlikely to pose a risk to the environment.

Belzutifan is not expected to be an endocrine disrupting compound and therefore no additional testing concerning these endpoints is required.

Considering the data available, belzutifan is not expected to pose a risk to the environment.

## 2.5.7. Conclusion on the non-clinical aspects

Binding of belzutifan to the PAS-B domain of HIF-2 α has been shown in vitro and efficacy of belzutifan on tumour reduction compared to vehicle has been shown in in vivo studies.

From the pharmacokinetic point of view, the dog and to a lesser extent the rat, were the most relevant species for non-clinical efficacy and safety studies.

Overall, the non-clinical data package evaluating the pharmacology and toxicity is considered adequate to support the marketing authorisation.

Belzutifan is not a PBT substance. Considering the ERA data, belzutifan is not expected to pose a risk to the environment.

<div style=\"page-break-after: always\"></div>

## 2.6. Clinical aspects

## 2.6.1. Introduction

## GCP inspection(s)

A routine GCP inspection for Study 005 has been performed. All in all, there seem to be no critical concerns on the acceptability of the clinical trial data for the submitted application assessment.

The Clinical trials were performed in accordance with GCP as claimed by the applicant.

The applicant has provided a statement to the effect that clinical trials conducted outside the community were carried out in accordance with the ethical standards of Directive 2001/20/EC.

## · Tabular overview of clinical studies

Table 11: Belzutifan Clinical Studies

| Study No. & Status                   | Study Title                                                                                                                                                                                         | Main Study Objective & Study Subjects                                                                                                                                                                                                                  | Treatments                                                                                                                                                                      | Study Design                                                                       |
|--------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------|
| Phase 1 studies                      | Phase 1 studies                                                                                                                                                                                     | Phase 1 studies                                                                                                                                                                                                                                        | Phase 1 studies                                                                                                                                                                 | Phase 1 studies                                                                    |
| MK - 6482-001 (PT2977-101) Ongoing   | A Phase 1, Dose-Escalation and Expansion Trial of PT2977, a HIF-2 α inhibitor, in Patients with Advanced Solid Tumors                                                                               | Identify the MTD and/or the RP2D of PT2977 in patients with advanced solid tumours. Part 1A: Adults with advanced solid tumours (N=43) Part 1B: Adults with advanced RCC (N=52) Part 2: Adults with other specified solid tumours; Part 2A: GBM (N=25) | Part 1A Dose- escalation 20, 40, 80, 120, 160, and 240 mg once daily; 120 mg twice daily PT2977 Part 1B - Part 2: Dose-expansion 120 mg twice daily PT2977 in patients with RCC | Open-Label Phase 1 dose-escalation and dose-expansion trial with dense PK sampling |
| MK - 6482-002 (PT2977-103) Completed | A Single-Dose, Open- Label, Randomized, Food- Effect Study in Healthy Volunteers with MK - 6482 Tablets                                                                                             | To determine the effect of food on the PK of a single-dose of 120 mg of MK - 6482 in normal healthy adults Adult healthy female or vasectomized male volunteers (N=16)                                                                                 | 120 mg MK - 6482                                                                                                                                                                | Phase 1, open-label, randomized, 2-period trial with dense PK sampling             |
| MK - 6482-006 (PT2977-104) Completed | A Phase 1, Randomized, Open-Label, Single-center, Three-way Crossover Study to Compare the Bioavailability, Pharmacokinetics and Safety of MK - 6482 for Formulations A and B in Healthy Volunteers | To characterize the safety, bioavailability, and PK of Formulation A and Formulation B Healthy adult WONCBP or vasectomized male volunteers (N = 18)                                                                                                   | 120 mg MK - 6482 Formulation A and Formulation B; and 200 mg of Formulation B                                                                                                   | Phase 1, randomized, open-label, 3-period, crossover trial with dense PK sampling  |
| MK - 6482-007 Completed              | A Single-dose Clinical Study to Evaluate the Pharmacokinetics of MK - 6482 in Healthy Female Participants                                                                                           | To obtain plasma pharmacokinetic data of MK-6482 and its metabolite in healthy Japanese and Caucasian female participants Healthy adult WONCBP (N = 49)                                                                                                | 40 mg MK - 6482                                                                                                                                                                 | Phase 1, open-label trial with dense PK sampling                                   |
| MK - 6482-008 Completed              | A Study to Investigate the Absorption, Metabolism, Excretion, and Mass Balance of MK - 6482 in Healthy Adults                                                                                       | To investigate the absorption, metabolism, excretion, and mass balance of MK - 6482 in humans Healthy adult WONCBP and vasectomized males (N = 6)                                                                                                      | 120 mg (~200 μ Ci) [ 14 C]MK - 6482                                                                                                                                             | Phase 1, single-dose, mass balance trial with dense PK sampling                    |

<div style=\"page-break-after: always\"></div>

| Study No. & Status      | Study Title                                                                                                                                                            | Main Study Objective & Study Subjects                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | Treatments                                                                                                                   | Study Design                                                                                                                                                    |
|-------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Phase 1 studies         | Phase 1 studies                                                                                                                                                        | Phase 1 studies                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | Phase 1 studies                                                                                                              | Phase 1 studies                                                                                                                                                 |
| MK - 6482-009 Completed | A Study to Evaluate the Effect of Multiple Doses of MK - 6482 on the Pharmacokinetics of Midazolam in Healthy Participants                                             | To assess and compare the PK profile of midazolam following a single oral 2-mg dose of midazolam given alone or after multiple doses of MK-6482 Healthy WONCBP (N = 14)                                                                                                                                                                                                                                                                                                                                  | 120 mg MK - 6482; 2 mg midazolam                                                                                             | Phase 1, open-label, fixed-sequence, 2- period trial with dense PK sampling                                                                                     |
| MK - 6482-014 Completed | A Study to Assess the Effect of Food on the Pharmacokinetics of the MK - 6482 Final Market Image Formulation in Healthy Participants                                   | To assess the effect of a high-fat meal on plasma PK of a single-dose of MK - 6482 120 mg administered using the final market image tablet formulation relative to plasma PK in the fasted state in healthy adult participants. Healthy adult WONCBP and vasectomized males (N=14)                                                                                                                                                                                                                       | Single-dose 120 mg MK - 6482 [fasted] Single-dose 120 mg MK-6482 [fed]                                                       | Phase 1, randomized, 2 period, crossover, single-site, open-label trial with dense PK sampling                                                                  |
| MK - 6482-019 Completed | An Open-label, Single- dose, 3-Period, Randomized Crossover Study to Evaluate the Impact of Crystallinity on the Pharmacokinetics of MK - 6482 in Healthy Participants | To compare the pharmacokinetic profile of MK-6482 in healthy adult participants following single 120-mg dose administration of the intended commercial formulation tablets to that of tablets with different levels of crystalline content (5% and 10%) Healthy adult WONCBP and vasectomized males (N=18)                                                                                                                                                                                               | Single-dose 120 mg MK - 6482: FMI tablets with 0% crystalline API Tablets spiked with 5% crystalline API Tablets spiked with | Phase 1, randomized, 3-period, crossover, single-site, open-label trial with dense PK sampling                                                                  |
| MK - 6482-020 Completed | An Open-Label, Single- Dose Study to Investigate the Influence of Hepatic Impairment on the Pharmacokinetics of MK - 6482                                              | To compare the plasma PK of MK - 6482 following a single oral 80 mg dose of MK - 6482 in participants with moderate hepatic impairment to that of healthy matched control participants. Estimation: The plasma PK (AUC 0-inf and C max ) of MK - 6482 following a single oral 80 mg dose of MK - 6482 to participants with moderate hepatic impairment will be estimated and compared with those in healthy matched control participants.                                                                | Single oral 80 mg dose                                                                                                       | Nonrandomized, parallel-group, multisite, open-label study of MK-6482 in participants with moderate hepatic impairment and healthy matched control participants |
| MK - 6482-021 Completed | An Open-Label, Single- Dose Study to Investigate the Influence of Renal Impairment on the Pharmacokinetics of MK - 6482                                                | To compare the plasma PK of MK - 6482 following administration of a single oral 120 mg dose of MK - 6482 to participants with ESRD before and after haemodialysis to each other and also to that of healthy matched control participants. Estimation: The plasma PK (AUC0-inf and Cmax) of MK - 6482 following a single oral 120 mg dose of MK - 6482 to participants with ESRD before and after HD will be estimated and compared with each other and to those in healthy matched control participants. | Single oral 120 mg dose                                                                                                      | Nonrandomized, parallel-group, single- site, open-label study of MK - 6482 in participants with ESRD and healthy matched control participants                   |

<div style=\"page-break-after: always\"></div>

| Study No. & Status                                     | Study Title                                                                                                                                                                                | Main Study Objective & Study Subjects                                                                                                                                                                                                                                | Treatments                                                           | Study Design                                                                                                                                   |
|--------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------|
| Phase 1 studies                                        | Phase 1 studies                                                                                                                                                                            | Phase 1 studies                                                                                                                                                                                                                                                      | Phase 1 studies                                                      | Phase 1 studies                                                                                                                                |
| MK - 6482-025 Completed                                | A Single-dose Clinical Study to Evaluate the Pharmacokinetics of Belzutifan (MK - 6482) in Healthy Japanese Female Participants                                                            | To obtain plasma PK data of belzutifan following a single oral dose of belzutifan. Healthy adult WONCBP: Panels A and B: UGT2B17 PM/CYP2C19 IM phenotype Panels C and D: UGT2B17/CYP2C19 dual PM phenotype (N=24)                                                    | 80 mg MK - 6482 (Panels A and C) 120 mg MK - 6482 (Panels B and D)   | Phase 1, nonrandomized, no- controlled, single-site, open-label trial with dense PK sampling                                                   |
| Phase 2 studies                                        | Phase 2 studies                                                                                                                                                                            | Phase 2 studies                                                                                                                                                                                                                                                      | Phase 2 studies                                                      | Phase 2 studies                                                                                                                                |
| MK - 6482-004 (PT2977-202) Ongoing; enrolment complete | An Open-Label Phase 2 Study to Evaluate PT2977 for the Treatment of von Hippel-Lindau Disease- Associated Renal Cell Carcinoma                                                             | To evaluate the efficacy of MK - 6482 for the treatment of VHL-RCC as measured by ORR per RECIST 1.1 Adults with VHL disease and RCC (N=61)                                                                                                                          | 120 mg once daily MK-6482                                            | Open-label, Phase 2 trial in patients with VHL disease and at least one measurable RCC tumour as defined by RECIST 1.1 with sparse PK sampling |
| MK - 6482-013 Ongoing; enrolment complete              | Phase 2 Study of MK - 6482 in Patients With Advanced Renal Cell Carcinoma                                                                                                                  | To compare the 120 mg QD dose and 200 mg QD dose of MK - 6482 with respect to ORR per RECIST 1.1 by BICR. Adults with previously treated advanced ccRCC (N = 154)                                                                                                    | 1) 120 mg once daily MK - 6482 versus 2) 200 mg once daily MK - 6482 | Multicentre, randomized, open- label, Phase 2 study comparing the 120 mg and 200 mg QD doses (1:1 randomization)                               |
| Phase 3 studies                                        | Phase 3 studies                                                                                                                                                                            | Phase 3 studies                                                                                                                                                                                                                                                      | Phase 3 studies                                                      | Phase 3 studies                                                                                                                                |
| MK - 6482-005 Ongoing; enrolment complete              | An Open-label, Randomized Phase 3 Study of MK - 6482 Versus Everolimus in Patients with Advanced Renal Cell Carcinoma That Has Progressed After Prior PD- 1/L1 and VEGF-Targeted Therapies | To compare MK - 6482 to everolimus with respect to PFS per RECIST 1.1 by BICR and OS Adult patients with advanced RCC previously treated with checkpoint inhibitor and VEGF-targeted therapies (N=746). Additionally, n=9 enrolled in the Japan safety run-in phase. | 1) 120 mg QD MK - 6482 versus 2) 10 mg QD daily everolimus           | Multinational, open- label, randomized, Phase 3 study comparing MK - 6482 with everolimus with sparse PK sampling                              |

## 2.6.2. Clinical pharmacology

## Bioanalytical methods

Quantitative LC-MS/MS methods were used for the determination of belzutifan and its glucuronide metabolite PT3317 in human plasma and urine and utilized in the clinical development programme. Method BAM.0419 measured belzutifan and PT3317 simultaneously in human plasma. Methods BAM.0774 and TM.2857 were established for measuring belzutifan in human plasma. Method BAM.0948 was established for measuring belzutifan and PT3317 in human urine. Accuracy and precision, selectivity, specificity, calibration curves, carry over, dilution linearity, and stability assays have been described in method validation reports. Relevant bioanalytical method validation reports and their amendments have been provided.

Bioanalytical reports for the following clinical studies have been provided: 001 (PT2977-101), 002 (PT2977103), 004 (PT 2977-202), 005, 006 (PT2977-104), 007, 008, 009, 013, 014, 019, and 025.

The belzutifan interference was also evaluated in bioanalytical method (bioanalytical report 06clrq) and found that the observed retention times for the diastereomers investigated differed from the retention time of MK6482 with no overlap between MK-6482 and these diastereomers.

<div style=\"page-break-after: always\"></div>

## PopPK modelling

The objectives of the pop-PK analysis were to: 1) Evaluate the impact of intrinsic/extrinsic factors on PK characteristics of belzutifan, 2) generate belzutifan exposure metrics for the subsequent use in exposureresponse analysis, and 3) compare exposures among subpopulations of interest, including by cancer type, sex, race-country, hepatic function, and renal function.

Data from studies 001, 002, 004, 006, 007, 014, 005, 013, and 025 are included in the current pop-PK analysis. N=8256 observations from 807 subjects were included in the model. In phase I studies dense PK sampling was performed, whereas in phase II and phase III studies sparse samples were obtained.

The pop-PK analysis was performed using the non-linear mixed effects modelling approach. This approach estimates the typical (mean) value of parameters and their IIV. Estimation methods in NONMEM were FOCE with interaction (FOCEI), with proportional models for residual variability. Covariates included in the previous pop-PK models were retained unless initial evaluations with the updated data presented a shift in any covariate effect of greater than 20% compared with the previous model results. Next, a univariate backward elimination of the covariates was performed to determine if they were still significant at a significance level of p&lt;0.001. Any covariates that were not significant were removed.

Stability of NONMEM models were assessed based on: acceptable basic GOF plots, number of significant digits ≥3 for all θ' s (also a criterion for successful termination), estimates of θ' s not close to a boundary, condition number (ratio of largest to smallest eigenvalue) &lt;1000, correlation less than 0.95 between any 2 parameters, and stability check performed for a selected basic model. Model selection was based on: the comparison of full vs. reduced models based on the Log-Likelihood criterion, decrease in unexplained variability, change towards CWRES against time randomly distributed around zero, and scientific plausibility of the model.

The final pop-PK model for MK-6482 (run35) comprised a 2-compartment model with first-order absorption and linear elimination.

<!-- formula-not-decoded -->

<!-- formula-not-decoded -->

<div style=\"page-break-after: always\"></div>

The model suggested that CL/F increases with increasing weight and for UGT2B17 EM and CYP2C19 RM or UM. CL/F decreased with increasing age and for UGT2B17 and CYP2C19 PM. Vc/F, Vp/F, and Q/F increased with increasing weight, and Vc/F decreased with increasing age. KA decreased for Formulation B (final market formulation) and if fed. F increases for UGT2B17 PM. For final parameter estimates and goodness-of-fit plots see Table 17 and Figure 9 below.

Table 12 Final popPK Model Parameters

| Parameter                                              | Estimate   | RSE (%)   | Asymptotic 95% CI   | Shrinkage (%)   |
|--------------------------------------------------------|------------|-----------|---------------------|-----------------|
| Fixed Effects                                          |            |           |                     |                 |
| CL/F (L/h)                                             | 5.52       | 2.60      | 5.24; 5.80          | --              |
| V c /F (L)                                             | 86.5       | 2.10      | 83.0; 90.0          | --              |
| Q/F (L/h)                                              | 5.42       | 11.5      | 4.20; 6.64          | --              |
| V p /F (L)                                             | 33.4       | 5.60      | 29.7; 37.1          | --              |
| KA (/h)                                                | 2.43       | 1.30      | 2.37; 2.49          | --              |
| Lag time (h)                                           | 0.165      | 1.10      | 0.161; 0.169        | --              |
| Fed status effect on KA                                | -0.870     | 6.90      | -0.988; -0.752      | --              |
| Body weight exponent on CL/F and Q/F                   | 0.605      | 10.0      | 0.487; 0.723        | --              |
| Body weight exponent on V c /F and V p /F              | 1.02       | 3.00      | 0.959; 1.08         | --              |
| UGT2B17 extensive metabolizer effect on CL/F           | 0.413      | 11.7      | 0.319; 0.507        | --              |
| UGT2B17 poor metabolizer effect on CL/F                | -0.394     | 6.20      | -0.442; -0.346      | --              |
| CYP2C19 poor metabolizer effect on CL/F                | -0.204     | 19.4      | -0.282; -0.126      | --              |
| CYP2C19 rapid or ultrarapid metabolizer effect on CL/F | 0.136      | 29.4      | 0.0576; 0.214       |                 |
| UGT2B17 poor metabolizer effect on F                   | 0.135      | 12.9      | 0.101; 0.169        | --              |
| FMF effect on KA                                       | -0.396     | 3.20      | -0.421; -0.371      | --              |
| Age exponent on V c /F                                 | -0.164     | 26.3      | -0.248; -0.0795     | --              |
| Age exponent on CL/F                                   | -0.366     | 18.3      | -0.498; -0.234      | --              |
| Random Effects                                         |            |           |                     |                 |
| IIV on CL/F                                            | 0.153      | 6.60      | 0.128; 0.178        | 7.5             |
| IIV on V c /F                                          | 0.0128     | 18.6      | 0.00843; 0.0172     | 44.1            |
| IIV on V p /F                                          | 0.146      | 37.4      | 0.135; 0.157        | 59.0            |
| IIV on KA                                              | 1.19       | 5.00      | 1.13; 1.257         | 19.2            |
| Residual Error                                         |            |           |                     |                 |
| RES HV                                                 | 0.266      | 4.90      | 0.241; 0.291        | --              |
| RES PAT                                                | 0.313      | 2.00      | 0.301; 0.325        | --              |
| EPS                                                    | 1 FIX      | 0         | --                  | 7.3             |

Abbreviations: CI=confidence interval; CL/F=apparent clearance; CYP=Cytochrome P450; EPS= ε ( random error); F=bioavailability; FMF=final market formulation; HV=healthy volunteer; IIV=inter-individual variability;

KA=absorption rate constant; PAT=patient; Q/F=apparent inter-compartmental clearance; RES=proportional residual error; RSE=relative standard error; UGT=Uridine 5'-diphospho-glucuronosyltransferase;

Vc /F=apparent central volume of distribution; Vp /F=apparent peripheral volume of distribution.

Note: The following η -correlations were estimated: CL/F-Vc/F: 40.9%; CL/F-Vp/F: 24.1; Vc /F-V p /F: 37.5%.

<div style=\"page-break-after: always\"></div>

Figure 9: GOF Plots Final popPK Model

<!-- image -->

Abbreviations: CWRES=conditional weighted residuals; DV=dependent variable (MK-6482 concentration); GOF=goodnessof-fit; IPRED=individual predictions; PRED=population predictions

Notes: Dots are individual data points and red lines are linear regression lines. In the two plots in the upper row, dashed black lines are lines of identity, while in the two plots in the lower row, dashed lines show the boundaries of the CWRES ± 5 interval.

A prediction-corrected VPC (pcVPC) and a nonparametric bootstrap analysis were performed to assess the robustness of the final pop-PK model parameters (Figure 10). In addition, the final population PK model for MK-6482 was fitted to 1000 bootstrap replicate datasets, stratified by study, to evaluate model stability and performance. The final population PK model parameter estimates were contained within the 95% CI determined by a bootstrap analysis based on 1000 replicates.

<div style=\"page-break-after: always\"></div>

Figure 10: pcVPC per Study for Final popPK Model

<!-- image -->

Abbreviations: Pred-corr conc=prediction-corrected concentration; VPC=visual predictive check. Notes: Blue dots are the prediction-corrected observed data points; the blue lines are the 50 th  (solid), 5 th  (dashed) and 95 th (dashed) percentiles of observed concentrations; and the black lines are the 50 th  (solid), 5 th  (dashed) and 95 th (dashed) percentiles of simulations. The grey bands represent the 95% prediction intervals for the corresponding black lines based on 500 simulations. Short yellow lines indicate bin intervals.

Geometric means and coefficients of variation (CV%) were calculated across the study population for CL/F, apparent total volume of distribution (Vd/F), KA, and derived PK parameters such as AUCss, and the absorption and elimination half-lives. Parameters in Table 11 are based on calculations using the individual post-hoc parameters of the final model for all subjects.

<div style=\"page-break-after: always\"></div>

Table 13: Individual Post-hoc Parameters

| Parameter       |   Geometric mean | Geometric %CV   |
|-----------------|------------------|-----------------|
| CL/F (L/h)      |             5.89 | 60.6%           |
| Vc/F (L)        |            86.9  | 27.6%           |
| Vp/F (L)        |            33.3  | 31.5%           |
| Vd/F (L)        |           120    | 28.2%           |
| KA (1/h)        |             1.37 | 112%            |
| AUCss (ug*h/mL) |            20.1  | 68.8%           |
| t1/2 eff (h)    |            14.2  | 47.9%           |

Abbreviations: AUCss=area under the plasma concentration-time curve for one dosing interval at steady state based on Dose*F/(CL/F); CL/F=apparent clearance; CV=coefficient of variation; F=bioavailability; GM=geometric mean; KA=absorption rate constant; SS=steady state; t1/2 abs=absorption half-life; t1/2 alpha=initial elimination half-life; t1/2 beta=terminal elimination half-life; t1/2 eff=effective elimination half-life; Vc/F=apparent central volume of distribution; Vdss/F=apparent total volume of distribution; Vp/F=apparent peripheral volume of distribution.

## PBPK

The objective of the PBPK analysis was to simulate the magnitude of CYP3A4 induction in populations with higher belzutifan exposures using midazolam as a prototypical CYP3A4 substrate.

All simulations were conducted using the Simcyp Simulator Version 19. Physicochemical and in vitro data, clinical single oral dose PK data (Study 006 120mg), and human pharmacokinetic-pharmacogenetic (PK-PGx) analysis were used to build the model. The PK-PGx analysis informed relative contribution of CYP2C19 and UGT2B17 to overall elimination. Validation of the model included the ability to describe the central tendency and variability in human pharmacokinetics of belzutifan using the final-market formulation in Caucasian (Study 006 200 mg) and Japanese (Study 007) participants. Acceptance criteria included geomean predicted belzutifan AUC0-inf and Cmax between 0.8- and 1.25-fold of observed values in P006 and P007. The PBPK model was subsequently adapted to include the CYP3A4 induction-related parameters (IndC50 and Indmax) informed by results from the clinical midazolam DDI Study 009.

Simulations were conducted in both the Northern European Caucasian ancestry and Japanese populations with 120 mg oral QD dosing of belzutifan in the fasted state for 7 days, followed by a single oral dose of 2 mg midazolam on Day 7 (Figure 11). The final predicted median (90% PI) AUC0-inf GMR is 0.62 (0.53, 0.70) and Cmax GMR is 0.69 (0.62, 0.76) in the Caucasian population, consistent with the observed clinical median (90% CI) A

UC0-inf GMR of 0.60 (0.53, 0.69) and Cmax GMR of 0.66 (0.5, 0.78) from Study 009.

<div style=\"page-break-after: always\"></div>

Figure 11: Prediction Relationship Midazolam AUC Ratio vs.. Belzutifan Exposure

<!-- image -->

BlueandGreenverticallinesshow the1Oth-90thpercentileofpredictedsteadystateAUCvaluesforCaucasianandJapanese population, respectively, with 120 mg QD dosing in VHL-RCC. The weak,moderate andstrong induction potential is defined byAUCRwindows of 0.8-&lt;0.5,0.5-&lt;0.2and0.2-0,respectively. Abbreviations:AUCR=AUC0-inf ratio(Midazolam+MK-6482/Midazolamalone):PI=Prediction interval;Cl=Confidence interval

## 2.6.2.1. Pharmacokinetics

## Absorption

The steady-state GM Tmax is predicted by the popPK model to be approximately 2 hours (1.98 hours, 56.8% CV) after 120 mg QD administration. The steady-state GM Cmax is 1.5 ng/mL. Based on the solubility of belzutifan, which does not exhibit reduced solubility at elevated pH, a study examining the impact of acidreducing agents was not considered needed.

Belzutifan is a Pgp substrate in vitro. The basolateral to apical/apical to basolateral (B-A/A-B) efflux ratio of belzutifan (1 μ M) in MDCKII-MDR1 cells was 1.5. In LLC-MDR1 cells the efflux ratio was 2.4 and 2.5 at 0.1 and 1 μ M, respectively, indicative of a relatively weak P-gp substrate transporter activity.

## Bioavailability

Formal bioavailability against IV administration was not determined. Relative oral bioavailability of belzutifan administered as either the FFP (fit-for-purpose formulation) or FMF (final market formulation) was assessed and compared in a Phase 1 study in healthy volunteers (Study 006). The FMF and FFP formulations were within bioequivalence bounds for AUC, but not Cmax. The GMR (90% CI) for Cmax was 86.83 (76.14 99.02). In the clinical pharmacology programme, the FFP formulation was used (in part of the subjects) in study 001, 002, 004, and 006.

## Influence of food

The impact of food on belzutifan PK when administered using FFP tablets (Study 002) and FMI tablets (Study 014) was evaluated at the proposed 120-mg dose in healthy participants following consumption of a high-fat, high-calorie meal and compared to a reference fasted state. Peak plasma belzutifan Cmax was lower under fed conditions (35% lower for the FFP and 24% lower for the FMI) and delayed (approximately 2 h).

<div style=\"page-break-after: always\"></div>

Table 14 The Effect of Food on the Pharmacokinetics of Belzutifan Administered as the FFP and FMI Formulations

|                           |    | AUCO-t            | AUCO-inf          | Cmax              |
|---------------------------|----|-------------------|-------------------|-------------------|
| Comparison                | N  | GMR (90% CI)      | GMR (90% CI)      | GMR (90% CI)      |
| FFPFed/Fasted (Study002)  | 16 | 0.94 (0.88, 1.00) | 0.97 (0.91, 1.02) | 0.65 (0.57, 0.73) |
| FMIFed/Fasted (Study 014) | 14 | 1.00 (0.94, 1.07) | 1.00 (0.94, 1.07) | 0.76 (0.64, 0.91) |

Abbreviations:Auc0-t/inf=areaundertheconcentration-timecurvefromtime0to24hours/toinfinity; Cmax=maximum concentration;FFP=fit-for-purposeformulation;FMI=finalmarketimage;GMR=geometric

meanratio;AuC=areaundertheconcentration-timecurve.

Source:[Module5.3.1.1:P002MK6482],[Module5.3.1.1P014MK6482]

## Distribution

Based on the population PK analysis, the mean (CV%) volume of distribution is 120 L (28.5%). The plasma protein binding of belzutifan is 45%, as measured by equilibrium dialysis, and the blood to plasma concentration ratio is 0.88. Based on pop-PK analysis, for 120 mg QD dosing, the geometric mean Vc/F (GeoCV%) was 86.9 L (27.6%) and Vp/F (GeoCV%) was 33.3 L (31.5%).

Belzutifan was not identified as a substrate for other transporters (except for Pgp, see absorption above). The metabolite PT3317 (M16) is a substrate of both OATP1B1 and OATP1B3, and active uptake of PT3317 was observed in cryopreserved human hepatocytes. PT3317 is also a substrate of the efflux transporters multidrug resistance-associated protein (MRP)2 and MRP3.

## Elimination

Following oral administration of radiolabelled belzutifan to healthy subjects, elimination occurred primarily via glucuronidation and oxidative metabolism, with metabolites eliminated in both urine and feces. Excretion was roughly equal via feces (51.7%) and urine (49.6%). Approximately 6% of the administered oral belzutifan dose was recovered as parent drug in urine. Trace levels of belzutifan were detected in the feces.

Based on the pop-PK analysis, the mean (CV%) clearance is 5.89 L/hr (60.6%) and the mean elimination half-life is approximately 14 hours in patients administered belzutifan.

Belzutifan is metabolized via UGT2B17 to form the glucuronic acid metabolite M16 (PT3317) and via CYP2C19 and to a lesser extent CYP3A4 to form oxidative metabolites, including the hydroxylated metabolite M9

<div style=\"page-break-after: always\"></div>

Table 15 : UGT2B17 is the most significant clearance pathway for belzutifan in participants expressing UGT2B17, while CYP2C19 is also a major pathway. The relevance of these pathways was investigated through PopPK analysis (see genetic polymorphisms below).

<div style=\"page-break-after: always\"></div>

Table 15: Mass Balance Data

|           |             | %oofTotalRadioactivity(%oofthedose)   | %oofTotalRadioactivity(%oofthedose)   | %oofTotalRadioactivity(%oofthedose)   |
|-----------|-------------|---------------------------------------|---------------------------------------|---------------------------------------|
| Component | Description | Plasma (0-48 hr)                      | Urine (0-96 hr)                       | Feces (0-144 hr)                      |
| MK-6482   | Parent      | 73                                    | 12 (6)                                | Trace                                 |
| M2        | Thiocyanate | 2                                     | ND                                    | ND                                    |
|           | R+Q+Glu     | 3                                     | 8 (4)                                 | ND                                    |
| M9        | P+O         | 2                                     | 6 (3)                                 | 81 (42)                               |
| M14       | P+O-F+S     | ND                                    | ND                                    | 5 (3)                                 |
| M16       | PtGlu       | ６                                     | 65 (32)                               | ND                                    |
| M18       | P+O-F+S     | ND                                    | ND                                    | 4 (2)                                 |
| M20       | P+O-F       | ND                                    | ND                                    | Trace                                 |
| M26       | R+Q-EtGlu   | Trace                                 | 3 (1)                                 | ND                                    |
| M27       | P+Q-EtGlu   | ND                                    | 2 (1)                                 | ND                                    |
| M28       | P-N+O+OH    | ND                                    | ND                                    | 7 (4)                                 |
| M29       | P-F+O+H     | ND                                    | ND                                    | Trace                                 |
| M30       | P-2F+O      | Trace                                 | Trace                                 | ND                                    |
| M31       | P-2F        | Trace                                 | Trace                                 | Trace                                 |
| M32       | P CN+QH+Glu | ND                                    | Trace                                 | ND                                    |
| M33       | P-CN+OH     | ND                                    | ND                                    | Trace                                 |

CN=cvanQ group;F=fluorine; Glu=glucuronide;hr=hour(s); HRMS=high resolution mass spectrometry; LC=liquid chromatography;ND=notdetectable;O=oxygen;OH=hydroxylgroup;P=parent;S=sulfur Pooledplasma,urineandfecesextractswereanalyzed byLC-HRMSandradiometric detection.Numbers representthe%radioactivityintheradiachramatogramassociated withparent compound and metabolites. Numbersinparenthesesrepresent%of the dose.Metabolites thatwere detected in trace amountwere detected byHRMSonly.

[Module5.3.3.1P008MK6482Table11-21

Belzutifan was the major drug-related component in plasma, accounting for 73% of the radioactivity. PT3317 (M16) was the most significant metabolite (approximately 9%). The observed PT3317 arithmetic mean Cmax and AUC024 at a dose of 120 mg were 0.6 μg/mL and 6.5 μ g·hr/mL, respectively. PT3317 had a mean terminal half-life of 13.9 hours, similar to belzutifan. Minor metabolites detected in plasma were M2 (thiocyanate), M4 (mono-hydroxylation and glucuronidation) and M9 (hydroxylation), while M26, M30, and M31 were detected in trace amounts. M2 showed evidence of persistence (in a plasma pool of 48 to 96-hour). M2 has been identified as thiocyanate, which has a long half-life and circulates at high endogenous levels in humans.

## Genetic polymorphisms

CYP2C19 and UGT2B17 are involved in the metabolism of belzutifan, and both display genetic polymorphisms. PopPK analyses have included individual phenotypic information for both genes, as covariates, in the modelling, and the quantitative impact of CYP2C19 and UGT2B17 phenotype on PK parameters was evaluated. The PopPK analyses indicated that in reference to a typical UGT2B17 EM and CYP2C19 EM/IM participant, the participant with CYP2C19 RM/UM phenotype, CYP2C19 PM phenotype, UGT2B17 IM phenotype, UGT2B17 PM phenotype, and UGT2B17/CYP2C19 dual PM phenotype are projected to have 0.879×, 1.25×, 1.41×, 2.65×, and 3.32× the exposures (AUCss), respectively.

<div style=\"page-break-after: always\"></div>

## Dose proportionality and time dependencies

Belzutifan PK was not observed to be dose-proportional following single and multiple dosing in Study 001 at doses above 120 mg (Table 21). However, in the formulation biocomparison study, Study 006 (a cross-over study), dose-proportionality was observed for both AUC and Cmax (~ 1.6-fold changes) following single-dose administration of the FMF at 120 mg and 200 mg in healthy participants.

Accumulation ratios of belzutifan and its metabolite PT3317 were calculated by AUC at steady-state/AUC after first dose in Study 001. AUC accumulation ratios ranged from 1.27 to 1.54 for Day 15/Day 1 across the 20240 mg QD dose-escalation range. Mean accumulation ratio was 1.49 in the 120 mg QD expansion cohort of patients with advanced RCC. For the metabolite PT3317, AUC accumulation ratios ranged from 1.13 to 1.48 for Day15/Day 1 across the 20-240 mg QD dose-escalation range (Table 21).

Table 16: Main PK Results Study 001

| PKParameter                                  | 20 mg QD                             | 40 mg QD                             | 80 mgQD                              | 120 mgQD Part 1A                     | 160 mg QD                            | 240 mg QD                            | 120 mg BID                           | 120 mg QD Part1B                     |
|----------------------------------------------|--------------------------------------|--------------------------------------|--------------------------------------|--------------------------------------|--------------------------------------|--------------------------------------|--------------------------------------|--------------------------------------|
| PKParameter                                  | (N=6)                                | (N=6)                                | (N=6)                                | (N=6)                                | (N=6)                                | (N= 7)                               | (N=6)                                | (N = 52)                             |
| Week 1 (Day 1)                               | Week 1 (Day 1)                       | Week 1 (Day 1)                       | Week 1 (Day 1)                       | Week 1 (Day 1)                       | Week 1 (Day 1)                       | Week 1 (Day 1)                       | Week 1 (Day 1)                       | Week 1 (Day 1)                       |
| Cmax (ng/mL) Mean (CV%)                      | 173 (47.2)                           | 572 (47.5)                           | 1241 (55.8)                          | 1502 (53.5)                          | 2042 (32.0)                          | 2540 (59.0)                          | 1277 (40.5)                          | 1328 (38.3)                          |
| Tmax (hr) Median (Min-Max)                   | 1.75 (0.5 4.1)                       | 1.50 (0.52.0)                        | 1.04 (0.52.0)                        | 1.52 (0.5-4.1)                       | 1.80 (1.2-4.0)                       | 2.00 (1.0-4.0)                       | 1.63 (0.5-4.0)                       | 1.62 (0.5-23.7)                      |
| AUCo-m (nghr/mL) Mean (CV%)                  | 1531 (44.3)                          | 5396 (24.5)                          | 12513 (43.3)                         | 17599 (24.4)                         | 16852 (28.4)                         | 24768 (41.2)                         | 8846 (28.5)                          | 14154 (40.5)                         |
| Week 3 (Nominal Day 15;Steady state)         | Week 3 (Nominal Day 15;Steady state) | Week 3 (Nominal Day 15;Steady state) | Week 3 (Nominal Day 15;Steady state) | Week 3 (Nominal Day 15;Steady state) | Week 3 (Nominal Day 15;Steady state) | Week 3 (Nominal Day 15;Steady state) | Week 3 (Nominal Day 15;Steady state) | Week 3 (Nominal Day 15;Steady state) |
| Cmax (ng/mL) Mean (CV%) GeoMean (GeoCV%)     | 245 (65.2) 210 (67.5)                | 541 (35.2) 510 (41.8)                | 1403 (40.4) 1316 (40.0)              | 1833 (32.9) 1746 (36.1)              | 2042 (12.6) 2028 (13.1)              | 2672 (42.4) 2475 (45.3)              | 2672 (33.1) 2560 (33.4)              | 1787 (38.1) 1671 (38.4)              |
| Tmax (hr) Median (Min-Max)                   | 1.00 (0.5-1.6)                       | 1.52 (1.04.0)                        | 2.00 (0.5 2.0)                       | 2.00 (0.5-6.1)                       | 1.01 (0.52.0)                        | 1.55 (1.0-2.0)                       | 1.52 (1.0-2.0)                       | 1.5 (0.5-4.3)                        |
| AUCoam (nghr/mL) Mean (CV%) GeoMean (GeoCV%) | 2171 (63.8) 1772 (88.4)              | 7137 (46.6) 6589 (46.2)              | 18369 (44.1) 16786 (51.3)            | 25812 (43.7) 24157 (39.7)            | 22272 (34.5) 21058 (40.4)            | 27875 (30.3) 26811 (31.5)            | 22256 (37.3)                         | 20424 (49.8) 18116(54.3)             |
| RAc for AUC Mean (CV%)                       | 1.27 (22.7)                          | 1.34 (25.1)                          | 1.52 (39.0)                          | 1.54 (49.4)                          | 1.41 (37.6)                          | 1.27 (21.2)                          | 2.38 (24.8)                          | 1.49 (48.2)                          |

Inter-individual variability was quantified using the popPK model. AUCss (%CV) was estimated to be 20.8 ug*h/mL (64.3%) and Cmaxss (%CV) was estimated to be 1540 ng/mL (46.1%).

## Special populations

The comparison of the observed single dose mean Cmax and AUC values in healthy participants to those in VHL and non-RCC solid tumour patients for 120 mg belzutifan shows similarity. -

The effects of age, sex, disease status/cancer type (healthy volunteers, and patients with VHL-RCC, advanced RCC, or other advanced non-RCC solid tumours), phenotype (UGT2B17 and CYP2C19 polymorphisms), body weight/BMI, race, ethnicity, formulation, food status, renal impairment, and hepatic impairment on belzutifan PK have been characterized in Phase 1 studies and/or pop-PK analyses. Effect of these factors on exposure, as compared to a typical subject, is shown in Figure 12 below.

Figure 12: Effect popPK Model Covariates on Exposure

<div style=\"page-break-after: always\"></div>

<!-- image -->

In a dedicated pharmacokinetic study (Study 021), belzutifan exposure (AUC0-INF) decreased by 6% and increased by 14% in patients with end-stage renal disease before and after haemodialysis, respectively. In the pop-PK analysis Renal impairment was not identified as a significant covariate. Based on this analysis in healthy subjects and patients with cancer, no clinically significant differences in the mean belzutifan exposure were observed between subjects with normal renal function and those with mild and moderate renal impairment (as evaluated by estimated glomerular filtration rate (eGFR)). A dedicated PK study in participants with moderate hepatic impairment (Study 020) did not show a clinically relevant effect on exposure. Belzutifan exposure (AUC0-INF) increased by 52% in patients with moderate hepatic impairment (Child-Pugh B). Patients with severe hepatic impairment have not been studied. Hepatic dysfunction (as

<div style=\"page-break-after: always\"></div>

evaluated by NCI index categories) was also not identified as a significant covariate in the pop-PK analysis. Participants with normal (752), mild (51), moderate (1), and missing (3) hepatic impairment were evaluated in the pop-PK dataset and no clinically significant differences in the mean belzutifan exposure were observed between subjects with normal liver function (total bilirubin and AST ≤ ULN), and those with mild hepatic impairment (total bilirubin ≤ ULN and AST &gt; ULN or total bilirubin &gt; 1 to 1.5 x ULN and any AST).

Body weight (range: 42.1 to 166 kg in the entire pop-PK dataset) showed a statistically significant covariate effect, therefore, body weight was included in the pop-PK model with an allometric coefficient for CL/F, Q/F, and volume parameters. These allometric coefficients estimated in the model (estimated coefficients of 0.61 and 1.02 for CL and volume terms, respectively) were close to the generally reported observations of allometric coefficients of 0.75 and 1.0 for the CL and volume terms, respectively, for small molecules. Over the 5th to 95th percentile range of body weight of 51 to 118 kg, the univariate assessments showed an exposure change of 29% to -22%. Age was evaluated as an intrinsic factor over the age range of 19 to 90 years. Over the 5th to 95th percentile range of age of 35 to 76 years in the pop-PK population, the univariate assessments showed an exposure change of -17% to 9% compared with a typical reference patient.

Gender (males/females), race or ethnicity was not identified as a significant covariate in the popPK model analysis. The claimed indication does not include paediatric patients.

Table 17: PK Studies by Age Group

<!-- image -->

| Trial       | Age<65 (N=544)   | Age ≥65-74 (N=199)   | Age ≥75-84 (N=60)   | Age ≥85 (N=4)   | Overall (N-807)   |
|-------------|------------------|----------------------|---------------------|-----------------|-------------------|
| MK-6482-001 | 53 (9.7%)        | 29 (14.6%)           | 12 (20.0%)          | 0 (0.0%)        | 94 (11.6%)        |
| MK-6482-002 | 16 (2.9%)        | 0 (0.0%)             | 0 (0.0%)            | 0 (0.0%)        | 16 (2.0%)         |
| MK-6482-004 | 59 (10.8%)       | 2 (1.0%)             | (%0'0)0             | 0 (0.0%)        | 61 (7.6%)         |
| MK-6482-006 | 18 (3.3%)        | 0 (0.0%)             | 0 (0.0%)            | 0 (0.0%)        | 18 (2.2%)         |
| MK-6482-007 | 48 (8.8%)        | 1 (0.5%)             | 0 (0.0%)            | 0 (0.0%)        | 49 (6.1%)         |
| MK-6482-014 | 14 (2.6%)        | 0 (0.0%)             | 0 (0.0%)            | 0 (0.0%)        | 14 (1.7%)         |
| MK-6482-005 | 232 (42.6%)      | 109 (54.8%)          | 34 (56.7%)          | 4 (100.0%)      | 379 (47.0%)       |
| MK-6482-013 | 80 (14.7%)       | 58 (29.1%)           | 14 (23.3%)          | 0 (0.0%)        | 152 (18.8%)       |
| MK-6482-025 | 24 (4.4%)        | 0 (0.0%)             | 0 (0.0%)            | 0 (0.0%)        | 24 (3.0%)         |

## Pharmacokinetic interaction studies

## In vitro

Studies with a panel of recombinant CYP and UGT enzymes demonstrated that belzutifan is a substrate of UGT2B17, CYP2C19, and CYP3A4. Belzutifan and the inactive metabolite PT3317 were assessed for their ability to inhibit CYP and UGT enzymes. Cut-offs for these assessments and provided in Table 23, and results are provided in Table 24 and Table 25. Findings above relevant cut-offs are highlighted in bold.

Table 18: Cut-offs Used in In Vitro DDI Evaluation

<div style=\"page-break-after: always\"></div>

|              |   50 × Cmax(u) a (µM) | 25 × Inlet Cmax(u) a (µM)   | 0.1 × dose/250 ml b (µM)   |
|--------------|-----------------------|-----------------------------|----------------------------|
| Parent drug  |                 129   | 367                         | 125.2                      |
| PT3317 (M16) |                  23.5 | NA                          | NA                         |

a Multiple dose Cmax,total 4.67 μ M (1.79 μ g/mL), Fu,p 0.55 and Cmax,u 2.6 μ M) (study 001) [Module 2.7.2 Section 2] Iin,max,u = estimated unbound maximum plasma concentration at the inlet to the liver, 14.67 µM [Module 2.6.5 Section 23] b Based on a 120 mg dose

NA - Not applicable

Table 19: In Vitro CYP Inhibition Belzutifan and PT3317 (Metabolite)

A) Belzutifan

| Enzyme   | Probe Reaction                    | Competitive inhibition   | TDI (Kobs)   | TDI (Kobs)   |
|----------|-----------------------------------|--------------------------|--------------|--------------|
|          |                                   | IC 50 * (μM)             | 10 μM        | 300 μM       |
| CYP1A2   | Phenacetin O- Deethylation        | >300                     | 0.019        | 0.029        |
| CYP2B6   | Bupropion Hydroxylation           | >300                     | 0.005        | 0.018        |
| CYP2C8   | Amodiaquine N- Deethylation       | >300                     | 0.000        | 0.016        |
| CYP2C9   | Diclofenac 4´ - Hydroxylation     | >300                     | 0.006        | 0.012        |
| CYP2C19  | S- Mephenytoin 4´- Hydroxylation  | 280.54 ± 21.84           | 0.003        | 0.006        |
| CYP2D6   | Dextromethorphan O- Demethylation | >300                     | 0.02         | 0.017        |
| CYP3A4   | Midazolam 1´- Hydroxylation       | >300                     | 0.009        | 0.016        |
| CYP3A4   | Testosterone 6 β - Hydroxylation  | >300                     | 0.004        | 0.012        |

<div style=\"page-break-after: always\"></div>

## B) PT3317

| Enzyme   | Probe Reaction                    | Competitive inhibition   | TDI (Kobs)   | TDI (Kobs)   |
|----------|-----------------------------------|--------------------------|--------------|--------------|
|          |                                   | IC 50 * (μM)             | 10 μM        | 300 μM       |
| CYP1A2   | Phenacetin O- Deethylation        | >300                     | 0.01         | 0.015        |
| CYP2B6   | Bupropion Hydroxylation           | 250.55 ± 17.05           | 0.004        | 0.002        |
| CYP2C8   | Amodiaquine N- Deethylation       | 203.89 ± 44.49           | 0.000        | 0.000        |
| CYP2C9   | Diclofenac 4´ - Hydroxylation     | >300                     | 0.006        | 0.004        |
| CYP2C19  | S- Mephenytoin 4´- Hydroxylation  | >300                     | 0.004        | 0.003        |
| CYP2D6   | Dextromethorphan O- Demethylation | >300                     | 0.014        | 0.015        |
| CYP3A4   | Midazolam 1´- Hydroxylation       | 166.56 ± 12.55           | 0.006        | 0.019        |
| CYP3A4   | Testosterone 6 β - Hydroxylation  | >300                     | 0.007        | 0.011        |

Table 20: In Vitro UGT Inhibition Belzutifan and PT3317 (Metabolite)

|             |                 |                         | MK-6482/belzutifan   | MK-6482/belzutifan                         | PT3317    | PT3317                                     |
|-------------|-----------------|-------------------------|----------------------|--------------------------------------------|-----------|--------------------------------------------|
| UGT Isoform | Test System     | Probe Substrate         | IC50 (µM)            | Inhibition at Highest Concentration Tested | IC50 (µM) | Inhibition at Highest Concentration Tested |
| 1A1         | HLM             | 17b-Estradiol (10 µM)   | >300                 | 41% at 300 µM                              | 149       | 62% at 300 µM                              |
| 1A4         | HLM             | Trifluoperazine (10 µM) | >300                 | 23% at 300 µM                              | >300      | -43% at 300 µM                             |
| 1A6         | HLM             | Deferiprone (10,000 µM) | >300                 | 8% at 300 µM                               | >300      | 13% at 300 µM                              |
| 1A9         | HLM             | Propofol (10 µM)        | >300                 | 13% at 300 µM                              | >300      | 32% at 300 µM                              |
| 2B7         | HLM             | Zidovudine (500 µM)     | >300                 | 25% at 300 µM                              | >300      | 45% at 300 µM                              |
| 2B17        | cDNA- expressed | Scopoletin (100 µM)     | 45                   | 88% at 300 µM                              | >300      | 51% at 300 µM                              |

The in vitro induction potential of belzutifan is described below (Table 21). A mRNA fold induction method was used by the applicant. Findings above relevant cut-offs are highlighted in bold.

Table 21: in vitro induction potential

|                    | Fold induction mRNA   | Fold induction mRNA   | Fold induction mRNA   | Fold induction mRNA   | Fold induction mRNA   | Fold induction mRNA   | Fold induction mRNA   | Fold induction mRNA   | Fold induction mRNA   |
|--------------------|-----------------------|-----------------------|-----------------------|-----------------------|-----------------------|-----------------------|-----------------------|-----------------------|-----------------------|
|                    | CYP1A2                | CYP1A2                | CYP1A2                | CYP2B6                | CYP2B6                | CYP2B6                | CYP3A4                | CYP3A4                | CYP3A4                |
| Concentration (µM) | Lot A                 | Lot B                 | Lot C                 | Lot A                 | Lot B                 | Lot C                 | Lot A                 | Lot B                 | Lot C                 |
| 0.1                | 1.14                  | 0.96                  | 1.12                  | 0.7                   | 1.01                  | 0.67                  | 1.28                  | 1.08                  | 0.86                  |
| 0.3                | 1.2                   | 1.02                  | 1.4                   | 0.63                  | 0.91                  | 0.91                  | 1.46                  | 1.2                   | 1.06                  |
| 1                  | 1.4                   | 1.08                  | 1.53                  | 0.66                  | 0.99                  | 1.16                  | 1.75                  | 1.13                  | 1.66                  |
| 3                  | 1.36                  | 0.81                  | 1.5                   | 0.63                  | 0.81                  | 1.31                  | 2.57                  | 1.26                  | 2.65                  |

<div style=\"page-break-after: always\"></div>

| 10                |   1.59 |   0.88 |   1.33 |   0.81 |   0.89 |   1.53 |   4.91 |   2.27 |   6.2 |
|-------------------|--------|--------|--------|--------|--------|--------|--------|--------|-------|
| 30                |   1.39 |   0.86 |   1.14 |   1.49 |   1.44 |   2.64 |   8.87 |   3.4  |  16.1 |
| Positive control* |  73.8  |  43.9  |  39.1  |  10.4  |  10.4  |  20.1  |   7.35 |   7.67 |  95.6 |

Belzutifan was identified as a Pgp transporter substrate in vitro. The potential for belzutifan or PT3317 to inhibit a panel of transporters is described below (Table 27). Findings above relevant cut-offs are highlighted in bold.

Table 22: In Vitro Transporter Inhibition Belzutifan and PT3317 (Metabolite)

## A) Belzutifan

| Transporter   | Cell Lines     | Probe Substrate              | IC50 (µM)    | Inhibition at Highest Concentration Tested   |
|---------------|----------------|------------------------------|--------------|----------------------------------------------|
| OATP1B1       | HEK293-OATP1B1 | [ 3 H]Pitavastatin (0.1 µ M) | 149.2 ± 11.9 | 49% at 150 µM                                |
| OATP1B3       | HEK293-OATP1B3 | [ 3 H]BSP (0.1 µ M)          | >150         | 21% at 150 µM                                |
| BSEP          | S f 9-BSEP     | [ 3 H]TCA (1 µ M)            | >300         | 19% at 300 µM                                |
| OCT1          | CHO-K1-OCT1    | [ 14 C]metformin (10 µ M)    | 46.9 ± 5.8   | 84% at 300 µM                                |
| OCT2          | HEK293-OCT2    | [ 14 C]metformin (5 µ M)     | 173.4 ± 4.0  | 70% at 300 µM                                |
| OAT1          | MDCKII-OAT1    | [ 3 H]Cidofovir (1 µ M)      | >300         | 17% at 300 µM                                |
| OAT3          | MDCKII-OAT3    | [ 3 H]ES (1 µ M)             | 99.2 ± 24.8  | 77 %at 300 µM                                |
| MATE1         | CHO-K1-MATE1   | [ 14 C]Metformin (5 µM)      | 39.0 ± 9.7   | 75% at 300 µM                                |
| MATE2K        | MDCKII-MATE2K  | [ 14 C]Metformin (5 µM)      | 0.7 ± 0.1    | 93% at 30 µM                                 |
| P-gp          | MDCKII-MDR1    | [ 3 H]Quinidine (0.1 µ M)    | >100         | 11% at 100 µM                                |
| P-gp          | LLC-PK1-MDR1   | [ 3 H]Digoxin (0.1 µ M)      | >100         | 18% at 100 µM                                |
| BCRP          | MDCKII-BCRP    | [ 3 H]Prazosin (2 µ M)       | >100         | -30% at 100 µM                               |
| BCRP          | S f 9-BCRP     | [ 3 H]MTX (10 µ M)           | >300         | 28% at 300 µM                                |

## B) PT3317

| Transporter   | Cell Lines     | Probe Substrate             | IC50 (µM)*   | Inhibition at Highest Concentration Tested   |
|---------------|----------------|-----------------------------|--------------|----------------------------------------------|
| OATP1B1       | HEK293-OATP1B1 | [ 3 H]Pitavastatin (0.1 µM) | 32.6 ± 3.5   | 80% at 150 µM                                |
| OATP1B3       | HEK293-OATP1B3 | [ 3 H]BSP (0.1 µM)          | 74.1 ± 13.4  | 62% at 150 µM                                |
| BSEP          | S f 9-BSEP     | [ 3 H]TCA (1 µM)            | >300         | -4% at 300 µM                                |
| OCT1          | CHO-K1-OCT1    | [ 14 C]metformin (10 µM)    | 215.1 ± 34.4 | 56% at 300 µM                                |
| OCT2          | HEK293-OCT2    | [ 14 C]metformin (5 µM)     | >300         | -10% at 300 µM                               |
| OAT1          | MDCKII-OAT1    | [ 3 H]Cidofovir (1 µM)      | >300         | -26% at 300 µM                               |
| OAT3          | MDCKII-OAT3    | [ 3 H]ES (1 µM)             | >300         | 21% at 300 µM                                |
| MATE1         | CHO-K1-MATE1   | [ 14 C]Metformin (5 µM)     | 74.0 ± 17.2  | 83% at 300 µM                                |
| MATE2K        | MDCKII-MATE2K  | [ 14 C]Metformin (5 µM)     | 14.9 ± 1.3   | 92% at 300 µM                                |
| P-gp          | MDCKII-MDR1    | [ 3 H]Quinidine (0.1 µM)    | >100         | -14% at 100 µM                               |
| P-gp          | LLC-PK1-MDR1   | [ 3 H]Digoxin (0.1 µM)      | >300         | 33% at 300 µM                                |
| BCRP          | MDCKII-BCRP    | [ 3 H]Prazosin (2 µM)       | >100         | -47% at 100 µM                               |
| BCRP          | S f 9-BCRP     | [ 3 H]MTX (10 µM)           | >300         | 12% at 300 µM                                |

## In vivo

Belzutifan is metabolized primarily by UGT2B17 and CYP2C19. Given that UGT2B17 and CYP2C19 are poor metabolizers that have no enzyme activity, the exposure profile observed in patients who are poor metabolizers was extrapolated to support the situation where belzutifan is co-administered with inhibitors of UGT2B17 or CYP2C19 (see section 'Genetic polymorphisms' above).

<div style=\"page-break-after: always\"></div>

The effect of belzutifan on midazolam PK (i.e. CYP3A4 induction) was assessed clinically in Study 009. Following seven daily dose administration of 120-mg belzutifan, the GMR (90% CI) for AUC0-inf for midazolam (midazolam + belzutifan/midazolam alone) was 0.60 (0.53, 0.69), i.e., approximately 40% reduction in AUC0-inf. The AUC0-24 showed an identical GMR (90% CI) of 0.60 (0.53, 0.67). The GMR (90% CI) for Cmax for midazolam (midazolam + belzutifan/midazolam alone) was 0.66 (0.55, 0.78), i.e., approximately 34% reduction in Cmax.

## 2.6.2.2. Pharmacodynamics

Belzutifan binds to HIF-2 α, and in conditions of impairment of VHL protein function, belzutifan blocks the HIF-2 α -HIF-1 β interaction, leading to reduced transcription and expression of HIF-2 α target genes.

HIF-2 α is the principal transcription factor responsible for regulating EPO synthesis in the adult kidney and liver (Haase V.H. Blood Rev. 2013). Consequently, circulating EPO level represents an on-target pharmacodynamic marker of belzutifan activity. Therefore, in the belzutifan programme, EPO as a target engagement marker was explored.

## Primary and Secondary pharmacology

In Study 001 in patients with advanced solid tumours, EPO levels rapidly decreased within hours after initiating belzutifan treatment, continued to decrease thereafter, and reached a plateau at approximately 2 to 3 weeks after initiating treatment (Figure 13). The magnitude of mean EPO reduction at steady state (Day 15) from baseline ranged from approximately -36% to -76% and was generally dose-dependent across the 20- to 120-mg dose range (Table 28). While the average percent change from baseline in the 80 mg and 120-mg groups was similar (-64.9% vs -69.4%), two out of 6 patients in the 80-mg cohort had EPO reductions of ≤ -35% (i.e., percentage change from baseline of ≤ -35%), while all patients in the 120-mg cohort had ≥45% reduction from baseline in EPO (data not shown). In Part 1B, at a dose of 120 mg QD in patients with advanced RCC (n=46), the mean percentage change from baseline in EPO was -65.5% at predose Week 3 (Day 15) timepoint.

<div style=\"page-break-after: always\"></div>

Figure 13: Mean Percentage Change in Erythropoietin From Baseline for First 15 Days - Study 001

<!-- image -->

BID=twice a day; QD=once a day.

Note: Predose values on nominal Day 8 (Week 2) and Day 15 (Week 3) are shown in the figure, representing 7 and 14 days of treatment.

Table 23: Percentage Change in EPO Levels at Week 3 Visit (Nominal Day 15, Predose) From Baseline in the Dose Escalation and Dose Expansion Phase Patients - Study 001

| Dose Cohort       |   Number of Patients (N) | Average %Change from Baseline (Range)   |
|-------------------|--------------------------|-----------------------------------------|
| 20 mg QD          |                        5 | -35.8 (-19.3 to -55.1)                  |
| 40 mg QD          |                        6 | -44.5 (-7.7 to -76.3)                   |
| 80 mg QD          |                        6 | -64.9 (-28.7 to -100.0)                 |
| 120 mg QD Part 1A |                        6 | -69.4 (-45.1 to -89.2)                  |
| 160 mg QD*        |                        5 | -67.8 (-50.0 to -94.7)                  |
| 240 mg QD         |                        7 | -75.7 (-58.7 to -100.0)                 |
| 120 mg BID        |                        5 | -73.0 (-56.2 to -86.2)                  |
| 120 mg QD Part 1B |                       46 | -65.5 (17.8 to -100.0)                  |
| 120 mg QD (All)   |                       52 | -65.9 (17.8 to -100.0)                  |

BID=twice a day; EPO=erythropoietin; QD=once daily.

Note: For 2 patients in Week 4, and 2 patients in Week 5, their post dose assessments were mapped to Week 3 for analysis. *One patient was excluded in the summary data for 160 mg QD dose cohort in this table, as the patient had very low EPO baseline measurement of 2.8 mIU/mL which is lower than the typical lower value of normal physiological reference range (3.5 mIU/mL) and very close to the lower limit of quantitation of 2.5 mIU/mL. This possibly erroneous low baseline value resulted in apparent large increases in percentage change from baseline in all post baseline values for this patient. With the inclusion of this patient, the average % change from baseline (range) in 160 mg QD dose cohort was 63.7 (721.4 to -94.7) for n=6.

N depicts the number of patients who were evaluable for this analysis (non-missing baseline and postbaseline value) in each of the dose cohorts.

In Study 004, at a dose of 120 mg QD in patients with VHL disease (n=52), the mean percentage change from baseline in EPO was -60.2% at pre-dose Week 3 (Day 15) timepoint.

<div style=\"page-break-after: always\"></div>

In Study 005 at a dose of 120 mg QD in patients with advanced RCC (n=318), the mean percentage change from baseline in EPO was -60.2% at pre-dose Week 3 (Day 15) timepoint.

Regarding secondary pharmacology, a clinical study evaluating potential QTc prolongation of belzutifan in healthy participants at higher doses to achieve supratherapeutic exposures of belzutifan was not considered feasible due to mechanism-related safety (anaemia) risks. Therefore, a cardiac safety analysis was performed with data from the Study 004. Data were available from 61 patients and the analyses included results up to Week 13. Based on these results (shown in the Clinical section), once daily dosing with 120 mg belzutifan had no clinically relevant effects on studied QTc or other ECG parameters.

## Table 24: Phase 2 Studies

| Phase 2 studies                                        | Phase 2 studies                                                                                                               | Phase 2 studies                                                                                                                                                   | Phase 2 studies                                                      | Phase 2 studies                                                                                                                                |
|--------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------|
| MK - 6482-004 (PT2977-202) Ongoing; enrolment complete | An Open-Label Phase 2 Study to Evaluate PT2977 for the Treatment of von Hippel-Lindau Disease-Associated Renal Cell Carcinoma | To evaluate the efficacy of MK - 6482 for the treatment of VHL-RCC as measured by ORR per RECIST 1.1 Adults with VHL disease and RCC (N=61)                       | 120 mg once daily MK-6482                                            | Open-label, Phase 2 trial in patients with VHL disease and at least one measurable RCC tumour as defined by RECIST 1.1 with sparse PK sampling |
| MK - 6482-013 Ongoing; enrolment complete              | Phase 2 Study of MK - 6482 in Patients With Advanced Renal Cell Carcinoma                                                     | To compare the 120 mg QD dose and 200 mg QD dose of MK - 6482 with respect to ORR per RECIST 1.1 by BICR. Adults with previously treated advanced ccRCC (N = 154) | 1) 120 mg once daily MK - 6482 versus 2) 200 mg once daily MK - 6482 | Multicentre, randomized, open-label, Phase 2 study comparing the 120 mg and 200 mg QD doses (1:1 randomization)                                |

## PK/PD

## Exposure-Response for Safety in Patients with Advanced RCC (Study 005)

The following safety endpoints were evaluated for Study 005:

- -Anaemia ≥Grade 3 (Hgb ≤7.9 g/dL)
- -Anaemia, all grades
- -Hypoxia ≥ Grade 3 (Decreased oxygen saturation at rest [e.g. , pulse oximeter &lt;88% or PaO2 ≤55 mm Hg])

<div style=\"page-break-after: always\"></div>

- -Hypoxia, all grades
- -Time to first dose reduction
- -Time to first dose interruption
- -Time to dose discontinuation

In Study 005, the median time to onset was 4.14 weeks after the start of treatment for anaemia ≥Grade 3 as well as hypoxia ≥Grade 3 . The median time to onset was 4.14 and 4.21 weeks after the start of treatment for all grades anaemia and hypoxia, respectively. Median onset times occurred after attainment of steady state, supporting the use of steady-state exposures as the appropriate parameter for the exposure-safety analysis.

Table 25: Incidence of Anaemia ≥Grade 3 and At All Grades Stratified by AUCavg Quartiles in MK-6482-005

|                                                                                                                                                               | Quartiles                                                                                                                                                     | Quartiles                                                                                                                                                     | Quartiles                                                                                                                                                     | Quartiles                                                                                                                                                     |                                                                                                                                                               |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                                                                                                                                               | Q1 (N= 95)                                                                                                                                                    | Q2 (N= 95)                                                                                                                                                    | Q3 (N= 94)                                                                                                                                                    | Q4 (N= 95)                                                                                                                                                    | Total (N = 379)                                                                                                                                               |
| AUCavg (µg.h/mL) Mean (range)                                                                                                                                 | 10.1 (5.25 - 12.7)                                                                                                                                            | 15.7 (12.7 - 18.5)                                                                                                                                            | 22.7 (18.6 - 27.4)                                                                                                                                            | 39.7 (27.5 - 128)                                                                                                                                             | 22.0 (5.25-128)                                                                                                                                               |
| Anaemia ≥Grade 3, n (%)                                                                                                                                       | 20 (20)                                                                                                                                                       | 26 (25)                                                                                                                                                       | 32 (34)                                                                                                                                                       | 46 (46)                                                                                                                                                       | 124 (33)                                                                                                                                                      |
| AUCavg (µg.h/mL) Mean (range)                                                                                                                                 | 10.3 (6.06 - 13.1)                                                                                                                                            | 16.2 (13.2 - 19.5)                                                                                                                                            | 23.8 (19.6 - 28.1)                                                                                                                                            | 40.3 (28.1 - 128)                                                                                                                                             | 22.6 (6.06 - 128)                                                                                                                                             |
| Anaemia all grades, n (%)                                                                                                                                     | 71 (75%)                                                                                                                                                      | 75 (79)                                                                                                                                                       | 89 (95)                                                                                                                                                       | 80 (84)                                                                                                                                                       | 315 (83)                                                                                                                                                      |
| Abbreviations: AUCavg=steady-state area under the concentration-time curve based on average dose intensity up to the event; N=number of patients; Q=quartile. | Abbreviations: AUCavg=steady-state area under the concentration-time curve based on average dose intensity up to the event; N=number of patients; Q=quartile. | Abbreviations: AUCavg=steady-state area under the concentration-time curve based on average dose intensity up to the event; N=number of patients; Q=quartile. | Abbreviations: AUCavg=steady-state area under the concentration-time curve based on average dose intensity up to the event; N=number of patients; Q=quartile. | Abbreviations: AUCavg=steady-state area under the concentration-time curve based on average dose intensity up to the event; N=number of patients; Q=quartile. | Abbreviations: AUCavg=steady-state area under the concentration-time curve based on average dose intensity up to the event; N=number of patients; Q=quartile. |

Event incidences for anaemia ≥ Grade 3 and all grades as well as hypoxia ≥Grade 3 and all grades were stratified by exposure quartile for AUCavg (Table 26).

Table 26: Incidence of Anaemia ≥Grade 3 and At All Grades Stratified by AUCavg Quartiles in MK-6482-005

|                               | Quartiles          | Quartiles          | Quartiles          | Quartiles         | Total             |
|-------------------------------|--------------------|--------------------|--------------------|-------------------|-------------------|
|                               | Q1 (N= 95)         | Q2 (N= 95)         | Q3 (N= 94)         | Q4 (N= 95)        | (N = 379)         |
| AUCavg (µg.h/mL) Mean (range) | 10.1 (5.25 - 12.7) | 15.7 (12.7 - 18.5) | 22.7 (18.6 - 27.4) | 39.7 (27.5 - 128) | 22.0 (5.25-128)   |
| Anaemia ≥Grade 3, n (%)       | 20 (20)            | 26 (25)            | 32 (34)            | 46 (46)           | 124 (33)          |
| AUCavg (µg.h/mL) Mean (range) | 10.3 (6.06 - 13.1) | 16.2 (13.2 - 19.5) | 23.8 (19.6 - 28.1) | 40.3 (28.1 - 128) | 22.6 (6.06 - 128) |
| Anaemia all grades, n (%)     | 71 (75%)           | 75 (79)            | 89 (95)            | 80 (84)           | 315 (83)          |

<div style=\"page-break-after: always\"></div>

Table 27: Incidence of Hypoxia ≥Grade 3 and At All Grades Stratified by AUCavg Quartiles in MK-6482-005

|                               | Quartiles          | Quartiles          | Quartiles          | Quartiles          |                    |
|-------------------------------|--------------------|--------------------|--------------------|--------------------|--------------------|
|                               | Q1 (N= 95)         | Q2 (N= 95)         | Q3 (N= 94)         | Q4 (N= 95)         | Total (N = 379)    |
| AUCavg (µg.h/mL) Mean (range) | 10.1 (5.25-12.7)   | 15.8 (12.9 - 18.6) | 22.9 (18.6 - 27.4) | 38.2 (27.4 - 79.3) | 21.7 (5.25 - 79.3) |
| Hypoxia ≥Grade 3, n (%)       | 4 (4)              | 12 (13)            | 11 (12)            | 13 (14)            | 40 (11)            |
| AUCavg (µg.h/mL) Mean (range) | 10.1 (5.25 - 13.0) | 15.8 (13.1 - 18.6) | 22.9 (18.7 - 27.4) | 38.4 (27.4 - 79.3) | 21.8 (5.25 - 79.3) |
| Hypoxia all grades, n (%)     | 6 (6)              | 15 (16)            | 17 (18)            | 18 (19)            | 56 (15)            |

Abbreviations: AUCavg=steady-state area under the concentration-time curve based on average dose intensity up to the event; N=number of patients; Q=quartile.

Model-based simulations illustrating the relationship of anaemia ≥ Grade 3 and at all grades incidences as a function of AUCavg in case of different baseline Hgb (10, 12, and 14 g/dL) are projected in Figure 14.

<div style=\"page-break-after: always\"></div>

Figure 14: Model-Predicted Incidence of Anaemia ≥Grade 3 (Top Panel) and Anaemia at All Grades (Bottom Panel) Versus AUCavg Based on Linear Logistic Regression Model Including AUCavg and Baseline Hgb as Predictors: Three Baseline Hgb Scenarios (10, 12, and 14 g/dL)

<!-- image -->

Note: Solid lines and shaded areas represent model predicted incidence and 95% CI based on the logistic regression fit of the form logit(prob[event]) AUC × slopeAUC + Baseline Hgb × slopeHgb + intercept.

Abbreviations: AUC=area under the concentration-time curve; AUCavg=steady-state AUC based on average dose intensity up to the event; CI=confidence interval; Hgb=haemoglobin.

Efficacy measures for patients with VHL-associated neoplasms did not show a notable trend with exposure (data not shown).

<div style=\"page-break-after: always\"></div>

## Exposure-Response for Safety in Patients with VHL-associated Neoplasms (Study 004)

The following safety endpoints were evaluated for Study 004:

- -Anaemia ≥Grade 3 (Hgb ≤7.9 g/dL)
- -Hypoxia ≥Grade 3 (Decreased oxygen saturation at rest [ e.g. , pulse oximeter &lt;88% or PaO2 ≤55 mm Hg])
- -Time to first dose reduction
- -Time to first dose interruption
- -Time to dose discontinuation

In Study 004, the median time to onset was 48 and 8 weeks after the start of treatment for anaemia ≥ Grade 3 and hypoxia ≥ Grade 3, respectively. Individual times to onset of AE ranged from 8 to 145 weeks. Median onset times occurred after attainment of steady-state, supporting the use of steady-state exposures as the appropriate parameter for the exposure-safety analysis.

## Table 28: Incidence of Anaemia ≥Grade 3 and Hypoxia ≥Grade 3 for MK-6482-004 Stratified by AUCavg Quartiles

|                                                                                          | Quartiles                                                                                | Quartiles                                                                                | Quartiles                                                                                | Quartiles                                                                                |                                                                                          |
|------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------|
|                                                                                          | Q1 (N=24)                                                                                | Q2 (N=23)                                                                                | Q3 (N=23)                                                                                | Q4 (N=24)                                                                                | Total (N=94)                                                                             |
| AUCavg (μg • hr/mL)                                                                      | 5.2 - 10.3                                                                               | 10.4 - 14.8                                                                              | 14.9 - 22                                                                                | 22.3 - 34.2                                                                              | 5.2 - 34.2                                                                               |
| Anaemia ≥Grade 3, n (%)                                                                  | 0 (0)                                                                                    | 1 (7)                                                                                    | 3 (20)                                                                                   | 3 (20)                                                                                   | 7 (11)                                                                                   |
| Hypoxia ≥Grade 3, n (%)                                                                  | 0 (0)                                                                                    | 0 (0)                                                                                    | 0 (0)                                                                                    | 1 (7)                                                                                    | 1 (2)                                                                                    |
| AUCavg=average area under the concentration-time curve until event; N=number; Q=quartile | AUCavg=average area under the concentration-time curve until event; N=number; Q=quartile | AUCavg=average area under the concentration-time curve until event; N=number; Q=quartile | AUCavg=average area under the concentration-time curve until event; N=number; Q=quartile | AUCavg=average area under the concentration-time curve until event; N=number; Q=quartile | AUCavg=average area under the concentration-time curve until event; N=number; Q=quartile |

Baseline Hgb was also evaluated as an independent predictor for the incidence of anaemia ≥ Grade 3. Figure 15 presents plots of anaemia ≥ Grade 3 incidence by baseline Hgb quartile together with a linear logistic regression fit. A statistically significant baseline Hgb relationship was found for anaemia ≥ Grade 3, with higher incidences for anaemia ≥ Grade 3 for the lower quartile of baseline Hgb.

<div style=\"page-break-after: always\"></div>

Figure 15:Incidence of Anaemia ≥Grade 3 Versus Baseline Hgb, With Incidence Grouped by Baseline Hgb Quartiles and a Linear Logistic Regression Fit

Study 4

<!-- image -->

Notes: Open squares represent individual values, represent subjects with event (at the top) and subjects with no event (at the bottom). Observations were jittered for improved visualization. Numbers depict n/N for each exposure quartile, with n being number of subjects with an event and N being total number of subjects.

Solid dot and vertical line represent incidence and 95% CI of observation at mean exposure within quartile; solid line represents logistic regression fit of the form logit(prob[event]) AUC × slope + intercept; dashed lines represent 95% CI; and horizontal lines represent width of exposure quartiles.

Mean baseline Hgb in Study 1: 12.2 g/dL; Mean baseline Hgb in Study 4: 13.8 g/dL

Abbreviations: CI=confidence interval; Hgb=haemoglobin.

Based on this finding, baseline Hgb was introduced in the logistic regression model and data from Study 001 and Study 004 were pooled.

Subsequently, a logistic regression was performed on the pooled data of both studies for anaemia ≥ Grade 3 incidence, including both exposure and baseline Hgb as predictors. Parameter estimates for this model are presented in Table 34 and model-based simulations illustrating the relationship of anaemia ≥ Grade 3 incidence as a function of AUCavg in case of different baseline Hgb (10, 12, and 14 g/dL) are projected in Figure 16.

<div style=\"page-break-after: always\"></div>

Table 29: Parameter Estimates of the Logistic Regression Model for Incidence of Anaemia ≥Grade 3 Including AUCavg and Baseline Hgb as Predictors Based on MK-6482-001 and MK-6482-004

| Parameter    |   Estimate |   Standard Error |   P value |
|--------------|------------|------------------|-----------|
| Intercept    |    7.639   |          2.335   | 0.00107   |
| AUCavg       |    0.07253 |          0.02643 | 0.006073  |
| Baseline Hgb |   -0.8872  |          0.1961  | 6.037e-06 |

Figure 16: Model-Predicted Incidence of Anaemia ≥Grade 3 Versus AUCavg Based on Linear Logistic Regression Model Including AUCavg and Baseline Hgb as Predictors: Three Baseline Hgb Scenarios (10, 12 and 14 g/dL)

<!-- image -->

Average AUC until event (ug.h/mL)

Notes: Solid lines and shaded areas represent model predicted incidence and 95% CI based on the logistic regression fit of the form logit(prob[event]) AUC × slopeAUC + Baseline Hgb × slopeHgb + intercept.

Abbreviations: AUCavg=steady-state AUCss based on average dose intensity up to the event; Hgb=haemoglobin,

## Dose justification

Study 001 was a combined dose-escalation and dose-expansion trial in patients with advanced solid tumours. In this study, no MTD was reached at up to 240 mg per day and the RP2D of 120 mg QD was selected as the optimal biological dose based on safety, PK, and pharmacodynamics considerations of possible plateauing of exposure and pharmacodynamic (EPO) response at this dose.

The exposure (Cmax and AUC0-tau) of belzutifan generally increased with doses from 20 to 120 mg QD, then was generally comparable at higher QD dose within the limit of 240 mg QD as the highest studied QD dose.

<div style=\"page-break-after: always\"></div>

## 2.6.3. Discussion on clinical pharmacology

The belzutifan clinical pharmacology development programme evaluated the PK and pharmacodynamics of belzutifan in patients with VHL-associated neoplasms, non-RCC solid tumours, and healthy participants. Specifically, PK has been characterised using 11 phase I clinical studies (see Table 16). In addition, PK samples were obtained in phase II and phase III studies. Generally, this is considered sufficient for characterisation of PK at the proposed dose of 120 mg, as the majority of the studies were conducted using this dose. The validation of the bioanalytical methods for the studies included in the clinical pharmacology programme is in line with the most recent guideline (i.e., ICH M10) and is adequately reported. Therefore, the PK parameters estimate derived from the clinical PK studies are considered acceptable. PK has further been analysed using popPK and PBPK models, which is further described below.

## PopPK modelling

The popPK model development shows a structured approach and followed a prespecified pharmacometrics analysis plan. The model is mainly descriptive and used to study effect of potential covariates (e.g., genetic polymorphisms) on exposure. In addition, the model is used for exposure-response analysis. Dense PK data is available for healthy volunteers and RCC patients from phase I studies. Sparse samples are available from the phase II and III studies. The data included is sufficient for the description of a complete pharmacokinetic profile for the intended dose regimen of 120 mg once daily (i.e., N=8256 observations from 807 subjects were included in the model). Handling of outliers was sufficiently documented and ~15% of the observed samples were BLQ, which is considered acceptable.

A 2 compartment structure was selected in the base model. Subsequently, candidate covariates were entered into the model using a stepwise selection procedure. This procedure involves stepwise testing of linear and non-linear relationships in a forward inclusion (objective function value [OFV] of 6.63, p &lt; 0.01 for 1 degree of freedom [DF]) and a backward exclusion step (OFV of 10.8, p &lt; 0.001 for 1 DF). Model equations and final parameter estimates are reported. Model parameters were estimated with reasonable precision (all relative standard errors [RSE] below 37.4%). In addition, pcVPCs provided per individual study indicated adequate predictive performance of the model. The impact of intrinsic/extrinsic factors on PK can therefore be evaluated and exposure estimates for PK-PD modelling can be obtained using the final popPK model described.

Although the established popPK model appeared to be reasonably accurate, the high shrinkage on the established volume of distribution suggests overprediction. Therefore, further clarification of the reasoning and possible clinical impact was requested during the procedure. The model qualification performed by the applicant is considered acceptable as a prediction-corrected visual prediction check (pcVPC) and a nonparametric bootstrap analysis were presented demonstrating the robustness of the final population pharmacokinetic (PK) model. The final population PK model successfully predicted the observed median, 5th, and 95th percentiles of observed drug concentrations.

## PBPK modelling

The PBPK model was used to evaluate the induction effect of belzutifan on midazolam in the Caucasian and Japanese population. Model development was sufficiently described. Absorption and distribution parameters were fitted/optimized to measured data and clearance parameters were derived from retrograde calculation using in vivo derived clearance and the expected relative contribution of the elimination pathways. Observed belzutifan data in Caucasian and Japanese could sufficiently be predicted. The data in 05PFJ7, however, indicates that induction effects were initially overpredicted, most likely due to suboptimal parametrization of

<div style=\"page-break-after: always\"></div>

induction parameters. Therefore, the clinical data from study 009 was used to update/optimize the induction parameters. As expected, the PBPK model predicted DDI subsequently closer to the values reported in the clinical study. Importantly, although data for higher belzutifan exposures is sparse, model predictions were in line with the individual belzutifan exposure vs midazolam AUC ratio data.

## Absorption

Despite being a Pgp substrate, the effect on bioavailability is considered limited/absent at the proposed dose, based on the mass balance study results (only trace amounts of the dose is recovered unchanged in faeces). In addition, from the in vitro experiments it also appears that transporter activity is limited. Considering the high in vitro passive permeability (34.3 × 10-6 cm/s across MDR1-MDCK cell monolayer) and the fact that belzutifan is a weak transporter substrate, clinically relevant effects of Pgp activity on exposure are not expected.

The (worst case) effect of food was evaluated using the 2 formulations used in the clinical pharmacology programme (FFP and FMI). The AUC is not affected by a high-fat, high-calorie meal whereas Cmax and Tmax are 24% reduced and ~2h delayed, respectively as AUC is most likely the driving factor for efficacy. In addition, the drug could be taken irrespective of food in the phase II and III studies. The method of administration is adequately described in the SmPC section 4.2, where it states that the tablets should be swallowed whole and may be taken with or without food.

The Cmax of the FMF was 13% lower than the FFP, i.e. a slight reduction. However, as the most likely parameter driving efficacy is expected to be the AUC, the reduction in Cmax likely will not have a large influence on the efficacy/safety profile. The relative bioequivalence data provided therefore supports a bridge between the FFP and FMF formulation.

## Distribution

Volumes of distribution (central and peripheral) were quantified using popPK analysis and are acceptable. Protein binding (45%) and blood-to-plasma ratio were determined using equilibrium dialysis at 10 uM and 1 uM, respectively, which is around the clinically relevant exposure. Protein binding was not tested in a range of clinically relevant concentrations. As the plasma binding is moderate, saturation of proteins binding is not expected and the value reported can in this case be accepted.

## Elimination

The mass balance study was performed with a single dose of 120 mg, which is the proposed dose in the SmPC. Around 100% of the dose administered was recovered. In addition, the accumulation ratio after multiple dosing is low (Study 001). Routes of excretion based on mass balance data are considered predictive also for multiple dosing.

## Metabolism

The elimination pathways are plausible. Belzutifan is metabolized via UGT2B17 to form the glucuronic acid metabolite M16 (PT3317) and via CYP2C19 and to a lesser extent CYP3A4 to form oxidative metabolites, including the hydroxylated metabolite M9. In addition, the data on genetic polymorphisms (i.e., UGT2B17 and CYP2C19 poor metabolisers) indicates that especially UGT2B17 is of major relevance and a contribution of CYP2C19 is also expected. From the exposure increase in CYP2C19 poor metabolizers it appears, however, that CYP2C19 is only responsible for part of elimination via hydroxylation (~20% of total elimination).

In vitro MK-6482 metabolism was determined by incubation with recombinant human enzymes. Metabolism was observed following incubation with CYP2C19 and to a lesser extent with CYP3A4. No metabolism was

<div style=\"page-break-after: always\"></div>

observed following incubation with CYP1A1, 1A2, 1B1, 2A6, 2B6, 2C8, 2C9, 2D6, 2E1, or 3A5. Although metabolism was observed to a lesser extent with CYP3A4 compared to CYP2C19, CYP3A4 protein abundance in humans in vivo is higher than CYP2C19 abundance. The applicant indicated that for UGT2B17/CYP2C19 PM/PM subjects, CYP3A4 could be a major elimination pathway. This is reflected in SmPC section 5.2. (SmPC)

It is agreed that M16 is the only metabolite at levels approaching a major metabolite (i.e. 9% of total radioactivity in plasma). This metabolite is shown to be not pharmacologically active and is expected to be renally excreted.

## Dose linearity and time dependency

Conflicting data has been shown regarding dose proportionality for doses above 120 mg in study 006 (exposure is dose proportional) and 001 (exposure is less than dose proportional). However, as study 006 was performed cross-over with 18 subjects, results will give a more precise prediction of exposure compared to study 001 (N=6, parallel study). Therefore, these results are considered more reliable. Exposure parameters are expected to linearly increase with dose between 120 mg and 200 mg.

It is noted that in study 001 doses are not dose proportional in the range 20 mg to 40 mg (i.e., &gt;3 fold increase in AUC with 2 fold increase in dose). Between the 40 mg and 120 mg dose increase in exposure is roughly dose proportional, considering the small number of subjects and the relatively large inter-individual variability. The range where belzutifan exposure is expected to be dose proportional is specified in SmPC section 5.2 where it states that plasma Cmax and AUC increased proportionally over a dose range of 40 mg to 120 mg.

A time dependent effect on exposure was not evident. The mean accumulation ratio of 1.49 (parent) and 1.42 (metabolite PT3317) are reasonably close to what is expected based on the half-lives and the dose interval in study 001.

## Special populations

For the majority of the sub-populations (gender, ethnic factors, weight, and age) exposure parameters (especially AUC) are retained within or close to 80-125% of the exposure found in a typical subject of 60 years old, weighing 78 kg, UGT2B17 EM and CYP2C19 EM/IM. Considering the large inter-individual variation (CV% AUCss 68.8%), these differences are unlikely clinically meaningful. No need for dose adjustments in the mentioned populations is therefore expected. The PI clarifies that based on a population pharmacokinetic analysis, age (range: 19 to 90 years), gender, ethnicity, race, and body weight (range: 42.1 to 166 kg) do not have a clinically meaningful effect on the pharmacokinetics of belzutifan.

Based on popPK analysis, the exposure metrics were comparable for all study subjects who were dosed at 120 mg QD, regardless of their hepatic or renal function. Data from dedicated pharmacokinetic studies in patients with impaired renal and hepatic function, which became available during the assessment, supports dosing recommendations in the Product Information, 120 mg belzutifan (three 40 mg tablets) administered once daily. Exposure change with age is relatively modest (-23% to 17% over the 5th to 95th percentile range) and dose adjustment is therefore not required.

## Genetic polymorphism

Differences in exposures between phenotypes for UGT2B17 and CYP2C19 have been studied using popPK modelling. Sufficient numbers of individuals for the different phenotype categories were included in the analysis (CYP2C19: PM=60, EM/IM=523, RM/UR=201, UGT2B17: PM=143, IM=355, and EM=289). However, the applicant was requested to indicate how many subjects were included in the popPK model that were

<div style=\"page-break-after: always\"></div>

CYP2C19-UGT2B17 dual poor metabolisers (and evaluate whether this is sufficient) and describe the therapeutic window. From the current analysis dataset it is indicated that belzutifan concentration data from 35 UGT2B17/CYP2C19 dual poor metabolizers were included in the popPK model. In addition, the effects of UGT2B17/CYP2C19 dual poor metaboliser status were informed by UGT2B17/CYP2C19 single poor metaboliser effects on clearance in the model, for which more subjects have been included, which was accepted. It is acknowledged that the therapeutic window is likely wide, due to the high interindividual variability, although clear limits have not been defined. The effect of phenotypes on exposure has sufficiently been described in 5.2 of the SmPC, where it is highlighted that although no dose adjustment is recommended, dual UGT2B17 and CYP2C19 poor metabolisers have higher belzutifan exposures, which may increase the incidence and severity of adverse reactions of belzutifan and should be closely monitored.

## Interactions-victim

No in vivo DDI studies have been performed with typical inhibitors of UGT2B17 and CYP2C19. Exposure in poor metabolisers is expected to be similar to the effect of a strong inhibitor of that pathway. A study with the strong CYP2C19 inducer rifampicin is recommended as post-approval measure (REC).  The applicant discussed how induction of UGT2B17 was evaluated. Major DDI effects on belzutifan in clinical practice are unlikely due to the absence of strong UGT2B17 inducers. This is reassuring. Interactions-perpetrator

Belzutifan or the M16 (PT3317) metabolite is not expected to inhibit CYP enzymes via competitive inhibition. Although for in vitro data IC50 was calculated instead of Ki, the tested substrate concentrations are reasonably close to the expected Km and therefore IC50/2 can be used as an estimate for Ki. The range of belzutifan concentrations tested (0.39-300 μ M) is sufficient and substrates and positive control inhibitors used were largely in line with examples mentioned in the draft ICH M12 guideline and EMA drug interaction guidance (https://www.ema.europa.eu/en/investigation-drug-interactions-scientific-guideline). For time dependent CYP inhibition a threshold of 0.01 minute-1 was used.

The frequency of concomitant usage of both sensitive and moderately sensitive substrates of CYP2C8 and CYP2B6 with belzutifan appears to be low. In addition, it is generally expected that the belzutifan induction effects for CYP2C8 and CYP2B6 will be less compared to effects on CYP3A4 (i.e. 40% reduction midazolam exposure). An in vivo clinical DDI study is therefore not considered required. Preliminary result on an in vitro induction report supported this notion. Coadministration of belzutifan with CYP3A4 substrates, including hormonal contraceptives, decreases concentrations of CYP3A4 substrates, which may reduce the efficacy of these substrates. The magnitude of this decrease may be more pronounced in patients who are dual UGT2B17 and CYP2C19 poor metabolisers.

Coadministration of belzutifan with hormonal contraceptives may therefore lead to contraceptive failure or an increase in breakthrough bleeding. This risk is clearly reflected in the SmPC section 4.5.

Belzutifan is not expected to be an (in vitro) inhibitor of UGT1A1, 1A4, 1A6, 1A9, or 2B7. Probe substrates chosen were appropriate. A potential for inhibition of UGT2B17 by belzutifan was identified based on in vitro evaluations. In principle an in vivo study was expected however the feasibility of an in vivo study was hampered by the availability of a sensitive substrate. It is agreed that a more than dose proportional increase in exposure would also be expected with increasing doses of belzutifan in case inhibition UGT2B17 inhibition would be clinically relevant, due to the importance of UGT2B17 in elimination. Of note, it is also considered reassuring that due to the absence of sensitive UGT2B17 substrates, major DDI effects in clinical practice are more unlikely.

<div style=\"page-break-after: always\"></div>

The induction potential, studied using the mRNA fold change method, confirmed that belzutifan is not an inducer of CYP1A2 (mRNA) and CYP2C19 (mRNA and enzyme activity) in vitro. The induction effect of belzutifan on CYP2C9 is expected not to be clinically relevant based on reference to literature investigations. However, it is not ruled out that belzutifan would be a (weak) inducer of CYP2C8 and CYP2B6. The SmPC reflects that that belzutifan is a CYP2B6 and CYP2C8 inducer in vitro, and that in vivo investigations have not yet been performed. The frequency of concomitant usage of both sensitive and moderately sensitive substrates of CYP2C8 and CYP2B6 with belzutifan appears to be low. In addition, it is generally expected that the belzutifan induction effects for CYP2C8 and CYP2B6 will be less compared to effects on CYP3A4 (i.e. 40% reduction midazolam exposure). An in vivo clinical DDI study is therefore not considered required.

CYP3A4 induction effects of belzutifan were studied with midazolam as a probe substrate in 15 healthy volunteers. Participants received midazolam 2 mg on Day 1, belzutifan 120 mg daily on Days 2 to 7, and belzutifan 120 mg co-administered with midazolam 2 mg on Day 8. Six days of dosing of MK-6482 prior to midazolam co-administration was used in study 009. The applicant justified that CYP3A4 activity reached a new steady state within 6 days based on PBPK modelling results in the second round of assessment.

Belzutifan also appeared to be a potential inhibitor of transporters OATP1B1, OATP1B3, OAT3, OCT1 MATE1 and MATE2K based on in vitro evaluation in the first round. Probe substrates and positive control inhibitors are in line with guidelines described above. In principle, an in vivo study should be performed (e.g. using substrates as mentioned in draft guideline ICH M12), unless the applicant is able to justify absence of such a study. The argumentation that the values Cinl,max,u/IC50 or Cmax,u/IC50 are below the threshold in ICHM12 for OATP-1B1, -1B3 and OAT3, which is currently finalized, is agreed. Therefore, an effect on these transporters can be excluded. In addition, absence of an effect on OCT1 has sufficiently been supported by the applicant. The applicant is recommended to perform an in vivo study to evaluate the effect of belzutifan on a sensitive MATE1 and MATE2K substrate (e.g. metformin, as indicated in ICHM12) (REC). Calculated Cinl,max,u/IC50 and Cmax,u/IC50 values for belzutifan interaction with MATE1 and MATE2K exceed the defined thresholds in ICHM12 guideline. The inhibition of these transporters is therefore currently considered clinically relevant and included in SmPC sections 4.5. and 5.2 (until in vivo data becomes available). The SmPC wording reads that based on in vitro data, MATE- 2K inhibition by belzutifan is expected at clinically relevant exposures, and inhibition of MATE1 cannot be excluded.

Lastly, belzutifan concentrations tested were too low for the assessment of the Pgp and BCRP inhibitory effect. However, as the inhibition at the highest concentration was low, and the highest concentration were only slightly below the cut-off (100 vs.. 129µM), this is not raised as a concern.

## Primary pharmacology

EPAS1 (the gene name for HIF-2 α) mRNA is expressed in most human tissues, with the highest expression in the lung, followed by the artery, adipose, thyroid, and mammary tissue. Human genetics suggest that constitutive activation of HIF-2 α is involved in tumorigenesis. However, there are several reports suggesting that HIF-2 α might play a tumour suppressor role in some contexts. Lower levels of HIF-2 α were observed in human sarcoma, lung or hepatic tumours in a number of studies. In addition, a number of mouse studies have shown that HIF-2 α may play a suppressive role in some tumour contexts. Therefore, uncertainties still exist regarding the actual role of HIF-2 α in tumorigenesis and the potential consequences of pharmacologically inhibiting HIF-2 α. Given these uncertainties, there is no clear pharmacological basis to support the use of belzutifan in non-clear RCC.

PD effects of belzutifan were measured by suppression of EPO to confirm target engagement. Within the studies 001, 004 and 005, belzutifan showed a rapid decrease of EPO levels after the treatment initiation,

<div style=\"page-break-after: always\"></div>

with a plateau reached at 2-3 weeks after initiating treatment. This supports the target engagement of belzutifan, i.e. inhibition HIF-1-alpha. Overall, the limited clinical PD data provide some support for the MoA, but the lack of a specific surrogate marker for efficacy is noted, although inclusion of such additional marker has been previously advised by the CHMP. The applicant, however, explained that a systemic biomarker that correlates with efficacy has not yet been identified, even though several tumour models have been investigated.

HIF-2 α is the principal transcription factor responsible for regulating EPO synthesis and consequently, circulating EPO level represents an on-target pharmacodynamic marker of belzutifan activity. Therefore, in the belzutifan programme, EPO as a target engagement marker was explored. The provided data give some support for the proposed dose of 120 mg QD from a primary pharmacology point of view.

## Secondary pharmacology

A cardiac safety analysis with data from Study 004 showed that once daily dosing with 120 mg belzutifan had no clinically relevant effects on studied QTc or other ECG parameters. Even though Study 004 is no conventional thorough QT/QTc study, this matter will not be pursued further, as i) the non-clinical evaluations do not indicate a QTc prolongation risk; and ii) no concerns arose during the safety assessment (i.e. very few [n=4] AEs possibly related to QT/QTc interval prolongation have been reported, of which only a single case (0.2%) of ventricular arrhythmia was considered drug-related. The following information ' At the recommended dose (120 mg once daily) for belzutifan, there were no clinically relevant effects on the QTc interval. ', is included in section 5.1 of the SmPC.

## PD interactions

No clinical data has been provided on potential PD interactions with other medicinal products. Potential PD interactions with VEGF TKIs were assessed in non-clinical RCC studies in RCC xenograft mice and no tolerability issues or PD interactions were observed.

## PK/PD

Although a relationship between exposure and ≥ grade 3 anaemia has been described, these events are expected to be manageable in clinical practice. For hypoxia (≥ grade 3 hypoxia and all grades hypoxia) the relationship between exposure and safety events is flatter. Therefore, it is expected that relatively few events can be prevented by a lower starting dose (e.g. in UGT2B17 poor metabolizers having higher exposures). An approach for dose reduction/discontinuation in the SmPC for both events of anaemia and hypoxia have been included in section 4.2 of the SmPC A dose of 120 mg for all patients, despite a high inter individual variability in exposure is therefore considered acceptable from a safety perspective.

KM curves for OS stratified by quartiles for belzutifan exposure were provided for aRCC. The KM curves for Q1 to Q3 exposures highly overlapped, with Q4 exposure curve separated. The OS data for belzutifan at IA1 and IA2 is consistent. The data suggest that there is a positive trend between exposures and OS.

## Dose justification

The proposed posology of 120 mg QD is considered sufficiently justified from a primary pharmacology point of view and based on the efficacy and safety data from the pivotal studies 005 and 004.

<div style=\"page-break-after: always\"></div>

## 2.6.4. Conclusions on clinical pharmacology

In general, the PK of belzutifan has sufficiently been described. Further investigations are needed regarding potential DDIs and will be conducted post-approval measures (RECs):

- A study with the strong CYP2C19 inducer to assess effect on belzutifan (victim) exposure is recommended
- In vivo study to evaluate the effect of belzutifan on a sensitive MATE1 and MATE2K substrate (e.g. metformin, as indicated in ICHM12).

## 2.6.5. Clinical efficacy

The applicant applies for two indications, see section 2.1.1. Study MK-6482-005 is the pivotal study for the advanced RCC indication and Study MK-6482-004 is the pivotal study for the VHL disease indication.

## 2.6.5.1. Dose response study(ies)

See the subsections 'PK/PD' and 'Dose justification' at the end of the clinical pharmacology section.

Prior to initiation of the pivotal clinical studies 004 and 005, no dedicated dose-response study had been performed.

More recently though, the Phase 2 Study 013 (Table 11; Agarwal et al. Ann Oncol. 2023 [abstract]) was conducted. Study 013 is an ongoing, open-label, multicentre, Phase 2 study to evaluate the efficacy and safety of belzutifan 200 mg QD and 120 mg QD in patients with advanced ccRCC that has progressed on or after systemic treatment with an anti-PD-1/L1 monotherapy or in combination with other agents (up to three prior systemic regimens) and who had measurable disease per RECIST 1.1. A total of 154 patients were randomized in a 1:1 ratio to receive either 200 mg QD (n=78) or 120 mg QD (n=76) of belzutifan. The primary objective was to compare belzutifan 200 mg QD and 120 mg QD with respect to objective response rate (ORR) based on RECIST 1.1 as assessed by blinded independent central review (BICR). The secondary endpoints included PFS (by BICR per RECIST 1.1), DOR, OS and safety. Demographics and baseline disease characteristics were generally well balanced for the two dose groups (ITT population). Belzutifan 200 mg QD was not superior to belzutifan 120 mg QD as assessed by ORR per RECIST 1.1 by BICR and no clinically meaningful differences were noted in PFS or OS between the two dose groups. The safety profiles of the two dose groups were generally similar, but the belzutifan 200 mg QD dose was associated with a higher rate of overall dose modifications and drug discontinuation, and a higher rate of intervention for the treatment of anaemia.

<div style=\"page-break-after: always\"></div>

## 2.6.5.2. Main studies

## RCC Indication

MK-6482-005: An Open-label, Randomized Phase 3 Study of MK-6482 Versus Everolimus in Participants with Advanced Renal Cell Carcinoma That Has Progressed After Prior PD-1/L1 and VEGF-Targeted Therapies

## Methods

Study MK-6482-005 (hereafter referred to as Study 005; LITESPARK-005; NCT04195750; EudraCT Number: 2019-003444-72; Choueiri et al. N Engl J Med. 2024) is an open-label, randomized phase 3 study comparing belzutifan vs everolimus in patients with unresectable, locally advanced or metastatic ccRCC that has progressed after prior PD-1/L1 and VEGF-targeted therapies (up to 3 prior treatment regimens).

At randomization, patients were stratified based on IMDC prognostic scores (0 vs 1-2 vs 3-6) and number of prior VEGF/VEGF receptor-targeted therapies for advanced RCC (1 vs 2-3) and were randomly assigned in a 1:1 ratio to receive either belzutifan (120 mg QD) or everolimus (10 mg QD). Patients were evaluated radiologically at Week 9 Day 1 from the date of randomization, then Q8W thereafter through Week 49, and then Q12W thereafter. The study design is depicted in Figure 17 .

Figure 17: Study 005 Schema

<!-- image -->

BICR=blinded independent central review; IMDC=International Metastatic Renal Cell Carcinoma Database Consortium; QD=once daily; RCC=renal cell carcinoma; VEGF=vascular endothelial growth factor.

a  Patients who discontinue study treatment for reasons other than BICR-verified disease progression should continue with imaging assessments per the protocol-defined schedule until disease progression is BICR-verified, initiation of a new anticancer treatment, death, withdrawal of consent or study conclusion or early termination, whichever occurs first.

## Study Participants

Key inclusion criteria were as follows:

1. Had unresectable, locally advanced or metastatic ccRCC.
2. Had measurable disease per RECIST 1.1 as assessed by the local site investigator/radiology.

<div style=\"page-break-after: always\"></div>

3. Had demonstrated radiographic disease progression on or after having received systemic treatment for locally advanced or metastatic RCC with both: PD-1/L1 checkpoint inhibitor and VEGF-TKI in sequence or in combination.
4. Had received no more than 3 prior systemic regimens for locally advanced or metastatic RCC.
5. Was at least 18 years of age, had haemoglobin ≥ 10 g/dL, and had a KPS score of at least 70%.

Key exclusion criteria were as follows:

1. Had any of the following: i) hypoxia as defined by pulse oximeter reading &lt;92% at rest; OR ii) required intermittent supplemental oxygen; OR iii) required chronic supplemental oxygen.
2. Had known CNS metastases and/or carcinomatous meningitis.

Note: Patients with previously treated brain metastases may have participated provided they were radiologically stable (i.e., without evidence of progression) for at least 4 weeks (28 days).

3. Had clinically significant cardiac disease OR poorly controlled hypertension OR moderate to severe hepatic impairment (Child-Pugh B or C).

## Treatments

Patients were randomized (1:1) to receive either belzutifan (120 mg QD) or everolimus (10 mg QD).

Dose modification approach are included in section 4.2 of the Belzutifan SmPC. For patients on the everolimus arm, dose adjustments and the management of AEs was to be made as described in the everolimus SmPC (Afinitor SmPC).

Treatment continued until documented radiographic disease progression (BICR verified), unacceptable AEs, intercurrent illness that prevented further administration of treatment, investigator's decision to discontinue the patient, patient withdrawal of consent, pregnancy of the patient, or administrative reasons requiring cessation of treatment.

Treatment could be continued after radiographic progression, as long as the investigator believed that the patient was still receiving clinical benefit from study intervention and that the potential benefit of continuing study intervention outweighs potential risks.

## Objectives and Outcomes/endpoints

The Study 005 objectives and endpoints are shown in Table 35. The dual primary endpoints were PFS by BICR per RECIST 1.1 and OS.

Table 30: Study 005 Objectives and Endpoints

| Objectives                                                                                                                                                                                      | Endpoints                                                                                                                          |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------|
| Primary                                                                                                                                                                                         |                                                                                                                                    |
| • To compare belzutifan to everolimus with respect to PFS per RECIST 1.1 as assessed by BICR. Hypothesis (H1): Belzutifan is superior to everolimus with respect to PFS per RECIST 1.1 by BICR. | • PFS : the time from randomization to the first documented disease progression or death due to any cause, whichever occurs first. |

<div style=\"page-break-after: always\"></div>

| Objectives                                                                                                                                                                                                                                                               | Endpoints                                                                                                                                                                              |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| • To compare belzutifan to everolimus with respect to OS. Hypothesis (H2): Belzutifan is superior to everolimus with respect to OS.                                                                                                                                      | • OS : the time from randomization to death due to any cause.                                                                                                                          |
| Secondary                                                                                                                                                                                                                                                                |                                                                                                                                                                                        |
| • To compare belzutifan to everolimus with respect to ORR based on RECIST 1.1 as assessed by BICR. Hypothesis (H3): Belzutifan increases ORR according to RECIST 1.1 by BICR compared to everolimus.                                                                     | • ORR : the proportion of patients with a BOR of either confirmed CR or PR.                                                                                                            |
| • To evaluate the DOR as assessed by BICR according to RECIST 1.1.                                                                                                                                                                                                       | • DOR : the time from first documented evidence of CR or PR until either disease progression or death due to any cause, whichever occurs first.                                        |
| • To evaluate the safety and tolerability of belzutifan compared to everolimus.                                                                                                                                                                                          | • AEs. • Study intervention discontinuation due to AEs.                                                                                                                                |
| • To evaluate TTD and change from baseline in HRQoL using the EORTC QLQ-C30 and the FKSI-DRS.                                                                                                                                                                            | PRO scores for the following domains: - EORTC QLQ-C30 global health status/HRQoL (Items 29 and 30), - EORTC QLQ-C30 physical functioning*(Items 1-5), - FKSI-DRS Subscale (Items 1-9). |
| • To characterize health utility as measured using the EuroQoL EQ-5D-5L.                                                                                                                                                                                                 | • Health utility scores*from the EQ-5D-5L.                                                                                                                                             |
| Tertiary/Exploratory                                                                                                                                                                                                                                                     |                                                                                                                                                                                        |
| • To evaluate the PK of belzutifan administered orally as monotherapy.                                                                                                                                                                                                   | • Steady-state trough concentration (C trough ).                                                                                                                                       |
| • To investigate the relationship between the genetic polymorphisms of UGT2B17 and CYP2C19 and the PK and response of belzutifan. Variation in UGT2B17 and CYP2C19 alleles may be analysed for association with any laboratory or clinical data collected in this study. | • Germline genetic variation in UGT2B17 and CYP2C19 and association to PK and laboratory/clinical data.                                                                                |

## Sample size

The planned sample size was approximately 736 patients. Approximately 483 deaths were expected at the final OS analysis. With 483 deaths, the study has ~85% power for detecting an HR of 0.75 at an initially assigned 0.019 (1-sided) significance level. Approximately ~626 events were expected at the final PFS analysis (i.e., the second IA of the study). With 626 PFS events, the study has ~97% power for detecting an HR of 0.70 at an initially assigned 0.005 (1-sided) significance level. Based on all randomized patients, the power of the ORR testing at the allocated α=0.001 was approximately 99.9% to detect a 15-percentage point difference between an underlying 5% response rate in the control arm and a 20% response rate in the experimental arm.

<div style=\"page-break-after: always\"></div>

## Randomisation and Blinding (masking)

At randomization, patients were stratified based on IMDC prognostic scores (0 vs 1-2 vs 3-6) and number of prior VEGF/VEGFR-targeted therapies for advanced RCC (1 vs 2-3) and were randomly assigned in a 1:1 ratio to receive either belzutifan (120 mg QD) or everolimus (10 mg QD).

Treatment allocation occurred centrally using an interactive response technology system which implemented a randomized allocation schedule(s) for study treatment assignment generated by the applicant.

This is an open-label study. Central imaging review was, however, performed by independent radiologists without knowledge of treatment assignment.

## Statistical methods

## Table 31: Study 005 Summary of Analysis Strategy for Key Efficacy Endpoints

| Analysis Populations                                                                                                                                                                                                                                                                            | Efficacy: ITT (all randomized patients); Safety: APaT (all randomized patients who received at least 1 dose of study treatment); PRO: FAS (all randomized patients who had at least 1 PRO assessment and at least 1 dose of study intervention)                                                                                                                                                         | Efficacy: ITT (all randomized patients); Safety: APaT (all randomized patients who received at least 1 dose of study treatment); PRO: FAS (all randomized patients who had at least 1 PRO assessment and at least 1 dose of study intervention)                                                                                                                                                         |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Statistical Methods for Key Efficacy Analyses                                                                                                                                                                                                                                                   | The primary hypotheses comparing belzutifan to everolimus with respect to PFS and OS was evaluated using a stratified log-rank test. The HR was estimated using a stratified Cox regression model. Event rates over time were estimated within each treatment group using the KM method. The stratified Miettinen and Nurminen method with strata weighted by sample size was used for analysis of ORR. | The primary hypotheses comparing belzutifan to everolimus with respect to PFS and OS was evaluated using a stratified log-rank test. The HR was estimated using a stratified Cox regression model. Event rates over time were estimated within each treatment group using the KM method. The stratified Miettinen and Nurminen method with strata weighted by sample size was used for analysis of ORR. |
| Statistical Methods for Key Safety Analyses                                                                                                                                                                                                                                                     | For analyses in which 95% CIs were provided for between-treatment differences in the percentage of patients with events, these analyses were performed using the Miettinen and Nurminen method.                                                                                                                                                                                                         | For analyses in which 95% CIs were provided for between-treatment differences in the percentage of patients with events, these analyses were performed using the Miettinen and Nurminen method.                                                                                                                                                                                                         |
| Interim and Final Analyses                                                                                                                                                                                                                                                                      | IA1                                                                                                                                                                                                                                                                                                                                                                                                     | • Timing: planned to be performed after ~563 PFS events had occurred AND ~7 months after last patient randomized. NOTE: IA1 could take place if the PFS events accrued slower than expected when patients had been followed up for ~7 months and ~525 PFS events had occurred. • Primary purpose: efficacy analyses for PFS, OS, and ORR.                                                               |
| Interim and Final Analyses                                                                                                                                                                                                                                                                      | IA2                                                                                                                                                                                                                                                                                                                                                                                                     | • Timing: to be performed after ~410 OS events have occurred AND at least 17 months after last patient randomized. • Primary purpose: efficacy analyses for OS and PFS (final analysis).                                                                                                                                                                                                                |
| Interim and Final Analyses                                                                                                                                                                                                                                                                      | FA                                                                                                                                                                                                                                                                                                                                                                                                      | • Timing: to be performed after ~483 OS events have occurred AND ~27 months after last patient randomized. • Primary purpose: efficacy analysis for OS.                                                                                                                                                                                                                                                 |
| APaT=all patients as treated; CI=confidence intervals; FA=final analysis; FAS=full analysis set; HR=hazard ratio; IA=interim analysis; ITT=intention-to-treat; KM=Kaplan-Meier; ORR=objective response rate; OS=overall survival; PFS=progression-free survival; PRO=patient-reported outcomes. | APaT=all patients as treated; CI=confidence intervals; FA=final analysis; FAS=full analysis set; HR=hazard ratio; IA=interim analysis; ITT=intention-to-treat; KM=Kaplan-Meier; ORR=objective response rate; OS=overall survival; PFS=progression-free survival; PRO=patient-reported outcomes.                                                                                                         | APaT=all patients as treated; CI=confidence intervals; FA=final analysis; FAS=full analysis set; HR=hazard ratio; IA=interim analysis; ITT=intention-to-treat; KM=Kaplan-Meier; ORR=objective response rate; OS=overall survival; PFS=progression-free survival; PRO=patient-reported outcomes.                                                                                                         |

Table 37 and Table 38 present the estimand and censoring strategy for the dual primary endpoint of PFS.

Two sensitivity analyses of the PFS primary analysis were performed with different sets of censoring rules. Sensitivity analysis 1 follows the ITT principle. That is, disease progressions/deaths are counted as events regardless of missed study visits or initiation of new anticancer therapy.

Sensitivity analysis 2 considers discontinuation of treatment due to reasons other than CR or initiation of new anticancer treatment, whichever occurs later, to be a disease progression event for patients without documented disease progression or death. If a patient meets multiple criteria for censoring, the censoring criterion that occurs earliest will be applied.

In addition, a supportive analysis for PFS using investigator assessment was conducted.

<div style=\"page-break-after: always\"></div>

Table 32: Estimand for PFS (Dual Primary) (Compiled from the Assessment Team)

| •   | Population                                                                                                                                                                                              | • Adults with advanced RCC that have progressed after prior PD-1/L1 and VEGF-targeted therapies.                                                                                                                                                                                                      |
|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| •   | Treatment condition<s>                                                                                                                                                                                  | • Belzutifan (120 mg QD) vs everolimus (10 mg QD)                                                                                                                                                                                                                                                     |
| •   | Endpoint (variable)                                                                                                                                                                                     | • Progression-free survival, defined as the time from randomisation to the first documented disease progression or death due to any cause, whichever occurs first. • Determination of disease progression was based on RECIST 1.1 criteria and assessed by blinded independent central review (BICR). |
| •   | Population- level summary                                                                                                                                                                               | • Median PFS; Percentage of patients alive and progression free at 6, 9, 12, 18, and 24 months. • The hazard ratio for belzutifan vs everolimus will also be presented.                                                                                                                               |
| •   | Intercurrent events and strategy to handle them                                                                                                                                                         | Intercurrent events and strategy to handle them                                                                                                                                                                                                                                                       |
| •   | New anti- cancer treatment                                                                                                                                                                              | • Hypothetical (From censoring strategy: Censored at last disease assessment before new anti-cancer treatment)                                                                                                                                                                                        |
| •   | Treatment discontinuation (and no other intercurrent event)                                                                                                                                             | • Treatment policy                                                                                                                                                                                                                                                                                    |
| •   | Additional note: For the primary PFS analysis, follow up times for patients were censored if disease progression or death documented immediately after two or more consecutive assessments were missed. | Additional note: For the primary PFS analysis, follow up times for patients were censored if disease progression or death documented immediately after two or more consecutive assessments were missed.                                                                                               |

Description of primary estimand for PFS: In adults with advanced RCC that have progressed after prior PD1/L1 and VEGF-targeted therapies, what is the difference between belzutifan (120 mg QD) and everolimus (10 mg QD) in time to BICR-assessed progression or death, in the situation where alternative anti-cancer therapies are not available and regardless of treatment discontinuation?

<div style=\"page-break-after: always\"></div>

Table 33: Censoring Rules for Primary and Sensitivity PFS Analyses

| Situation                                                                                                                                  | Primary Analysis                                                                                                                            | Sensitivity Analysis 1                                                 | Sensitivity Analysis 2                                                                                                                                                                                 |
|--------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Disease progression or death documented after ≤1 missed disease assessment, and before new anticancer therapy, if any                      | Progressed at date of documented disease progression or death                                                                               | Progressed at date of documented disease progression or death          | Progressed at date of documented disease progression or death                                                                                                                                          |
| Disease progression or deathdocumented immediately after≥2 consecutive missed disease assessments or after new anti-cancer therapy, if any | Censored at last disease assessment prior to the earlierdate of≥2 consecutive missed disease assessments and new anticancer therapy, if any | Progressed at date of documented disease progression or death          | Progressed at date of documented disease progression or death                                                                                                                                          |
| No disease progression and no death; new anticancer treatment is not initiated                                                             | Censored atlast disease assessment                                                                                                          | Censored atlast disease assessment                                     | Progressed at treatment discontinuation due to reasons other than CR: otherwise censored at last disease assessment if participant is still receiving study treatment or has completed study treatment |
| No disease progression and no death; new anticancer treatmentis initiated                                                                  | Censored at last disease assessment before new anticancer treatment                                                                         | Censored at last disease assessment                                    | Progressed at date of new anticancer treatment                                                                                                                                                         |
| Abbreviations: CR = complete response; PFS = progression-free survival                                                                     | Abbreviations: CR = complete response; PFS = progression-free survival                                                                      | Abbreviations: CR = complete response; PFS = progression-free survival | Abbreviations: CR = complete response; PFS = progression-free survival                                                                                                                                 |

Table 34: Estimand for OS (Dual Primary) (Compiled from the Assessment Team)

| • Population                                      | • Adults with advanced RCC that have progressed after prior PD-1/L1 and VEGF-targeted therapies                                                 |
|---------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------|
| • Treatment condition<s>                          | • Belzutifan (120 mg QD) vs everolimus (10 mg QD)                                                                                               |
| • Endpoint (variable)                             | • Overall survival, defined as the time from randomisation to death.                                                                            |
| • Population- level summary                       | • Median OS; Percentage of patients alive at 6, 12, 18, 24 and 30 months. The hazard ratio for belzutifan vs everolimus will also be presented. |
| • Intercurrent events and strategy to handle them | • Intercurrent events and strategy to handle them                                                                                               |
| • New anti- cancer treatment                      | • Treatment policy                                                                                                                              |
| • Treatment discontinuation                       | • Treatment policy                                                                                                                              |

<div style=\"page-break-after: always\"></div>

Description of estimand for OS: In adults with advanced RCC that have progressed after prior PD-1/L1 and VEGF-targeted therapies, what is the difference between belzutifan (120 mg QD) and everolimus (10 mg QD) in time to death, regardless of treatment discontinuation or use of new anti-cancer therapy?

The overall type I error rate over the primary and secondary hypotheses is controlled at 2.5% (1-sided), with 0.5% initially allocated to PFS (H1), 1.9% initially allocated to OS (H2) and 0.1% initially allocated to ORR (H3). By using the graphical approach of Maurer and Bretz, if one hypothesis is rejected, the alpha will be shifted to other hypotheses (Figure 18).

Figure 18: Multiplicity Diagram for Type I Error Control (One-Sided)

<!-- image -->

Subgroup analyses were planned for PFS, OS, and ORR; among other things per the stratification factors but also per number of prior lines of therapy (1 vs 2 vs 3).

## Results

## Recruitment and participant flow

This study is ongoing; key study milestone dates are listed in Table 40.

Table 35: Study 005 Key Study Milestones

| First Patient, First Visit   | Data Cutoff      | Database Lock Date   |
|------------------------------|------------------|----------------------|
| 27-FEB-2020                  | IA1: 01-NOV-2022 | IA1: 08-DEC-2022     |
| 27-FEB-2020                  | IA2: 13-JUN-2023 | IA2: 20-JUL-2023     |
| 27-FEB-2020                  | FA: 15-APR-2024  | FA: 23-MAY-2024      |

At IA1, the median duration of follow-up was 13.5 months (range: 0.2 to 31.8 months) and was similar for the 2 intervention groups. At IA2, the median duration of follow-up was 17.8 months (range: 0.2 to 39.1 months) and similar between the 2 groups.

<div style=\"page-break-after: always\"></div>

A total of 996 patients with advanced RCC were screened, and 746 patients across 147 sites in 23 countries (Brazil, Canada, Chile, Colombia, Czech Republic, Denmark, Finland, France, Germany, Hong Kong, Hungary, Italy, Japan, Norway, Russia, South Korea, Spain, Sweden, Taiwan, Turkey, UK, Ukraine, and US) were randomized and are thus included in the ITT population for analysis of efficacy Figure 19. Nine patients were enrolled in a Japan Safety Run-in Cohort. These patients were not randomized to treatment in the study; all received belzutifan. These patients are not included in the ITT population.

A total of 732 patients (372 in the belzutifan group and 360 in the everolimus group) received at least 1 dose of study intervention. All non-allocated patients were screen failures who did not meet inclusion or exclusion criteria.

Figure 19: Study 005 Participant Flow

<!-- image -->

Abbreviations: APaT=all patients as treated; I/E=inclusion/exclusion; ITT=intent-to-treat.

a  See Clinical AR for the reasons for not meeting I/E criteria.

Data cutoff: 13-JUN-2023

<div style=\"page-break-after: always\"></div>

## Conduct of the study

The original protocol was finalized on 30-SEP-2019 and amended as described in Table 36 (Japan-specific amendments not shown). All amendments were completed prior to the database cut-off dates of 01-NOV2022 for IA1.

Table 36: Study 005 Protocol Amendments

| Document (Date of Issue)   | Overall Rationale                                                                                                                                                                                                                                                                                                                                                            |
|----------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Amendment 6 (13-JUL-2022)  | To update the timing of statistical analyses and reduce the total number of interim analyses in the study.                                                                                                                                                                                                                                                                   |
| Amendment 4 (16-FEB-2021)  | To update contraception appendix to align with programme-wide requirements.                                                                                                                                                                                                                                                                                                  |
| Amendment 2 (14-MAY-2020)  | To provide an update of the preclinical toxicology section to reflect recent preclinical toxicology findings, provide inclusion/exclusion criteria clarifications and/or refinement, provide clarifications on the Schedule of Assessment procedures, and enact minor language changes throughout the protocol to provide clarifications and ensure consistency in language. |
| Amendment 1 (18-DEC-2019)  | To add a safety run-in component for Japan to ensure the correct dose of belzutifan is used in that patient population.                                                                                                                                                                                                                                                      |

Regarding Amendment 6 (13-JUL-2022), the following additional information was provided:

| Section#andName                                                                                                                                                                             | Description of Change                                                                                                                                                                                                                                                                                                                                                                  | BriefRationale                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 9.1 Statistical Analysis Plan Summary 9.7.1 Efficacy Interim Analysis 9.8.1 Objective Response Rate 9.8.2 Progression-free Survival 9.8.3OverallSurvival 9.9SampleSizeandPower Calculations | Updated number of IAs from 3 to 2. Update accrualdurationfrom18to22 months. Update dropout rate for PFS per BIRC analyses from10%to20%. Update timing of the ORR analysis at IA1 instead of IA2. Update expected timing (and follow up time) for statistical analyses. Update target/expected event number and analysis timing for PFS and OS; update correspondingpower andboundaries | Updated to align with Section 4.1. Actual accrual was longer than planned. A higher dropout rate than assumed was observed based onblinded event monitoringforPFSBIRC. ORR expected to be sufficiently mature at IAl given the longer enrollment and updated minimum follow up time for IA1. CombineIA1 andIA2intoIA1 and adjustexpected follow-up time for new IA1 for more data maturity and to reduce study complexity. UpdatetimingofsubsequentIA/FAtoavoidmultiple analysesin closeproximity of each other. |

Important protocol deviations were reported for 280 patients (37.5%). These primarily concerned safety reporting, i.e., in 229 patients (30.7%), meaning that the patient had a reportable safety event and/or follow up safety event information that was not reported per the timelines outlined in the protocol. None of these important protocol deviations were considered clinically important. No patient's data were, therefore, excluded from analysis due to an important protocol deviation.

<div style=\"page-break-after: always\"></div>

## Baseline data

Table 37 shows the patients' baseline demographic and disease characteristics.

Table 37: Study 005 Patient Characteristics (ITT Population)

746

581

(77.9)

165

(22.1)

433

(58.0)

313

(42.0)

237

(31.8)

70

6

62.4

10.0

63.0

5

90

(12.1)

8

17

1

588

(78.8)

37

164

(22.0)

373

(50.0)

209

(28.0)

478

(64.1)

266

(35.7)

2

325

(43.6)

410

(55.0)

11

162

(21.7)

493

(66.1)

91

(12.2)

|                                     | Belzutifan   | Belzutifan   | Everolimus   | Everolimus   | Total   | Total   |
|-------------------------------------|--------------|--------------|--------------|--------------|---------|---------|
|                                     | n            | (%)          | n            | (%)          | n       | (%)     |
| Patients in population              | 374          |              | 372          |              | 746     |         |
| Sex                                 |              |              |              |              |         |         |
| Male                                | 297          | (79.4)       | 284          | (76.3)       | 581     | (77.9)  |
| Female                              | 77           | (20.6)       | 88           | (23.7)       | 165     | (22.1)  |
| Age (Years)                         |              |              |              |              |         |         |
| < 65                                | 232          | (62.0)       | 201          | (54.0)       | 433     | (58.0)  |
| >= 65                               | 142          | (38.0)       | 171          | (46.0)       | 313     | (42.0)  |
| >=65 to <75                         | 105          | (28.1)       | 132          | (35.5)       | 237     | (31.8)  |
| >=75 to <85                         | 33           | (8.8)        | 37           | (9.9)        | 70      | (9.4)   |
| >=85                                | 4            | (1.1)        | 2            | (0.5)        | 6       | (0.8)   |
| Mean                                | 61.6         |              | 63.1         |              | 62.4    |         |
| SD                                  | 10.2         |              | 9.7          |              | 10.0    |         |
| Median                              | 62.0         |              | 63.0         |              | 63.0    |         |
| Range                               | 22 to        | 90           | 33 to        | 87           | 22 to   | 90      |
| Race                                |              |              |              |              |         |         |
| American Indian Or Alaska Native    | 3            | (0.8)        | 2            | (0.5)        | 5       | (0.7)   |
| Asian                               | 43           | (11.5)       | 47           | (12.6)       | 90      | (12.1)  |
| Black Or African American           | 4            | (1.1)        | 4            | (1.1)        | 8       | (1.1)   |
| Multiple                            | 6            | (1.6)        | 11           | (3.0)        | 17      | (2.3)   |
| Native Hawaiian Or Other Pacific    | 0            | (0.0)        | 1            | (0.3)        | 1       | (0.1)   |
| White                               | 297          | (79.4)       | 291          | (78.2)       | 588     | (78.8)  |
| Missing                             | 21           | (5.6)        | 16           | (4.3)        | 37      | (5.0)   |
| Geographic Region of Enrolling Site |              |              |              |              |         |         |
| North America                       | 75           | (20.1)       | 89           | (23.9)       | 164     | (22.0)  |
| Western Europe                      | 191          | (51.1)       | 182          | (48.9)       | 373     | (50.0)  |
| Rest of the World                   | 108          | (28.9)       | 101          | (27.2)       | 209     | (28.0)  |
| Karnofsky Performance Scale         |              |              |              |              |         |         |
| 90/100                              | 238          | (63.6)       | 240          | (64.5)       | 478     | (64.1)  |
| 70/80                               | 135          | (36.1)       | 131          | (35.2)       | 266     | (35.7)  |
| Missing                             | 1            | (0.3)        | 1            | (0.3)        | 2       | (0.3)   |
| ECOG Performance Status             |              |              |              |              |         |         |
| 0                                   | 161          | (43.0)       | 164          | (44.1)       | 325     | (43.6)  |
| 1                                   | 208          | (55.6)       | 202          | (54.3)       | 410     | (55.0)  |
| 2                                   | 5            | (1.3)        | 6            | (1.6)        | 11      | (1.5)   |
| IMDC Risk Categories                |              |              |              |              |         |         |
| Favourable                          | 79           | (21.1)       | 83           | (22.3)       | 162     | (21.7)  |
| Intermediate                        | 249          | (66.6)       | 244          | (65.6)       | 493     | (66.1)  |
| Poor                                | 46           | (12.3)       | 45           | (12.1)       | 91      | (12.2)  |

<div style=\"page-break-after: always\"></div>

66

680

(91.2)

698

(93.6)

47

1

73

503

(67.4)

169

(22.7)

1

85

(11.4)

66

164

(22.0)

425

(57.0)

6

518

(69.4)

228

(30.6)

377

(50.5)

369

(49.5)

98

(13.1)

323

(43.3)

319

(42.8)

6

| 1                                                     | 34                                                    | (9.1) (90.9)                                          | 32 340                                                | (8.6) (91.4)                                          | 66 680                                                | (8.8)                                                 |
|-------------------------------------------------------|-------------------------------------------------------|-------------------------------------------------------|-------------------------------------------------------|-------------------------------------------------------|-------------------------------------------------------|-------------------------------------------------------|
| >= 2                                                  | 340                                                   |                                                       |                                                       |                                                       |                                                       | (91.2)                                                |
| RCC Histology                                         | RCC Histology                                         | RCC Histology                                         | RCC Histology                                         | RCC Histology                                         | RCC Histology                                         | RCC Histology                                         |
| Clear Cell                                            | 347                                                   | (92.8)                                                | 351                                                   | (94.4)                                                | 698                                                   | (93.6)                                                |
| Clear Cell Component                                  | 26                                                    | (7.0)                                                 | 21                                                    | (5.6)                                                 | 47                                                    | (6.3)                                                 |
| Missing                                               | 1                                                     | (0.3)                                                 | 0                                                     | (0.0)                                                 | 1                                                     | (0.1)                                                 |
| Sarcomatoid Feature                                   | Sarcomatoid Feature                                   | Sarcomatoid Feature                                   | Sarcomatoid Feature                                   | Sarcomatoid Feature                                   | Sarcomatoid Feature                                   | Sarcomatoid Feature                                   |
| Yes                                                   | 42                                                    | (11.2)                                                | 31                                                    | (8.3)                                                 | 73                                                    | (9.8)                                                 |
| No                                                    | 255                                                   | (68.2)                                                | 248                                                   | (66.7)                                                | 503                                                   | (67.4)                                                |
| Unknown                                               | 77                                                    | (20.6)                                                | 92                                                    | (24.7)                                                | 169                                                   | (22.7)                                                |
| Missing                                               | 0                                                     | (0.0)                                                 | 1                                                     | (0.3)                                                 | 1                                                     | (0.1)                                                 |
| RCC Stage at Initial Diagnosis                        | RCC Stage at Initial Diagnosis                        | RCC Stage at Initial Diagnosis                        | RCC Stage at Initial Diagnosis                        | RCC Stage at Initial Diagnosis                        | RCC Stage at Initial Diagnosis                        | RCC Stage at Initial Diagnosis                        |
| I                                                     | 39                                                    | (10.4)                                                | 46                                                    | (12.4)                                                | 85                                                    | (11.4)                                                |
| II                                                    | 34                                                    | (9.1)                                                 | 32                                                    | (8.6)                                                 | 66                                                    | (8.8)                                                 |
| III                                                   | 84                                                    | (22.5)                                                | 80                                                    | (21.5)                                                | 164                                                   | (22.0)                                                |
| IV                                                    | 216                                                   | (57.8)                                                | 209                                                   | (56.2)                                                | 425                                                   | (57.0)                                                |
| Missing                                               | 1                                                     | (0.3)                                                 | 5                                                     | (1.3)                                                 | 6                                                     | (0.8)                                                 |
| Prior Nephrectomy                                     | Prior Nephrectomy                                     | Prior Nephrectomy                                     | Prior Nephrectomy                                     | Prior Nephrectomy                                     | Prior Nephrectomy                                     | Prior Nephrectomy                                     |
| Yes                                                   | 260                                                   | (69.5)                                                | 258                                                   | (69.4)                                                | 518                                                   | (69.4)                                                |
| No                                                    | 114                                                   | (30.5)                                                | 114                                                   | (30.6)                                                | 228                                                   | (30.6)                                                |
| Number of prior VEGF/VEGF receptor targeted therapies | Number of prior VEGF/VEGF receptor targeted therapies | Number of prior VEGF/VEGF receptor targeted therapies | Number of prior VEGF/VEGF receptor targeted therapies | Number of prior VEGF/VEGF receptor targeted therapies | Number of prior VEGF/VEGF receptor targeted therapies | Number of prior VEGF/VEGF receptor targeted therapies |
| 1                                                     | 187                                                   | (50.0)                                                | 190                                                   | (51.1)                                                | 377                                                   | (50.5)                                                |
| 2-3                                                   | 187                                                   | (50.0)                                                | 182                                                   | (48.9)                                                | 369                                                   | (49.5)                                                |
| Number of prior lines of therapy                      | Number of prior lines of therapy                      | Number of prior lines of therapy                      | Number of prior lines of therapy                      | Number of prior lines of therapy                      | Number of prior lines of therapy                      | Number of prior lines of therapy                      |
| 1                                                     | 46                                                    | (12.3)                                                | 52                                                    | (14.0)                                                | 98                                                    | (13.1)                                                |
| 2                                                     | 157                                                   | (42.0)                                                | 166                                                   | (44.6)                                                | 323                                                   | (43.3)                                                |
| 3                                                     | 169                                                   | (45.2)                                                | 150                                                   | (40.3)                                                | 319                                                   | (42.8)                                                |
| 4                                                     | 2                                                     | (0.5)                                                 | 4                                                     | (1.1)                                                 | 6                                                     | (0.8)                                                 |

## Prior systemic anticancer therapies

Prior 1L systemic anticancer therapies were received by 100% of patients, prior 2L systemic anticancer therapies by 86.9%, and prior 3L systemic anticancer therapies by 43.6%. Table 43 shows the most commonly received prior systemic anticancer therapies.

<div style=\"page-break-after: always\"></div>

Table 38: Most Common (≥2% in Each Group) Prior Therapy Agents (ITT Population)

| Prior Therapy—no. (%)*                        | Belzutifan (N = 374)   | Everolimus (N = 372)   |
|-----------------------------------------------|------------------------|------------------------|
| First Line                                    | N = 374                | N = 372                |
| Sunitinib                                     | 115 (30.7)             | 115 (30.9)             |
| Pazopanib or pazopanib hydrochloride          | 85 (22.7)              | 74 (19.9)              |
| Nivolumab + ipilimumab                        | 54 (14.4)              | 49 (13.2)t             |
| Pembrolizumab + axitinib                      | 30 (8.0)               | 42 (11.3)              |
| Nivolumab+ cabozantinib                       | 14 (3.7)               | 14 (3.8)               |
| Avelumab + axitinib                           | 9 (2.4)                | 11 (3.0)               |
| Cabozantinibt                                 | 7 (1.9)                | 9 (2.4)                |
| Investigational drug + nivolumab + ipilimumab | 3 (0.8)                | 9 (2.4)                |
| Second Line                                   | N=328                  | N =320                 |
| Nivolumab                                     | 142 (38.0)             | 124 (33.3)             |
| Cabozantinibt                                 | 70 (18.7)              | 73 (19.6)              |
| Sunitinib                                     | 29 (7.8)               | 31 (8.3)               |
| Axitinib                                      | 21 (5.6)               | 26 (7.0)               |
| Pazopanib or pazopanib hydrochloride          | 13 (3.5)               | 14 (3.8)               |
| Nivolumab + ipilimumab                        | 12 (3.2)               | 12 (3.2)               |
| Third Line                                    | N = 171                | N = 154                |
| Cabozantinibt                                 | 82 (21.9)              | 54 (14.5)              |
| Nivolumab                                     | 42 (11.2)              | 58 (15.6)              |
| Axitinib                                      | 13 (3.5)               | 17 (4.6)               |

## Baseline demographic and disease characteristics of patients subgroup

Table 44  shows the baseline demographic and disease characteristics of the subgroup of patients that received two or more lines of therapy that included a PD-(L)1 inhibitor and at least two VEGF-targeted therapies.

Table 39: Study 005 Patient Characteristics (ITT Population with ≥2 Prior VEGF-Targeted Therapies)

369

291

(78.9)

78

(21.1)

|                        | Belzutifan   | Belzutifan   | Everolimus   | Everolimus   | Total   | Total   |
|------------------------|--------------|--------------|--------------|--------------|---------|---------|
|                        | n            | (%)          | n            | (%)          | n       | (%)     |
| Patients in population | 187          |              | 182          |              | 369     |         |
| Sex                    |              |              |              |              |         |         |
| Male                   | 148          | (79.1)       | 143          | (78.6)       | 291     | (78.9)  |
| Female                 | 39           | (20.9)       | 39           | (21.4)       | 78      | (21.1)  |
| Age (Years)            |              |              |              |              |         |         |

<div style=\"page-break-after: always\"></div>

220

(59.6)

149

(40.4)

220

(59.6)

107

(29.0)

42

(11.4)

62.4

9.6

63.0

2

43

(11.7)

5

6

1

287

(77.8)

25

85

(23.0)

203

(55.0)

81

(22.0)

229

(62.1)

140

(37.9)

156

(42.3)

207

(56.1)

6

81

(22.0)

243

(65.9)

45

(12.2)

28

341

(92.4)

344

(93.2)

24

1

28

253

(68.6)

88

(23.8)

43

(11.7)

34

90

(24.4)

| < 65                                | 120        | (64.2)   | 100      | (54.9)   | 220      | (59.6)   |
|-------------------------------------|------------|----------|----------|----------|----------|----------|
| >= 65                               | 67         | (35.8)   | 82       | (45.1)   | 149      | (40.4)   |
| < 65                                | 120        | (64.2)   | 100      | (54.9)   | 220      | (59.6)   |
| >=65 to <75                         | 45         | (24.1)   | 62       | (34.1)   | 107      | (29.0)   |
| >=75 to <85                         | 22         | (11.8)   | 20       | (11.0)   | 42       | (11.4)   |
| Mean                                | 62.0       |          | 62.8     |          | 62.4     |          |
| SD                                  | 9.3        |          | 9.9      |          | 9.6      |          |
| Median                              | 62.0       |          | 63.5     |          | 63.0     |          |
| Range                               | 40 to 81   |          | 33 to 82 |          | 33 to 82 |          |
| Race                                |            |          |          |          |          |          |
| American Indian Or Alaska Native    | 2          | (1.1)    | 0        | (0.0)    | 2        | (0.5)    |
| Asian                               | 20         | (10.7)   | 23       | (12.6)   | 43       | (11.7)   |
| Black Or African American           | 2          | (1.1)    | 3        | (1.6)    | 5        | (1.4)    |
| Multiple                            | 2          | (1.1)    | 4        | (2.2)    | 6        | (1.6)    |
| Native Hawaiian Or Other Pacific    | 0          | (0.0)    | 1        | (0.5)    | 1        | (0.3)    |
| Islander White                      | 147        | (78.6)   | 140      | (76.9)   | 287      | (77.8)   |
| Missing                             | 14         | (7.5)    | 11       | (6.0)    | 25       | (6.8)    |
| Geographic Region of Enrolling Site |            |          |          |          |          |          |
| North America                       | 46         | (24.6)   | 39       | (21.4)   | 85       | (23.0)   |
| Western Europe                      | 104        | (55.6)   | 99       | (54.4)   | 203      | (55.0)   |
| Rest of the World                   | 37         | (19.8)   | 44       | (24.2)   | 81       | (22.0)   |
| Karnofsky Performance Scale         |            |          |          |          |          |          |
| 90/100                              | 116        | (62.0)   | 113      | (62.1)   | 229      | (62.1)   |
| 70/80                               | 71         | (38.0)   | 69       | (37.9)   | 140      | (37.9)   |
| ECOG Performance Status             |            |          |          |          |          |          |
| 0                                   | 77         | (41.2)   | 79       | (43.4)   | 156      | (42.3)   |
| 1                                   | 106        | (56.7)   | 101      | (55.5)   | 207      | (56.1)   |
| 2                                   | 4          | (2.1)    | 2        | (1.1)    | 6        | (1.6)    |
| IMDC Risk Categories                |            |          |          |          |          |          |
| Favourable                          | 40         | (21.4)   | 41       | (22.5)   | 81       | (22.0)   |
| Intermediate                        | 122        | (65.2)   | 121      | (66.5)   | 243      | (65.9)   |
| Poor                                | 25         | (13.4)   | 20       | (11.0)   | 45       | (12.2)   |
| Number of Organs Involved with      | Disease at | Baseline |          |          |          |          |
| 1                                   | 17         | (9.1)    | 11       | (6.0)    | 28       | (7.6)    |
| >= 2                                | 170        | (90.9)   | 171      | (94.0)   | 341      | (92.4)   |
| RCC Histology                       |            |          |          |          |          |          |
| Clear Cell                          | 172        | (92.0)   | 172      | (94.5)   | 344      | (93.2)   |
| Clear Cell Component                | 14         | (7.5)    | 10       | (5.5)    | 24       | (6.5)    |
| Missing                             | 1          | (0.5)    | 0        | (0.0)    | 1        | (0.3)    |
| Sarcomatoid Feature                 |            |          |          |          |          |          |
| Yes                                 | 14         | (7.5)    | 14       | (7.7)    | 28       | (7.6)    |
| No                                  | 132        | (70.6)   | 121      | (66.5)   | 253      | (68.6)   |
| Unknown                             | 41         | (21.9)   | 47       | (25.8)   | 88       | (23.8)   |
| RCC Stage at Initial Diagnosis      |            |          |          |          |          |          |
| I                                   | 18         | (9.6)    | 25       | (13.7)   | 43       | (11.7)   |
| II                                  | 20         | (10.7)   | 14       | (7.7)    | 34       | (9.2)    |
| III                                 | 51         | (27.3)   | 39       | (21.4)   | 90       | (24.4)   |

<div style=\"page-break-after: always\"></div>

201

(54.5)

1

274

(74.3)

95

(25.7)

369

63

(17.1)

300

(81.3)

6

| IV                                                    | 97                                                    | (51.9)                                                | 104                                                   | (57.1)                                                | 201                                                   | (54.5)                                                |
|-------------------------------------------------------|-------------------------------------------------------|-------------------------------------------------------|-------------------------------------------------------|-------------------------------------------------------|-------------------------------------------------------|-------------------------------------------------------|
| Missing                                               | 1                                                     | (0.5)                                                 | 0                                                     | (0.0)                                                 | 1                                                     | (0.3)                                                 |
| Prior Nephrectomy                                     |                                                       |                                                       |                                                       |                                                       |                                                       |                                                       |
| Yes                                                   | 142                                                   | (75.9)                                                | 132                                                   | (72.5)                                                | 274                                                   | (74.3)                                                |
| No                                                    | 45                                                    | (24.1)                                                | 50                                                    | (27.5)                                                | 95                                                    | (25.7)                                                |
| Number of prior VEGF/VEGF receptor targeted therapies | Number of prior VEGF/VEGF receptor targeted therapies | Number of prior VEGF/VEGF receptor targeted therapies | Number of prior VEGF/VEGF receptor targeted therapies | Number of prior VEGF/VEGF receptor targeted therapies | Number of prior VEGF/VEGF receptor targeted therapies | Number of prior VEGF/VEGF receptor targeted therapies |
| 2-3                                                   | 187                                                   | (100.0)                                               | 182                                                   | (100.0)                                               | 369                                                   | (100.0)                                               |
| Number of prior lines of therapy                      | Number of prior lines of therapy                      | Number of prior lines of therapy                      | Number of prior lines of therapy                      | Number of prior lines of therapy                      | Number of prior lines of therapy                      | Number of prior lines of therapy                      |
| 2                                                     | 27                                                    | (14.4)                                                | 36                                                    | (19.8)                                                | 63                                                    | (17.1)                                                |
| 3                                                     | 158                                                   | (84.5)                                                | 142                                                   | (78.0)                                                | 300                                                   | (81.3)                                                |
| 4                                                     | 2                                                     | (1.1)                                                 | 4                                                     | (2.2)                                                 | 6                                                     | (1.6)                                                 |
| Database Cutoff Date: 01NOV2022                       | Database Cutoff Date: 01NOV2022                       | Database Cutoff Date: 01NOV2022                       | Database Cutoff Date: 01NOV2022                       | Database Cutoff Date: 01NOV2022                       | Database Cutoff Date: 01NOV2022                       | Database Cutoff Date: 01NOV2022                       |

## Numbers analysed

The ITT population serves as the population for primary efficacy analyses, which included all 746 patients (374 belzutifan; 372 everolimus) randomized to study intervention according to the intervention group to which they were randomized.

The APaT (all patients as treated) population is used for the analysis of safety data in this study, which included all 732 randomized patients who received at least 1 dose of study intervention (372 belzutifan; 360 everolimus).

## Outcomes and estimation

## Primary efficacy endpoints - progression-free survival

## ITT population

At IA1, Study 005 met the predefined success criterion for superiority based on PFS, one of the dual primary endpoints ( Table 45 ;Figure 20 ).

Table 40: Study 005 Interim Analysis 1 - Analysis of Progression-Free Survival (Primary Censoring Rule) Based on BICR per RECIST 1.1 (ITT Population) DCO 01-NOV-2022

|                                                                                    | Belzutifan (N=374)   | Everolimus (N=372)   |
|------------------------------------------------------------------------------------|----------------------|----------------------|
| Number of Events (%)                                                               | 257 (68.7)           | 262 (70.4)           |
| Death                                                                              | 23 (6.1)             | 40 (10.8)            |
| Documented progression                                                             | 234 (62.6)           | 222 (59.7)           |
| Number of Censored (%)                                                             | 117 (31.3)           | 110 (29.6)           |
| Last assessment prior to 2 or more consecutive missed assessments                  | 1 (0.3)              | 4 (1.1)              |
| Last assessment showing no progression                                             | 91 (24.3)            | 23 (6.2)             |
| Last radiologic assessment prior to new anti-cancer therapy showing no progression | 21 (5.6)             | 68 (18.3)            |
| Randomization                                                                      | 4 (1.1)              | 15 (4.0)             |
| Kaplan-Meier Estimates (months) a                                                  |                      |                      |
| Median (95% CI)                                                                    | 5.6 (3.9, 7.0)       | 5.6 (4.8, 5.8)       |
| [Q1, Q3]                                                                           | [1.9, 16.7]          | [2.1, 9.2]           |
| Person-months                                                                      | 2718.2               | 1953.8               |

<div style=\"page-break-after: always\"></div>

0.00077

0.0 (NR, NR)

| Event Rate / 100 Person-months   | 9.5               | 13.4              |
|----------------------------------|-------------------|-------------------|
| vs Everolimus                    |                   |                   |
| Hazard Ratio (95% CI) b          | 0.75 (0.63, 0.90) |                   |
| p-value c                        | 0.00077           |                   |
| Rate at month 6 (%) (95% CI)     | 46.6 (41.3, 51.7) | 42.5 (36.8, 48.0) |
| Rate at month 9 (%) (95% CI)     | 40.4 (35.2, 45.4) | 28.4 (23.2, 33.8) |
| Rate at month 12 (%) (95% CI)    | 33.4 (28.4, 38.5) | 17.1 (12.7, 22.1) |
| Rate at month 18 (%) (95% CI)    | 24.0 (19.0, 29.4) | 8.3 (4.9, 12.7)   |
| Rate at month 24 (%) (95% CI)    | 19.7 (14.1, 26.0) | 0.0 (NR, NR)      |

a  From product-limit (Kaplan-Meier) method for censored data.

b  Based on Cox regression model with Efron's method of tie handling with treatment as a covariate stratified by International Metastatic RCC Database Consortium (IMDC) risk group (favourable vs. intermediate vs. poor) and number of prior VEGF/VEGF receptor targeted therapies for advanced RCC (1 vs. 2-3).

- c  One-sided p-value based on log-rank test similarly stratified by IMDC risk group and number of prior VEGF/VEGF receptor targeted therapies for advanced RCC.

NR = Not reached.

Database Cutoff Date: 01NOV2022

Figure 20: Study 005 Interim Analysis 1- Kaplan-Meier Plot of Progression-Free Survival (Primary Censoring Rule) Based on BICR per RECIST 1.1 (ITT Population)

<!-- image -->

| At Risk    |   At Risk |   At Risk |   At Risk |   At Risk |   At Risk |   At Risk |   At Risk |   At Risk |   At Risk |   At Risk |   At Risk |
|------------|-----------|-----------|-----------|-----------|-----------|-----------|-----------|-----------|-----------|-----------|-----------|
| Belzutifan |       374 |       218 |       157 |       134 |        85 |        55 |        32 |        20 |        11 |         1 |         0 |
| Everolimus |       372 |       226 |       113 |        68 |        31 |        17 |        10 |         4 |         0 |         0 |         0 |

Time in Months

Database Cutoff Date: 01NOV2022

<div style=\"page-break-after: always\"></div>

At IA2, PFS results were consistent with those at IA1. The PFS HR was 0.74 (95% CI: 0.63, 0.88; 1-sided nominal p =0.00031) and the median PFS was 5.6 months (95% CI: 3.8, 6.5) in the belzutifan group vs 5.6 months (95% CI: 4.8, 5.8) in the everolimus group.

## Sub-group of patients who received two or more lines of therapy

The IA1 PFS results for the subgroup of patients that received two or more lines of therapy that included a PD-(L)1 inhibitor and at least two VEGF-targeted therapies are shown in Table 46 and Figure 21 .

Table 41: Study 005 Interim Analysis 1 - Analysis of Progression-Free Survival (Primary Censoring Rule) Based on BICR per RECIST 1.1 (ITT Population with ≥2 Prior VEGF-Targeted Therapies)

2 (1.1)

0.00713

0.0 (NR, NR)

|                                                                                    | Belzutifan (N=187)   | Everolimus (N=182)   |
|------------------------------------------------------------------------------------|----------------------|----------------------|
| Number of Events (%)                                                               | 127 (67.9)           | 130 (71.4)           |
| Death                                                                              | 16 (8.6)             | 21 (11.5)            |
| Documented progression                                                             | 111 (59.4)           | 109 (59.9)           |
| Number of Censored (%)                                                             | 60 (32.1)            | 52 (28.6)            |
| Last assessment prior to 2 or more consecutive missed assessments                  | 0 (0)                | 2 (1.1)              |
| Last assessment showing no progression                                             | 48 (25.7)            | 10 (5.5)             |
| Last radiologic assessment prior to new anti-cancer therapy showing no progression | 11 (5.9)             | 35 (19.2)            |
| Randomization                                                                      | 1 (0.5)              | 5 (2.7)              |
| Kaplan-Meier Estimates (months) a Median (95% CI)                                  | 4.6 (3.5, 7.3)       | 5.4 (3.8, 6.5)       |
| [Q1, Q3]                                                                           | [1.9, 19.2]          | [1.9, 9.1]           |
| Person-months                                                                      | 1318.2               | 904.3                |
| Event Rate / 100 Person-months                                                     | 9.6                  | 14.4                 |
| vs Everolimus                                                                      |                      |                      |
| Hazard Ratio (95% CI) b                                                            | 0.73 (0.57, 0.94)    |                      |
| p-value c                                                                          | 0.00713              |                      |
| Rate at month 6 (%) (95% CI)                                                       | 44.2 (36.8, 51.3)    | 42.5 (34.3, 50.3)    |
| Rate at month 9 (%) (95% CI)                                                       | 39.4 (32.1, 46.5)    | 25.8 (18.6, 33.5)    |
| Rate at month 12 (%) (95% CI)                                                      | 32.8 (25.8, 39.9)    | 14.5 (8.8, 21.5)     |
| Rate at month 18 (%) (95% CI)                                                      | 25.6 (18.8, 32.9)    | 5.8 (2.2, 12.0)      |
| Rate at month 24 (%) (95% CI)                                                      | 23.7 (16.7, 31.5)    | 0.0 (NR, NR)         |

NR = Not reached.

Database Cutoff Date: 01NOV2022

<div style=\"page-break-after: always\"></div>

| Belzutifan   |   187 |   104 |   74 |   64 |   43 |   30 |   15 |   8 |   5 | 0 0   |
|--------------|-------|-------|------|------|------|------|------|-----|-----|-------|
| Everolimus   |   182 |   107 |   54 |   30 |   12 |    6 |    4 |   3 |   0 | 0 0   |

Figure 21: Study 005 Interim Analysis 1- Kaplan-Meier Plot of Progression-Free Survival (Primary Censoring Rule) Based on BICR per RECIST 1.1 (ITT Population with ≥2 Prior VEGF-Targeted Therapies)

<!-- image -->

Database Cutoff Date: 01NOV2022

## Primary efficacy endpoints -overall survival

## ITT population

At FA, Study 005 did not meet the predefined success criterion for superiority based on OS, the other dual primary endpoint (Table 42 and Figure 22). The p-value did not cross the statistical hypothesis testing pvalue boundary of 0.0208.

<div style=\"page-break-after: always\"></div>

Table 42: Study 005 Final Analysis - Analysis of Overall Survival (ITT Population) DCO 15 April 2024

|                                  | Belzutifan (N=374)   | Everolimus (N=372)   |
|----------------------------------|----------------------|----------------------|
| Number of Events (%)             | 254 (67.9)           | 259 (69.6)           |
| Kaplan-Meier Estimates (months)a |                      |                      |
| Median (95% CI)                  | 21.4 (18.2, 24.3)    | 18.2 (15.8, 21.8)    |
| [Q1, Q3]                         | [8.4, ]              | [7.8, ]              |
| Person-months                    | 7809.3               | 7296.0               |
| Event Rate/ 100Person-months     | 3.3                  | 3.5                  |
| vs Everolimus                    |                      |                      |
| Hazard Ratio (95% CI)b           | 0.92 (0.77, 1.10)    |                      |
| p-valuec                         | 0.17644              |                      |
| Rate at month 6 (%) (95% CI)     | 81.6 (77.2, 85.1)    | 81.1 (76.8, 84.8)    |
| Rate at month 12 (%) (95% CI)    | 67.9 (62.9, 72.4)    | 65.8 (60.7, 70.3)    |
| Rate at month 18 (%) (95% CI)    | 55.3 (50.2, 60.2)    | 50.7 (45.5,55.6)     |
| Rate at month 24 (%) (95% CI)    | 45.2 (40.1, 50.1)    | 41.2 (36.2,46.2)     |
| Rate at month 30 (%) (95% CI)    | 35.9 (31.0, 40.8)    | 33.1 (28.3,38.0)     |
| Rate at month 36 (%) (95% CI)    | 32.0 (27.1, 37.0)    | 28.0 (23.1,33.1)     |

From product-limit (Kaplan-Meier) method for censored data.

b Based on Cox regression model with Efron's method of tie handling with treatment as a covariate stratified by International Metastatic RCC Database Consortium (IMDC) risk group (favorable vs. intermediate vs. poor) and Number of prior VEGF/VEGF receptor targeted therapies for advanced RCC (1 vs. 2-3).

c One-sided p-value based on log-rank test stratified by International Metastatic RCC Database

Consortium (IMDC) risk group (favorable vs. intermediate vs. poor) and Number of prior VEGF/VEGF

receptor targeted therapies for advanced RCC (1 vs. 2-3).

NR = Not reached.

DatabaseCutoffDate:15APR2024

<div style=\"page-break-after: always\"></div>

Figure 22: Study 005 Final Analysis - Kaplan-Meier Plot of Overall Survival (ITT Population)

<!-- image -->

AtRisk

Belzutifan

Everolimus

5274254

3743473

305

372

347

301

224207

270

244

212

189

188

169

148

111

75

54

170

152

128

92

64

38

Database Cutoff Date: 15APR2024

## Sub-group of patients who received two or more lines of therapy

The FA OS results for the subgroup of patients that received two or more lines of therapy that included a PD(L)1 inhibitor and at least two VEGF-targeted therapies are shown in Table 48 and Figure 23 . Of note, at FA the number of belzutifan participants with ≥2 prior VEGF changed from 187 to 188 due to data update.

Table 43: Study 005 Final Analysis - Analysis of Overall Survival (ITT Population with ≥2 Prior VEGF-Targeted Therapies)

|                                   | Belzutifan (N=188)   | Everolimus (N=182)   |
|-----------------------------------|----------------------|----------------------|
| Number of Events (%)              | 128 (68.1)           | 125 (68.7)           |
| Kaplan-Meier Estimates (months) a |                      |                      |
| Median (95% CI)                   | 21.8 (17.4, 25.8)    | 18.1 (14.2, 23.9)    |
| [Q1, Q3]                          | [8.2, NR]            | [7.1, NR]            |
| Person-months                     | 3911.3               | 3588.4               |
| Event Rate / 100 Person-months    | 3.3                  | 3.5                  |
| vs Everolimus                     |                      |                      |
| Hazard Ratio (95% CI) b           | 0.94 (0.74, 1.21)    |                      |
| p-value c                         | 0.32554              |                      |
| Rate at month 6 (%) (95% CI)      | 80.9 (74.5, 85.8)    | 80.2 (73.7, 85.3)    |
| Rate at month 12 (%) (95% CI)     | 66.5 (59.3, 72.7)    | 64.3 (56.9, 70.8)    |
| Rate at month 18 (%) (95% CI)     | 55.3 (47.9, 62.1)    | 50.5 (43.1, 57.5)    |

31

20

18

12

4

5

0

1

<div style=\"page-break-after: always\"></div>

| Rate at month 24 (%) (95% CI)   | 46.3 (39.0, 53.2)   | 42.9 (35.6, 49.9)   |
|---------------------------------|---------------------|---------------------|
| Rate at month 30 (%) (95% CI)   | 35.7 (28.8, 42.6)   | 34.9 (28.0, 41.8)   |
| Rate at month 36 (%) (95% CI)   | 32.0 (25.2, 38.9)   | 29.7 (22.8, 36.9)   |

- a  From product-limit (Kaplan-Meier) method for censored data.
- b  Based on Cox regression model with Efron's method of tie handling with treatment as a covariate.
- c Nominal one-sided p-value based on log-rank test.

NR = Not reached.

Database Cutoff Date: 15APR2024

| Belzutifan   |   188 |   152 |   135 |   125 |   112 |   104 |   95 |   87 |   73 |   57 |   43 |   28 |   13 |   7 |   0 | 0 0   |
|--------------|-------|-------|-------|-------|-------|-------|------|------|------|------|------|------|------|-----|-----|-------|
| Everolimus   |   182 |   146 |   128 |   117 |   101 |    92 |   83 |   78 |   64 |   49 |   34 |   22 |   12 |   6 |   2 | 1 0   |

Figure 23: Study 005 Final Analysis - Kaplan-Meier Plot of Overall Survival (ITT Population with ≥2 Prior VEGF-Targeted Therapies)

<!-- image -->

Database Cutoff Date: 15APR2024

## Subsequent anticancer therapies

At the OS FA (DCO 15-APR-2024), in the belzutifan group 53.5% of patients had initiated subsequent anticancer therapies vs 67.5% in the everolimus group.

The most frequently reported subsequent anticancer therapies in the belzutifan group were everolimus (83/374=22.2%), cabozantinib (s-malate) (79/374=21.1%), lenvatinib (mesilate) (57/374=15.2%), and axitinib (51/374=13.6%). Two patients (0.5%) in the belzutifan group again received belzutifan as subsequent anticancer therapy (one as monotherapy and one in combination with other medicinal products). The most frequently reported subsequent anticancer therapies in the everolimus group were cabozantinib (smalate) (95/374=25.5%), lenvatinib (mesilate) (69/372=18.5%), axitinib (66/372=17.7%), and everolimus (51/372=13.7%). Of the 51 patients (13.7%) in the everolimus group who again received everolimus as subsequent anticancer therapy, 11/372=3.0% received it as monotherapy and 40/372=10.8% received it in combination with other medicinal products (lenvatinib [mesilate] in 36/40 cases).

<div style=\"page-break-after: always\"></div>

## Secondary efficacy endpoint - objective response rate

## ITT population

At IA1, Study 005 met the predefined success criterion for superiority based on the key secondary endpoint ORR ( Table 49 ; Table 50 ). The p-value crossed the prespecified boundary for statistical significance of 0.001.

Table 44: Study 005 Interim Analysis 1 - Analysis of Objective Response (Confirmed) Based on BICR per RECIST 1.1 (ITT Population) DCO 01NOV2022

18.4 (14.0, 23.2)

&lt;0.00001

|            |     |                     |                                      | Difference in %vs. Everolimus   | Difference in %vs. Everolimus   |
|------------|-----|---------------------|--------------------------------------|---------------------------------|---------------------------------|
| Treatment  | N   | Number of Responses | Objective Response Rate (%) (95% CI) | Estimate (95% CI) a             | p-Value b                       |
| Belzutifan | 374 | 82                  | 21.9 (17.8, 26.5)                    | 18.4 (14.0, 23.2)               | <0.00001                        |
| Everolimus | 372 | 13                  | 3.5 (1.9, 5.9)                       |                                 |                                 |

Database Cutoff Date: 01NOV2022

Table 45: Study 005 Interim Analysis 1 - Summary of Best Objective Response (Confirmed) Based on BICR per RECIST 1.1 (ITT Population) 01NOV2022.

372

|                                  | Belzutifan   | Belzutifan   | Belzutifan   | Everolimus   | Everolimus   | Everolimus   |
|----------------------------------|--------------|--------------|--------------|--------------|--------------|--------------|
|                                  | n            | (%)          | 95% CI †     | n            | (%)          | 95% CI †     |
| Number of Patients in Population | 374          |              |              | 372          |              |              |
| Complete Response (CR)           | 10           | (2.7)        | (1.3, 4.9)   | 0            | (0.0)        | (0.0, 1.0)   |
| Partial Response (PR)            | 72           | (19.3)       | (15.4, 23.6) | 13           | (3.5)        | (1.9, 5.9)   |
| Overall Response (CR+PR)         | 82           | (21.9)       | (17.8, 26.5) | 13           | (3.5)        | (1.9, 5.9)   |
| Stable Disease (SD)              | 147          | (39.3)       | (34.3, 44.5) | 245          | (65.9)       | (60.8, 70.7) |
| Disease Control (CR+PR+SD)       | 229          | (61.2)       | (56.1, 66.2) | 258          | (69.4)       | (64.4, 74.0) |
| Progressive Disease (PD)         | 126          | (33.7)       | (28.9, 38.7) | 80           | (21.5)       | (17.4, 26.0) |
| Not Evaluable ‡                  | 5            | (1.3)        | (0.4, 3.1)   | 8            | (2.2)        | (0.9, 4.2)   |
| No Assessment +                  | 14           | (3.7)        | (2.1, 6.2)   | 26           | (7.0)        | (4.6, 10.1)  |

Responses are based on BICR assessment per RECIST 1.1.

†  Based on the binomial exact confidence interval method for binomial data.

‡  Not Evaluable (NE) includes subjects with insufficient data for assessment of response per RECIST 1.1.

+ No Assessment includes subjects without post-baseline assessment on the data cutoff date.

Stable Disease (SD) includes both SD and Non-CR/Non-PD.

Database Cutoff Date: 01NOV2022.

At IA2, ORR results were consistent with those at IA1: the ORR was 22.7% (95% CI: 18.6, 27.3) in the belzutifan group and 3.5% (95% CI: 1.9, 5.9) in the everolimus group, including 3.5% vs 0% CRs, respectively.

## Sub-group of patients who received two or more lines of therapy

The IA1 ORR and BOR results for the subgroup of patients that received two or more lines of therapy that included a PD-(L)1 inhibitor and at least two VEGF-targeted therapies are shown in Table 46, respectively.

<div style=\"page-break-after: always\"></div>

Table 46: Study 005 Interim Analysis 1 - Analysis of Objective Response (Confirmed) Based on BICR per RECIST 1.1 (ITT Population with ≥2 Prior VEGF-Targeted Therapies)

20.8 (14.3, 27.8)

&lt;0.00001

|            |     |                     |                                      | Difference in %vs. Everolimus   | Difference in %vs. Everolimus   |
|------------|-----|---------------------|--------------------------------------|---------------------------------|---------------------------------|
| Treatment  | N   | Number of Responses | Objective Response Rate (%) (95% CI) | Estimate (95% CI) a             | p-Value b                       |
| Belzutifan | 187 | 45                  | 24.1 (18.1, 30.8)                    | 20.8 (14.3, 27.8)               | <0.00001                        |
| Everolimus | 182 | 6                   | 3.3 (1.2, 7.0)                       |                                 |                                 |

Responses are based on BICR per RECIST 1.1.

a  Based on Miettinen &amp; Nurminen method

b Nominal one-sided p-value for testing. H0: difference in % = 0 versus H1: difference in % &gt; 0.

Database Cutoff Date: 01NOV2022

Table 47: Study 005 Interim Analysis 1 - Summary of Best Objective Response (Confirmed) Based on BICR per RECIST 1.1 (ITT Population with ≥2 Prior VEGF-Targeted Therapies)

6

(3.3)

122

|                                      | Belzutifan   | Belzutifan   | Belzutifan   | Everolimus   | Everolimus   | Everolimus   |
|--------------------------------------|--------------|--------------|--------------|--------------|--------------|--------------|
|                                      | n            | (%)          | 95% CI †     | n            | (%)          | 95% CI †     |
| Number of Participants in Population | 187          |              |              | 182          |              |              |
| Complete Response (CR)               | 5            | (2.7)        | (0.9, 6.1)   | 0            | (0.0)        | (0.0, 2.0)   |
| Partial Response (PR)                | 40           | (21.4)       | (15.7, 28.0) | 6            | (3.3)        | (1.2, 7.0)   |
| Overall Response (CR+PR)             | 45           | (24.1)       | (18.1, 30.8) | 6            | (3.3)        | (1.2, 7.0)   |
| Stable Disease (SD)                  | 63           | (33.7)       | (27.0, 40.9) | 116          | (63.7)       | (56.3, 70.7) |
| Disease Control (CR+PR+SD)           | 108          | (57.8)       | (50.3, 64.9) | 122          | (67.0)       | (59.7, 73.8) |
| Progressive Disease (PD)             | 64           | (34.2)       | (27.5, 41.5) | 43           | (23.6)       | (17.7, 30.5) |
| Not Evaluable ‡                      | 4            | (2.1)        | (0.6, 5.4)   | 4            | (2.2)        | (0.6, 5.5)   |
| No Assessment +                      | 11           | (5.9)        | (3.0, 10.3)  | 13           | (7.1)        | (3.9, 11.9)  |

Responses are based on BICR assessment per RECIST 1.1.

†  Based on the binomial exact confidence interval method for binomial data.

‡  Not Evaluable (NE) includes subjects with insufficient data for assessment of response per RECIST 1.1.

+ No Assessment includes subjects without post-baseline assessment on the data cutoff date.

Stable Disease (SD) includes both SD and Non-CR/Non-PD.

Database Cutoff Date: 01NOV2022.

## Secondary efficacy endpoints - duration of response and time to response

## ITT population

At IA1, the median DOR based on BICR per RECIST 1.1 was not reached (range: 1.7+ to 23.2+ months) for the belzutifan group vs 17.2 months (range: 3.8 to 18.0+) for the everolimus group. The median time to response TTR was 3.7 months (95% CI: 1.7, 16.6) vs 3.7 months (95% CI: 1.8, 5.4), respectively.

The IA2 results are shown in Table 48.

<div style=\"page-break-after: always\"></div>

Table 48: Study 005 Interim Analysis 2 - Summary of Time to Response and Duration of Response Based on BICR per RECIST 1.1 in Patients with a Confirmed Response (ITT Population) DCO 13JUN2023

85                              13

3.5 (1.2)

3.7 (1.8-5.4)

10 (76.9)

|                                                            | Belzutifan (N=374)   | Everolimus (N=372)   |
|------------------------------------------------------------|----------------------|----------------------|
| Number of patients with response a                         | 85                   | 13                   |
| Time to Response (months)                                  |                      |                      |
| Mean (SD)                                                  | 5.4 (4.0)            | 3.5 (1.2)            |
| Median (Range)                                             | 3.8 (1.7-22.0)       | 3.7 (1.8-5.4)        |
| Response Duration b (months)                               |                      |                      |
| Median (Range)                                             | 19.5 (1.9+ - 31.6+)  | 13.7 (3.8 - 21.2+)   |
| Number (% b ) of Patients with Extended Response Duration: |                      |                      |
| ≥6 months                                                  | 75 (93.9)            | 10 (76.9)            |
| ≥9 months                                                  | 65 (82.5)            | 8 (61.5)             |
| ≥12 months                                                 | 54 (73.2)            | 8 (61.5)             |
| ≥15 months                                                 | 40 (62.1)            | 6 (46.2)             |
| ≥18 months                                                 | 21 (51.1)            | 4 (30.8)             |
| ≥21 months                                                 | 18 (48.4)            | 1 (15.4)             |

\"+\" indicates there is no progressive disease by the time of last disease assessment. Database Cutoff Date: 13JUN2023

## Sub-group of patients who received two or more lines of therapy

The IA1 TTR and DOR results for the subgroup of patients that received two or more lines of therapy that included a PD-(L)1 inhibitor and at least two VEGF-targeted therapies are shown in Table 54.

Table 49: Study 005 Interim Analysis 1 - Summary of Time to Response and Duration of Response Based on BICR per RECIST 1.1 in Patients with a Confirmed Response (ITT Population with ≥2 Prior VEGF-Targeted Therapies)

45                              6

3.1 (1.4)

3.0 (1.8-5.4)

17.2 (3.8 - 17.2 )

4 (66.7)

2 (66.7)

2 (66.7)

1 (66.7)

0 (NR)

0 (NR)

|                                                                | Belzutifan (N=187)   | Everolimus (N=182)   |
|----------------------------------------------------------------|----------------------|----------------------|
| Number of participants with response a                         | 45                   | 6                    |
| Time to Response (months)                                      |                      |                      |
| Mean (SD)                                                      | 4.7 (3.8)            | 3.1 (1.4)            |
| Median (Range)                                                 | 3.7 (1.7-16.6)       | 3.0 (1.8-5.4)        |
| Response Duration b (months)                                   |                      |                      |
| Median (Range)                                                 | NR (1.9+ - 23.1+)    | 17.2 (3.8 - 17.2 )   |
| Number (% b ) of Participants with Extended Response Duration: |                      |                      |
| ≥6 months                                                      | 35 (90.2)            | 4 (66.7)             |
| ≥9 months                                                      | 23 (81.6)            | 2 (66.7)             |
| ≥12 months                                                     | 14 (72.0)            | 2 (66.7)             |
| ≥15 months                                                     | 8 (66.4)             | 1 (66.7)             |
| ≥18 months                                                     | 4 (58.1)             | 0 (NR)               |
| ≥21 months                                                     | 2 (58.1)             | 0 (NR)               |

<div style=\"page-break-after: always\"></div>

a  Includes participants with confirmed complete response or partial response

b  From product-limit (Kaplan-Meier) method for censored data.

\"+\" indicates there is no progressive disease by the time of last disease assessment.

NR = Not Reached.

Database Cutoff Date: 01NOV2022

## Secondary efficacy endpoint - patient-reported outcomes

## ITT

PROs were completed on Day 1 of Weeks 1, 3, 5, and 9, every 4 weeks thereafter, at the treatment discontinuation visit, and at the 30-day follow-up.

The PRO analyses are based on the PRO Full Analysis Set (FAS) population, defined as randomized patients who have at least one PRO assessment available for the specific endpoint and have received at least one dose of the study intervention.

For PRO analyses, no adjustments for multiple testing were applied; therefore, all p-values and CIs are nominal and descriptive.

At IA2, compliance rates (% in those expected to complete questionnaires) for the FKSI-DRS by visit and by treatment at baseline were 96.2% for the belzutifan group and 94.4% for the everolimus group; at Week 17, compliance rates were 90.4% for the belzutifan group and 91.3% for the everolimus group. The compliance rates for EORTC QLQ-C30 were similar to those for the FKSI-DRS.

Completion rates were ≥60% up to Week 17 in the belzutifan group and up to Week 13 in the everolimus group for both questionnaires. As expected, completion rates for each instrument generally decreased at each time point through Week 157 as patients discontinued study treatment.

For brevity, the EQ-5D-5L VAS data are not included.

## FKSI-DRS

A change in FKSIDRS score of ≥3 was considered clinically meaningful; a decrease in score denotes deterioration. FKSI-DRS score change from baseline to Week 17 numerically favoured belzutifan over everolimus, but differences did not reach criteria to be considered clinically meaningful.

## EORTC QCQ-C30

A change in EORTC QCQC30 score of ≥10 was considered clinically meaningful; a decrease in score denotes deterioration. Changes from baseline in EORTC QLQ-C30 global health status/QoL generally showed numerically less change in the belzutifan group vs everolimus, but overall, there were no clinically relevant deteriorations in either treatment group.

## Time to deterioration using FKSI-DRS and EORTC QLQ-C30

Time to confirmed deterioration was defined as the time from baseline to the first onset of a ≥10 -point deterioration for EORTC QLQC30 and ≥3 -point deterioration for FKSI-DRS, with confirmation at the subsequent visit.

The percentage of patients with confirmed deterioration in FKSI-DRS was generally lower in the belzutifan group (29.0%) than in the everolimus group (41.3%). The time to confirmed deterioration in the FKSI-DRS scores was numerically longer in the belzutifan group compared with the everolimus group, i.e., not reached

<div style=\"page-break-after: always\"></div>

(95% CI: 21.26, NR) vs 11.99 months (95% CI: 5.55, 15.38) in the everolimus group, respectively, with an HR of 0.53 (95% CI: 0.41, 0.69).

For EORTC QLQ-C30 global health status/QoL, the percentage of patients with confirmed deterioration was similar in both treatment groups (36.2% in the belzutifan group and 39.9% in the everolimus group). The time to confirmed deterioration in the EORTC QLQ-C30 global health status/QoL scores was numerically longer in the belzutifan group compared with the everolimus group. i.e., 19.35 months (95% CI: 11.89, NR) vs 10.19 months (95% CI: 6.47, 12.98), respectively, with an HR of 0.75 (95% CI: 0.58, 0.96.

## Ancillary analyses

## ITT population

## Sensitivity Analysis

At IA1, the results for sensitivity analysis 1 were: PFS HR 0.75 (95% CI: 0.63, 0.88); median PFS 5.6 months (95% CI: 4.2, 7.3) vs 5.6 months (95% CI: 5.4, 6.3). As patients who received new anticancer therapy did not continue with BICR assessments for progression, patients who were censored for this reason in the primary analysis were switched to another censoring category.

The results for sensitivity analysis 2 were: PFS HR 0.68 (95% CI: 0.58, 0.80); median PFS 5.6 months (95% CI: 3.8, 6.2) vs 5.3 months (95% CI: 4.0, 5.6).

PFS by investigator was consistent with the primary analysis by BICR at IA1 (PFS HR: 0.68; 95% CI: 0.58, 0.81; with median PFS 5.6 months [95% CI: 5.2, 7.4] vs 5.4 months [95% CI: 4.1, 5.6]) and at IA2 (PFS HR: 0.67; 95% CI: 0.57, 0.79).

Concordance of PD assessment between the BICR and investigator assessments was 90% and 78% for the belzutifan and everolimus groups, respectively, meaning that for 23 patients (10%) in the belzutifan group and 58 patients (22%) in the everolimus group the BICR assessment disagreed with the investigator assessment of PD.

Subgroup analyses were performed for PFS (Figure 24 ; IA1 results), OS (Figure 25 ; IA2 results [results of FA OS subgroup analysis were not provided]), and ORR (Figure 26 ; IA1 results).

<div style=\"page-break-after: always\"></div>

Figure 24; Study 005 Interim Analysis 1 - Forest Plot of PFS Hazard Ratio by Subgroup Factors Based on BICR per RECIST 1.1 (Primary Censoring Rule) (ITT Population)

<!-- image -->

Only patients with data in the specified subgroups are included.

Based on Cox model: stratified for overall population and unstratified for subgroups.

Database Cutoff Date: 01NOV2022

Belzutifan←Favor →Everolimus

<div style=\"page-break-after: always\"></div>

Figure 25: Study 005 Interim Analysis 2 - Forest Plot of OS Hazard Ratio by Subgroup Factors (ITT Population)

<!-- image -->

Only patients with data in the specified subgroups are included. Based on Cox model: stratified for overall population and unstratified for subgroups. Database Cutoff Date: 13JUN2023

<div style=\"page-break-after: always\"></div>

Figure 26; Study 005 Interim Analysis 1 - Forest Plot of Difference in Objective Response Rate (Confirmed) by Subgroup Factors Based on BICR per RECIST 1.1 (ITT Population)

<!-- image -->

Belzutifan

#Event/N

63/297

17/56

37/187

45/187

12/46

30/157

40/169

Race

White

AllOthers targetedtherapiesforadvancedRCC

NumberofpriorVEGF/VEGFreceptor

2-3

1

Number of prior lines of therapy

2

3

Everolimus

#Event/N

11/291

0/65

7/190

6/182

3/52

4/166

6/150

Total

#Event/N

74/588

17/121

44/377

51/369

15/98

34/323

46/319

ORRDiff

17.4

30.4

16.1

20.8

20.3

16.7

19.7

Only patients with data in the specified subgroups are included.

Miettinen and Nurminen method: stratified for overall population and unstratified for subgroups.

Database Cutoff Date: 01NOV2022

Additional information related to the reasons for early censoring for PFS and, if relevant, subsequent anticancer therapy were submitted and are summarized in Table 50.

Table 50: Summary of Reasons of Censoring for Time of Censoring ≤6 months for ProgressionFree Survival Based on BICR Assessment per RECIST 1.1 (Primary Censoring Rule) (ITT Population)

|                                                                                    | Belzutifan (N=374)   | Everolimus (N=372)   |
|------------------------------------------------------------------------------------|----------------------|----------------------|
| CensoredSubjects≤6months(%)                                                        | 25 (6.7)             | 79 (21.2)            |
| Last assessmentpriorto2ormoreconsecutivemissed assessmentsi                        | 2 (0.5)              | 4 (1.1)              |
| Lastassessmentshowingnoprogression                                                 | 0 (0.0)              | 0 (0.0)              |
| Last radiologic assessment prior to new anti-cancer therapy showing no progression | 19 (5.1)             | 60 (16.1)            |
| Randomization                                                                      | 4 (1.1)              | 15 (4.0)             |

95% CI

(12.4, 22.8)

(19.9, 43.4)

(10.0, 22.8)

(14.3, 27.7)

(6.4, 35.5)

(12.6, 27.1)

(10.5, 23.8)

0

10

20

30

40

Everolimus←Favor→Belzutifan

<div style=\"page-break-after: always\"></div>

Table 51 shows an overview of reasons for treatment discontinuation for the patients who received new anticancer therapy before a BICR PFS event could be observed (and were therefore censored in the primary PFS analysis).

Table 51: Disposition of Patients (ITT Population Censored for Primary BICR PFS Due to Start of Subsequent Anticancer Therapy)

|                                      | Belzutifan   | Belzutifan   | Everolimus   | Everolimus   | Total   | Total   |
|--------------------------------------|--------------|--------------|--------------|--------------|---------|---------|
|                                      | n            | (%)          | n            | (%)          | n       | (%)     |
| Participant in population            | 22           |              | 77           |              | 99      |         |
| Status for Trial                     |              |              |              |              |         |         |
| Discontinued                         | 12           | (54.5)       | 30           | (39.0)       | 42      | (42.4)  |
| Death                                | 12           | (54.5)       | 29           | (37.7)       | 41      | (41.4)  |
| Lost To Follow-Up                    | 0            | (0.0)        | 1            | (1.3)        | 1       | (1.0)   |
| Participants Ongoing                 | 10           | (45.5)       | 47           | (61.0)       | 57      | (57.6)  |
| Status for Study Medication in Trial |              |              |              |              |         |         |
| Started                              | 22           |              | 71           |              | 93      |         |
| Discontinued                         | 22           | (100.0)      | 71           | (100.0)      | 93      | (100.0) |
| Adverse Event                        | 4            | (18.2)       | 19           | (26.8)       | 23      | (24.7)  |
| Clinical Progression                 | 2            | (9.1)        | 2            | (2.8)        | 4       | (4.3)   |
| Non-Study Anti-Cancer Therapy        | 2            | (9.1)        | 7            | (9.9)        | 9       | (9.7)   |
| Physician Decision                   | 0            | (0.0)        | 2            | (2.8)        | 2       | (2.2)   |
| Progressive Disease                  | 11           | (50.0)       | 35           | (49.3)       | 46      | (49.5)  |
| Withdrawal By Subject                | 3            | (13.6)       | 6            | (8.5)        | 9       | (9.7)   |

If the overall count of participant is calculated and displayed within a section in the first row, then it is used as the denominator for the percentage calculation. Otherwise, participant in population is used as the denominator for the percentage calculation.

Each participant is counted once for Trial Status based on the latest Survival Follow-up record. Each participant is counted once for Study Medication Status based on the latest corresponding disposition record.

DatabaseCutoffDate:01NOV2022

## VHL Indication

MK-6482-004: An Open Label Phase 2 Study to Evaluate PT2977 for the Treatment of von Hippel Lindau Disease-Associated Renal Cell Carcinoma

## Methods

Study 004 is an ongoing phase 2, single-arm, open-label study to evaluate the efficacy and safety of belzutifan in patients with VHL-RCC, not requiring immediate surgery. The study design is shown in Figure 27.

Patients were required to have a diagnosis of VHL disease based on a germline VHL alteration. The diagnosis of RCC could be radiologic (histologic diagnosis not required). Patients were required to have at least 1 measurable solid RCC tumour and no RCC tumour &gt;3.0 cm that required immediate surgical intervention. Patients could also have VHL disease-associated tumours in other organ systems.

<div style=\"page-break-after: always\"></div>

Patients were evaluated with imaging every 12 weeks for a minimum 3 years after allocation, then every 24 weeks thereafter to assess response to treatment. All images obtained were submitted to an IRC to assess objective response using RECIST 1.1. Radiographic response assessments were made separately for each VHL-associated organ system using RECIST 1.1, e.g., RCC, pancreatic lesions, pNET, and CNS haemangioblastoma.

Figure 27: Study 004 Study schema

<!-- image -->

QD=once daily; RCC=renal cell carcinoma; VEGF=vascular endothelial growth factor; VHL=von Hippel-Lindau

## Study Participants

A total of 67 patients were screened and 61 were allocated to receive study treatment across 11 study sites in 4 countries. Participating countries were Denmark, France, United Kingdom, and United States.

Key Inclusion Criteria: Male or female ≥ 18 years of age; diagnosis of VHL disease, based on a germline VHL alteration; had at least 1 measurable solid RCC tumour and no RCC tumour &gt;3.0 cm that requires immediate surgical intervention (diagnosis of RCC could be radiological, histological diagnosis not required and patients could have VHL disease-associated tumours in other organ systems); and had an ECOG PS of 0 to 1.

Key Exclusion Criteria: Any systemic anticancer therapy (included anti-VEGF therapy or a systemic investigational anticancer agent); surgical procedure for VHL disease or any major surgical procedure completed within 4 weeks prior to study enrolment; received prior treatment with belzutifan or another HIF2α inhibitor; immediate need for surgical intervention for tumour treatment; evidence of metastatic disease on screening imaging.

## Treatments

Belzutifan was administered as tablets in a dose of 120 mg once daily.

Treatment continued until documented radiographic disease progression (BICR verified), unacceptable AEs, intercurrent illness that prevented further administration of treatment, investigator's decision to discontinue the patient, patient withdrawal of consent, pregnancy of the patient, or administrative reasons requiring cessation of treatment.

Treatment could be continued after radiographic progression, as long as the investigator believed that the patient was still receiving clinical benefit from study intervention and that the potential benefit of continuing study intervention outweighs potential risks.

<div style=\"page-break-after: always\"></div>

## Objectives

The primary objective of Study 004 is to evaluate the efficacy of belzutifan for the treatment of VHL diseaseassociated RCC as measured by ORR per RECIST 1.1 by an IRC.

The secondary efficacy objectives of the study are as follows:

- To evaluate efficacy of belzutifan for the treatment of VHL disease-associated RCC measured by:
- o Duration of response (DOR)
- o Time to response (TTR)
- o Progression-free survival (PFS)
- o Time to Surgery (TTS)
- To evaluate efficacy of belzutifan for the treatment of VHL disease-associated non-RCC tumours (retinal and CNS haemangioblastomas, pancreatic, adrenal, endolymphatic sac tumour, and epididymal cystadenomas)

## Outcomes/endpoints and estimands

The primary endpoint of the study is ORR , defined as the proportion of patients with a best confirmed response of complete response (CR) or partial response (PR) as determined by RECIST 1.1 and as assessed by an IRC.

Table 52: Primary Estimand for Study 004: ORR

| • Population                                                                                                                                                    | • Adults with a diagnosis of VHL disease based on a germline VHL alteration and at least 1 measurable solid RCC tumour and no RCC tumour >3.0 cm that required immediate surgical intervention.   |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| • Treatment condition<s>                                                                                                                                        | • Belzutifan (120 mg QD)                                                                                                                                                                          |
| • Endpoint (variable)                                                                                                                                           | • Best overall response (BoR) of confirmed complete response (CR) or partial response (PR). • Based on RECIST 1.1 criteria and assessed by independent central review (IRC).                      |
| • Population-level summary                                                                                                                                      | • Percentage of patients with CR or PR.                                                                                                                                                           |
| • Intercurrent events and strategy to handle them                                                                                                               | • Intercurrent events and strategy to handle them                                                                                                                                                 |
| • New anti-cancer treatment                                                                                                                                     | • Composite: Counted as a non-responder if new anti-cancer treatment was received before a confirmed BoR of CR or PR.                                                                             |
| • Treatment discontinuation (and no other intercurrent event)                                                                                                   | • Treatment policy                                                                                                                                                                                |
| Additional note • For any other events leading to missing assessments which precluded the determination of a BoR, patients were also counted as non-responders. | Additional note • For any other events leading to missing assessments which precluded the determination of a BoR, patients were also counted as non-responders.                                   |

<div style=\"page-break-after: always\"></div>

Description of estimand: In adults with a diagnosis of VHL disease and at least one measurable solid RCC tumour and no RCC tumour &gt; 3.0 cm that required immediate surgical intervention who received Belzutifan (120 mg QD), what is the percentage of patients who had a BoR of CR or PR before receiving any additional new anti-cancer treatment?

The secondary endpoints are DOR, TTR, PFS and TTS.

DOR is defined as the interval from the first documentation of response, as determined by RECIST 1.1, to the earlier of the first documentation of disease progression or death from any cause, and calculated for patients with a best confirmed response of CR or PR.

Table 53: Second Estimand for Study 004: DOR

| • Population                                                                                                                                                                                             | • Adults with a diagnosis of VHL disease based on a germline VHL alteration and at least 1 measurable solid RCC tumour and no RCC tumour >3.0 cm that required immediate surgical intervention and who have responded to                                                                 |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| • Treatment condition<s>                                                                                                                                                                                 | • Belzutifan (120 mg QD)                                                                                                                                                                                                                                                                 |
| • Endpoint (variable)                                                                                                                                                                                    | • Duration of response, defined as the time from first confirmed response to documented disease progression or death due to any cause, whichever occurs first. • Determination of disease progression was based on RECIST 1.1 criteria and assessed by independent central review (IRC). |
| • Population- level summary                                                                                                                                                                              | • Median DOR; Percentage of patients alive and progression free at 26, 39, and 52 weeks.                                                                                                                                                                                                 |
| • Intercurrent events and strategy to handle them                                                                                                                                                        | • Intercurrent events and strategy to handle them                                                                                                                                                                                                                                        |
| • New anti- cancer treatment                                                                                                                                                                             | • Hypothetical (From censoring strategy: Censored at last disease assessment before new anti-cancer treatment)                                                                                                                                                                           |
| • Treatment discontinuation (and no other intercurrent event)                                                                                                                                            | • Treatment policy                                                                                                                                                                                                                                                                       |
| Additional note • For the primary DOR analysis, follow up times for patients were censored if disease progression or death documented immediately after two or more consecutive assessments were missed. | Additional note • For the primary DOR analysis, follow up times for patients were censored if disease progression or death documented immediately after two or more consecutive assessments were missed.                                                                                 |

Description of estimand: In adults who responded to belzutifan (120 mg QD) and who had a diagnosis of VHL disease and at least 1 measurable solid RCC tumour and no RCC tumour &gt;3.0 cm that required immediate surgical intervention, what is the duration of the response in the situation where alternative anti-cancer therapies are not available and regardless of treatment discontinuation?

TTR is defined as the interval from the start of study treatment to the first documentation of a response, as determined by RECIST 1.1, and calculated for patients with a best confirmed response of CR or PR.

PFS is defined as the interval from the start of study treatment until the earlier of the first documentation of disease progression determined by RECIST 1.1 or death from any cause.

<div style=\"page-break-after: always\"></div>

TTS is defined as the interval from the start of study treatment to the date of surgery.

## Sample size

The planned sample size for this study was approximately 50 patients. Even though no hypothesis testing was performed, the required sample size was based on the following assumptions: The null hypothesis is that the ORR is 15% (P0=0.15). The alternative hypothesis is that the ORR is 30% (P1=0.3). A sample size of 50 patients would provide greater than 80% power for this null and alternative hypothesis using a one-sided test at a 0.05 level of significance.

## Randomisation and blinding (masking)

Study 004 is a single-arm study.

## Statistical methods

Efficacy and safety were assessed in all patients that received at least one dose of belzutifan in Study 004, resulting in the Efficacy Analysis Set and the Safety Analysis Set both consisting of all 61 included patients.

Per statistical analysis plan, the final analysis would be performed after at least 36 weeks after enrolment of the last patient.

Periodic reviews of the trial data were performed to evaluate the safety and efficacy results. In this filing data from 2 DCOs was submitted: 01 June 2020 and 01 Apr 2022.No adjustment for multiplicity was performed for this study.

## Results

## Recruitment and participant flow

This study is ongoing; key study milestone dates for this report are listed in Table 54 .

Table 54: Study 004 Key Study Milestones

| First Patient, First Visit   | Data Cutoff   | Database Lock Date   |
|------------------------------|---------------|----------------------|
| 31-MAY-2018                  | 01-APR-2022   | 02-JUN-2022          |
|                              | 03-APR-2023   | 02-JUN-2023          |

The study enrolled 61 patients from 11 study sites in 4 countries during approximately 10 months - the first patient was included in May 2018 and the last patient in March 2019.

The number of study sites and subjects enrolled per country are as follows:

<div style=\"page-break-after: always\"></div>

<!-- image -->

| Country      |   Totalnumberofsites enrollingpatients |   Totalnumberofsubjects enrolled |
|--------------|----------------------------------------|----------------------------------|
| UK           |                                      1 |                                1 |
| Denmark      |                                      1 |                                6 |
| France       |                                      1 |                                3 |
| UnitedStates |                                      8 |                               48 |

67 patients were screened for eligibility, and 6 were considered ineligible for study participation because they did not meet the inclusion and/or did meet the exclusion criteria.

Figure 28: Study 004 participant flow

<!-- image -->

Date of Data Cut-off: 01APR2022

<div style=\"page-break-after: always\"></div>

## Conduct of the study

The original protocol was finalized on 10-NOV-2017 and amended 16 times. All amendments were completed prior to the database cut-off dates of 01-APR-2022 for IA2.

## Baseline data

Table 60 shows the patients' baseline characteristics.

Table 55: Study 004 - Demographic and Baseline Characteristics Safety Analysis Set

|                                           | Belzutifan (N=61)   |
|-------------------------------------------|---------------------|
| Age (years)                               |                     |
| N                                         | 61                  |
| Mean (SD)                                 | 41.0 (13.46)        |
| Median                                    | 41.0                |
| Min, Max                                  | 19, 66              |
| Sex, n(%)                                 |                     |
| Male                                      | 32 ( 52.5)          |
| Female                                    | 29 ( 47.5)          |
| Ethnicity, n(%)                           |                     |
| Hispanic or Latino                        | 6 ( 9.8)            |
| Not Hispanic or Latino                    | 54 ( 88.5)          |
| Unknown                                   | 1 ( 1.6)            |
| Race, n(%)                                |                     |
| American Indian or Alaska Native          | 0                   |
| Asian                                     | 1 ( 1.6)            |
| Black or African American                 | 2 ( 3.3)            |
| Native Hawaiian or Other Pacific Islander | 1 ( 1.6)            |
| White                                     | 55 ( 90.2)          |
| Unknown                                   | 2 ( 3.3)            |
| Weight (kg)                               |                     |
| N                                         | 61                  |
| Mean (SD)                                 | 79.74 (23.368)      |
| Median                                    | 74.40               |
| Min, Max                                  | 47.7, 147.6         |
| Height (cm)                               |                     |
| N                                         | 59                  |
| Mean (SD)                                 | 169.49 (10.985)     |
| Median                                    | 169.00              |
| Min, Max                                  | 148.0, 195.0        |
| BMI (kg/m 2 )                             |                     |
| N                                         | 59                  |
| Mean (SD)                                 | 27.76 (7.372)       |
| Median                                    | 26.34               |
| Min, Max                                  | 17.2, 52.0          |
| ECOG Performance Status, n(%)             |                     |
| 0                                         | 50 ( 82.0)          |
| 1                                         | 10 ( 16.4)          |
| 2                                         | 1 ( 1.6)            |

Baseline is defined as the last available measurement prior to the first dose administered.

Date of Data Cut-off: 01APR2022

<div style=\"page-break-after: always\"></div>

Table 56 Disease History and Characteristics Safety Analysis Set

<!-- image -->

|                                                                               | Belzutifan (N=61)    |
|-------------------------------------------------------------------------------|----------------------|
| Time from Original Diagnosis of VHL associated RCC to First Dose (months) [l] |                      |
| n                                                                             | 45                   |
| Mean (SD) Median                                                              | 103.43(96.231) 77.60 |
| Q1，Q3                                                                         | 24.54，136.97         |
| Min, Max                                                                      | 0.5, 389.4           |
| Time from Last Surgery to First Dose (months)                                 |                      |
| n                                                                             | 59                   |
| Mean (SD)                                                                     | 37.01(38.493)        |
| Median                                                                        | 23.49                |
| Q1，Q3                                                                         | 9.66， 41.13          |
| Min, Max                                                                      | 0.6, 137.6           |
| Number of Prior Surgeries per Subject                                         |                      |
| n                                                                             | 59                   |
| Mean (SD)                                                                     | 5.5 (3.34)           |
| Median                                                                        | 5.0                  |
| Min, Max                                                                      | 1, 15                |
| Age at time of VHL associated RCC diagnosis (years) [2]                       |                      |
| n                                                                             | 45                   |
| Mean (SD)                                                                     | 33.8 (13.06)         |
| Median                                                                        | 32.0                 |
| Min, Max                                                                      | 15， 62               |

There were 9 patients included in Study 004 with an RCC of 3 cm or greater diameter. Of these, for 5 patients, surgery was deemed not necessary based on tumour size and slow growth. For 4 patients, surgery was considered undesirable because of multiple previous kidney surgeries.

All patients had VHL-RCC at baseline. Consistent with the multiorgan nature of VHL disease, all patients had at least 1 other VHL disease-associated tumour at baseline. Concurrent non-RCC tumour types included 51 (83.6%) patients with CNS HB, 32 (52.5%) with pancreatic lesions, 17 (27.9%) had retinal HB, 10 (16.4%) had epididymal cystadenomas, 3 (4.9%) had adrenal lesions, 2 (3.3%) had other lesions (not specified), and 1 (1.6%) had endolymphatic sac tumours per investigator assessment. Per IRC assessment, the concurrent non-RCC tumour types included 50 (82.0%) patients with CNS HB, 61 (100%) with pancreatic lesions, 22 (36.1%) with pNET, 12 (19.7%) had retinal HB.

A total of 59 patients (96.7%) had at least 1 prior surgery for other VHL-associated neoplasms, including nephrectomy (65.6%), nervous system neoplasm surgery (59.0%), eye laser surgery (21.3%), craniotomy (21.3%), and kidney ablation (19.7%).

## Numbers analysed

Efficacy and safety were assessed in all patients that received at least one dose of belzutifan in Study 004, resulting in the Efficacy Analysis Set and the Safety Analysis Set both consisting of all 61 included patients.

Per inclusion criteria, all patients had a VHL-associated RCC, and the primary and secondary efficacy outcomes in VHL-associated RCC were evaluated in 61 patients.

<div style=\"page-break-after: always\"></div>

50 patients had a measurable CNS haemangioblastoma at baseline per IRC and were evaluated for ORR and DOR of belzutifan in this tumour type.

22 patients had a measurable pNET at baseline per IRC and were evaluated for ORR and DOR of belzutifan in this tumour type.

## Outcomes and estimation

## Primary efficacy endpoint - objective response rate in VHL-RCC

The confirmed ORR (per RECIST 1.1 by IRC) was 63.9% (95% CI: 50.6, 75.8), with 4 CRs (Table 63).

Table 57: Study 004 - Summary of Best Overall Tumour Response for RCC Tumours (RECIST 1.1) IRC Efficacy Analysis Set

|                                                | Belzutifan (N=61)   |
|------------------------------------------------|---------------------|
| Best Overall Response, n (%)                   |                     |
| Complete Response (CR)                         | 4 ( 6.6)            |
| Partial Response (PR)                          | 35 ( 57.4)          |
| Stable Disease (SD)                            | 21 ( 34.4)          |
| Progressive Disease (PD)                       | 0                   |
| Not Evaluable (NE)                             | 1 ( 1.6)            |
| Ongoing with unconfirmed response, n (%)       | 3 ( 4.9)            |
| Ongoing without a response, n (%)              | 7 ( 11.5)           |
| Objective response rate CR + PR (ORR), n (%)   | 39 ( 63.9)          |
| 95% Confidence interval                        | (50.6, 75.8)        |
| 90% Confidence interval                        | (52.6, 74.2)        |
| Disease Control Rate CR + PR + SD (DCR), n (%) | 60 ( 98.4)          |
| 95% Confidence interval                        | (91.2, 100.0)       |
| 90% Confidence interval                        | (92.5, 99.9)        |

Note: 95% and 90% confidence intervals are constructed using 2-sided Clopper-Pearson method.

Best overall response of RCC CR and PR should be confirmed by a second assessment at least 4 weeks after the initial  response. Date of Data Cut-off: 01APR2022

ORR as assessed by the investigator showed results comparable to the primary analysis, with an ORR of 60.7% (95% CI 47.3-72.9), including one CR (1.6%) and 36 partial responses (59%).

## Secondary efficacy endpoint - duration of response in VHL-RCC

The median DOR (per RECIST 1.1 by IRC) was not reached (range: 5.4+ to 35.8+ months). Based on KM estimation, most responders had a DOR ≥18 months (29 [93.5%]) and the majority had a DOR ≥30 months (10 [86.6%]).

<div style=\"page-break-after: always\"></div>

Table 58: Study 004 - Summary of Duration of Response for RCC Tumours (RECIST 1.1) - IRC Efficacy Analysis Set

|                                                                          | Belzutifan (N=61)   |
|--------------------------------------------------------------------------|---------------------|
| Patients with Confirmed Response, n (%) (at April 01, 2022 data cut-off) | 39 ( 63.9)          |
| Responders who Progressed or Died (%)                                    | 5 ( 12.8)           |
| Duration of Response (Months) 95% CI                                     |                     |
| N                                                                        | 39                  |
| Mean [1]                                                                 | 23.5                |
| Median (95% CI)                                                          | NE (NE, NE)         |
| Q1 (95% CI)                                                              | NE (19.3, NE)       |
| Q3 (95% CI)                                                              | NE (NE, NE)         |
| Min, Max                                                                 | 5.4+, 35.8+         |
| Number (%) of Patients with Extended Response                            |                     |
| >=6 Months                                                               | 36 (100.0)          |
| >=12 Months                                                              | 35 (100.0)          |
| >=18 Months                                                              | 29 ( 93.5)          |
| >=24 Months                                                              | 22 ( 86.6)          |
| >=30 Months                                                              | 10 ( 86.6)          |
| >=36 Months                                                              | 0 (NR)              |

NE: Not Estimable.

NR: Not Reached.

Duration of Response is analysed using the Kaplan-Meier estimator. Median, first and third quartiles of Duration of Response are reported along with 95% Brookmeyer-Crowley confidence intervals.

[1] Arithmetic mean.

[2] % is calculated by Kaplan-Meier method.

+ indicates there was no progressive disease by the time of last disease assessment.

Date of Data Cut-off: 01APR2022

Figure 29 Kaplan-Meier Plot of duration of response for the RCC tumours (RECIST 1.1)-IRCEfficacy Analysis Set

<!-- image -->

Duration of Responseis analyzed using theKaplan-Meier estimator and their 95&amp; confidence intervals are estimated with thegeneralizedBrookmeyer-Crowleymethod. NE = Not estimable.

DateofDataCut-off:01APR2022

<div style=\"page-break-after: always\"></div>

## Secondary efficacy endpoint - time to response in VHL-associated RCC

The median time to response (TTR) in the 39 responders was 11.1 months (range 2.7-30.5 months).

Despite longer time to response based on RECIST v1.1, most patients (41, 67.2%) showed RCC tumour sum of diameter reduction at 1 st  tumour scan (Figure 30).

Figure 30: Spider Plot - Percentage Change in Total Sum of RCC Target Lesion Diameters from Baseline to Post-Baseline (RECIST 1.1) - IRC

<!-- image -->

## Secondary efficacy endpoints - VHL-CNS haemangioblastomas

In the 50 patients with measurable CNS HB at baseline, the confirmed ORR (per RECIST 1.1 by IRC) was 44.0% (95% CI: 30.0, 58.7), with 4 (8.0%) CRs and 18 partial responses (36%).

ORR as assessed by the investigator (in 51 patients with CNS haemangioblastoma per investigator assessment) showed somewhat lower percentages compared to the IRC-based primary analysis, with an ORR of 35.3% (95% CI 22.4-49.9), including 4 CRs (7.8%) and 14 partial responses (27.5%).

<div style=\"page-break-after: always\"></div>

Table 59: Study 004 - Summary of Best Overall Tumour Response for CNS Haemangioblastoma (RECIST 1.1)   IRC Efficacy Analysis Set

|                                                                              | Belzutifan (N=61) CNS Haemangioblastoma   |
|------------------------------------------------------------------------------|-------------------------------------------|
| Patients with VHL Disease Associated Non-RCC Tumours at Baseline, N1 (N1/N%) | 50 ( 82.0)                                |
| Best Overall Response, n (n/N1%)                                             |                                           |
| Complete Response (CR)                                                       | 4 ( 8.0)                                  |
| Partial Response (PR)                                                        | 18 ( 36.0)                                |
| Stable Disease (SD)                                                          | 23 ( 46.0)                                |
| Progressive Disease (PD)                                                     | 3 ( 6.0)                                  |
| Not Evaluable (NE)                                                           | 2 ( 4.0)                                  |
| Ongoing with unconfirmed response, n (n/N1%)                                 | 1 ( 2.0)                                  |
| Ongoing without a response, n (n/N1%)                                        | 13 ( 26.0)                                |
| Objective response rate CR + PR (ORR), n (n/N1%)                             | 22 ( 44.0)                                |
| 95% Confidence interval                                                      | (30.0, 58.7)                              |
| 90% Confidence interval                                                      | (32.0, 56.6)                              |
| Disease Control Rate CR + PR + SD (DCR), n (n/N1%)                           | 45 ( 90.0)                                |
| 95% Confidence interval                                                      | (78.2, 96.7)                              |
| 90% Confidence interval                                                      | (80.1, 96.0)                              |

Note: 95% and 90% confidence intervals are constructed using 2-sided Clopper-Pearson method.

Best overall response of RCC CR and PR should be confirmed by a second assessment at least 4 weeks after the initial  response.

Patients evaluable at baseline per IRC are included

Date of Data Cut-off: 01APR2022

<div style=\"page-break-after: always\"></div>

Figure 31: Spider Plot - Percentage Change in Total Sum of CNS Haemangioblastoma Target Lesion Diameters from Baseline to Post-Baseline (RECIST 1.1) - IRC

<!-- image -->

Date of Data Cut-off: 01APR2022

Note: n=30 (of the 50 patients with CNS-HB, 30 had target lesions at baseline and 20 had only non-target lesions).

The median DOR (per RECIST 1.1 by IRC) was not reached; based on KM estimation, most of the responders (12 [90.2%]) remained in response at ≥ 30 months. The median TTR was 5.4 months (range: 2.3 to 33.1 months).

Table 60: Summary of Duration of Response for CNS Haemangioblastomas (RECIST 1.1) - IRC

|                                                                              | Belzutifan (N=61) CNS Haemangioblastoma   |
|------------------------------------------------------------------------------|-------------------------------------------|
| Patients with VHL Disease Associated Non-RCC Tumours at Baseline, N1/N       | 50 ( 82.0)                                |
| Patients with Confirmed Response, n (n/N1%) (at April 01, 2022 data cut-off) | 22 ( 44.0)                                |
| Responders who Progressed or Died (%)                                        | 4 ( 18.2)                                 |
| Duration of Response (Months) 95% CI                                         |                                           |
| Mean [1]                                                                     | 23.9                                      |
| Median (95% CI)                                                              | NE (30.9, NE)                             |
| Q1 (95% CI)                                                                  | 31.3 ( 5.5, NE )                          |
| Q3 (95% CI)                                                                  | NE (NE, NE)                               |
| Min, Max                                                                     | 3.7+, 38.7+                               |
| Number (%) of Patients with Extended Response Duration [2]                   |                                           |
| >=6 Months                                                                   | 19 ( 95.2)                                |
| >=12 Months                                                                  | 16 ( 90.2)                                |
| >=18 Months                                                                  | 14 ( 90.2)                                |
| >=24 Months                                                                  | 13 ( 90.2)                                |
| >=30 Months                                                                  | 12 ( 90.2)                                |
| >=36 Months                                                                  | 2 ( 72.2)                                 |
| >=42 Months                                                                  | 0 (NR)                                    |

NE: Not Estimable.

<div style=\"page-break-after: always\"></div>

NR: Not Reached.

Duration of Response is analysed using the Kaplan-Meier estimator. Median, first and third quartiles of Duration of Response are reported along with 95% Brookmeyer-Crowley confidence intervals.

[1] Arithmetic mean.

- [2] % is calculated by Kaplan-Meier method.
+ indicates there was no progressive disease by the time of last disease assessment. Date of Data Cut-off: 01APR2022

Figure 32: Kaplan-Meier Plot of duration of response for the CNS tumours (RECIST 1.1)-IRCEfficacy Analysis Set

<!-- image -->

Durationof Response is analyzed usingthe Kaplan-Meier estimator and their 95&amp;confidence intervalsareestimatedwith thegeneralizedBrookmeyer-Crowleymethod. NE = Not estimable.

Date of Data Cut-off: 01APR2022

## Secondary efficacy endpoints - VHL-Pancreatic Neuroendocrine Tumours

In the 22 patients with a measurable pNET at baseline per IRC, the confirmed ORR was 90.9% (95% CI 70.898.9), with 7 complete responses (31.8%) and 13 partial responses (59.1%).

ORR as assessed by the investigator was not reported.

<div style=\"page-break-after: always\"></div>

Table 61: Study 004 - Summary of Best Overall Tumour Response for Pancreatic Neuroendocrine Tumours (RECIST 1.1) - IRC Efficacy Analysis Set

|                                                                              | Belzutifan (N=61) Pancreatic Neuroendocrine   |
|------------------------------------------------------------------------------|-----------------------------------------------|
| Patients with VHL Disease Associated Non-RCC Tumours at Baseline, N1 (N1/N%) | 22 ( 36.1)                                    |
| Best Overall Response, n (n/N1%)                                             |                                               |
| Complete Response (CR)                                                       | 7 ( 31.8)                                     |
| Partial Response (PR)                                                        | 13 ( 59.1)                                    |
| Stable Disease (SD)                                                          | 2 ( 9.1)                                      |
| Progressive Disease (PD)                                                     | 0                                             |
| Not Evaluable (NE)                                                           | 0                                             |
| Ongoing with unconfirmed response, n (n/N1%)                                 | 0                                             |
| Ongoing without a response, n (n/N1%)                                        | 0                                             |
| Objective response rate CR + PR (ORR), n (n/N1%)                             | 20 ( 90.9)                                    |
| 95% Confidence interval                                                      | (70.8, 98.9)                                  |
| 90% Confidence interval                                                      | (74.1, 98.4)                                  |
| Disease Control Rate CR + PR + SD (DCR), n (n/N1%)                           | 22 (100.0)                                    |
| 95% Confidence interval                                                      | (84.6, 100.0)                                 |
| 90% Confidence interval                                                      | (87.3, 100.0)                                 |

Note: 95% and 90% confidence intervals are constructed using 2-sided Clopper-Pearson method.

Best overall response of RCC CR and PR should be confirmed by a second assessment at least 4 weeks after the initial response.

Date of Data Cut-off: 01APR2022

The median duration of response in the 20 patients with a complete or partial response by IRC, was not estimable at the time of the second interim analysis at DCO 01 April 2022.

Based on the Kaplan-Meier curve, that is included below for completeness, 19 (100%) had a duration of response of at least 18 months.

Table 62: Summary of Duration of Response for Pancreatic Neuroendocrine Tumours (RECIST 1.1) - IRC

|                                                                              | Belzutifan (N=61) Pancreatic Neuroendocrine   |
|------------------------------------------------------------------------------|-----------------------------------------------|
| Patients with VHL Disease Associated Non-RCC Tumours at Baseline, N1/N       | 22 ( 36.1)                                    |
| Patients with Confirmed Response, n (n/N1%) (at April 01, 2022 data cut-off) | 20 ( 90.9)                                    |
| Responders who Progressed or Died (%)                                        | 0                                             |
| Duration of Response (Months) 95% CI                                         |                                               |
| Mean [1]                                                                     | 27.4                                          |
| Median (95% CI)                                                              | NE (NE, NE)                                   |
| Q1 (95% CI)                                                                  | NE (NE, NE)                                   |
| Q3 (95% CI)                                                                  | NE (NE, NE)                                   |
| Min, Max                                                                     | 11.0+, 37.3+                                  |

<div style=\"page-break-after: always\"></div>

| Number (%) of Patients with Extended Response Duration [2] >=6 Months   | 20 (100.0)   |
|-------------------------------------------------------------------------|--------------|
| >=12 Months                                                             | 19 (100.0)   |
| >=18 Months                                                             | 19 (100.0)   |
| >=24 Months                                                             | 15 (100.0)   |
| >=30 Months                                                             | 8 (100.0)    |
| >=36 Months                                                             | 1 (100.0)    |
| >=42 Months                                                             | 0 (NR)       |

NE: Not Estimable.

NR: Not Reached.

Duration of Response is analysed using the Kaplan-Meier estimator. Median, first and third quartiles of Duration of Response are reported along with 95% Brookmeyer-Crowley confidence intervals.

- [1] Arithmetic mean.

[2] % is calculated by Kaplan-Meier method.

+ indicates there was no progressive disease by the time of last disease assessment. Date of Data Cut-off: 01APR2022

Figure 33: Kaplan-Meier Plot of Duration of Response for the Pancreatic Neuroendocrine Tumours (RECIST 1.1)-IRC- Efficacy Analysis Set

<!-- image -->

Durationof Response is analyzed using the Kaplan-Meierestimator and their 95&amp; confidence intervals areestimated with thegeneralizedBrookmeyer-Crowleymethod. NE = Not estimable.

DateofDataCut-off:01APR2022

## Ancillary analyses

## Subgroup analysis by VHL gene alteration status

The ORR, DOR, and TTR for VHL-RCC and non-RCC tumours were submitted in the CSR for the following subgroups in the efficacy analysis set - VHL gene alteration status: VHL deletion (partial or complete) or VHL gene mutation.

In VHL-RCC, the observed ORRs with VHL deletion were numerically lower than with VHL-mutation (44.4% vs.72.1%). For non-RCC tumours, ORRs (VHL deletion vs VHL mutation) were generally comparable. The median TTR across VHL tumours in patients with VHL deletion tended to be longer than with VHL mutation, including RCC (20.8 vs. 8.2 months), pNET (13.5 vs. 5.5 months), and CNS haemangioblastoma (5.5 vs. 4.3 months).

<div style=\"page-break-after: always\"></div>

## Surgeries or procedures for VHL-RCC, CNS HB, pNET and other VHL Neoplasms

Nine of the 61 patients underwent VHL disease-related surgical procedures during treatment and/or follow-up (Figure 34). Seven of these 9 patients had at least 1 surgical procedure during belzutifan treatment. Of these 7 patients, three had a (partial) nephrectomy and one had cryotherapy for RCC, two had retinal laser coagulation for CNS-HB and one had two brain surgeries (drainage and resection of a cystic CNS-HB). For some patients (n=4), local treatment was performed for a growing RCC while the other VHL-associated tumours in these individuals were still responding to treatment. Belzutifan was continued in two of these patients, and stopped in two other patients. The two patients undergoing retinal laser coagulation had ongoing responses of their other VHL-associated tumours and belzutifan was continued in both. The patient who underwent brain surgery for a growing CNS-HB continued belzutifan, because the VHL-associated RCC was still responding to treatment.

Seven (11.5%) patients underwent surgery for VHL-RCC in the study, including while on treatment and during follow-up. The reason for treatment discontinuation for the (additional) three patients who underwent surgical interventions during follow-up was disease progression of their VHL-RCC and they subsequently underwent partial nephrectomy.

Figure 34: Study 004 - Distribution of All Surgeries Pre- and Post- Treatment Initiation over Time for Individual Patients Safety Analysis Set

<!-- image -->

Horizontal bars represent each patient.

Only pre-treatment surgeries less than 10 years prior to treatment initiation are presented. Length of the bars on the right side of the y-axis represents duration of treatment at time of data cut-off. Surgery is defined as a tumour reduction procedure excluding radiation Date of Data Cut-off: 01APR2022

## Analyses of response of co-occurring VHL-associated tumours

An analysis was performed showing per patient the tumour response of different tumours (RCC, CNS-HB, and/or pNET) that co-manifested in individual patients. Inspection of the spider plots provided for each individual patient shows that, for most cases, the changes in tumour diameter from baseline show a concordant pattern for different tumours within a patient. Based on the Sum of Diameter (SOD) of target lesions by tumour type in individual patients, of the 41 patients that had more than one tumour type, most

<div style=\"page-break-after: always\"></div>

(35/41, 85.4%) had concordant responses. Based on measurements of individual lesions (for example two separate pNETs in a single patient), the concordance was 70.7% across different tumour types.

In Study 004, treatment was to be permanently discontinued in case of radiographic disease progression of VHL-associated RCC. Because the applied indication also covers patients with a VHL-associated HB or pNET that requires treatment (and the presence of a VHL-associated RCC requiring treatment is not mandatory), the applicant also provided data on patients in whom the VHL-associated RCC did not show radiographic disease progression, while other VHL-associated tumours that were present in the same patient no longer responded to treatment.

Based on IRC-assessment, during treatment with belzutifan, there were 10 patients that had progressive disease of VHL-associated CNS-HB, but a VHL-associated RCC that did not show progression of disease Table 69, Table 70). Of note, based on investigator-assessment, these 10 patients did not show progression of CNS-HB. Therefore, study treatment was not discontinued because of progression of CNS-HB in any of these patients. Seven patients remained on treatment and three patients discontinued treatment because of other reasons than IRC-assessed progression of CNS-HB.

Table 63: Study 004 Study Patients who had not Progressed in RCC, but Progressed in Other Tumours (CNS-HB and/or pNET)

| Pt ID   | RCC Tumour response a (no PD)   | RCC Tumour response a (no PD)   | CNS-HB Tumour response a   | CNS-HB Tumour response a   | pNET Tumour Response a, b   | Status             |
|---------|---------------------------------|---------------------------------|----------------------------|----------------------------|-----------------------------|--------------------|
| Pt ID   | Per IRC                         | Per Inv.                        | Per IRC                    | Per Inv.                   | Per IRC                     | Status             |
| XXX     | PR                              | PR                              | PD                         | NON-CR/NON-PD              | -                           | Off study          |
| XXX     | PR                              | PR                              | PD                         | NON-CR/NON-PD              | -                           | LTFU               |
| XXX     | SD                              | SD                              | PD                         | PR                         | -                           | LTFU               |
| XXX     | CR                              | CR                              | PD                         | SD                         | CR                          | On study treatment |
| XXX     | PR                              | PR                              | PD                         | CR                         | -                           | On study treatment |
| XXX     | PR                              | PR                              | PD                         | PR                         | PR                          | On study treatment |
| XXX     | PR                              | PR                              | PD                         | NON-CR/NON-PD              | CR                          | On study treatment |
| XXX     | PR                              | PR                              | PD                         | NON-CR/NON-PD              | PR                          | On study treatment |
| XXX     | PR                              | PR                              | PD                         | NON-CR/NON-PD              | -                           | On study treatment |
| XXX     | PR                              | SD                              | PD                         | SD                         | CR                          | On study treatment |

Note: Pt IDs anonymized by assessor.

CNS-HB=central nervous system haemangioblastoma; CR=complete response; ID=identification; Inv=investigator;

IRC=Independent Review Committee; LTFU=long-term follow-up; PD=progressive disease; pNET=pancreatic neuroendocrine tumour; PR=partial response; Pt=patient; RCC=renal cell carcinoma; SD=stable disease.

a : The tumour responses entered are PD or the last assessment if have not progressed as of data cutoff.

b : pNET assessment is only per IRC.

-: Patients had no pNET at baseline per IRC.

Date of Data Cut-off: 01APR2022

## Updated ORR and DOR data from 03-APR-2023 DCO

An updated efficacy analysis for Study 004, with a DCO of 03-APR-2023 was provided at which time the median follow-up was about 1 year longer (Table 70). At this time, median exposure to belzutifan was 48.7 months (range: 1.9 to 58.1 months).

<div style=\"page-break-after: always\"></div>

Table 64: Objective Response Rate Over Time at Different Data Cutoff Dates

|                                                                                                                                                                          | Data cutoff 01-APR-2022                                                                                                                                                  | Data cutoff 03-APR-2023                                                                                                                                                  |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Follow-up duration, median [months] (range)                                                                                                                              | 37.7 (4.2 to 46.1)                                                                                                                                                       | 49.7 (4.2 to 58.1)                                                                                                                                                       |
| RCC - ORR, % (95% CI) (n=61)                                                                                                                                             | 63.9% (50.6, 75.8)                                                                                                                                                       | 67.2% (54.0, 78.7)                                                                                                                                                       |
| CNS HB - ORR, %(95% CI) (n=50)                                                                                                                                           | 44.0% (30.0, 58.7)                                                                                                                                                       | 48.0% (33.7, 62.6)                                                                                                                                                       |
| pNET - ORR, %(95% CI) (n=22)                                                                                                                                             | 90.9% (70.8, 98.9)                                                                                                                                                       | 90.9% (70.8, 98.9)                                                                                                                                                       |
| CI=confidence interval; CNS=central nervous system; HB=haemangioblastoma; ORR=objective response rate; pNET=pancreatic neuroendocrine tumours; RCC=renal cell carcinoma. | CI=confidence interval; CNS=central nervous system; HB=haemangioblastoma; ORR=objective response rate; pNET=pancreatic neuroendocrine tumours; RCC=renal cell carcinoma. | CI=confidence interval; CNS=central nervous system; HB=haemangioblastoma; ORR=objective response rate; pNET=pancreatic neuroendocrine tumours; RCC=renal cell carcinoma. |

Updated DOR results across tumour types were as follows, with the median DOR remaining not reached in all 3 tumour types:

- -in VHL-associated RCC, the range of DOR was 8.6+ to 44.4+ months, based on KM estimation, 17 (87.2%) patients had a DOR ≥ 36 months and 3 (71.5%) patients had a DOR ≥ 42 months.
- -in VHL-associated CNS-HB, the range of DOR was 0.0+ to 47.5+ months, based on KM estimation, 8 (80.8%) patients had a DOR ≥ 36 months and 7 (80.8%) patients had a DOR ≥ 42 months; and
- -in VHL-associated pNET, the range of DOR was 11.0+ to 48.3+ months for those with pNETs, based on KM estimation, 10 (94.7%) patients had a DOR ≥ 36 months, and 3 (94.7%) patients had a DOR ≥ 42 months.

## Supportive study - MK-6482-015 (Study 015)

Study 015 (NCT04924075) is an ongoing, uncontrolled phase 2 study to evaluate the efficacy and safety of belzutifan 120 mg QD in 5 cohorts of patients: with advanced pheochromocytoma/paraganglioma [PPGL] (Cohort A1), pNET (Cohort A2), advanced wtGIST (Cohort C), advanced solid tumours with HIF-2 α related genetic alterations (Cohort D), and VHL-associated tumours who have at least 1 measurable RCC, pNET, or PPGL tumour (Cohort B1).

In Cohort B1, the planned maximum enrolment is 92 patients (32 with RCC, 30 with pNET, and 30 with PPGL). A patient with different VHL-associated tumours can count for all three tumour types, therefore the study could also be completed with 32 included patients.

Upon request, interim results were first provided for 23 patients with VHL disease (18 patients with RCC) that were enrolled in the China population in Cohort B1. All patients were still receiving study treatment at the DCO of 9-NOV-2023, at which time median follow-up was 8.4 months (range: 5.6 to 10.6 months) and median exposure to study drug was 35.7 weeks (range: 23.9 to 46.3 weeks). The applicant later provided updated results with a longer follow-up (DCO 23-MAY-24). The results of both interim analyses are shown in Table 71.

<div style=\"page-break-after: always\"></div>

Table 65: Interim Efficacy Results Study 015 Cohort B1 (n=23)

|                                      | DCO 9-Nov-2023 Median FU 8.4 months   | DCO 23-May-2024 Median FU 14.9 months   |
|--------------------------------------|---------------------------------------|-----------------------------------------|
| VHL-associated RCC (n=18)            |                                       |                                         |
| ORR per RECIST v1.1 by BICR (95% CI) | 38.9% (17.3-64.3)                     | 83.3% (58.6-96.4)                       |
| PR/CR                                | 38.9% (n=7) / 0%                      | 83.3% (n=15)/0%                         |
| DOR (median, months)                 | NR (range 2.6+ to 5.5+)               | NR (range 2.7+ to 11.1+)                |
| VHL-associated CNS-HB (n=8)          |                                       | (n=10)                                  |
| ORR per RECIST v1.1 by BICR (95% CI) | 37.5% (8.5-75.5)                      | 60.0% (26.2-87.8)                       |
| PR/CR                                | 37.5% (n=3) / 0%                      | 60% (n=6) /0%                           |
| DOR (median, months)                 | NR (range 2.8+ to 5.7+)               | NR (range 5.6+ to 14.1+)                |
| VHL-associated pNET (n=12)           |                                       |                                         |
| ORR per RECIST v1.1 by BICR (95% CI) | 33.3% (9.9-65.1)                      | 66.7% (34.9-90.1)                       |
| PR/CR                                | 33.3% (n=4) / 0%                      | 66.7% (n=8)/0%                          |
| DOR (median months)                  | NR                                    | NR (2.8+ to 11.3+)                      |

NR: not reached, '+': indicates there is no progressive disease by the time of the last disease assessment.

## Supportive study - von Hippel-Lindau Natural History Study

A retrospective, non-interventional study was conducted to describe the natural history of disease for patients with VHL-RCC. The study used data registered by the US National Cancer Institute (NCI) in a hereditary database, linked to internal and external databases including the US National Death Index. The analyses were conducted to further elucidate the natural history of disease for patients with VHL RCC undergoing active surveillance in the absence of therapy and used to benchmark efficacy results of Study 004, a single-arm study. As most patients (approximately 80%) in the Study 004 population are from the US, and the NCI has one of the largest known clinical databases of medical records related to the treatment and care of patients with this rare condition, this US database was selected for natural history study.

<div style=\"page-break-after: always\"></div>

Figure 35: Patient Disposition

<!-- image -->

Analyses were conducted in the Primary Study Population of patients who met the study eligibility criteria and a subgroup of patients ('Trial Population Subgroup') who met additional key eligibility criteria that closely matched those of Study 004 with a focus on the growth rate assessment. Analysis of the Trial Population Subgroup was used to benchmark Study 004 results. An analysis of radiographic outcomes and growth rate for renal solid tumours was performed for a subset of patients in the Trial Populati on Subgroup with ≥3 serial tumour measurements for unique tumour(s) before the first occurrence of: death or last clinical encounter, initiation of investigational or oncologic therapy, or first renal tumour-reduction procedure impacting the

<div style=\"page-break-after: always\"></div>

tumour. Radiographic assessments of renal solid tumours were performed by IRC using RECIST criteria and the same imaging laboratory and charter used for Study 004.

The NHS included 244 patients in the Trial Population Subgroup. The median age of patients at the patientlevel index date was 41.3 years (IQR: 32.4 to 51.3), and 46% were female. All patients had a genetic diagnosis of VHL disease. The median baseline tumour size of the largest tumour, based on IRC assessment, was 2.5 cm (IQR: 1.9 to 3.1). A prior renal surgery with therapeutic intent was reported for 64.8% of patients. The median length of follow-up after the patient-level index date in the Trial Population Subgroup was approximately 10 years (122.3 months), with most patients having at least 2 years of follow-up (91%), and the majority (75%) had at least 5 years of follow-up. In this cohort study, the real-world ORR (assessed per RECIST v1.1 by IRC), with observation only, i.e. the chance of spontaneous regression of VHL-related RCC, was 1.8% for patients with up to 5 years of follow-up.

Among the 186 patients in the Trial Population Subgroup with ≥ 1 surgery, 29.5% had renal surgery within 2 years and 57.0% within 5 years of follow-up. 42 (17.2%) patients died during follow-up, with 10% within the first 7 years

## Summary of main efficacy results

The following tables summarise the efficacy results from the main studies supporting the present application. These summaries should be read in conjunction with the discussion on clinical efficacy as well as the benefitrisk assessment (see later sections).

Table 66: Summary of Efficacy for Trial MK-6482-005 (Study 005)

| Title : An Open-label, Randomized Phase 3 Study of MK-6482 Versus Everolimus in Participants with Advanced Renal Cell Carcinoma That Has Progressed After Prior PD-1/L1 and VEGF-Targeted Therapies   | Title : An Open-label, Randomized Phase 3 Study of MK-6482 Versus Everolimus in Participants with Advanced Renal Cell Carcinoma That Has Progressed After Prior PD-1/L1 and VEGF-Targeted Therapies                                                       | Title : An Open-label, Randomized Phase 3 Study of MK-6482 Versus Everolimus in Participants with Advanced Renal Cell Carcinoma That Has Progressed After Prior PD-1/L1 and VEGF-Targeted Therapies                                                               |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Study identifier                                                                                                                                                                                      | MK-6482-005 (Study 005; LITESPARK-005) EudraCT: 2019-003444-72                                                                                                                                                                                            | MK-6482-005 (Study 005; LITESPARK-005) EudraCT: 2019-003444-72                                                                                                                                                                                                    |
| Design                                                                                                                                                                                                | Open-label, multicentre, randomized, efficacy, safety, parallel-assignment, active-controlled interventional study                                                                                                                                        | Open-label, multicentre, randomized, efficacy, safety, parallel-assignment, active-controlled interventional study                                                                                                                                                |
|                                                                                                                                                                                                       | Duration of main phase:                                                                                                                                                                                                                                   | The study is ongoing; estimated duration is approximately 5.5 years from first patient, first visit (27-FEB-2020).                                                                                                                                                |
|                                                                                                                                                                                                       | Duration of Run-in phase:                                                                                                                                                                                                                                 | The study enrolled 9 patients in a Japan-specific Safety Run-in Cohort. These patients were not randomized to treatment in the study; all received belzutifan. These patients were not included in the intent-to-treat (ITT) population for analysis of efficacy. |
|                                                                                                                                                                                                       | Duration of Extension phase:                                                                                                                                                                                                                              | Not applicable.                                                                                                                                                                                                                                                   |
| Hypothesis                                                                                                                                                                                            | • Belzutifan is superior to everolimus with respect to the dual primary endpoints of progression-free survival (PFS) by BICR per RECIST) 1.1 and overall survival (OS). • Belzutifan increases objective response rate (ORR), the key secondary endpoint, | • Belzutifan is superior to everolimus with respect to the dual primary endpoints of progression-free survival (PFS) by BICR per RECIST) 1.1 and overall survival (OS). • Belzutifan increases objective response rate (ORR), the key secondary endpoint,         |

<div style=\"page-break-after: always\"></div>

| Treatment groups          | Belzutifan 120 mg once daily (QD)                                                                                                                                   | Belzutifan 120 mg taken orally once daily (QD) Treatment continued until documented radiographic disease progression (BICR verified), unacceptable AEs, intercurrent illness that prevented further administration of treatment, investigator's decision to discontinue the patient, patient withdrawal of consent, pregnancy of the patient, or administrative reasons requiring cessation of treatment. Treatment could be continued after radiographic progression, as long as the investigator believed that the patient was still receiving clinical benefit from study intervention and that the potential benefit of continuing study intervention outweighs potential risks.   | Belzutifan 120 mg taken orally once daily (QD) Treatment continued until documented radiographic disease progression (BICR verified), unacceptable AEs, intercurrent illness that prevented further administration of treatment, investigator's decision to discontinue the patient, patient withdrawal of consent, pregnancy of the patient, or administrative reasons requiring cessation of treatment. Treatment could be continued after radiographic progression, as long as the investigator believed that the patient was still receiving clinical benefit from study intervention and that the potential benefit of continuing study intervention outweighs potential risks.   |
|---------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Treatment groups          | Everolimus 10 mg QD                                                                                                                                                 | Everolimus 10 mg taken orally QD 372 patients were randomized to receive everolimus (ITT population).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | Everolimus 10 mg taken orally QD 372 patients were randomized to receive everolimus (ITT population).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| Endpoints and definitions | Dual Primary Endpoints                                                                                                                                              | PFS by BICR per RECIST 1.1 OS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | PFS was defined as the time from randomization to the first documented disease progression or death due to any cause, whichever occurs first OS was defined as the time from randomization to death due to any cause.                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| Endpoints and definitions | Key Secondary Endpoint                                                                                                                                              | ORR by BICR per RECIST 1.1                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | ORR was defined as complete response (CR) or partial response (PR).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| Database lock             | Interim Analysis 1 (IA1): Data cutoff date 01-NOV-2022; database lock 08-DEC-2022 Interim Analysis 2 (IA2): Data cutoff date 13-JUN-2023; database lock 20-JUL-2023 | Interim Analysis 1 (IA1): Data cutoff date 01-NOV-2022; database lock 08-DEC-2022 Interim Analysis 2 (IA2): Data cutoff date 13-JUN-2023; database lock 20-JUL-2023                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | Interim Analysis 1 (IA1): Data cutoff date 01-NOV-2022; database lock 08-DEC-2022 Interim Analysis 2 (IA2): Data cutoff date 13-JUN-2023; database lock 20-JUL-2023                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |

OS Fi l A

l

i

(FA)  D

t

t

ff d

t

15 APR 2024  d t b

l

k

<div style=\"page-break-after: always\"></div>

| Results and Analysis                            | Results and Analysis                                                                                                                                                                                                                                  | Results and Analysis                                                                                                                                                                                                                                  | Results and Analysis                                                                                                                                                                                                                                  | Results and Analysis                                                                                                                                                                                                                                  |
|-------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Analysis description                            | Primary Analysis                                                                                                                                                                                                                                      | Primary Analysis                                                                                                                                                                                                                                      | Primary Analysis                                                                                                                                                                                                                                      | Primary Analysis                                                                                                                                                                                                                                      |
| Analysis population and time point description  | Intent-to-treat (ITT) population: The ITT population was the population for the primary efficacy analyses. The ITT population included all 746 patients randomized to study treatment according to the treatment group to which they were randomized. | Intent-to-treat (ITT) population: The ITT population was the population for the primary efficacy analyses. The ITT population included all 746 patients randomized to study treatment according to the treatment group to which they were randomized. | Intent-to-treat (ITT) population: The ITT population was the population for the primary efficacy analyses. The ITT population included all 746 patients randomized to study treatment according to the treatment group to which they were randomized. | Intent-to-treat (ITT) population: The ITT population was the population for the primary efficacy analyses. The ITT population included all 746 patients randomized to study treatment according to the treatment group to which they were randomized. |
| Descriptive statistics and estimate variability | Treatment group                                                                                                                                                                                                                                       | Treatment group                                                                                                                                                                                                                                       | Belzutifan 120 mg QD                                                                                                                                                                                                                                  | Everolimus 10 mg QD                                                                                                                                                                                                                                   |
| Descriptive statistics and estimate variability | Number of subjects                                                                                                                                                                                                                                    | Number of subjects                                                                                                                                                                                                                                    | 374                                                                                                                                                                                                                                                   | 372                                                                                                                                                                                                                                                   |
| Descriptive statistics and estimate variability | Interim Analysis 1                                                                                                                                                                                                                                    | Interim Analysis 1                                                                                                                                                                                                                                    | Interim Analysis 1                                                                                                                                                                                                                                    | Interim Analysis 1                                                                                                                                                                                                                                    |
| Descriptive statistics and estimate variability | PFS at IA1                                                                                                                                                                                                                                            | PFS at IA1                                                                                                                                                                                                                                            | PFS at IA1                                                                                                                                                                                                                                            | PFS at IA1                                                                                                                                                                                                                                            |
| Descriptive statistics and estimate variability | Median, months (Kaplan-Meier [KM] estimates)                                                                                                                                                                                                          | Median, months (Kaplan-Meier [KM] estimates)                                                                                                                                                                                                          | 5.6                                                                                                                                                                                                                                                   | 5.6                                                                                                                                                                                                                                                   |
| Descriptive statistics and estimate variability | 95% confidence interval (CI)                                                                                                                                                                                                                          | 95% confidence interval (CI)                                                                                                                                                                                                                          | 3.9, 7.0                                                                                                                                                                                                                                              | 4.8, 5.8                                                                                                                                                                                                                                              |
| Descriptive statistics and estimate variability | OS at FA                                                                                                                                                                                                                                              | OS at FA                                                                                                                                                                                                                                              | OS at FA                                                                                                                                                                                                                                              | OS at FA                                                                                                                                                                                                                                              |
| Descriptive statistics and estimate variability | Median, months (KM estimates)                                                                                                                                                                                                                         | Median, months (KM estimates)                                                                                                                                                                                                                         | 21.4                                                                                                                                                                                                                                                  | 18.2                                                                                                                                                                                                                                                  |
| Descriptive statistics and estimate variability | 95% CI                                                                                                                                                                                                                                                | 95% CI                                                                                                                                                                                                                                                | 18.2, 24.3                                                                                                                                                                                                                                            | 15.8, 21.8                                                                                                                                                                                                                                            |
| Descriptive statistics and estimate variability | ORR at IA1                                                                                                                                                                                                                                            | ORR at IA1                                                                                                                                                                                                                                            | ORR at IA1                                                                                                                                                                                                                                            | ORR at IA1                                                                                                                                                                                                                                            |
| Descriptive statistics and estimate variability | ORR (%)                                                                                                                                                                                                                                               | ORR (%)                                                                                                                                                                                                                                               | 21.9                                                                                                                                                                                                                                                  | 3.5                                                                                                                                                                                                                                                   |
| Descriptive statistics and estimate variability | 95% CI                                                                                                                                                                                                                                                | 95% CI                                                                                                                                                                                                                                                | 17.8, 26.5                                                                                                                                                                                                                                            | 1.9, 5.9                                                                                                                                                                                                                                              |
| Effect estimate per comparison                  | Dual primary endpoint:                                                                                                                                                                                                                                | Comparison groups                                                                                                                                                                                                                                     | Comparison groups                                                                                                                                                                                                                                     | Belzutifan versus everolimus                                                                                                                                                                                                                          |
| Effect estimate per comparison                  | PFS at IA1                                                                                                                                                                                                                                            | Hazard ratio                                                                                                                                                                                                                                          | Hazard ratio                                                                                                                                                                                                                                          | 0.75                                                                                                                                                                                                                                                  |
| Effect estimate per comparison                  | PFS at IA1                                                                                                                                                                                                                                            | 95% CI                                                                                                                                                                                                                                                | 95% CI                                                                                                                                                                                                                                                | 0.63, 0.90                                                                                                                                                                                                                                            |
| Effect estimate per comparison                  | PFS at IA1                                                                                                                                                                                                                                            | P-value                                                                                                                                                                                                                                               | P-value                                                                                                                                                                                                                                               | 0.00077                                                                                                                                                                                                                                               |
| Effect estimate per comparison                  | PFS at IA1                                                                                                                                                                                                                                            | HR and 95% CI based on stratified Cox regression model with Efron's method of tie handling.                                                                                                                                                           | HR and 95% CI based on stratified Cox regression model with Efron's method of tie handling.                                                                                                                                                           | HR and 95% CI based on stratified Cox regression model with Efron's method of tie handling.                                                                                                                                                           |
| Effect estimate per comparison                  | PFS at IA1                                                                                                                                                                                                                                            | One-sided p-value based on stratified log-rank test.                                                                                                                                                                                                  | One-sided p-value based on stratified log-rank test.                                                                                                                                                                                                  | One-sided p-value based on stratified log-rank test.                                                                                                                                                                                                  |
| Effect estimate per comparison                  | Dual primary endpoint: OS at FA                                                                                                                                                                                                                       | Comparison groups                                                                                                                                                                                                                                     | Comparison groups                                                                                                                                                                                                                                     | Belzutifan versus everolimus                                                                                                                                                                                                                          |
| Effect estimate per comparison                  | Dual primary endpoint: OS at FA                                                                                                                                                                                                                       | Hazard ratio                                                                                                                                                                                                                                          | Hazard ratio                                                                                                                                                                                                                                          | 0.92                                                                                                                                                                                                                                                  |
| Effect estimate per comparison                  | Dual primary endpoint: OS at FA                                                                                                                                                                                                                       | 95% CI                                                                                                                                                                                                                                                | 95% CI                                                                                                                                                                                                                                                | 0.77, 1.10                                                                                                                                                                                                                                            |
| Effect estimate per comparison                  | Dual primary endpoint: OS at FA                                                                                                                                                                                                                       | P-value                                                                                                                                                                                                                                               | P-value                                                                                                                                                                                                                                               | 0.17644                                                                                                                                                                                                                                               |
| Effect estimate per comparison                  | Dual primary endpoint: OS at FA                                                                                                                                                                                                                       | HR and 95% CI based on stratified Cox regression model with Efron's method of tie handling.                                                                                                                                                           | HR and 95% CI based on stratified Cox regression model with Efron's method of tie handling.                                                                                                                                                           | HR and 95% CI based on stratified Cox regression model with Efron's method of tie handling.                                                                                                                                                           |
| Effect estimate per comparison                  | Dual primary endpoint: OS at FA                                                                                                                                                                                                                       | One-sided p-value based on stratified log-rank test.                                                                                                                                                                                                  | One-sided p-value based on stratified log-rank test.                                                                                                                                                                                                  | One-sided p-value based on stratified log-rank test.                                                                                                                                                                                                  |
| Effect estimate per comparison                  | Key secondary endpoint: ORR at IA1                                                                                                                                                                                                                    | Comparison groups                                                                                                                                                                                                                                     | Comparison groups                                                                                                                                                                                                                                     | Belzutifan versus everolimus                                                                                                                                                                                                                          |
| Effect estimate per comparison                  | Key secondary endpoint: ORR at IA1                                                                                                                                                                                                                    | Difference in %                                                                                                                                                                                                                                       | Difference in %                                                                                                                                                                                                                                       | 18.4                                                                                                                                                                                                                                                  |
| Effect estimate per comparison                  | Key secondary endpoint: ORR at IA1                                                                                                                                                                                                                    | 95% CI                                                                                                                                                                                                                                                | 95% CI                                                                                                                                                                                                                                                | 14.0, 23.2                                                                                                                                                                                                                                            |
| Effect estimate per comparison                  | Key secondary endpoint: ORR at IA1                                                                                                                                                                                                                    | P-value                                                                                                                                                                                                                                               | P-value                                                                                                                                                                                                                                               | <0.00001                                                                                                                                                                                                                                              |
| Effect estimate per comparison                  | Key secondary endpoint: ORR at IA1                                                                                                                                                                                                                    | Difference estimate based on stratified Miettinen & Nurminen method.                                                                                                                                                                                  | Difference estimate based on stratified Miettinen & Nurminen method.                                                                                                                                                                                  | Difference estimate based on stratified Miettinen & Nurminen method.                                                                                                                                                                                  |

<div style=\"page-break-after: always\"></div>

|                                                 | One-sided                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | One-sided                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | p-value for testing.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | p-value for testing.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
|-------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Notes                                           | The study at IA1 met the predefined success criterion for superiority based on PFS and ORR. At FA, the results of OS did not meet the predefined success criterion. Median duration of follow-up was 13.5 months at IA1 and 19.6 months at FA. Stratification factors used for efficacy analyses include the following: International Metastatic RCC Database Consortium (IMDC) risk group (favourable vs. intermediate vs. poor) and number of prior VEGF/VEGF receptor-targeted therapies for advanced RCC (1 vs. 2-3). | The study at IA1 met the predefined success criterion for superiority based on PFS and ORR. At FA, the results of OS did not meet the predefined success criterion. Median duration of follow-up was 13.5 months at IA1 and 19.6 months at FA. Stratification factors used for efficacy analyses include the following: International Metastatic RCC Database Consortium (IMDC) risk group (favourable vs. intermediate vs. poor) and number of prior VEGF/VEGF receptor-targeted therapies for advanced RCC (1 vs. 2-3). | The study at IA1 met the predefined success criterion for superiority based on PFS and ORR. At FA, the results of OS did not meet the predefined success criterion. Median duration of follow-up was 13.5 months at IA1 and 19.6 months at FA. Stratification factors used for efficacy analyses include the following: International Metastatic RCC Database Consortium (IMDC) risk group (favourable vs. intermediate vs. poor) and number of prior VEGF/VEGF receptor-targeted therapies for advanced RCC (1 vs. 2-3). | The study at IA1 met the predefined success criterion for superiority based on PFS and ORR. At FA, the results of OS did not meet the predefined success criterion. Median duration of follow-up was 13.5 months at IA1 and 19.6 months at FA. Stratification factors used for efficacy analyses include the following: International Metastatic RCC Database Consortium (IMDC) risk group (favourable vs. intermediate vs. poor) and number of prior VEGF/VEGF receptor-targeted therapies for advanced RCC (1 vs. 2-3). |
| Analysis description                            | Subgroup of patients who received two or more lines of therapy                                                                                                                                                                                                                                                                                                                                                                                                                                                            | Subgroup of patients who received two or more lines of therapy                                                                                                                                                                                                                                                                                                                                                                                                                                                            | Subgroup of patients who received two or more lines of therapy                                                                                                                                                                                                                                                                                                                                                                                                                                                            | Subgroup of patients who received two or more lines of therapy                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| Analysis population and time point description  | Approved indication subgroup: The approved indication subgroup included the 369 patients that received two or more lines of therapy that included a PD-(L)1 inhibitor and at least two VEGF-targeted therapies.                                                                                                                                                                                                                                                                                                           | Approved indication subgroup: The approved indication subgroup included the 369 patients that received two or more lines of therapy that included a PD-(L)1 inhibitor and at least two VEGF-targeted therapies.                                                                                                                                                                                                                                                                                                           | Approved indication subgroup: The approved indication subgroup included the 369 patients that received two or more lines of therapy that included a PD-(L)1 inhibitor and at least two VEGF-targeted therapies.                                                                                                                                                                                                                                                                                                           | Approved indication subgroup: The approved indication subgroup included the 369 patients that received two or more lines of therapy that included a PD-(L)1 inhibitor and at least two VEGF-targeted therapies.                                                                                                                                                                                                                                                                                                           |
| Descriptive statistics and estimate variability | Treatment group                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | Treatment group                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | Belzutifan 120 mg QD                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | Everolimus 10 mg QD                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| Descriptive statistics and estimate variability | Number of subjects                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | Number of subjects                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 187                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 182                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| Descriptive statistics and estimate variability | Interim Analysis 1                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | Interim Analysis 1                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | Interim Analysis 1                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | Interim Analysis 1                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| Descriptive statistics and estimate variability | PFS at IA1                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | PFS at IA1                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | PFS at IA1                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | PFS at IA1                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| Descriptive statistics and estimate variability | Median, months (Kaplan-Meier [KM] estimates)                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | Median, months (Kaplan-Meier [KM] estimates)                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 4.6                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 5.4                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| Descriptive statistics and estimate variability | 95% confidence interval (CI)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 95% confidence interval (CI)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 3.5, 7.3                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 3.8, 6.5                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| Descriptive statistics and estimate variability | OS at FA                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | OS at FA                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | OS at FA                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | OS at FA                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| Descriptive statistics and estimate variability | Median, months (KM estimates)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | Median, months (KM estimates)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 21.8                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 18.1                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| Descriptive statistics and estimate variability | 95% CI                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 95% CI                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 17.4 25.8                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 14.2, 23.9                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| Descriptive statistics and estimate variability | ORR at IA1                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | ORR at IA1                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| Descriptive statistics and estimate variability | ORR (%)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | ORR (%)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 24.1                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 3.3                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| Descriptive statistics and estimate variability | 95% CI                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 95% CI                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 18.1, 30.8                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 1.2, 7.0                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| Effect estimate per comparison                  | Dual primary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | Comparison groups                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | Comparison groups                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | Belzutifan versus everolimus                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| Effect estimate per comparison                  | endpoint:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | Hazard ratio                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | Hazard ratio                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 0.73                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| Effect estimate per comparison                  | PFS at IA1                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 95% CI                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 95% CI                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 0.57, 0.94                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| Effect estimate per comparison                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | HR and 95% CI based on Cox regression model with Efron's method of tie handling.                                                                                                                                                                                                                                                                                                                                                                                                                                          | HR and 95% CI based on Cox regression model with Efron's method of tie handling.                                                                                                                                                                                                                                                                                                                                                                                                                                          | HR and 95% CI based on Cox regression model with Efron's method of tie handling.                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| Effect estimate per comparison                  | Dual primary endpoint:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | Comparison groups                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | Comparison groups                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | Belzutifan versus everolimus                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| Effect estimate per comparison                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | Hazard ratio                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | Hazard ratio                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 0.94                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| Effect estimate per comparison                  | OS at FA                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 95% CI                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 95% CI                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 0.74, 1.21                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| Effect estimate per comparison                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | HR and 95% CI based on Cox regression model with Efron's method of tie handling.                                                                                                                                                                                                                                                                                                                                                                                                                                          | HR and 95% CI based on Cox regression model with Efron's method of tie handling.                                                                                                                                                                                                                                                                                                                                                                                                                                          | HR and 95% CI based on Cox regression model with Efron's method of tie handling.                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| Effect estimate per comparison                  | Key secondary endpoint:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | Comparison groups                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | Comparison groups                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | Belzutifan versus everolimus                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| Effect estimate per comparison                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | Difference in %                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | Difference in %                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 20.8                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| Effect estimate per comparison                  | ORR at IA1                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 95% CI                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 95% CI                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 14.3, 27.7                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| Effect estimate per comparison                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | Difference estimate based on Miettinen & Nurminen method.                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | Difference estimate based on Miettinen & Nurminen method.                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | Difference estimate based on Miettinen & Nurminen method.                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |

<div style=\"page-break-after: always\"></div>

Table 67: Summary of Efficacy for Trial MK-6482-004 (Study 004)

| Title : An Open Label Phase 2 Study to Evaluate PT2977 for the Treatment of von Hippel Lindau Disease-Associated Renal Cell Carcinoma   | Title : An Open Label Phase 2 Study to Evaluate PT2977 for the Treatment of von Hippel Lindau Disease-Associated Renal Cell Carcinoma   | Title : An Open Label Phase 2 Study to Evaluate PT2977 for the Treatment of von Hippel Lindau Disease-Associated Renal Cell Carcinoma                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
|-----------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Study identifier                                                                                                                        | MK-6482-004 (LITESPARK-004); P004V02MK6482 EudraCT: 2018-000125-30 NCT: NCT03401788                                                     | MK-6482-004 (LITESPARK-004); P004V02MK6482 EudraCT: 2018-000125-30 NCT: NCT03401788                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| Design                                                                                                                                  | Open-label, multicentre, nonrandomized, interventional study                                                                            | Open-label, multicentre, nonrandomized, interventional study                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| Design                                                                                                                                  | Duration of main phase: Duration of Run-in phase: Duration of Extension                                                                 | Ongoing, estimated duration until 2026 Not applicable Not applicable                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| Hypothesis                                                                                                                              | phase: Not applicable                                                                                                                   | phase: Not applicable                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| Treatment group                                                                                                                         | Belzutifan                                                                                                                              | Belzutifan 120 mg taken orally once daily (QD) until treatment discontinuation for reasons including disease progression and unacceptable adverse events. Treatment beyond disease progression is permitted with Sponsor consultation. 61 patients were allocated to receive belzutifan. Discontinued study treatment as of the data cutoff of 01-APR-2022: 23 (37.7%) patients Most common reasons: Patient decision to discontinue study drug: 11 (18.0%) Disease progression per Response Evaluation Criteria in Solid Tumours Version 1.1 (RECIST 1.1) for VHL disease-associated RCC tumours: 6 (9.8%) |
| Endpoints and definitions                                                                                                               | Primary endpoint                                                                                                                        | Overall response rate (ORR) for RCC The proportion of patients with a best confirmed response of complete response (CR) or partial response (PR) as determined by RECIST 1.1 and as assessed by an independent review committee (IRC)                                                                                                                                                                                                                                                                                                                                                                       |
| Endpoints and definitions                                                                                                               | Secondary endpoints                                                                                                                     | Duration of response (DOR) for RCC The interval from the first documentation of response, as determined by RECIST 1.1, to the earlier of the first documentation of disease progression or death from any cause, and calculated for patients with a best confirmed response of CR or PR                                                                                                                                                                                                                                                                                                                     |
| Endpoints and definitions                                                                                                               | Secondary endpoints                                                                                                                     | Time to response (TTR) for RCC The interval from the start of study treatment to the first documentation of a response, as determined by RECIST 1.1, and calculated for patients with a best confirmed response of CR or PR                                                                                                                                                                                                                                                                                                                                                                                 |
| Endpoints and definitions                                                                                                               | Secondary endpoints                                                                                                                     | Efficacy for the treatment of VHL disease-associated non-RCC tumours ORR, DOR, and TTR for non-RCC tumours associated with VHL disease in individual organ systems                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| Database lock                                                                                                                           | 02-JUN-2022, with a data cutoff date of 01-APR-2022                                                                                     | 02-JUN-2022, with a data cutoff date of 01-APR-2022                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| Results and Analysis                                                                                                                    | Results and Analysis                                                                                                                    | Results and Analysis                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |

<div style=\"page-break-after: always\"></div>

| Analysis description                            | Primary Analysis                                                                                                                                                                                                                                 | Primary Analysis                                                                                                                                                                                                                                 |
|-------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Analysis population and time point description  | Efficacy Analysis Set, which includes all 61 patients who received at least 1 dose of study intervention. Results are derived from an interim analysis based on a data cutoff date of 01-APR- 2022 and median follow-up duration of 37.7 months. | Efficacy Analysis Set, which includes all 61 patients who received at least 1 dose of study intervention. Results are derived from an interim analysis based on a data cutoff date of 01-APR- 2022 and median follow-up duration of 37.7 months. |
| Descriptive statistics and estimate variability | Treatment group                                                                                                                                                                                                                                  | Belzutifan 120 mg QD                                                                                                                                                                                                                             |
|                                                 | Number of subjects                                                                                                                                                                                                                               | 61                                                                                                                                                                                                                                               |
|                                                 | VHL-RCC (n=61)                                                                                                                                                                                                                                   | VHL-RCC (n=61)                                                                                                                                                                                                                                   |
|                                                 | ORR (%) 95% confidence interval (CI)                                                                                                                                                                                                             | 63.9 50.6, 75.8                                                                                                                                                                                                                                  |
|                                                 | DOR (median, months) Range (months; '+' indicates there is no progressive disease by the time of last disease assessment)                                                                                                                        | not reached (NR) 5.4+ to 35.8+                                                                                                                                                                                                                   |
|                                                 | TTR (median, months) Range (months)                                                                                                                                                                                                              | 11.1 2.7 to 30.5                                                                                                                                                                                                                                 |
|                                                 | VHL-CNS haemangioblastoma (n=50)                                                                                                                                                                                                                 | VHL-CNS haemangioblastoma (n=50)                                                                                                                                                                                                                 |
|                                                 | ORR (%) 95% CI                                                                                                                                                                                                                                   | 44 30.0, 58.7                                                                                                                                                                                                                                    |
|                                                 | DOR (median, months) Range (months)                                                                                                                                                                                                              | NR 3.7+ to 38.7+                                                                                                                                                                                                                                 |
|                                                 | TTR (median, months)                                                                                                                                                                                                                             | 5.4 2.3 to                                                                                                                                                                                                                                       |
|                                                 | VHL-Pancreatic neuroendocrine tumours (n=22)                                                                                                                                                                                                     | VHL-Pancreatic neuroendocrine tumours (n=22)                                                                                                                                                                                                     |
|                                                 | ORR (%) 95% CI                                                                                                                                                                                                                                   | 90.9 70.8, 98.9                                                                                                                                                                                                                                  |
|                                                 | DOR (median, months) Range (months)                                                                                                                                                                                                              | NR 11.0+ to 37.3+                                                                                                                                                                                                                                |
|                                                 | TTR (median, months)                                                                                                                                                                                                                             | 8.2                                                                                                                                                                                                                                              |
|                                                 | Range (months)                                                                                                                                                                                                                                   | 2.5 to 16.4                                                                                                                                                                                                                                      |
|                                                 | Range (months)                                                                                                                                                                                                                                   | 33.1                                                                                                                                                                                                                                             |
| Effect estimate                                 | Not applicable; study                                                                                                                                                                                                                            |                                                                                                                                                                                                                                                  |
|                                                 | single-arm                                                                                                                                                                                                                                       |                                                                                                                                                                                                                                                  |

## 2.6.5.3. Clinical studies in special populations

Two specific studies, one in hepatic impairment (Study 020) and one in renal impairment (Study 021), were completed and results submitted during the procedure. There were no specific studies in the paediatric population. The patients in the age categories above 65 included in the studies that are part of the CRSD (Studies 001, 004, 005, and 013) are included in Table 74.

<div style=\"page-break-after: always\"></div>

Table 68: Clinical Studies in Special Populations

| Total N = 576 patients                                        | Controlled Trials (Study 005) N=372   | Non-controlled trials (Study 001, Study 004, Study 013) N=204   |
|---------------------------------------------------------------|---------------------------------------|-----------------------------------------------------------------|
| Renal impairment* patients (Subjects number /total number)    | 130/372 #                             | 51/204                                                          |
| Hepatic impairment** patients (Subjects number /total number) | 34/372 #                              | 16/204                                                          |
| Paediatric patients <18 years (Subjects number /total number) | 0                                     | 0                                                               |
| Age 65-74 (Subjects number /total number)                     | 105/372                               | 52/204                                                          |
| Age 75-84 (Subjects number /total number)                     | 32/372                                | 13/204                                                          |
| Age 85+ (Subjects number /total number)                       | 4/372                                 | 0                                                               |

## 2.6.6. Discussion on clinical efficacy

The applicant applied for the two indications.

Below, the efficacy assessment is discussed for both indications separately.

The proposed posology of 120 mg belzutifan QD, (see section 2.6.4. for that the proposed posology) is considered sufficiently justified. Moreover, the results from Study 013 (Table 11 ; Agarwal et al. Ann Oncol. 2023 [abstract]) - that slightly favour 120 mg QD over 200 mg QD - provide further support for the proposed posology.

## Advanced RCC indication

## Design and conduct of clinical studies

Study design. The pivotal Study MK-6482-005 is an open-label, randomized phase 3 study to compare the efficacy and safety of belzutifan with that of everolimus in patients with unresectable, locally advanced or metastatic ccRCC that has progressed after prior PD-1/L1 and VEGF-targeted therapies (up to 3 prior treatment regimens). This study design is in general acceptable, and it is noted that crossover was not allowed, which aids assessment of OS.

Patient population. Although the eligibility criteria are in general acceptable, they describe a heterogeneous study population, i.e., expanding from 2L to 4L. Demonstration of internal consistency across subgroups is, therefore, considered crucial. These concerns were already expressed in EMA SA (EMA/CHMP/SAWP/179301/2019).

<div style=\"page-break-after: always\"></div>

Comparator. The active comparator in Study 005 is everolimus. The pivotal study for the 2009 approval of everolimus for 2L+ treatment was vs placebo and at the time of approval, although everolimus showed a statistically significant gain in PFS, the CHMP had concerns over the lack of an OS benefit (Afinitor EPAR). Currently, everolimus (as monotherapy) is not/no longer recommended for 2L treatment in European clinical guidelines (2021 ESMO; 2023 EAU). For 2L treatment, following a 1L combination of immunotherapy + TKI, both guidelines recommend a(ny) VEGF-targeted therapy that has not been given in 1L. Importantly, cabozantinib that is recommended for 2L treatment has demonstrated an OS benefit over everolimus (Cabometyx SmPC).

In addition, the EMA SA recommended to restrict inclusion to 3L and 4L patients with OS as primary endpoint and stated that data needed to show a convincing and statistically significant OS gain. It is acknowledged that there was no globally accepted standard of care post-PD-1/L1 and post-VEGF targeted therapies at the time Study 005 was conducted. The proposed indication wording ' following a PD-(L)1 inhibitor and a VEGF targeted therapy in sequence or in combination ' could have been acceptable if a statistically significant OS benefit had been shown as demonstration of efficacy, which is not the case.

Treatment could be continued after radiographic progression, as long as the investigator believed that the patient was still receiving clinical benefit from study intervention and that the potential benefit of continuing study intervention outweighs potential risks. The proposed SmPC recommendation in section 4.2 to only continue treatment until disease progression (or unacceptable toxicity) is acceptable.

Objectives, endpoints and estimands. The dual primary endpoints were PFS per RECIST 1.1 as assessed by BICR and OS. Both are supported, with the knowledge that OS data are crucial for the B/R assessment.

For the primary PFS analysis, patients who receive new anti-cancer therapy were censored at the last available assessment before this occurs. This is targeting a treatment effect in the (hypothetical) situation where alternative anti-cancer therapies are not available and is not in line with the EMA guidance (EMA/CHMP/27994/2008/Rev.1). For the pre-planned sensitivity analysis 1, patients had an event recorded for all known progressions or deaths, or were censored at last disease assessment regardless of whether they received new anti-cancer therapy or missed assessments. This represents a treatment policy estimand strategy, which is in line with above EMA guidance, but requires that patients continue to be followed up for assessments after experiencing these intercurrent events which may not be feasible.

ORR (by BICR per RECIST 1.1) was a key secondary endpoint. Other secondary endpoints were DOR and PRO scores. ORR and DOR are standard in oncology and thus acceptable. The censoring rules for the analysis of DOR were not in line with the above EMA guidance. Regarding the PRO scores, informative value of QoL assessment is relevantly limited by the open-label design of Study 005. No adjustments for multiple testing were applied for PRO analyses and the results are, therefore, merely descriptive.

Statistical methods. The stratification factors, i.e., IMDC prognostic score (0 vs 1-2 vs 3-6) and number of prior VEGF/VEGF receptor-targeted therapies for advanced RCC (1 vs 2-3), are acceptable. It is noted though, that 'line of treatment' (2L vs 3L vs 4L) which was recommended as a stratification factor in EMA SA (EMA/CHMP/SAWP/179301/2019) was not implemented as such.

The study was sufficiently powered for the dual primary endpoints of OS and the secondary endpoint of ORR. The overall Type I error was controlled for all three endpoints using the graphical approach of Mauer and Bretz. This is considered to be acceptable from a statistical perspective.

With the exception of the planned censoring rules for PFS and DOR, which are discussed above, the planned statistical analyses are acceptable.

<div style=\"page-break-after: always\"></div>

Study conduct. The original protocol was finalized on 30-SEP-2019 and amended as described in Table 36 , with all amendments completed prior to the database cut-off dates of 01-NOV-2022 for IA1 (and 13-JUN-2023 for IA2). The applicant has provided justification for changes on number of PFS events at IA1. The changes in the SAP were made based on monitoring of blinded aggregate total BICR PFS events versus expected timelines, indicating that IA1 was not initiated based on events within separate groups. As events accrued slower than expected, it is considered acceptable to conduct an interim analysis based on follow-up period, as planned in amended SAP. The results based on 552 and 525 events are consistent with IA1 results.

Important protocol deviations were reported for 280 patients (37.5%), primarily concerning safety reporting and were not considered clinically important.

## Efficacy data and additional analyses

Demographics and other baseline characteristics. Regarding the participant flow, it is agreed to not include the nine patients in the Japan Safety Run-in Cohort in the ITT, as they were not randomized. Also, excluding the 241 patients (screen failures) who did not meet inclusion or exclusion criteria is not considered to have a relevant impact on the external validity of the study results. Few patients in both study groups did not receive study treatment, i.e., two patients (0.5%) in the belzutifan group and 12 patients (3.2%) in the everolimus group.

The study population is considered in general representative of the proposed target population. Importantly, however, only patients with ccRCC were enrolled and the large majority of patients (86.1%) received study treatment as 3-4L therapy).

The prior systemic anticancer therapies received were in line with current clinical guidelines (2021 ESMO; 2023 EAU).

Primary endpoint - PFS by BICR per RECIST 1.1. The results of the primary PFS analysis in the ITT population by BICR at IA1 were to be used for the B/R assessment. The PFS results by BICR at IA2 were consistent with those at IA1.

It is acknowledged that the IA1 PFS results are statistically significant. The clinical relevance of the modest PFS benefit over a comparator, everolimus, with low activity (ORR of 3.5%) is questioned.

In terms of the percentage of the total patients in the ITT populations, including the category of clinical progression, 13/374 (3%) patients in the belzutifan group and 37/372 (10%) in the everolimus group received new anticancer therapy following investigator-assessed PD and were subsequently censored without further follow up for a BICR-assessed PD. In the context of an open-label study, this imbalance is concerning as it introduces uncertainty in the evaluation of the PFS benefit.

In addition, the censoring reason of 'randomisation' merely provides the description of 'source date' for censoring, whereas a patient censored on the date of randomization may have had a reason for censoring due to e.g., no postbaseline assessments, initiation of new anticancer therapy, or progressive disease/death immediately after ≥2 consecutive missed visits.

PFS sensitivity analysis 1 (targeting the preferred treatment effect as described in EMA guidance) and PFS sensitivity analysis 2 are generally consistent with the primary analysis. To support an evaluation of the likely treatment effect for the EMA-preferred estimand, further sensitivity analyses were requested: Firstly, patients who received new anticancer therapy and remain alive and progression free, were censored at the last known alive date instead of last assessment date. As expected, when patients who were censored due to receiving

<div style=\"page-break-after: always\"></div>

new anticancer therapy were followed up until their date of death or last known date alive, the hazard ratio tended towards 1 (PFS HR 0.90; 95% CI: 0.77, 1.07) and the median PFS was slightly lower in the belzutifan than in the everolimus group (median PFS 5.6 [95% CI: 4.6, 7.3] vs 5.9 months [95% CI: 5.6, 7.2]).

Given that patients were not followed up after receiving new anticancer therapy and the imbalance in informative censoring between the arms, uncertainty remains in the PFS results. Additionally, the decision to exclude patients who discontinued treatment due to an AE before being non-administratively censored hampers the evaluation of the results of the requested sensitivity analyses. Based on what has been provided the EMA-preferred treatment effect for PFS (i.e. based on the treatment policy strategy) cannot be estimated but is likely to be weaker than the estimated effect in the primary analysis.

The PFS results by investigator assessment were also consistent with those of PFS by BICR. When comparing the PFS results by investigator assessment with the results of the primary analysis of PFS by BICR, however, it is noted that in both groups fewer patients were censored, primarily because of less censoring due to the 'Last radiologic assessment prior to new anticancer therapy showing no progression', with, in addition, a smaller difference between groups for this censoring reason (3.2% vs 9.1%). Further, the 'crossing of the KM curves' is far less apparent (KM plot for PFS by investigator not shown). The differences in the early shape of the KM curves between PFS by BICR and investigator assessment can thus (at least in part) be attributed to an imbalance in censoring rate (higher in the everolimus arm) in the BICR analysis. Nevertheless, a statistically significant PFS benefit was also apparent by investigator assessment.

The PFS results were in general consistent across the per protocol investigated subgroups. The least favourable PFS HR point estimate was for the subgroup of patients from Western Europe (0.89 [95% CI: 0.70, 1.13]).

During the procedure, the applicant restricted the indication to the subgroup of patients who progressed following two or more prior lines of therapy including a PD-1/L1 inhibitor and at least two VEGF-targeted therapies. PFS was consistent with the ITT analysis showing a PFS benefit with a HR of 0.73 (95%CI: 0.57, 0.94) which is considered acceptable.

Primary endpoint - OS. At the OS FA belzutifan did not show a statistically significant OS benefit over everolimus. At the time of the EMA SA, CHMP stated that the data would need to show a convincing and statistically significant OS gain.

For OS, there is no clear definition of loss to follow up in the protocol. Censoring for OS is based on the derived last known to be alive date; to capture as many OS events as possible, prior to each database lock, the applicant conducted a survival sweep, where sites were requested to provide updated survival status for all randomized patients. This is acceptable.

The OS results were in general consistent across the per protocol investigated subgroups.

Subsequent anticancer therapies, were received by a higher percentage of patients in the everolimus group (67.5%) compared with the belzutifan group (53.5%). In both groups, the most frequently reported subsequent anticancer therapies are generally in line with the recommendations in current clinical guidelines (2021 ESMO). The 11 patients (3.0%) who again received everolimus as monotherapy as subsequent anticancer therapy, in 8 cases (2.2%) this was for 'logistic reasons' in three (0.8%) cases everolimus (as monotherapy) was again given after an intervening non-everolimus line of therapy. This is acceptable.

In the restricted indication to the subgroup of patients who progressed following two or more prior lines of therapy including a PD-1/L1 inhibitor and at least two VEGF-targeted therapies, OS was consistent with the ITT analysis. The OS is considered not inferior to the comparator everolimus and therefore acceptable.

<div style=\"page-break-after: always\"></div>

Secondary endpoint - ORR by BICR per RECIST 1.1. At IA1, the predefined success criterion for superiority was also met for the key secondary endpoint ORR. The ORR results at IA2 were consistent with those at IA1. The ORR results were in general consistent across the per protocol investigated subgroups (Figure 26; IA1 results). In the restricted patient population represented by the subgroup of patients who progressed following two or more prior lines of therapy including a PD-1/L1 inhibitor and at least two VEGF-targeted therapies the ORR was numerical higher in the belzutifan (24.1%) compared to everolimus (3.3%) treated.

Secondary efficacy endpoints - DOR and time to response. At IA2, the DOR was numerically longer for belzutifan compared to everolimus. As for the primary analysis of PFS, the censoring rules for the analysis of DOR are not in line with EMA guidance (EMA/CHMP/27994/2008/Rev.1). Of the patients who were censored for DOR at IA2 (48 in the belzutifan arm and three in the everolimus arm; data not shown), only three patients in the belzutifan arm were censored because of receiving new anticancer therapy though. The rest were censored for having an ongoing response based on an assessment within the previous five months.

The median time to response was similar for belzutifan and everolimus.

Secondary endpoint - PROs. Although change from baseline to Week 17 in FKSI-DRS score and EORTC QCQ-C30 score numerically favoured belzutifan over everolimus, differences did not reach criteria to be considered clinically meaningful and there were no clinically relevant deteriorations in either treatment group, respectively.

The informative value of the PRO assessments is limited by the open-label design of Study 005. PRO results are therefore merely descriptive limiting their value for the B/R assessment.

## Ancillary analyses - Information on patients censored within 6 months of randomisation.

The large majority (60/68) of patients in the everolimus arm who were censored for reason of the 'Last radiologic assessment prior to new anticancer therapy showing no progression' were censored within 6 months of randomization. Further, all 10 patients who had received 1 prior line of therapy and were censored within 6 months of randomisation were censored for reason of the 'Last radiologic assessment prior to new anticancer therapy showing no progression' (data not shown).

Information on subsequent therapy by line was provided for these censored patients and the subsequent anticancer therapies received (in both treatment groups) were generally in line with the recommendations in current clinical guidelines.

Proposed advanced RCC indication. Belzutifan binds to HIF2α, and in conditions of impairment of VHL protein function, blocks the HIF2α -HIF1β interaction, leading to reduced transcription and expression of HIF2α target genes. Belzutifan demonstrated anti -tumour activity in mouse xenograft models of VHL-deficient RCC, while no (statistically significant) activity was observed in VHL-proficient tumours, the VHL gene and/or loss of VHL protein function is present in the vast majority of ccRCCs (Escudier et al. Ann Oncol. 2019; 2023 EAU Guidelines), but it is not in non-ccRCC. Furthermore, only patients with the clear cell subtype RCC were allowed to enrol into Study 005. Consequently, a restricted indication to the clear cell subtype RCC has been agreed.

In addition, the indication wording was slightly amended taking into account Study 005 inclusion criterion #3 and EMA guidance (EMA/CHMP/483022/2019). The thereafter proposed wording ' as monotherapy ' and ' following a PD-(L)1 inhibitor and a VEGF targeted therapy in sequence or in combination ' was agreed.

<div style=\"page-break-after: always\"></div>

Following an Oral Explanation the applicant, proposed to further restrict the indication to patients with advanced clear cell RCC who progressed following two or more prior lines of therapy that included a PD-1/L1 inhibitor and at least two VEGF-targeted therapies .

Importantly: i) the number of prior VEGF/VEGF receptor-targeted therapies for advanced RCC (1 vs 2-3) was a stratification factor in Study 005; this subgroup comprises a substantial part of the ITT population (369/746=49.5%); ii) the baseline patient characteristics are similar between this subgroup and the ITT population and iii) the efficacy results for this subgroup are consistent with those for the ITT population.

The uncertainties and limitations related to the efficacy in the ITT population also applicable to the restricted subgroup. Moreover, there was no type I error control for the efficacy analyses in the subgroup and the efficacy results in this subgroup are, therefore, considered exploratory.

This restricted indication positions belzutifan in the treatment of advanced ccRCC from 2L+ to 3L+, in line with the recommendation given in the context of the EMA SA. In addition, according to ESMO clinical guidelines recommendations (ESMO 2024), patients are expected to have been treated with cabozantinib in 1L or 2L. For the 3L+ disease setting, the current clinical guidelines recommend either a VEGF-targeted therapy not previously administered, belzutifan, or everolimus.

In Study 005, the efficacy of belzutifan in the subgroup of patients who progressed following two or more prior lines of therapy including a PD-1/L1 inhibitor and at least two VEGF-targeted therapies showed a clinically relevant PFS gain, a numerically higher ORR and a similar OS to everolimus, authorized in this disease setting and recommended by current clinical guidelines.

The final agreed indication is therefore:

Welireg is indicated as monotherapy for the treatment of adult patients with advanced clear cell renal cell carcinoma that progressed following two or more lines of therapy that included a PD-(L)1 inhibitor and at least two VEGF-targeted therapies.

## VHL disease indication

## Design and conduct of clinical studies

Study design. Study MK-6482-004 (hereafter referred to as Study 004) is an ongoing Phase 2, single-arm, open-label study to evaluate the efficacy and safety of belzutifan in patients with VHL-RCC, not requiring immediate surgery. Enrolment is complete with 61 included patients. Belzutifan was administered in a dose of 120 mg once daily, which is also the dose used in the randomized Study 005 and the proposed posology in the SmPC.

Treatment was to be permanently discontinued for intolerability, or for persistent grade 3-4 toxicity, or in case of radiographic disease progression of VHL-associated RCC. Three patients were treated beyond disease progression of their VHL-associated RCC, but with other VHL-associated tumours still responding to treatment. The SmPC states that treatment should continue until disease progression or unacceptable toxicity, which is supported.

Patient population. The study population consists of relatively fit patients (ECOG PS 0 or 1) with at least one measurable VHL-associated RCC, though no greater than 3 cm which would require immediate surgery.

<div style=\"page-break-after: always\"></div>

Patients could also have other VHL-associated tumours (pNET, CNS haemangioblastoma) which were assessed separately for response to treatment using RECIST v1.1 criteria.

Major surgical procedures within 4 weeks, and major cardiovascular events (such as myocardial infarction, cerebrovascular accidents) in the 6 months prior to screening were also exclusion criteria. This is adequately reflected in section 5.1 of the SmPC.

Objectives, endpoints and estimands. The primary objective of Study 004 was to evaluate the efficacy of belzutifan in VHL-associated RCC, with ORR as measured per RECIST v1.1 criteria by an independent review committee in this tumour type being the primary endpoint. ORR is considered a suitable endpoint for a single-arm trial to isolate a drug effect (activity).

With ORR as primary endpoint, duration of response is the most important secondary endpoint to assess the durability and with that the clinical relevance of a response to treatment. Time to response is also considered relevant, considering that, in the current indication, belzutifan is an alternative (in case surgery is considered not suitable or undesirable) to surgical treatment which has an immediate effect. It is therefore important to be informed about the time expected with belzutifan treatment to see a treatment response.

The censoring rules (and the estimand) for DOR are not in line with the EMA preferred approach, which is to continue the assessment and detection of progression events regardless of use of new anti-cancer treatment. Further analysis provided based on EMA preferred approach are presented below in Secondary endpoint DOR in VHL-related RCC. Efficacy of belzutifan in terms of ORR in VHL-associated non-RCC tumours was a secondary endpoint. ORR by RECIST v1.1 in the tumour types included in the indication (i.e. haemangioblastoma and pNET) was also assessed by an IRC.

Time to surgery is difficult to interpret in light of the proposed indication which includes patients for whom surgery is undesirable or unsuitable. Time to surgery as measured in Study 004 cannot be extrapolated to the target population and is therefore not considered relevant.

Statistical methods. The sample size of approximately 50 patients was determined on the basis of a onesided test of 0.5 level of significance. This level of evidence, while sufficient for a Phase 2 exploratory study is not sufficient for regulatory decision making. For the interpretation of the single-arm results the 95% confidence interval will be used and not the 90% confidence interval.

Although the intended sample size was 50 patients, the final sample size was 61 patients. This over-enrolment occurred because high interest remained from both study sites and patients. Results for ORR and DOR based only on the first 50 patients who received study intervention were provided and were consistent with the original analyses.

Study conduct. There were 9 global protocol amendments which are considered not to have impacted study integrity. The efficacy analysis was to be performed with a data cut-off (DCO) of at least 36 weeks after enrolment of the last patient, in line with the protocol-defined timeline for Assessment of Efficacy: ' The data cutoff date for analysis will be at least 36 weeks after enrolment of the last patient '. An interim analysis was performed with a DCO of 01-JUN-2020 and the second interim analysis (IA2) was performed with a DCO of 01-APR-2022 which was the prespecified final analysis per protocol. Updated analysis with DCO 03-APR-2023 was also provided.

<div style=\"page-break-after: always\"></div>

## Efficacy data and additional analyses

## Participant flow and numbers analysed and Demographics and other baseline characteristics.

The study enrolled 61 patients from 11 study sites in 4 countries during approximately 10 months - the first patient was included in May 2018 and the last patient in March 2019.

In general, young and fit patients were included, as is expected for the disease under study and the study population defined by the in/exclusion criteria.

All patients had VHL-RCC at baseline. Consistent with the multiorgan nature of VHL disease, all patients had at least 1 other VHL disease-associated tumour at baseline. Per IRC assessment, the concurrent non-RCC tumour types included 50 (82.0%) patients with CNS HB, 61 (100%) with pancreatic lesions, 22 (36.1%) with pNET, and 12 (19.7%) with retinal HB. Investigator-assessment, however, identified 32 (52.5%) patients with pancreatic lesions and no pNETs were described. The difference between the percentage of patients with pancreatic lesions and pNET between investigator and IRC-assessment were due to the absence of protocol-defined specific selection criteria for pancreatic lesions or pNETs. Pancreatic lesions were initially evaluated by the IRC following RECIST v1.1 and identified at baseline in all 61 patients (encompassing cystic lesions /cystadenomas and pNETs). Further IRC evaluation of these lesions, distinguishing pNETs and nonpNET lesions, identified pNETs in 22 patients. Data on these patients represents the most clinically meaningful assessment relevant to VHL patients.

A total of 59 patients (96.7%) had at least 1 prior surgery for other VHL-associated neoplasms, including nephrectomy (65.6%), nervous system neoplasm surgery (59.0%), eye laser surgery (21.3%), craniotomy (21.3%), and kidney ablation (19.7%).

The presence of an RCC &gt;3 cm that required immediate surgical resection was an exclusion criterion for Study 004, however 9 patients included in Study 004 have an RCC lesion ≥3 cm. Of these, surgery was deemed not necessary based on tumour size and slow growth for 4 patients. For four other patients, surgery was considered undesirable because of multiple previous kidney surgeries. These patients, for whom local treatments have become undesirable because of the risk of serious morbidity are the patients for whom treatment with belzutifan can provide clinical benefit, as is reflected in the proposed indication.

Primary endpoint - ORR in VHL-related RCC. The confirmed ORR (per RECIST v1.1 by ICR) for VHLassociated RCC was 63.9% (39/61 patients), including 4 complete responses (6.6%) and 35 partial responses (57.4%). The response rate of 63.9% is considered clinically relevant. Based on the fact that the underlying disease mechanism does not change over the disease course, and since no intercurrent therapies are given that could modulate the expected belzutifan treatment effect the response rate seen in first line treatment is likely to be comparable between patients earlier and later in the disease course.

ORR as assessed by the investigator showed results comparable to the primary analysis, with an ORR of 60.7% (95% CI: 47.3, 72.9), including one CR (1.6%) and 36 partial responses (59%).

At the DCO of 03-APR-2023, the results for ORR remained similar, but with more 7 complete responses (11.5%).

Secondary endpoint - DOR in VHL-related RCC . The median duration of response in the 39 responders, was not estimable at the time of the IA2 DCO. Based on the Kaplan-Meier curve, of 29 evaluable patients at that time point, 93.5% had a duration of response of at least 18 months. As of the DCO of 01 April 2022, 55 patients were still on study with 38 still receiving study treatment. At the DCO of 03-APR-2023, median duration of response still had not been reached.

<div style=\"page-break-after: always\"></div>

Reasons for censoring for DOR were provided along with an additional analysis by which patients were followed-up until progression event investigator or IRC-based. The results showed that the DOR results were consistent for each tumour type across the two censoring approaches and were consistent with the original analyses.

Secondary endpoint - TTR in VHL-related RCC . The median time to response (TTR) in the 39 responders was 11.1 months and it is noted that the median TTR seems to vary across tumour types: in Study 005, 3.7 months for advanced RCC, and in Study 004, 5.4 months for VHL-CNS HB, 8.2 months for pNET and 11.1 months for VHL-RCC, with ranges up to &gt;30 months. Especially in Study 004, the median TTR is strikingly long compared to what is seen with other antitumoral mechanisms of action, half of the responses occurring after more than one year of therapy. This was explained by the fact that definition of response per RECIST v1.1 was established primarily for advanced solid tumours, but for VHL-RCC, the therapy's goal is not to achieve rapid tumour shrinkage per se. Slow(er) tumour shrinkage would also be acceptable and this is certainly different from treating more aggressive advanced solid tumours. In addition, the majority of patients (67.2%) did show early RCC tumour SOD reduction after the first ~3 months of therapy, albeit not fulfilling the criteria for response by RECIST v1.1. The change in disease course after start of belzutifan treatment, with a decrease in tumour diameters while the tumours were growing before start of treatment, supports a treatment effect of belzutifan. The indolent nature of VHL-RCC could also be a contributing factor for the longer TTR, that could be supported by the shorter TTR (3.7 months) in advanced RCC Study 005.

Because the proposed indication is in patients who require therapy but for whom local therapy will lead to morbidity (is not suitable or undesirable), it is important to evaluate if this rather long time on treatment before a response occurs can be clinically justified. Information about the disease course on treatment was provided which showed that, despite taking a rather long time to reach a response by RECIST v1.1, there was an early and ongoing decrease in tumour diameter with belzutifan treatment. No patients had first progression of their tumours before a response occurred. The rather long time on treatment before a response occurs is, therefore, acceptable.

Secondary endpoint - PFS in VHL-related RCC . The median PFS was 39.2 months, but as stated previously, given the uncontrolled design of the trial in a rare disease (which limits the information on the natural course of disease), this time-to-event endpoint is considered not interpretable.

Secondary endpoint - ORR and DOR in CNS haemangioblastoma. Of the 61 study patients, 50 had a measurable CNS haemangioblastoma at baseline per IRC. The confirmed ORR in this subgroup was 44.0% (95% CI 30-58.7), with 4 complete responses (8%) and 18 partial responses (36%).

ORR as assessed by the investigator (in 51 patients with CNS haemangioblastoma per investigator assessment) showed somewhat lower percentages compared to the IRC-based primary analysis, with an ORR of 35.3% (95% CI 22.4-49.9), including 4 CRs (7.8%) and 14 partial responses (27.5%).

At the DCO of 03-APR-2023, the results for ORR had improved slightly.

The median duration of response in the 22 patients with a complete or partial response by IRC, was not estimable at the time of the IA2 DCO. Based on the Kaplan-Meier curve, of the 14 evaluable patients at that time point, 90.2% had a duration of response of at least 18 months.

At the updated DCO of 03-APR-2023, median duration of response still had not been reached.

Reasons for censoring for DOR were provided, see ' Secondary endpoint - DOR in VHL-related RCC'.

<div style=\"page-break-after: always\"></div>

Regarding the disease course for CNS haemangioblastomas on treatment there were three patients who did have SD or PR of their CNS-HB depicted after PD (rightfully not included in the efficacy analysis for ORR or DOR). Most patients, however, had tumour response dynamics of their CNS-HB with an early and ongoing decrease in tumour diameter with belzutifan treatment, similar to observed for RCC. Which is in line with the observed sufficiently high concordance of efficacy in different VHL-associated tumours in response to belzutifan treatment.

The ORR for VHL-associated CNS haemangioblastoma is lower than that reported for VHL-associated RCCs. However, responses appear durable, and the clinical relevance of these efficacy estimates should also be viewed in light of the unmet medical need of patients with VHL-associated haemangioblastomas. For patients with an RCC, a resection is in principle almost always possible, but might lead to loss of kidney function, for which renal replacement therapy is available. For patients with CNS haemangioblastoma, depending on the location, a resection might lead to serious morbidity in the form of neurological functional loss (for which there is no treatment). Therefore, the responses observed for CNS haemangioblastomas are acceptable in the context of the high unmet medical need.

Secondary endpoint - ORR and DOR in pNET. Of the 61 study patients, 22 had a measurable pNET at baseline per IRC. The confirmed ORR in this subgroup was 90.9% (95% CI 70.8-98.9), with 7 complete responses (31.8%) and 13 partial responses (59.1%). The ORR result was unchanged at the DCO of 03-APR2023.

The median duration of response in the 20 patients with a complete or partial response by IRC, was not estimable at the time of the IA2 DCO. Based on the Kaplan-Meier curve, 19 patients (100%) had a duration of response of at least 18 months. At the updated DCO of 03-APR-2023, median duration of response still had not been reached.

The reported ORR for patients with a pNET that was measurable at baseline is very high (as was the percentage of complete responses) and also in this tumour type, responses appear durable.

Subgroup analyses. A subgroup analysis was performed for ORR, DOR, and TTR for VHL-RCC and non-RCC tumours by VHL gene alteration status: VHL deletion (partial or complete) or VHL gene mutation. In VHLRCC, the observed ORRs with VHL deletion were numerically lower than with VHL-mutation (44.4% vs.72.1%). For non-RCC tumours, ORRs (VHL deletion vs VHL mutation) were generally comparable. The median TTR across VHL tumours in patients with VHL deletion tended to be longer than with VHL mutation, including RCC (20.8 vs. 8.2 months), pNET (13.5 vs. 5.5 months), and CNS haemangioblastoma (5.5 vs. 4.3 months). Given the limited sample size and the (resulting) wide and overlapping CIs, subgroup analyses of ORR in VHL-RCC and non-RCC tumours by VHL gene deletion or mutation should be interpreted with caution.

Ancillary analyses. Nine of the 61 patients had surgical interventions while on study, of which 7 underwent surgical treatment of VHL-related tumours during study treatment. The provided information on these 7 patients who had surgical interventions while on belzutifan does not raise concern.

The performed analyses of response of co-occurring VHL-associated tumours showed general concordance of tumour responses on an aggregate level. Belzutifan thus appears to have a similar effect on different tumours within the same patient for most patients.

Supportive study - Study 015. The first interim ORR results for Study 015 showed lower percentages compared to the results from Study 004. However, an updated analysis with a longer median duration of treatment and follow-up (now crossing the median time to response in Study 004 of 11.1 months), showed

<div style=\"page-break-after: always\"></div>

improved ORR results. The sample size for these interim analyses of Study 015 is, however, even smaller than for Study 004, which prevents drawing firm conclusions.

Supportive study - VHL Natural History Study. Results from a retrospective cohort study including 244 patients from the NHS database from the US, with inclusion criteria closely matching those for Study 004 were provided. In this cohort study, the real-world ORR (assessed per RECIST v1.1 by IRC), with observation only, i.e. the chance of spontaneous regression of VHL-related RCC, was 1.8% for patients with up to 5 years of follow-up. This provides support for the use of ORR, the primary endpoint for Study 004, as a measure of an anti-tumour effect.

Proposed VHL disease indication. By definition (with the 'index' RCC not requiring immediate surgery), the patients included in Study 004 are considered to be relatively early in the disease course, and the inclusion criteria imply that observation only would have been the standard-of-care treatment outside of the clinical trial. The target population in the applied indication consists instead of patients later in the disease course, being patients with ' VHL-associated RCC, HB or pNET that require therapy but for whom local therapies are unsuitable or undesirable ', which represents a patient population with more advanced disease.

The applicant provided a more detailed comparison between the population defined by the in- and exclusion criteria of the pivotal Study 004 and the target population as reflected in the proposed indication. Result showed that for most patients a local therapy was not suitable or desirable anymore, due to a high risk of morbidity. Moreover, patients included in Study 004 were likely not candidates for (further) active surveillance and would require therapy for their VHL-associated tumours in the near future. It is therefore agreed that the study population is correctly reflected in the indication.

The initial proposed indication included the wording ' or undesirable ' which was considered redundant and removed from the indication. A patient's preference is always part of clinical treatment decision making and a patient's refusal of localized procedures would make him/her ' unsuitable ' (which is included in the wording of the indication).

Patients with metastatic disease were excluded from Study 004 therefore the indication was amended to reflect the status of the disease from locally advanced and/or metastatic to localized (added text bold and underlined): ' patients with von Hippel-Lindau disease who require therapy for associated, localized renal cell carcinoma (RCC), … '.

The presence (as per inclusion criteria) of a VHL-associated RCC was not included in the indication. However, as all VHL-associated tumours share the common underlying pathophysiology of a germline alteration in the VHL gene and consequent upregulation of the HIF-2 α pathway, it is biologically plausible that the response in a given tumour type is independent of the presence or absence of another tumour type. This argument presented by the applicant was also supported by literature. More importantly, spider plots provided for each individual patient show that, for most cases, the changes in tumour diameter from baseline have a concordant pattern for the different tumours within a patient. Sum of diameter of target lesions by tumour type in individual patients (41 patients that had more than one tumour type, most (35/41, 85.4%) had concordant responses. Based on measurements of individual lesions the concordance was 70.7% across different tumour types. These results suggest sufficiently high concordance of tumour shrinkage in different VHL-associated tumours in response to belzutifan treatment.

In conclusion, based on biological plausibility and the provided clinical data it is agreed that the chance of response (efficacy) for patients with VHL disease in whom a CNS-HB or pNET is the main symptomatic tumour (and not RCC) can be extrapolated from the Study 004 results. It can therefore be accepted that the

<div style=\"page-break-after: always\"></div>

presence of a VHL-associated RCC, as was required for the pivotal study, does not have to be included in the indication.

The notion that the efficacy data for different VHL-associated tumours can be taken together to support a B/R evaluation in the population of VHL-patients as a whole, is also important in light of the necessary discussion on the comprehensiveness of the current data package. The fact that the efficacy in CNS-HB and pNET was analysed as secondary endpoints does not necessarily mean that these results are less relevant, because the methodology used was the same as for the primary endpoint of ORR in VHL-associated RCC.

The agreed indication in the VHL patient population is as follow:

Welireg is indicated as monotherapy for the treatment of adult patients with von Hippel-Lindau disease who require therapy for associated, localised renal cell carcinoma (RCC), central nervous system (CNS) haemangioblastomas, or pancreatic neuroendocrine tumours (pNET), and for whom localised procedures are unsuitable.

## Additional efficacy data needed in the context of a Conditional MA

A full MA is not considered appropriate since the supporting data are not considered comprehensive. Moreover, the efficacy for non-RCC tumours was only a secondary endpoint of Study 004 with data provided from an interim analysis of a small, single-arm study. Altogether these uncertainties prevent the results from Study 004 to be considered sufficiently comprehensive for a full MA while a conditional marketing authorization (CMA) is considered appropriate. To confirm the benefits observed in Study 004, long term efficacy and safety data from Study 004 should be submitted by Q1 of 2027, which is subject to a specific obligation laid down in the MA (SOB1),

Efficacy and safety data for at least 64 patients from Study 015 Cohort B1 should be submitted by Q1 of 2027, which is subject to a specific obligation laid down in the MA (SOB2).

## Patient and healthcare provider engagement

## Patient engagement

The CHMP invited the EURopean Organisation for Rare DISeases (EURORDIS) to share patients' perspectives regarding the assessment of belzutifan for the applied indications on behalf of its patient/carer members. The response from EURORDIS included information on the impact of the condition on daily life and the therapeutic options. In addition, comments from patients who took/are taking part in belzutifan clinical trials were included. Trial participants described the evolution of their tumours while on belzutifan in line with the results presented by the applicant. According to the participants, side effects can be severe. Typically, belzutifan does not seem to be a valid option for a prophylactic approach in newly diagnosed patients, or when the size of the tumour(s) is still limited While it can be indicated for the stage of disease when the number of tumours is too high, it requires too many interventions, or it associated with high surgical risks. Some participants suggested testing a dose reduction to minimize side-effects.

The input of EURORDIS was welcomed and the comments from patients who took part in belzutifan clinical trials are acknowledged.

<div style=\"page-break-after: always\"></div>

## Healthcare provider engagement

The CHMP invited the European Organisation for Research and Treatment of Cancer (EORTC) to share perspectives regarding the assessment of belzutifan for the applied indications on behalf of healthcare professionals' organisations. The response from the EORTC had the following conclusion:

Systemic treatment with belzutifan would be a welcome addition to the treatment options for patients with VHL disease. Given the decades-long evolution of the disease, long-term evidence is necessary to inform clinical practice and patient decisions.

The input of the EORTC is welcomed and the above conclusion is agreed.

## 2.6.7. Conclusions on the clinical efficacy

## Advanced RCC indication

The efficacy of belzutifan in the subgroup of patients who progressed following two or more prior lines of therapy including a PD-1/L1 inhibitor and at least two VEGF-targeted therapies showed a positive effect on PFS, a numerically higher ORR and a similar OS to everolimus, authorized in this disease setting and recommended by current clinical guidelines.

## VHL disease indication

The response rate of 63.9% in VHL-associated RCC is rather high and the responses appear durable. These results together with the ORR and DOR results in VHL-associated CNS-HB and pNET are considered clinically relevant. Nevertheless, the comprehensiveness of the data presented is not considered sufficient for a full MA while a CMA is considered appropriate.

The CHMP considers the following measures (SOBs) necessary to address the missing efficacy data in the context of a conditional MA:

- In order to confirm the efficacy and safety of belzutifan as monotherapy for the treatment of adult patients with von Hippel-Lindau disease who require therapy for associated, localised renal cell carcinoma (RCC), central nervous system (CNS) haemangioblastomas, or pancreatic neuroendocrine tumours (pNET), and for whom localised procedures are unsuitable, the MAH should submit the final results of the ongoing study MK6482-004, an open-label Phase II single-arm study to further investigate the long-term efficacy and safety of belzutifan for the treatment of von Hippel-Lindau disease-associated Renal Cell Carcinoma.

- In order to confirm the efficacy and safety of belzutifan as monotherapy for the treatment of adult patients with von Hippel-Lindau disease who require therapy for associated, localised RCC, CNS haemangioblastomas, or pNET, and for whom localised procedures are unsuitable, the MAH should submit efficacy and safety data from at least 64 patients with at least 24 months follow-up of cohort B1 for the ongoing study MK-6482-015, an uncontrolled Phase II study to evaluate the efficacy and safety of belzutifan in patients with von Hippel Lindau disease-associated tumours who have at least 1 measurable RCC, pNET, or pheochromocytoma/paraganglioma (PPGL) tumour.

## 2.6.8. Clinical safety

Belzutifan safety profile is based on patients from Study 005 (advanced RCC) and patients from Study 004 (patients with VHL disease).

<div style=\"page-break-after: always\"></div>

In addition, pooled safety data are provided in the form of the cumulative running safety dataset (CRSD; n=576), which predominantly includes patients from Study 005 as well as patients with advanced solid tumours from the phase 1 study MK-6482-001 (Study 001), patients from Study 004, and patients with advanced RCC from the phase 2 study MK 6482 013 (Study 013).

The all-patients-as-treated (APaT) population was used for the analysis of safety data, which included all enrolled patients who received at least a single dose of study treatment and patients were included in the treatment group corresponding to the study treatment they received.

Table 69: Safety Datasets and Treatment Group Nomenclature

| Dataset                                                 | Population                                                                                                                                                                   | Nomenclature in Tables                                     | Nomenclature in Text       |
|---------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------|----------------------------|
| MK-6482-005 belzutifan                                  | Safety data from patients with advanced RCC who received belzutifan 120 mg QD in MK-6482-005                                                                                 | MK-6482-005 Data for Belzutifan 120 mg QD                  | belzutifan group (n=372) a |
| MK-6482-005 everolimus                                  | Safety data from patients with advanced RCC who received everolimus 10 mg QD in MK-6482-005                                                                                  | MK-6482-005 Data for Everolimus 10 mg QD                   | everolimus group (n=360)   |
| MK-6482-004 belzutifan                                  | Safety data from patients with VHL-RCC who received belzutifan 120 mg QD in MK-6482-004                                                                                      | MK-6482-004 Data for Belzutifan 120 mg QD                  | Study 004 (n=61)           |
| Belzutifan cumulative running safety dataset (120 mg) c | All patients who received at least 1 dose of belzutifan 120 mg QD in MK-6482-001 Part 1A and 1B b (n=58); MK-6482-004 (n=61); MK-6482-005 (n=381) a ; and MK-6482-013 (n=76) | Cumulative Running Safety Dataset for Belzutifan 120 mg QD | CRSD (n=576) a             |

APaT=all-patients-as-treated; CRSD=Cumulative Running Safety Dataset; N=number; QD=once daily; RCC=renal cell carcinoma; VHL=Von Hippel-Lindau.

a  Japan Safety Run-in patients from MK-6482-005 are included in the CRSD but are not included in the belzutifan group in the APaT population.

b  55 of these 58 patients had sporadic RCC. The other 3 patients had pancreatic neuroendocrine tumours, ovarian cancer, and brain cancer/meningioma.

- c  Data cutoff dates: Study 005: 13-JUN-2023; Study 004: 01-APR-2022; Study 001: 01 APR-2022; and Study 013: 10-FEB-2023.

## Baseline demographic and other characteristics for the APaT population,

The majority of patients in the CRSD were male (76.6%) and White (82.5%); the median age was 61.0 years, with 35.8% and 8.5% ≥65 and ≥75 years old, respectively; 48.3% and 50.0% of patients had an ECOG PS of 0 and 1, respectively; and 39.2% and 38.4% of patients were from Western Europe and North America, respectively.

Of note, Study 004 enrolled patients with nonmetastatic cancer with no prior systemic therapy, while Studies 001, 005, and 013, enrolled patients with advanced solid tumours/advanced RCC who had experienced disease progression on or after prior treatment.

Compared with the CRSD, the Study 004 APaT population included younger patients (median age: 41.0 vs 61.0 years); more patients with an ECOG PS of 0 (82.0% vs 48.3%); more patients from North America (78.7% vs 38.4%); and less patients from Western Europe (21.3% vs 39.2%).

<div style=\"page-break-after: always\"></div>

## 2.6.8.1. Patient exposure

A summary of drug exposure across the safety datasets is shown in Table 76.

Table 70: Summary of Drug Exposure (APaT Population)

13.5

9.2

12.60

0.10 to 55.43

|                              | MK-6482-005 Data for Belzutifan 120 mg QD (N=372)   | MK-6482-005 Data for Everolimus 10 mg QD (N=360)   | MK-6482-004 Data for Belzutifan 120 mg QD (N=61)   | Cumulative Running Safety Dataset for Belzutifan 120 mg QD j (N=576)   |
|------------------------------|-----------------------------------------------------|----------------------------------------------------|----------------------------------------------------|------------------------------------------------------------------------|
| Duration On Therapy (months) |                                                     |                                                    |                                                    |                                                                        |
| Mean                         | 10.9                                                | 6.9                                                | 33.7                                               | 13.5                                                                   |
| Median                       | 7.6                                                 | 3.9                                                | 37.3                                               | 9.2                                                                    |
| SD                           | 9.73                                                | 6.69                                               | 10.08                                              | 12.60                                                                  |
| Range                        | 0.10 to 35.84                                       | 0.03 to 33.25                                      | 1.94 to 46.06                                      | 0.10 to 55.43                                                          |

Duration of exposure is the time from the first dose date to the last dose date.

j  Includes all patients who received at least one dose of belzutifan 120 mg QD in MK-6482-001 Part 1A, 1B, MK-6482-004, MK-6482-013, and MK-6482-005 including patients from the Japan safety run-in cohort.

In Study 005, among patients treated with belzutifan, 73 (19.6%) patients had at least one dose reduction. A total of 69 (18.5%) and 16 (4.3%) patients had dose reductions to 80 mg and 40 mg, respectively. In Study 004, 15 (24.6%) patients had at least one dose reduction. A total of 11 (18.0%) and 4 (6.6%) patients had a dose reduction to 80 mg and 40 mg, respectively.

## 2.6.8.2. Adverse events

The adverse event summary is shown in Table 77.

Table 71: Adverse Event Summary (APaT Population)

|                                                     | MK-6482-005 Data for Belzutifan 120 mg QD   | MK-6482-005 Data for Belzutifan 120 mg QD   | MK-6482-005 Data for Everolimus 10 mg QD   | MK-6482-005 Data for Everolimus 10 mg QD   | MK-6482-004 Data for Belzutifan 120 mg QD   | MK-6482-004 Data for Belzutifan 120 mg QD   | Cumulative Running Safety Dataset for Belzutifan 120 mg QD j   | Cumulative Running Safety Dataset for Belzutifan 120 mg QD j   |
|-----------------------------------------------------|---------------------------------------------|---------------------------------------------|--------------------------------------------|--------------------------------------------|---------------------------------------------|---------------------------------------------|----------------------------------------------------------------|----------------------------------------------------------------|
|                                                     | n                                           | (%)                                         | n                                          | (%)                                        | n                                           | (%)                                         | n                                                              | (%)                                                            |
| Patients in population                              | 372                                         |                                             | 360                                        |                                            | 61                                          |                                             | 576                                                            |                                                                |
| with one or more adverse events                     | 369                                         | (99.2)                                      | 357                                        | (99.2)                                     | 61                                          | (100.0)                                     | 572                                                            | (99.3)                                                         |
| with no adverse event                               | 3                                           | (0.8)                                       | 3                                          | (0.8)                                      | 0                                           | (0.0)                                       | 4                                                              | (0.7)                                                          |
| with drug-related a adverse events                  | 331                                         | (89.0)                                      | 322                                        | (89.4)                                     | 61                                          | (100.0)                                     | 526                                                            | (91.3)                                                         |
| with toxicity grade 3-5 adverse events              | 230                                         | (61.8)                                      | 225                                        | (62.5)                                     | 27                                          | (44.3)                                      | 355                                                            | (61.6)                                                         |
| with toxicity grade 3-5 drug-related adverse events | 144                                         | (38.7)                                      | 142                                        | (39.4)                                     | 11                                          | (18.0)                                      | 217                                                            | (37.7)                                                         |
| with serious adverse events                         | 157                                         | (42.2)                                      | 137                                        | (38.1)                                     | 18                                          | (29.5)                                      | 236                                                            | (41.0)                                                         |
| with serious drug-related adverse events            | 49                                          | (13.2)                                      | 47                                         | (13.1)                                     | 4                                           | (6.6)                                       | 71                                                             | (12.3)                                                         |
| who died                                            | 13                                          | (3.5)                                       | 19                                         | (5.3)                                      | 2                                           | (3.3)                                       | 19                                                             | (3.3)                                                          |
| who died due to a drug-related adverse event        | 1                                           | (0.3)                                       | 2                                          | (0.6)                                      | 0                                           | (0.0)                                       | 1                                                              | (0.2)                                                          |
| with dose modification b due to an adverse event    | 191                                         | (51.3)                                      | 225                                        | (62.5)                                     | 32                                          | (52.5)                                      | 288                                                            | (50.0)                                                         |
| with dose interruption due to an adverse event      | 162                                         | (43.5)                                      | 173                                        | (48.1)                                     | 26                                          | (42.6)                                      | 235                                                            | (40.8)                                                         |
| with dose reduction due to an                       | 52                                          | (14.0)                                      | 53                                         | (14.7)                                     | 10                                          | (16.4)                                      | 89                                                             | (15.5)                                                         |

576

572

4

526

355

217

236

71

19

1

288

235

89

<div style=\"page-break-after: always\"></div>

37

27

| adverse event discontinued drug due to an adverse event   |   22 | (5.9)   |   53 | (14.7)   | 4 (6.6)   |   37 | (6.4)   |
|-----------------------------------------------------------|------|---------|------|----------|-----------|------|---------|
| discontinued drug due to a serious adverse event          |   16 | (4.3)   |   30 | (8.3)    | 3 (4.9)   |   27 | (4.7)   |

a  Determined by the investigator to be related to the drug.

b  Defined as an action taken of dose reduced, drug interrupted or drug withdrawn.

Non-serious adverse events up to 30 days of last dose and serious adverse events up to 90 days of last dose are included.

MedDRA 26.0 preferred terms \"Neoplasm Progression\", \"Malignant Neoplasm Progression\" and \"Disease Progression\" not related to the drug are excluded.

Grades are based on NCI CTCAE version 5.0 for MK-6482-005 and MK-6482-013 and version 4.03 for all other studies.

j  Includes all patients who received at least one dose of belzutifan 120 mg QD in MK-6482-001 Part 1A, 1B, MK-6482004, MK-6482-013, and MK-6482-005 including patients from the Japan safety run-in cohort.

## All-causality adverse events

All-Grade and Grade 3-5 AEs regardless of causality are shown in Table 78 and Table 79 , respectively.

Table 72: Patients With Adverse Events by Decreasing Incidence of Preferred Term (Incidence ≥10% in One or More Treatment Groups) (APaT Population)

576

572

4

479

246

139

105

102

123

93

103

62

78

94

82

103

79

110

77

70

60

68

67

43

56

49

|                                                | MK-6482-005 Data for Belzutifan 120 mg QD   | MK-6482-005 Data for Belzutifan 120 mg QD   | MK-6482-005 Data for Everolimus 10 mg QD   | MK-6482-005 Data for Everolimus 10 mg QD   | MK-6482-004 Data for Belzutifan 120 mg QD   | MK-6482-004 Data for Belzutifan 120 mg QD   | Cumulative Running Safety Dataset for Belzutifan 120 mg QD j   | Cumulative Running Safety Dataset for Belzutifan 120 mg QD j   |
|------------------------------------------------|---------------------------------------------|---------------------------------------------|--------------------------------------------|--------------------------------------------|---------------------------------------------|---------------------------------------------|----------------------------------------------------------------|----------------------------------------------------------------|
|                                                | n                                           | (%)                                         | n                                          | (%)                                        | n                                           | (%)                                         | n                                                              | (%)                                                            |
| Patients in population with one or more events | 372                                         |                                             | 360                                        |                                            | 61                                          |                                             | 576                                                            |                                                                |
| adverse                                        | 369                                         | (99.2)                                      | 357                                        | (99.2)                                     | 61                                          | (100.0 )                                    | 572                                                            | (99.3)                                                         |
| with no adverse events                         | 3                                           | (0.8)                                       | 3                                          | (0.8)                                      | 0                                           | (0.0)                                       | 4                                                              | (0.7)                                                          |
| Anaemia                                        | 308                                         | (82.8)                                      | 204                                        | (56.7)                                     | 55                                          | (90.2)                                      | 479                                                            | (83.2)                                                         |
| Fatigue                                        | 117                                         | (31.5)                                      | 91                                         | (25.3)                                     | 45                                          | (73.8)                                      | 246                                                            | (42.7)                                                         |
| Nausea                                         | 67                                          | (18.0)                                      | 41                                         | (11.4)                                     | 24                                          | (39.3)                                      | 139                                                            | (24.1)                                                         |
| Constipation                                   | 62                                          | (16.7)                                      | 29                                         | (8.1)                                      | 14                                          | (23.0)                                      | 105                                                            | (18.2)                                                         |
| Oedema peripheral                              | 60                                          | (16.1)                                      | 61                                         | (16.9)                                     | 9                                           | (14.8)                                      | 102                                                            | (17.7)                                                         |
| Dyspnoea                                       | 56                                          | (15.1)                                      | 51                                         | (14.2)                                     | 16                                          | (26.2)                                      | 123                                                            | (21.4)                                                         |
| Back pain                                      | 55                                          | (14.8)                                      | 30                                         | (8.3)                                      | 11                                          | (18.0)                                      | 93                                                             | (16.1)                                                         |
| Arthralgia                                     | 54                                          | (14.5)                                      | 27                                         | (7.5)                                      | 13                                          | (21.3)                                      | 103                                                            | (17.9)                                                         |
| Asthenia                                       | 54                                          | (14.5)                                      | 61                                         | (16.9)                                     | 2                                           | (3.3)                                       | 62                                                             | (10.8)                                                         |
| Decreased appetite                             | 54                                          | (14.5)                                      | 57                                         | (15.8)                                     | 3                                           | (4.9)                                       | 78                                                             | (13.5)                                                         |
| Hypoxia                                        | 54                                          | (14.5)                                      | 4                                          | (1.1)                                      | 1                                           | (1.6)                                       | 94                                                             | (16.3)                                                         |
| Vomiting                                       | 48                                          | (12.9)                                      | 32                                         | (8.9)                                      | 7                                           | (11.5)                                      | 82                                                             | (14.2)                                                         |
| Dizziness                                      | 46                                          | (12.4)                                      | 6                                          | (1.7)                                      | 28                                          | (45.9)                                      | 103                                                            | (17.9)                                                         |
| Alanine aminotransferase increased             | 45                                          | (12.1)                                      | 32                                         | (8.9)                                      | 12                                          | (19.7)                                      | 79                                                             | (13.7)                                                         |
| Headache                                       | 45                                          | (12.1)                                      | 27                                         | (7.5)                                      | 29                                          | (47.5)                                      | 110                                                            | (19.1)                                                         |
| Diarrhoea                                      | 44                                          | (11.8)                                      | 71                                         | (19.7)                                     | 11                                          | (18.0)                                      | 77                                                             | (13.4)                                                         |
| Aspartate aminotransferase increased           | 43                                          | (11.6)                                      | 32                                         | (8.9)                                      | 7                                           | (11.5)                                      | 70                                                             | (12.2)                                                         |
| COVID-19                                       | 37                                          | (9.9)                                       | 33                                         | (9.2)                                      | 8                                           | (13.1)                                      | 60                                                             | (10.4)                                                         |
| Blood creatinine increased                     | 32                                          | (8.6)                                       | 44                                         | (12.2)                                     | 7                                           | (11.5)                                      | 68                                                             | (11.8)                                                         |
| Cough                                          | 31                                          | (8.3)                                       | 74                                         | (20.6)                                     | 7                                           | (11.5)                                      | 67                                                             | (11.6)                                                         |
| Pruritus                                       | 29                                          | (7.8)                                       | 60                                         | (16.7)                                     | 3                                           | (4.9)                                       | 43                                                             | (7.5)                                                          |
| Abdominal pain                                 | 27                                          | (7.3)                                       | 19                                         | (5.3)                                      | 12                                          | (19.7)                                      | 56                                                             | (9.7)                                                          |
| Hypertension                                   | 25                                          | (6.7)                                       | 24                                         | (6.7)                                      | 9                                           | (14.8)                                      | 49                                                             | (8.5)                                                          |

<div style=\"page-break-after: always\"></div>

42

44

41

56

38

24

37

31

15

23

20

33

25

12

7

| Pyrexia                           |   22 | (5.9)   |   46 | (12.8)   |   1 | (1.6)   |   42 | (7.3)   |
|-----------------------------------|------|---------|------|----------|-----|---------|------|---------|
| Weight increased                  |   22 | (5.9)   |    3 | (0.8)    |  10 | (16.4)  |   44 | (7.6)   |
| Insomnia                          |   21 | (5.6)   |   19 | (5.3)    |   9 | (14.8)  |   41 | (7.1)   |
| Myalgia                           |   21 | (5.6)   |   13 | (3.6)    |  15 | (24.6)  |   56 | (9.7)   |
| Urinary tract infection           |   21 | (5.6)   |   21 | (5.8)    |   8 | (13.1)  |   38 | (6.6)   |
| Rash                              |   17 | (4.6)   |   68 | (18.9)   |   1 | (1.6)   |   24 | (4.2)   |
| Vision blurred                    |   16 | (4.3)   |    4 | (1.1)    |  13 | (21.3)  |   37 | (6.4)   |
| Anxiety                           |   14 | (3.8)   |    8 | (2.2)    |   7 | (11.5)  |   31 | (5.4)   |
| Hypertriglyceridemia              |   14 | (3.8)   |   53 | (14.7)   |   0 | (0.0)   |   15 | (2.6)   |
| Muscle spasms                     |   13 | (3.5)   |    5 | (1.4)    |   7 | (11.5)  |   23 | (4.0)   |
| Stomatitis                        |   13 | (3.5)   |  136 | (37.8)   |   2 | (3.3)   |   20 | (3.5)   |
| Upper respiratory tract infection |   12 | (3.2)   |    7 | (1.9)    |  11 | (18.0)  |   33 | (5.7)   |
| Hyperglycaemia                    |   10 | (2.7)   |   54 | (15.0)   |   4 | (6.6)   |   25 | (4.3)   |
| Disturbance in attention          |    3 | (0.8)   |    1 | (0.3)    |   8 | (13.1)  |   12 | (2.1)   |
| Pneumonitis                       |    3 | (0.8)   |   51 | (14.2)   |   0 | (0.0)   |    7 | (1.2)   |

Every patient is counted a single time for each applicable row and column.

Non-serious adverse events up to 30 days of last dose and serious adverse events up to 90 days of last dose are included.

MedDRA 26.0 preferred terms \"Neoplasm Progression\", \"Malignant Neoplasm Progression\" and \"Disease Progression\" not related to the drug are excluded.

j  Includes all patients who received at least one dose of belzutifan 120 mg QD in MK-6482-001 Part 1A, 1B, MK-6482-004, MK-6482-013, and MK-6482-005 including patients from the Japan safety run-in cohort.

Table 73: Patients With Grade 3-5 Adverse Events by Decreasing Incidence of Preferred Term (Incidence ≥5% in One or More Treatment Groups) (APaT Population)

576

355

165

70

20

7

0

|                                                        | MK-6482-005 Data for Belzutifan 120 mg QD   | MK-6482-005 Data for Belzutifan 120 mg QD   | MK-6482-005 Data for Everolimus 10 mg QD   | MK-6482-005 Data for Everolimus 10 mg QD   | MK-6482-004 Data for Belzutifan 120 mg QD   | MK-6482-004 Data for Belzutifan 120 mg QD   | Cumulative Running Safety Dataset for Belzutifan 120 mg QD j   | Cumulative Running Safety Dataset for Belzutifan 120 mg QD j   |
|--------------------------------------------------------|---------------------------------------------|---------------------------------------------|--------------------------------------------|--------------------------------------------|---------------------------------------------|---------------------------------------------|----------------------------------------------------------------|----------------------------------------------------------------|
|                                                        | n                                           | (%)                                         | n                                          | (%)                                        | n                                           | (%)                                         | n                                                              | (%)                                                            |
| Patients in population with one or more adverse events | 372 230                                     | (61.8)                                      | 360 225                                    | (62.5)                                     | 61 27                                       | (44.3)                                      | 576 355                                                        | (61.6)                                                         |
| Anaemia                                                | 121                                         | (32.5)                                      | 65                                         | (18.1)                                     | 7                                           | (11.5)                                      | 165                                                            | (28.6)                                                         |
| Hypoxia                                                | 39                                          | (10.5)                                      | 4                                          | (1.1)                                      | 1                                           | (1.6)                                       | 70                                                             | (12.2)                                                         |
| Hypertension                                           | 8                                           | (2.2)                                       | 11                                         | (3.1)                                      | 6                                           | (9.8)                                       | 20                                                             | (3.5)                                                          |
| Hyperglycaemia                                         | 2                                           | (0.5)                                       | 20                                         | (5.6)                                      | 1                                           | (1.6)                                       | 7                                                              | (1.2)                                                          |
| Hypertriglyceridemia                                   | 0                                           | (0.0)                                       | 18                                         | (5.0)                                      | 0                                           | (0.0)                                       | 0                                                              | (0.0)                                                          |

Every patient is counted a single time for each applicable row and column.

Non-serious adverse events up to 30 days of last dose and serious adverse events up to 90 days of last dose are included.

MedDRA 26.0 preferred terms \"Neoplasm Progression\", \"Malignant Neoplasm Progression\" and \"Disease Progression\" not related to the drug are excluded.

Grades are based on NCI CTCAE version 5.0 for MK-6482-005 and MK-6482-013 and version 4.03 for all other studies.

j  Includes all patients who received at least one dose of belzutifan 120 mg QD in MK-6482-001 Part 1A, 1B, MK-6482-004, MK-6482-013, and MK-6482-005 including patients from the Japan safety run-in cohort.

## Drug-related adverse events

All-Grade and Grade 3-5 drug-related AEs (as determined by the investigator) are shown in Table 74 and

<div style=\"page-break-after: always\"></div>

Table 75 , respectively.

Table 74: Patients With Drug-Related Adverse Events by Decreasing Incidence of Preferred Term (Incidence ≥5% in One or More Treatment Groups) (APaT Population)

(91.3)

(74.3)

(32.3)

(13.4)

(13.5)

(6.3)

(10.8)

(8.9)

(8.2)

(6.1)

(4.5)

(8.0)

(7.6)

(3.5)

(7.5)

(3.8)

(2.3)

(3.1)

(2.1)

(2.3)

(2.4)

(4.3)

(2.3)

(0.5)

(1.9)

(1.6)

(1.4)

(1.6)

(1.2)

(0.7)

(0.7)

|                                      | MK-6482-005 Data for Belzutifan 120 mg QD   | MK-6482-005 Data for Belzutifan 120 mg QD   | MK-6482-005 Data for Everolimus 10 mg QD   | MK-6482-005 Data for Everolimus 10 mg QD   | MK-6482-004 Data for Belzutifan 120 mg QD   | MK-6482-004 Data for Belzutifan 120 mg QD   | Cumulative Running Safety Dataset for Belzutifan 120 mg QD j   | Cumulative Running Safety Dataset for Belzutifan 120 mg QD j   |
|--------------------------------------|---------------------------------------------|---------------------------------------------|--------------------------------------------|--------------------------------------------|---------------------------------------------|---------------------------------------------|----------------------------------------------------------------|----------------------------------------------------------------|
|                                      | n                                           | (%)                                         | n (%)                                      | n (%)                                      | n (%)                                       | n (%)                                       | n (%)                                                          | n (%)                                                          |
| Patients in population               | 372                                         |                                             | 360                                        |                                            | 61                                          |                                             | 576                                                            |                                                                |
| with one or more adverse events      | 331                                         | (89.0)                                      | 322                                        | (89.4)                                     | 61                                          | (100.0)                                     | 526                                                            | (91.3)                                                         |
| Anaemia                              | 267                                         | (71.8)                                      | 123                                        | (34.2)                                     | 54                                          | (88.5)                                      | 428                                                            | (74.3)                                                         |
| Fatigue                              | 79                                          | (21.2)                                      | 60                                         | (16.7)                                     | 39                                          | (63.9)                                      | 186                                                            | (32.3)                                                         |
| Hypoxia                              | 44                                          | (11.8)                                      | 0                                          | (0.0)                                      | 1                                           | (1.6)                                       | 77                                                             | (13.4)                                                         |
| Nausea                               | 39                                          | (10.5)                                      | 21                                         | (5.8)                                      | 15                                          | (24.6)                                      | 78                                                             | (13.5)                                                         |
| Asthenia                             | 32                                          | (8.6)                                       | 39                                         | (10.8)                                     | 1                                           | (1.6)                                       | 36                                                             | (6.3)                                                          |
| Dyspnoea                             | 31                                          | (8.3)                                       | 19                                         | (5.3)                                      | 11                                          | (18.0)                                      | 62                                                             | (10.8)                                                         |
| Alanine aminotransferase increased   | 29                                          | (7.8)                                       | 19                                         | (5.3)                                      | 7                                           | (11.5)                                      | 51                                                             | (8.9)                                                          |
| Aspartate aminotransferase increased | 28                                          | (7.5)                                       | 21                                         | (5.8)                                      | 4                                           | (6.6)                                       | 47                                                             | (8.2)                                                          |
| Decreased appetite                   | 24                                          | (6.5)                                       | 35                                         | (9.7)                                      | 2                                           | (3.3)                                       | 35                                                             | (6.1)                                                          |
| Diarrhoea                            | 22                                          | (5.9)                                       | 57                                         | (15.8)                                     | 2                                           | (3.3)                                       | 26                                                             | (4.5)                                                          |
| Headache                             | 22                                          | (5.9)                                       | 8                                          | (2.2)                                      | 11                                          | (18.0)                                      | 46                                                             | (8.0)                                                          |
| Oedema peripheral                    | 21                                          | (5.6)                                       | 29                                         | (8.1)                                      | 5                                           | (8.2)                                       | 44                                                             | (7.6)                                                          |
| Pruritus                             | 17                                          | (4.6)                                       | 47                                         | (13.1)                                     | 2                                           | (3.3)                                       | 20                                                             | (3.5)                                                          |
| Dizziness                            | 16                                          | (4.3)                                       | 1                                          | (0.3)                                      | 15                                          | (24.6)                                      | 43                                                             | (7.5)                                                          |
| Arthralgia                           | 13                                          | (3.5)                                       | 4                                          | (1.1)                                      | 5                                           | (8.2)                                       | 22                                                             | (3.8)                                                          |
| Thrombocytopenia                     | 11                                          | (3.0)                                       | 24                                         | (6.7)                                      | 0                                           | (0.0)                                       | 13                                                             | (2.3)                                                          |
| Blood creatinine increased           | 10                                          | (2.7)                                       | 24                                         | (6.7)                                      | 2                                           | (3.3)                                       | 18                                                             | (3.1)                                                          |
| Rash                                 | 10                                          | (2.7)                                       | 56                                         | (15.6)                                     | 0                                           | (0.0)                                       | 12                                                             | (2.1)                                                          |
| Stomatitis                           | 9                                           | (2.4)                                       | 125                                        | (34.7)                                     | 1                                           | (1.6)                                       | 13                                                             | (2.3)                                                          |
| Vision blurred                       | 8                                           | (2.2)                                       | 1                                          | (0.3)                                      | 5                                           | (8.2)                                       | 14                                                             | (2.4)                                                          |
| Myalgia                              | 7                                           | (1.9)                                       | 6                                          | (1.7)                                      | 8                                           | (13.1)                                      | 25                                                             | (4.3)                                                          |
| Lymphocyte count decreased           | 4                                           | (1.1)                                       | 8                                          | (2.2)                                      | 4                                           | (6.6)                                       | 13                                                             | (2.3)                                                          |
| Hypertriglyceridaemia                | 3                                           | (0.8)                                       | 45                                         | (12.5)                                     | 0                                           | (0.0)                                       | 3                                                              | (0.5)                                                          |
| Cough                                | 2                                           | (0.5)                                       | 33                                         | (9.2)                                      | 0                                           | (0.0)                                       | 11                                                             | (1.9)                                                          |
| Disturbance in attention             | 2                                           | (0.5)                                       | 0                                          | (0.0)                                      | 6                                           | (9.8)                                       | 9                                                              | (1.6)                                                          |
| Dry mouth                            | 2                                           | (0.5)                                       | 5                                          | (1.4)                                      | 4                                           | (6.6)                                       | 8                                                              | (1.4)                                                          |
| Palpitations                         | 2                                           | (0.5)                                       | 0                                          | (0.0)                                      | 4                                           | (6.6)                                       | 9                                                              | (1.6)                                                          |
| Dysgeusia                            | 1                                           | (0.3)                                       | 19                                         | (5.3)                                      | 3                                           | (4.9)                                       | 7                                                              | (1.2)                                                          |
| Hyperglycaemia                       | 1 1                                         | (0.3)                                       | 37                                         | (10.3)                                     | 2                                           | (3.3)                                       | 4                                                              | (0.7)                                                          |
| Pneumonitis                          |                                             | (0.3)                                       | 48                                         | (13.3)                                     | 0                                           | (0.0)                                       | 4                                                              | (0.7)                                                          |

Every patient is counted a single time for each applicable row and column.

Non-serious adverse events up to 30 days of last dose and serious adverse events up to 90 days of last dose are included.

j  Includes all patients who received at least one dose of belzutifan 120 mg QD in MK-6482-001 Part 1A, 1B, MK-6482004, MK-6482-013, and MK-6482-005 including patients from the Japan safety run-in cohort.

## Table 75: Patients With Grade 3-5 Drug-Related Adverse Events by Decreasing Incidence of Preferred Term (Incidence ≥1 Patient in CRSD) (APaT Population)

| MK-6482-005 Data for Belzutifan 120   | MK-6482-005 Data for Everolimus 10   | MK-6482-004 Data for Belzutifan 120   | Cumulative Running Safety Dataset for   |
|---------------------------------------|--------------------------------------|---------------------------------------|-----------------------------------------|

<div style=\"page-break-after: always\"></div>

576

217

140

57

7

5

4

4

3

3

2

2

2

2

2

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

|                                        | mg QD   | mg QD   | mg QD   | mg QD       | mg QD   | mg QD   | Belzutifan 120 mg QD j   | Belzutifan 120 mg QD j   |
|----------------------------------------|---------|---------|---------|-------------|---------|---------|--------------------------|--------------------------|
|                                        | n       | (%)     | n       | (%)         | n       | (%)     | n                        | (%)                      |
| Patients in population                 | 372     |         | 360     |             | 61      |         | 576                      |                          |
| with one or more adverse events        | 144     | (38.7)  | 142     | (39.4)      | 11      | (18.0)  | 217                      | (37.7)                   |
| Anaemia                                | 101     | (27.2)  | 39      | (10.8)      | 7       | (11.5)  | 140                      | (24.3)                   |
| Hypoxia                                | 32      | (8.6)   | 0       | (0.0)       | 1       | (1.6)   | 57                       | (9.9)                    |
| Fatigue                                | 1       | (0.3)   | 7       | (1.9)       | 3       | (4.9)   | 7                        | (1.2)                    |
| Alanine aminotransferase increased     | 3       | (0.8)   | 0       | (0.0)       | 0       | (0.0)   | 5                        | (0.9)                    |
| Asthenia                               | 4       | (1.1)   | 7       | (1.9)       | 0       | (0.0)   | 4                        | (0.7)                    |
| Dyspnoea                               | 2       | (0.5)   | 2       | (0.6)       | 0       | (0.0)   | 4                        | (0.7)                    |
| Aspartate aminotransferase increased   | 2       | (0.5)   | 0       | (0.0)       | 0       | (0.0)   | 3                        | (0.5)                    |
| Nausea                                 | 1       | (0.3)   | 1       | (0.3)       | 0       | (0.0)   | 3                        | (0.5)                    |
| Acidosis                               | 2       | (0.5)   | 0       | (0.0)       | 0       | (0.0)   | 2                        | (0.3)                    |
| Diarrhoea                              | 2       | (0.5)   | 2       | (0.6)       | 0       | (0.0)   | 2                        | (0.3)                    |
| Hepatic enzyme increased               | 2       | (0.5)   | 0       | (0.0)       | 0       | (0.0)   | 2                        | (0.3)                    |
| Hypertension                           | 1       | (0.3)   | 3       | (0.8)       | 0       | (0.0)   | 2                        | (0.3)                    |
| Hypophosphataemia                      | 1       | (0.3)   | 1       | (0.3)       | 0       | (0.0)   | 2                        | (0.3)                    |
| Acute respiratory failure              | 0       | (0.0)   | 0       | (0.0)       | 0       | (0.0)   | 1                        | (0.2)                    |
| Angina pectoris                        | 0       | (0.0)   | 0       | (0.0)       | 0       | (0.0)   | 1                        | (0.2)                    |
| Blood calcium increased                | 1       | (0.3)   | 0       | (0.0)       | 0       | (0.0)   | 1                        | (0.2)                    |
| Constipation                           | 0       | (0.0)   | 0       | (0.0)       | 0       | (0.0)   | 1                        | (0.2)                    |
| Disseminated intravascular coagulation | 1       | (0.3)   | 0       | (0.0)       | 0       | (0.0)   | 1                        | (0.2)                    |
| Enterocolitis                          | 1       | (0.3)   | 0       | (0.0)       | 0       | (0.0)   | 1                        | (0.2)                    |
| Gamma-glutamyltransferase increased    | 1       | (0.3)   | 1       | (0.3)       | 0       | (0.0)   | 1                        | (0.2)                    |
| General physical health deterioration  | 1       | (0.3)   | 3       | (0.8)       | 0       | (0.0)   | 1                        | (0.2)                    |
| Generalised oedema                     | 1       | (0.3)   | 0       | (0.0)       | 0       | (0.0)   | 1                        | (0.2)                    |
| Haemoglobin decreased                  | 0       | (0.0)   | 0       | (0.0)       | 0       | (0.0)   | 1                        | (0.2)                    |
| Headache                               | 0       | (0.0)   | 0       | (0.0)       | 0       | (0.0)   | 1                        | (0.2)                    |
| Hepatic failure                        | 1       | (0.3)   | 0       | (0.0)       | 0       | (0.0)   | 1                        | (0.2)                    |
| Hypocalcaemia                          | 1       | (0.3)   | 0       | (0.0)       | 0       | (0.0)   | 1                        | (0.2)                    |
| Liver function test increased          | 1       | (0.3)   | 0       | (0.0)       | 0       | (0.0)   | 1                        | (0.2)                    |
| Lung disorder                          | 1       | (0.3)   | 0       | (0.0)       | 0       | (0.0)   | 1                        | (0.2)                    |
| Lymphocyte count decreased             | 1       | (0.3)   | 3       | (0.8)       | 0       | (0.0)   | 1                        | (0.2)                    |
| Multiple organ dysfunction syndrome    | 1       | (0.3)   | 0       | (0.0)       | 0       | (0.0)   | 1                        | (0.2)                    |
| Neutropenia                            | 1       | (0.3)   | 4       | (1.1)       | 0       | (0.0)   | 1                        | (0.2)                    |
| Neutrophil count decreased             | 1       | (0.3)   | 1       | (0.3)       | 0       | (0.0)   | 1                        | (0.2)                    |
| Pericardial effusion                   | 1       | (0.3)   | 0       | (0.0) (0.0) | 0       | (0.0)   | 1                        | (0.2)                    |
| Platelet count decreased               | 0       | (0.0)   | 0 0     | (0.0)       | 0 0     | (0.0)   | 1                        | (0.2) (0.2)              |
| Pleural effusion                       | 1       | (0.3)   | 1       | (0.3)       |         | (0.0)   | 1                        | (0.2)                    |
| Pneumonia                              | 0       | (0.0)   |         |             | 0       | (0.0)   | 1 1                      | (0.2)                    |
| Pneumonitis                            | 0       | (0.0)   | 13      | (3.6)       | 0       | (0.0)   |                          |                          |
| Respiratory failure                    | 1       | (0.3)   | 0       | (0.0)       | 0       | (0.0)   | 1                        | (0.2)                    |
| Retinal oedema                         | 1       | (0.3)   | 0       | (0.0)       | 0       | (0.0)   | 1                        | (0.2)                    |
| Thrombocytopenia                       | 1       | (0.3)   | 0       | (0.0)       | 0       | (0.0)   | 1                        | (0.2)                    |
| Type 2 diabetes mellitus               | 0       | (0.0)   | 1       | (0.3)       | 0       | (0.0)   | 1                        | (0.2)                    |
| Urinary tract infection                |         | (0.0)   | 0       | (0.0)       |         | (1.6)   | 1                        | (0.2)                    |
| Vomiting                               | 0 1     | (0.3)   | 2       | (0.6)       | 1       | (0.0)   | 1                        | (0.2)                    |
| Weight increased                       | 1       | (0.3)   | 0       | (0.0)       | 0 0     | (0.0)   | 1                        | (0.2)                    |

<div style=\"page-break-after: always\"></div>

Non-serious adverse events up to 30 days of last dose and serious adverse events up to 90 days of last dose are included.

Grades are based on NCI CTCAE version 5.0 for MK-6482-005 and MK-6482-013 and version 4.03 for all other studies.

j  Includes all patients who received at least one dose of belzutifan 120 mg QD in MK-6482-001 Part 1A, 1B, MK-6482-004, MK-6482-013, and MK-6482-005 including patients from the Japan safety run-in cohort.

## Adverse drug reactions (ADRs)

In accordance with the report from CIOMS Working Group VI and ICH guidelines (CPMP/ICH/377/95), the applicant defined Adverse Drug Reactions (ADRs) as any noxious and unintentional responses to belzutifan related to any dose from any available sources (nonclinical data, biological plausibility, clinical trials, postmarketing reporting, literature, etc.) for which, after thorough assessment, a reasonable possibility for causal association with belzutifan is determined. Hence, the following methodology was used for the identification of ADRs:

1. A comprehensive analysis of the totality of the available safety data, regardless of investigator's causality assessment, based on:
- a. Frequency of AEs: most reported AEs, SAEs reported in &gt;1 patient, AEs leading to permanent treatment discontinuation, and AEs leading to death.
- b. Thorough narrative review of SAE cases of concern.
- c. Comparative incidence of selected AEs reported in the literature from clinical trials and/or epidemiological studies.
2. Biological plausibility and known mechanism of toxicity of belzutifan

In accordance with the methodology described above, anaemia, hypoxia, dyspnoea, fatigue, nausea, and dizziness are ADRs for belzutifan. Based on results from IA1 of Study 005 and after evaluating all available data, the applicant determined that weight increased was also an ADR for belzutifan.

The following PTs were included to ascertain the respective ADRs:

- -Anaemia: PTs of anaemia and haemoglobin decreased
- -Hypoxia: PT of hypoxia
- -Dyspnoea: PT of dyspnoea
- -Fatigue:  PT of fatigue
- -Dizziness: PT of dizziness
- -Nausea: PT of nausea
- -Weight increased: PT of weight

## Serious adverse events, deaths, and other significant events

## SAEs

A summary of SAEs across safety datasets is shown in Table 76.

<div style=\"page-break-after: always\"></div>

Table 76: Patients With Serious Adverse Events by System Organ Class and Preferred Term (Incidence ≥5% in One or More Treatment Groups) (APaT Population)

576

236

27

41

|                                                        | MK-6482-005 Data for Belzutifan 120 mg QD   | MK-6482-005 Data for Belzutifan 120 mg QD   | MK-6482-005 Data for Everolimus 10 mg QD   | MK-6482-005 Data for Everolimus 10 mg QD   | MK-6482-004 Data for Belzutifan 120 mg QD   | MK-6482-004 Data for Belzutifan 120 mg QD   | Cumulative Running Safety Dataset for Belzutifan 120 mg QD j   | Cumulative Running Safety Dataset for Belzutifan 120 mg QD j   |
|--------------------------------------------------------|---------------------------------------------|---------------------------------------------|--------------------------------------------|--------------------------------------------|---------------------------------------------|---------------------------------------------|----------------------------------------------------------------|----------------------------------------------------------------|
|                                                        | n                                           | (%)                                         | n                                          | (%)                                        | n                                           | (%)                                         | n                                                              | (%)                                                            |
| Patients in population with one or more adverse events | 372 157                                     | (42.2)                                      | 360 137                                    | (38.1)                                     | 61 18                                       | (29.5)                                      | 576 236                                                        | (41.0)                                                         |
| Blood and lymphatic system disorders                   | 21                                          | (5.6)                                       | 8                                          | (2.2)                                      | 1                                           | (1.6)                                       | 28                                                             | (4.9)                                                          |
| Anaemia                                                | 20                                          | (5.4)                                       | 8                                          | (2.2)                                      | 1                                           | (1.6)                                       | 27                                                             | (4.7)                                                          |
| Infections and infestations                            | 41                                          | (11.0)                                      | 56                                         | (15.6)                                     | 5                                           | (8.2)                                       | 66                                                             | (11.5)                                                         |
| Respiratory, thoracic and mediastinal disorders        | 48                                          | (12.9)                                      | 41                                         | (11.4)                                     | 2                                           | (3.3)                                       | 67                                                             | (11.6)                                                         |
| Hypoxia                                                | 28                                          | (7.5)                                       | 0                                          | (0.0)                                      | 1                                           | (1.6)                                       | 41                                                             | (7.1)                                                          |
| Vascular disorders                                     | 1                                           | (0.3)                                       | 5                                          | (1.4)                                      | 4                                           | (6.6)                                       | 6                                                              | (1.0)                                                          |

Every patient is counted a single time for each applicable row and column.

Serious adverse events up to 90 days of last dose of study intervention are included.

j  Includes all patients who received at least one dose of belzutifan 120 mg QD in MK-6482-001 Part 1A, 1B, MK-6482-004, MK-6482-013, and MK-6482-005 including patients from the Japan safety run-in cohort.

A summary of drug-related SAEs as determined by investigators across safety datasets is shown in Table 77.

Table 77: Patients With Drug-Related Serious Adverse Events by Decreasing Incidence of Preferred Term (Incidence ≥1 Patient in CRSD) (APaT Population)

576

71

31

20

3

2

1

1

1

1

1

1

1

1

1

1

|                                                        | MK-6482-005 Data for Belzutifan 120 mg QD   | MK-6482-005 Data for Belzutifan 120 mg QD   | MK-6482-005 Data for Everolimus 10 mg QD   | MK-6482-005 Data for Everolimus 10 mg QD   | MK-6482-004 Data for Belzutifan 120 mg QD   | MK-6482-004 Data for Belzutifan 120 mg QD   | Cumulative Running Safety Dataset for Belzutifan 120 mg QD j   | Cumulative Running Safety Dataset for Belzutifan 120 mg QD j   |
|--------------------------------------------------------|---------------------------------------------|---------------------------------------------|--------------------------------------------|--------------------------------------------|---------------------------------------------|---------------------------------------------|----------------------------------------------------------------|----------------------------------------------------------------|
|                                                        | n                                           | (%)                                         | n                                          | (%)                                        | n                                           | (%)                                         | n                                                              | (%)                                                            |
| Patients in population with one or more adverse events | 372 49                                      | (13.2)                                      | 360 47                                     | (13.1)                                     | 61 4                                        | (6.6)                                       | 576 71                                                         | (12.3)                                                         |
| Hypoxia                                                | 21                                          | (5.6)                                       | 0                                          | (0.0)                                      | 1                                           | (1.6)                                       | 31                                                             | (5.4)                                                          |
| Anaemia                                                | 16                                          | (4.3)                                       | 5                                          | (1.4)                                      | 1                                           | (1.6)                                       | 20                                                             | (3.5)                                                          |
| Diarrhoea                                              | 3                                           | (0.8)                                       | 1                                          | (0.3)                                      | 0                                           | (0.0)                                       | 3                                                              | (0.5)                                                          |
| Dyspnoea                                               | 1                                           | (0.3)                                       | 1                                          | (0.3)                                      | 0                                           | (0.0)                                       | 2                                                              | (0.3)                                                          |
| Acute respiratory failure                              | 0                                           | (0.0)                                       | 0                                          | (0.0)                                      | 0                                           | (0.0)                                       | 1                                                              | (0.2)                                                          |
| Angina pectoris                                        | 0                                           | (0.0)                                       | 0                                          | (0.0)                                      | 0                                           | (0.0)                                       | 1                                                              | (0.2)                                                          |
| Blood calcium increased                                | 1                                           | (0.3)                                       | 0                                          | (0.0)                                      | 0                                           | (0.0)                                       | 1                                                              | (0.2)                                                          |
| Constipation                                           | 0                                           | (0.0)                                       | 0                                          | (0.0)                                      | 0                                           | (0.0)                                       | 1                                                              | (0.2)                                                          |
| Cystoid macular oedema                                 | 1                                           | (0.3)                                       | 0                                          | (0.0)                                      | 0                                           | (0.0)                                       | 1                                                              | (0.2)                                                          |
| Disseminated intravascular coagulation                 | 1                                           | (0.3)                                       | 0                                          | (0.0)                                      | 0                                           | (0.0)                                       | 1                                                              | (0.2)                                                          |
| Enterocolitis                                          | 1                                           | (0.3)                                       | 0                                          | (0.0)                                      | 0                                           | (0.0)                                       | 1                                                              | (0.2)                                                          |
| Generalised oedema                                     | 1                                           | (0.3)                                       | 0                                          | (0.0)                                      | 0                                           | (0.0)                                       | 1                                                              | (0.2)                                                          |
| Haemorrhage intracranial                               | 0                                           | (0.0)                                       | 0                                          | (0.0)                                      | 1                                           | (1.6)                                       | 1                                                              | (0.2)                                                          |
| Hepatic enzyme increased                               | 1                                           | (0.3)                                       | 0                                          | (0.0)                                      | 0                                           | (0.0)                                       | 1                                                              | (0.2)                                                          |

<div style=\"page-break-after: always\"></div>

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

| Lethargy                            | 1 (0.3)   |   0 | (0.0)   | 0       | (0.0) 1 (0.2)   |
|-------------------------------------|-----------|-----|---------|---------|-----------------|
| Liver function test increased       | 1 (0.3)   |   0 | (0.0)   | 0 (0.0) | 1 (0.2)         |
| Lung disorder                       | 1 (0.3)   |   0 | (0.0)   | 0 (0.0) | 1 (0.2)         |
| Multiple organ dysfunction syndrome | 1 (0.3)   |   0 | (0.0)   | 0 (0.0) | 1 (0.2)         |
| Nausea                              | 0 (0.0)   |   0 | (0.0)   | 0 (0.0) | 1 (0.2)         |
| Pericardial effusion                | 1 (0.3)   |   0 | (0.0)   | 0 (0.0) | 1 (0.2)         |
| Pleural effusion                    | 1 (0.3)   |   0 | (0.0)   | 0 (0.0) | 1 (0.2)         |
| Pneumonia                           | 0 (0.0)   |   2 | (0.6)   | 0 (0.0) | 1 (0.2)         |
| Pyrexia                             | 1 (0.3)   |   0 | (0.0)   | 0 (0.0) | 1 (0.2)         |
| Respiratory failure                 | 1 (0.3)   |   0 | (0.0)   | 0 (0.0) | 1 (0.2)         |
| Respiratory tract infection         | 0 (0.0)   |   0 | (0.0)   | 0 (0.0) | 1 (0.2)         |
| Retinal oedema                      | 1 (0.3)   |   0 | (0.0)   | 0 (0.0) | 1 (0.2)         |
| Type 2 diabetes mellitus            | 0 (0.0)   |   1 | (0.3)   | 0 (0.0) | 1 (0.2)         |
| Urinary tract infection             | 0 (0.0)   |   0 | (0.0)   | 1 (1.6) | 1 (0.2)         |
| Vomiting                            | 1 (0.3)   |   1 | (0.3)   | 0 (0.0) | 1 (0.2)         |

Every patient is counted a single time for each applicable row and column.

Serious adverse events up to 90 days of last dose of study intervention are included.

j  Includes all patients who received at least one dose of belzutifan 120 mg QD in MK-6482-001 Part 1A, 1B, MK-6482-004, MK-6482-013, and MK-6482-005 including patients from the Japan safety run-in cohort.

## Deaths

The number (and percentage) of patients with AEs leading to death across safety datasets is shown in Table 78.

Table 78: Patients With Adverse Events Resulting in Death by System Organ Class and Preferred Term (Incidence &gt;0% in One or More Treatment Groups) (APaT Population)

576

19

1

1

1

1

0

0

1

1

1

|                                                        | MK-6482-005 Data for Belzutifan 120 mg QD   | MK-6482-005 Data for Belzutifan 120 mg QD   | MK-6482-005 Data for Everolimus 10 mg QD   | MK-6482-005 Data for Everolimus 10 mg QD   | MK-6482-004 Data for Belzutifan 120 mg QD   | MK-6482-004 Data for Belzutifan 120 mg QD   | Cumulative Running Safety Dataset for Belzutifan 120 mg QD j   | Cumulative Running Safety Dataset for Belzutifan 120 mg QD j   |
|--------------------------------------------------------|---------------------------------------------|---------------------------------------------|--------------------------------------------|--------------------------------------------|---------------------------------------------|---------------------------------------------|----------------------------------------------------------------|----------------------------------------------------------------|
|                                                        | n                                           | (%)                                         | n                                          | (%)                                        | n                                           | (%)                                         | n                                                              | (%)                                                            |
| Patients in population with one or more adverse events | 372 13                                      | (3.5)                                       | 360 19                                     | (5.3)                                      | 61 2                                        | (3.3)                                       | 576 19                                                         | (3.3)                                                          |
| Cardiac disorders                                      | 2                                           | (0.5)                                       | 0                                          | (0.0)                                      | 0                                           | (0.0)                                       | 4                                                              | (0.7)                                                          |
| Acute coronary syndrome                                | 0                                           | (0.0)                                       | 0                                          | (0.0)                                      | 0                                           | (0.0)                                       | 1                                                              | (0.2)                                                          |
| Cardiac arrest                                         | 0                                           | (0.0)                                       | 0                                          | (0.0)                                      | 0                                           | (0.0)                                       | 1                                                              | (0.2)                                                          |
| Myocardial infarction                                  | 1                                           | (0.3)                                       | 0                                          | (0.0)                                      | 0                                           | (0.0)                                       | 1                                                              | (0.2)                                                          |
| Pericardial haemorrhage                                | 1                                           | (0.3)                                       | 0                                          | (0.0)                                      | 0                                           | (0.0)                                       | 1                                                              | (0.2)                                                          |
| Gastrointestinal disorders                             | 1                                           | (0.3)                                       | 2                                          | (0.6)                                      | 0                                           | (0.0)                                       | 1                                                              | (0.2)                                                          |
| Intra-abdominal haemorrhage                            | 0                                           | (0.0)                                       | 1                                          | (0.3)                                      | 0                                           | (0.0)                                       | 0                                                              | (0.0)                                                          |
| Pancreatitis acute                                     | 0                                           | (0.0)                                       | 1                                          | (0.3)                                      | 0                                           | (0.0)                                       | 0                                                              | (0.0)                                                          |
| Upper gastrointestinal haemorrhage                     | 1                                           | (0.3)                                       | 0                                          | (0.0)                                      | 0                                           | (0.0)                                       | 1                                                              | (0.2)                                                          |
| General disorders and administration site conditions   | 2                                           | (0.5)                                       | 0                                          | (0.0)                                      | 0                                           | (0.0)                                       | 2                                                              | (0.3)                                                          |
| Death                                                  | 1                                           | (0.3)                                       | 0                                          | (0.0)                                      | 0                                           | (0.0)                                       | 1                                                              | (0.2)                                                          |
| Multiple organ dysfunction syndrome                    | 1                                           | (0.3)                                       | 0                                          | (0.0)                                      | 0                                           | (0.0)                                       | 1                                                              | (0.2)                                                          |
| Infections and infestations                            | 3                                           | (0.8)                                       | 11                                         | (3.1)                                      | 0                                           | (0.0)                                       | 3                                                              | (0.5)                                                          |

<div style=\"page-break-after: always\"></div>

1

0

0

0

1

1

1

1

1

1

0

2

2

0

0

1

| Abdominal sepsis                                                    | 1 (0.3)   |   0 | (0.0)   |   0 | (0.0)   | 1 (0.2)   |
|---------------------------------------------------------------------|-----------|-----|---------|-----|---------|-----------|
| COVID-19                                                            | 0 (0.0)   |   2 | (0.6)   |   0 | (0.0)   | 0 (0.0)   |
| COVID-19 pneumonia                                                  | 0 (0.0)   |   4 | (1.1)   |   0 | (0.0)   | 0 (0.0)   |
| Clostridium difficile infection                                     | 0 (0.0)   |   1 | (0.3)   |   0 | (0.0)   | 0 (0.0)   |
| Pneumonia                                                           | 1 (0.3)   |   3 | (0.8)   |   0 | (0.0)   | 1 (0.2)   |
| Sepsis                                                              | 1 (0.3)   |   1 | (0.3)   |   0 | (0.0)   | 1 (0.2)   |
| Injury, poisoning and procedural complications                      | 1 (0.3)   |   0 | (0.0)   |   1 | (1.6)   | 2 (0.3)   |
| Road traffic accident                                               | 1 (0.3)   |   0 | (0.0)   |   0 | (0.0)   | 1 (0.2)   |
| Toxicity to various agents                                          | 0 (0.0)   |   0 | (0.0)   |   1 | (1.6)   | 1 (0.2)   |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | 1 (0.3)   |   0 | (0.0)   |   0 | (0.0)   | 1 (0.2)   |
| Gastric cancer                                                      | 1 (0.3)   |   0 | (0.0)   |   0 | (0.0)   | 1 (0.2)   |
| Nervous system disorders                                            | 1 (0.3)   |   0 | (0.0)   |   0 | (0.0)   | 1 (0.2)   |
| Seizure                                                             | 1 (0.3)   |   0 | (0.0)   |   0 | (0.0)   | 1 (0.2)   |
| Psychiatric disorders                                               | 0 (0.0)   |   1 | (0.3)   |   1 | (1.6)   | 2 (0.3)   |
| Assisted suicide                                                    | 0 (0.0)   |   1 | (0.3)   |   0 | (0.0)   | 0 (0.0)   |
| Suicide attempt                                                     | 0 (0.0)   |   0 | (0.0)   |   1 | (1.6)   | 2 (0.3)   |
| Renal and urinary disorders                                         | 1 (0.3)   |   1 | (0.3)   |   0 | (0.0)   | 2 (0.3)   |
| Acute kidney injury                                                 | 1 (0.3)   |   1 | (0.3)   |   0 | (0.0)   | 2 (0.3)   |
| Respiratory, thoracic and mediastinal disorders                     | 1 (0.3)   |   4 | (1.1)   |   0 | (0.0)   | 1 (0.2)   |
| Pleural effusion                                                    | 0 (0.0)   |   1 | (0.3)   |   0 | (0.0)   | 0 (0.0)   |
| Pulmonary embolism                                                  | 0 (0.0)   |   2 | (0.6)   |   0 | (0.0)   | 0 (0.0)   |
| Respiratory failure                                                 | 1 (0.3)   |   1 | (0.3)   |   0 | (0.0)   | 1 (0.2)   |

Every patient is counted a single time for each applicable row and column.

Serious adverse events up to 90 days of last dose of study intervention are included.

j  Includes all patients who received at least one dose of belzutifan 120 mg QD in MK-6482-001 Part 1A, 1B, MK-6482-004, MK-6482-013, and MK-6482-005 including patients from the Japan safety run-in cohort.

## Other significant events

Anaemia and hypoxia were identified as the most important adverse drug reactions of special interest.

<div style=\"page-break-after: always\"></div>

## Anaemia

## Table 79: Adverse Events Of Anaemia By Maximum Toxicity Grade (APaT Population)

Participants With Adverse Events of Anemia by Maximum Toxicity Grade (Incidence &gt; O% in One or More Treatment Groups) (APaT Population)

|                                | MK-6482-005Datafor Belzitifan 120 mg QD   | MK-6482-005Datafor Belzitifan 120 mg QD   | MK-6482-005 Data for Everolimus 10mg QD   | MK-6482-005 Data for Everolimus 10mg QD   | MK-6482-004Datafor Belzitifan 120 mg QD   | MK-6482-004Datafor Belzitifan 120 mg QD   | CumulativeRunningSafety Dataset for Belzutifan 120 mg QDi   | CumulativeRunningSafety Dataset for Belzutifan 120 mg QDi   |
|--------------------------------|-------------------------------------------|-------------------------------------------|-------------------------------------------|-------------------------------------------|-------------------------------------------|-------------------------------------------|-------------------------------------------------------------|-------------------------------------------------------------|
|                                | n                                         | (%)                                       | n                                         | (%)                                       | n                                         | (%)                                       | n                                                           | (%)                                                         |
| Participants in population     | 372                                       |                                           | 360                                       |                                           | 19                                        |                                           | 576                                                         |                                                             |
| with one or more adverseevents | 309                                       | (83.1)                                    | 205                                       | (56.9)                                    | 55                                        | (90.2)                                    | 485                                                         | (84.2)                                                      |
| Grade 1                        | 32                                        | (8.6)                                     | 31                                        | (8.6)                                     | 24                                        | (39.3)                                    | 71                                                          | (12.3)                                                      |
| Grade 2                        | 156                                       | (41.9)                                    | 109                                       | (30.3)                                    | 24                                        | (39.3)                                    | 248                                                         | (43.1)                                                      |
| Grade 3                        | 119                                       | (32.0)                                    | 64                                        | (17.8)                                    | 7                                         | (11.5)                                    | 164                                                         | (28.5)                                                      |
| Grade 4                        | 2                                         | (0.5)                                     | 1                                         | (0.3)                                     | 0                                         | (0.0)                                     | 2                                                           | (0.3)                                                       |
| withno adverse events          | 63                                        | (16.9)                                    | 155                                       | (43.1)                                    | 6                                         | (9.8)                                     | 91                                                          | (15.8)                                                      |

Only the highest reported grade ofa given adverse event is counted for the individual participant.

GradesarebasedonNCICTCAEversion5.0forMK-6482-005and MK-6482-013andversion4.03forallother studies

Non-serious adverse events up to 30 days oflast dose and serious adverse events up to 90 days of last dose are included.

Importantidentified riskAnemia=PTAnemia+PT Haemoglobindecreased.

jIncludes all participants who received at least one dose of belzutifan120 mg QD in MK-6482-001 Part 1A, 1B, MK-6482-004,MK-6482-013, and MK-6482-005 including participants from the Japan safetyrun-in cohort.

DatabasecutoffdateforMK-6482-001:01APR2022

DatabasecutoffdateforMK-6482-004:01APR2022

DatabasecutoffdateforMK-6482-013:10FEB2023

DatabasecutoffdateforMK-6482-005:13JUN2023

Anaemia led to dose modifications in 10.9% of patients in the CRSD, and only two patients (0.3%) discontinued belzutifan because of anaemia. From the patients with anaemia, this ADR was handled with a dose reduction in (63/485 =) 13.0% of cases.

In Study 005, median time to onset of anaemia was 29.0 days (range: 1 to 834 days) in the belzutifan group. Among the 309 patients with anaemia in the belzutifan group, 62 (20.1%) were treated with erythropoietin-stimulating agent (ESAs) only, 67 (21.7%) received blood transfusion only, and 42 (13.6%) received both an ESA and blood transfusion. Anaemia events were resolved or resolving for about half of the patients.

In Study 004, median time to onset of anaemia was 30.0 days (range: 1 to 255 days). Among the 55 patients with anaemia, 9 (16.4%) received ESA only, 1 (1.8%) received blood transfusion only, and 5 (9.1%) received both an ESA and blood transfusion. Anaemia events were resolved for 12 (21.8%) patients and not resolved for 42 (76.4%) patients.

In the CRSD, median time to onset of anaemia was 29.0 days (range: 1 to 834 days). Of the 485 patients with anaemia, 22.9% were treated with ESA only, 17.5% were treated with blood transfusion only, and 12.8% were treated with ESA and blood transfusion. Approximately half of the patients with anaemia reported the outcome of the event as either resolved (34.0%) or resolving (13.6%).

<div style=\"page-break-after: always\"></div>

## Hypoxia

## Table 80: Adverse Events Of Hypoxia By Maximum Toxicity Grade (APaT Population)

Participants With Adverse Events of Hypoxia by Maximum Toxicity Grade (Incidence &gt; O% in One or More Treatment Groups) (APaT Population)

|                                | MK-6482-005Data for Belzutifan 120 mg QD   | MK-6482-005 Data for Everolimus 10mg QD   | MK-6482-004 Data for Belzutifan120mgQD   | CumulativeRunningSafety DatasetforBelzutifan120mg QD   |
|--------------------------------|--------------------------------------------|-------------------------------------------|------------------------------------------|--------------------------------------------------------|
| Participants in population     | 372                                        | 360                                       | 61                                       | 576                                                    |
| withone or more adverse events | 54 (14.5)                                  | 4 (1.1)                                   | 1 (1.6)                                  | 94 (16.3)                                              |
| Grade2                         | 15 (4.0)                                   | 0 (0.0)                                   | 0 (0.0)                                  | 24 (4.2)                                               |
| Grade3                         | 38 (10.2)                                  | 3 (0.8)                                   | 1 (1.6)                                  | 68 (11.8)                                              |
| Grade4                         | 1 (0.3)                                    | 1 (0.3)                                   | 0 (0.0)                                  | 2 (0.3)                                                |
| with no adverse events         | 318 (85.5)                                 | 356 (98.9)                                | 60 (98.4)                                | 482 (83.7)                                             |

<!-- image -->

Hypoxia was often managed by dose modifications (in 66/94 = 70.2% of patients with this ADR), i.e., in 11.5% of patients in the CRSD. Eight patients in the CRSD discontinued belzutifan because of hypoxia (1.4%).

In Study 005, median time to onset of hypoxia was 30.5 days (range: 1 to 643 days) in the belzutifan group. Among the 54 patients with hypoxia in the belzutifan group, 70.4% were treated with supplemental oxygen. The outcome of most hypoxia AEs was resolved (81.5% in the belzutifan group).

In Study 004, hypoxia was reported by 1 (1.6%) patient, 56 days after starting the study intervention. The event was Grade 3 in severity, was also an SAE, and assessed as related to study intervention by the investigator. The event was managed through dose reduction; no supplemental oxygen was required, and the event was resolved after 51 days.

In the CSRD, median time to onset of hypoxia was 30.5 days (range: 1 to 952 days). The median duration of an episode of hypoxia was 15 days (range: 1 to 1458+ days). Of the 94 patients with hypoxia, 70.2% received oxygen therapy. The outcome of hypoxia was reported as resolved in 79.8% patients, not resolved in 13.8%, and resolving and resolved with sequelae in 3.2% each.

## 2.6.8.3. Laboratory findings

Across the safety datasets, the most common laboratory test of any grade which increased from baseline was haemoglobin decreased in each group (88.0% in Study 005 belzutifan group, 76.1% in Study 005 everolimus group, 93.4% in Study 004, and 88.6% in CRSD). The next most common (≥40% of patients) laboratory tests with maximum postbaseline toxicity grade of 3 to 4 were: creatinine increased (48.9%) in the Study 005 belzutifan group; ALT increased (40.5%), creatinine increased (57.7%), and lymphocytes decreased (53.0%) in the Study 005 everolimus group; creatinine decreased (67.2%) and glucose increased (55.7%) in the Study 004 group; and creatinine increased (50.0%) in CRSD.

Across the safety datasets, the most common laboratory test which increased from baseline with maximum postbaseline toxicity grade of 3 to 4 was haemoglobin decreased in each group (28.3% in Study 005 belzutifan group, 17.1% in Study 005 everolimus group, 9.8% in Study 004, and 25.6% in CRSD). By group, the next most common (≥3% of patients) laboratory tests with maximum postbaseline toxicity grade of 3 to

<div style=\"page-break-after: always\"></div>

4 were: ALT increased (3.0%), AST increased (3.0%), lymphocytes decreased (7.8%), neutrophils decreased (3.0%), potassium increased (3.0%), and sodium increased (3.0%) in the Study 005 belzutifan group; creatinine increased (3.4%), lymphocyte decreased (19.7%), potassium decreased (3.7%), and sodium increased (3.4%) in the Study 005 everolimus group; glucose increased (6.6%) in the Study 004 group; and ALT increased (3.0%) and lymphocytes decreased (8.3%) in CRSD.

## Vital signs

No clinically relevant changes in vital signs were observed for patients treated with belzutifan, apart from an increase in body weight (ADR 'weight increased') and a slight (stable/temporary) decrease in oxygen saturation (ADR 'hypoxia') (data not shown).

## 2.6.8.4. Safety in special populations

## Age

Table 87 summarizes safety by age category.

Table 81: Adverse Events Summary by Age Category

|                                                                                         | Cumulative Running Safety Dataset for Belzutifan 120 mg QD j   | Cumulative Running Safety Dataset for Belzutifan 120 mg QD j   | Cumulative Running Safety Dataset for Belzutifan 120 mg QD j   | Cumulative Running Safety Dataset for Belzutifan 120 mg QD j   | Cumulative Running Safety Dataset for Belzutifan 120 mg QD j   | Cumulative Running Safety Dataset for Belzutifan 120 mg QD j   | Cumulative Running Safety Dataset for Belzutifan 120 mg QD j   | Cumulative Running Safety Dataset for Belzutifan 120 mg QD j   |
|-----------------------------------------------------------------------------------------|----------------------------------------------------------------|----------------------------------------------------------------|----------------------------------------------------------------|----------------------------------------------------------------|----------------------------------------------------------------|----------------------------------------------------------------|----------------------------------------------------------------|----------------------------------------------------------------|
|                                                                                         | <65                                                            | <65                                                            | 65-74                                                          | 65-74                                                          | 75-84                                                          | 75-84                                                          | >= 85                                                          | >= 85                                                          |
|                                                                                         | n                                                              | (%)                                                            | n                                                              | (%)                                                            | n                                                              | (%)                                                            | n                                                              | (%)                                                            |
| Subjects in population                                                                  | 370                                                            |                                                                | 157                                                            |                                                                | 45                                                             |                                                                | 4                                                              | (0.0)                                                          |
| with one or more adverse events                                                         | 366                                                            | (98.9)                                                         | 157                                                            | (100.0)                                                        | 45                                                             | (100.0)                                                        | 4                                                              | (100.0)                                                        |
| with serious adverse events                                                             | 152                                                            | (41.1)                                                         | 68                                                             | (43.3)                                                         | 15                                                             | (33.3)                                                         | 1                                                              | (25.0)                                                         |
| -Fatal                                                                                  | 11                                                             | (3.0)                                                          | 7                                                              | (4.5)                                                          | 1                                                              | (2.2)                                                          | 0                                                              | (0.0)                                                          |
| -Life-threatening                                                                       | 19                                                             | (5.1)                                                          | 3                                                              | (1.9)                                                          | 1                                                              | (2.2)                                                          | 0                                                              | (0.0)                                                          |
| discontinued drug due to an adverse event                                               | 22                                                             | (5.9)                                                          | 11                                                             | (7.0)                                                          | 4                                                              | (8.9)                                                          | 0                                                              | (0.0)                                                          |
| Psychiatric disorders a                                                                 | 60                                                             | (16.2)                                                         | 26                                                             | (16.6)                                                         | 5                                                              | (11.1)                                                         | 0                                                              | (0.0)                                                          |
| Nervous system disorders a                                                              | 174                                                            | (47.0)                                                         | 66                                                             | (42.0)                                                         | 15                                                             | (33.3)                                                         | 0                                                              | (0.0)                                                          |
| Accidents and injuries b                                                                | 41                                                             | (11.1)                                                         | 19                                                             | (12.1)                                                         | 5                                                              | (11.1)                                                         | 0                                                              | (0.0)                                                          |
| Cardiac disorders a                                                                     | 35                                                             | (9.5)                                                          | 28                                                             | (17.8)                                                         | 8                                                              | (17.8)                                                         | 0                                                              | (0.0)                                                          |
| Vascular disorders a                                                                    | 50                                                             | (13.5)                                                         | 29                                                             | (18.5)                                                         | 9                                                              | (20.0)                                                         | 0                                                              | (0.0)                                                          |
| Cerebrovascular disorders c                                                             | 11                                                             | (3.0)                                                          | 3                                                              | (1.9)                                                          | 2                                                              | (4.4)                                                          | 0                                                              | (0.0)                                                          |
| Infections and infestations a                                                           | 157                                                            | (42.4)                                                         | 59                                                             | (37.6)                                                         | 16                                                             | (35.6)                                                         | 1                                                              | (25.0)                                                         |
| Anticholinergic syndrome d                                                              | 0                                                              | (0.0)                                                          | 0                                                              | (0.0)                                                          | 0                                                              | (0.0)                                                          | 0                                                              | (0.0)                                                          |
| Quality of life decreased d                                                             | 0                                                              | (0.0)                                                          | 0                                                              | (0.0)                                                          | 0                                                              | (0.0)                                                          | 0                                                              | (0.0)                                                          |
| Sum of postural hypotension, falls, black outs, syncope, dizziness, ataxia, fractures e | 81                                                             | (21.9)                                                         | 36                                                             | (22.9)                                                         | 36                                                             | (80.0)                                                         | 0                                                              | (0.0)                                                          |

a  Based on the respective system organ class.

b  Includes preferred terms listed for 'Accidents and injuries (SMQ)'.

c  Includes preferred terms listed for 'Ischaemic central nervous system vascular conditions (SMQ)', 'Haemorrhagic central nervous system vascular conditions (SMQ)', 'Central nervous system vascular disorders, not specified as haemorrhagic or ischaemic (SMQ)', 'Conditions associated with central nervous system haemorrhages and cerebrovascular accidents (SMQ)'.

d  Based on the respective preferred term.

e  Includes preferred terms 'Orthostatic hypotension', 'Fall', 'Loss of consciousness', 'Amnesia', 'Syncope', 'Dizziness', and all preferred terms associated with high level term 'Coordination and balance disturbances', and all preferred terms associated with high level group term 'Fractures'.

Every patient is counted a single time for each applicable row and column.

Non-serious adverse events up to 30 days of last dose and serious adverse events up to 90 days of last

<div style=\"page-break-after: always\"></div>

dose are included.

- MedDRA preferred terms 'Neoplasm progression', 'Malignant neoplasm progression' and 'Disease progression' not related to the drug are excluded.
- j  Includes all patients who received at least one dose of belzutifan 120 mg QD in MK-6482-001 Part 1A, 1B, MK-6482-004, MK-6482-013, and MK-6482-005 including patients from the Japan safety run-in cohort.

## Gender

Table 82: Adverse Event Summary by Sex (Male, Female) (APaT Population)

|                                                     | MK-6482-005 Data for Belzutifan 120 mg QD   | MK-6482-005 Data for Belzutifan 120 mg QD   | MK-6482-005 Data for Belzutifan 120 mg QD   | MK-6482-005 Data for Belzutifan 120 mg QD   | MK-6482-005Data for Everolimus 10 mg QD   | MK-6482-005Data for Everolimus 10 mg QD   | MK-6482-005Data for Everolimus 10 mg QD   | MK-6482-005Data for Everolimus 10 mg QD   | MK-6482-004 Data for Belzutifan 120 mg QD   | MK-6482-004 Data for Belzutifan 120 mg QD   | MK-6482-004 Data for Belzutifan 120 mg QD   | MK-6482-004 Data for Belzutifan 120 mg QD   | Cumulative Running Safety Dataset for Belzutifan 120 mg QDi   | Cumulative Running Safety Dataset for Belzutifan 120 mg QDi   | Cumulative Running Safety Dataset for Belzutifan 120 mg QDi   | Cumulative Running Safety Dataset for Belzutifan 120 mg QDi   |
|-----------------------------------------------------|---------------------------------------------|---------------------------------------------|---------------------------------------------|---------------------------------------------|-------------------------------------------|-------------------------------------------|-------------------------------------------|-------------------------------------------|---------------------------------------------|---------------------------------------------|---------------------------------------------|---------------------------------------------|---------------------------------------------------------------|---------------------------------------------------------------|---------------------------------------------------------------|---------------------------------------------------------------|
|                                                     | M                                           | M                                           | F                                           | F                                           | M                                         | M                                         | F                                         | F                                         | M                                           | M                                           | F                                           | F                                           | M                                                             | M                                                             | F                                                             | F                                                             |
|                                                     | n                                           | (%)                                         | n                                           | (%)                                         | n                                         | (%)                                       | n                                         | (%)                                       | n                                           | (%)                                         | n                                           | (%)                                         | n                                                             | (%)                                                           | n                                                             | (%)                                                           |
| Participants in population                          | 295                                         |                                             | 77                                          |                                             | 276                                       |                                           | 84                                        |                                           | 32                                          |                                             | 29                                          |                                             | 441                                                           |                                                               | 135                                                           |                                                               |
| with one or more adverse events                     | 292                                         | (99.0)                                      | 77                                          | (100.0)                                     | 273                                       | (98.9)                                    | 84                                        | (100.0)                                   | 32                                          | (100.0)                                     | 29                                          | (100.0)                                     | 437                                                           | (99.1)                                                        | 135                                                           | (100.0)                                                       |
| with no adverse event                               | 3                                           | (1.0)                                       | 0                                           | (0.0)                                       | 3                                         | (1.1)                                     | 0                                         | (0.0)                                     | 0                                           | (0.0)                                       | 0                                           | (0.0)                                       | 4                                                             | (0.9)                                                         | 0                                                             | (0.0)                                                         |
| with drug-related adverse events                    | 259                                         | (87.8)                                      | 72                                          | (93.5)                                      | 245                                       | (88.8)                                    | 77                                        | (91.7)                                    | 32                                          | (100.0)                                     | 29                                          | (100.0)                                     | 397                                                           | (90.0)                                                        | 129                                                           | (95.6)                                                        |
| with toxicity grade 3-5 adverse events              | 178                                         | (60.3)                                      | 52                                          | (67.5)                                      | 173                                       | (62.7)                                    | 52                                        | (61.9)                                    | 11                                          | (34.4)                                      | 16                                          | (55.2)                                      | 269                                                           | (61.0)                                                        | 86                                                            | (63.7)                                                        |
| with toxicity grade 3-5 drug-related adverse events | 108                                         | (36.6)                                      | 36                                          | (46.8)                                      | 109                                       | (39.5)                                    | 33                                        | (39.3)                                    | 2                                           | (6.3)                                       | 9                                           | (31.0)                                      | 161                                                           | (36.5)                                                        | 56                                                            | (41.5)                                                        |
| with serious adverse events                         | 127                                         | (43.1)                                      | 30                                          | (39.0)                                      | 107                                       | (38.8)                                    | 30                                        | (35.7)                                    | 6                                           | (18.8)                                      | 12                                          | (41.4)                                      | 188                                                           | (42.6)                                                        | 48                                                            | (35.6)                                                        |
| with serious drug-related adverse events            | 37                                          | (12.5)                                      | 12                                          | (15.6)                                      | 38                                        | (13.8)                                    | 9                                         | (10.7)                                    | 2                                           | (6.3)                                       | 2                                           | (6.9)                                       | 57                                                            | (12.9)                                                        | 14                                                            | (10.4)                                                        |
| who died                                            | 12                                          | (4.1)                                       | 1                                           | (1.3)                                       | 14                                        | (5.1)                                     | 5                                         | (6.0)                                     | 2                                           | (6.3)                                       | 0                                           | (0.0)                                       | 18                                                            | (4.1)                                                         | 1                                                             | (0.7)                                                         |
| who died due to a drug-related adverse event        | 1                                           | (0.3)                                       | 0                                           | (0.0)                                       | 2                                         | (0.7)                                     | 0                                         | (0.0)                                     | 0                                           | (0.0)                                       | 0                                           | (0.0)                                       | 1                                                             | (0.2)                                                         | 0                                                             | (0.0)                                                         |
| withdosemodificationbdueto an adverse event         | 144                                         | (48.8)                                      | 47                                          | (61.0)                                      | 168                                       | (60.9)                                    | 57                                        | (67.9)                                    | 14                                          | (43.8)                                      | 18                                          | (62.1)                                      | 216                                                           | (49.0)                                                        | 72                                                            | (53.3)                                                        |
| with dose interruption due to an adverse event      | 124                                         | (42.0)                                      | 38                                          | (49.4)                                      | 130                                       | (47.1)                                    | 43                                        | (51.2)                                    | 11                                          | (34.4)                                      | 15                                          | (51.7)                                      | 178                                                           | (40.4)                                                        | 57                                                            | (42.2)                                                        |
| withdosereductionduetoan adverseevent               | 37                                          | (12.5)                                      | 15                                          | (19.5)                                      | 42                                        | (15.2)                                    | 11                                        | (13.1)                                    | 2                                           | (6.3)                                       | 8                                           | (27.6)                                      | 61                                                            | (13.8)                                                        | 28                                                            | (20.7)                                                        |
| discontinueddrugduetoan adverseevent                | 18                                          | (6.1)                                       | 4                                           | (5.2)                                       | 38                                        | (13.8)                                    | 15                                        | (17.9)                                    | 4                                           | (12.5)                                      | 0                                           | (0.0)                                       | 33                                                            | (7.5)                                                         | 4                                                             | (3.0)                                                         |
| discontinued drug due to a serious adverse event    | 14                                          | (4.7)                                       | 2                                           | (2.6)                                       | 23                                        | (8.3)                                     | 7                                         | (8.3)                                     | 3                                           | (9.4)                                       | 0                                           | (0.0)                                       | 25                                                            | (5.7)                                                         | 2                                                             | (1.5)                                                         |

aDeterminedby the investigator toberelated to thedrug.

Non-serious adverse events up to 30 days of last dose and serious adverse events up to 90 days of last dose are included.

b Defined as an action taken of dose reduced, drug interrupted or drug withdrawn.

MedDRA 26.0 preferred terms \"Neoplasm Progression\", \"Malignant Neoplasm Progression\" and \"Disease Progression\" not related to the drug are excluded.

Grades are based on NCI CTCAE version 5.0 for MK-6482-005 and MK-6482-013 and version 4.03 for all other studies.

j Includes all participants who received at least one dose of belzutifan 120 mg QD in MK-6482-001 Part 1A, 1B, MK-6482-004, MK-6482-013, and MK-6482-005 including participants from the Japan safety run-in cohort.

In the CRSD, 23.4% of patients were female. All between-group differences in safety parameters were &lt;10%.

## Race

No analysis of safety data per race category was provided for the CSRD.

<div style=\"page-break-after: always\"></div>

ECOG-PS

## Table 83: Adverse Event Summary by ECOG Status Category (0, 1, 2) (APaT Population)

|                                                     | Cumulative Running Safety Dataset for Belzutifan 120 mg QDi   | Cumulative Running Safety Dataset for Belzutifan 120 mg QDi   | Cumulative Running Safety Dataset for Belzutifan 120 mg QDi   | Cumulative Running Safety Dataset for Belzutifan 120 mg QDi   | Cumulative Running Safety Dataset for Belzutifan 120 mg QDi   | Cumulative Running Safety Dataset for Belzutifan 120 mg QDi   |
|-----------------------------------------------------|---------------------------------------------------------------|---------------------------------------------------------------|---------------------------------------------------------------|---------------------------------------------------------------|---------------------------------------------------------------|---------------------------------------------------------------|
|                                                     | [0] Normal Activity                                           | [0] Normal Activity                                           | [1] Symptoms, but ambulatory                                  | [1] Symptoms, but ambulatory                                  | [2] Ambulatory but unable to work                             | [2] Ambulatory but unable to work                             |
|                                                     | n                                                             | (%)                                                           | n                                                             | (%)                                                           | n                                                             | (%)                                                           |
| Participants in population                          | 278                                                           |                                                               | 288                                                           |                                                               | 10                                                            |                                                               |
| with one or more adverse events                     | 277                                                           | (99.6)                                                        | 285                                                           | (99.0)                                                        | 10                                                            | (100.0)                                                       |
| with no adverse event                               | 1                                                             | (0.4)                                                         | 3                                                             | (1.0)                                                         | 0                                                             | (0.0)                                                         |
| with drug-related? adverse events                   | 256                                                           | (92.1)                                                        | 260                                                           | (90.3)                                                        | 10                                                            | (100.0)                                                       |
| with toxicity grade 3-5 adverse events              | 139                                                           | (50.0)                                                        | 209                                                           | (72.6)                                                        | 7                                                             | (70.0)                                                        |
| with toxicity grade 3-5 drug-related adverse events | 88                                                            | (31.7)                                                        | 124                                                           | (43.1)                                                        | 5                                                             | (50.0)                                                        |
| with serious adverse events                         | 92                                                            | (33.1)                                                        | 138                                                           | (47.9)                                                        | 6                                                             | (60.0)                                                        |
| with serious drug-related adverse events            | 29                                                            | (10.4)                                                        | 40                                                            | (13.9)                                                        | 2                                                             | (20.0)                                                        |
| who died                                            | 5                                                             | (1.8)                                                         | 14                                                            | (4.9)                                                         | 0                                                             | (0.0)                                                         |
| who died due to a drug-related adverse event        | 1                                                             | (0.4)                                                         | 0                                                             | (0.0)                                                         | 0                                                             | (0.0)                                                         |
| with dose modificationb due to an adverse event     | 122                                                           | (43.9)                                                        | 161                                                           | (55.9)                                                        | 5                                                             | (50.0)                                                        |
| withdoseinterruptionduetoanadverseevent             | 98                                                            | (35.3)                                                        | 133                                                           | (46.2)                                                        | 4                                                             | (40.0)                                                        |
| with dose reduction due to an adverse event         | 39                                                            | (14.0)                                                        | 47                                                            | (16.3)                                                        | 3                                                             | (30.0)                                                        |
| discontinued drug due to an adverse event           | 9                                                             | (3.2)                                                         | 28                                                            | (9.7)                                                         | 0                                                             | (0.0)                                                         |

MedDRA 26.0 preferred terms \"Neoplasm Progression\", \"Malignant Neoplasm Progression\" and \"Disease Progression\" not related to the drug are excluded.

Grades are based on NCI CTCAE version 5.0for MK-6482-005 and MK-6482-013 and version 4.03for all other studies.

j Includes all participants who received at least one dose of belzutifan 120 mg QD in MK-6482-001 Part 1A, 1B, MK-6482-004, MK-6482-013, and MK-6482-005 including participants from the Japan safety run-in cohort.

In the CRSD, almost all patients had an ECOG PS of 0 (48.2%) or 1 (50%); there were 10 patients with an ECOG PS of 2 (1.7%). There were more drug-related grade 3-5 AEs and dose modifications due to an AE for patients with a worse ECOG PS.

## Renal and hepatic impairment

## Safety in patients with mild to moderate renal impairment

Based on the eligibility criteria, patients with severe renal impairment (eGFR &lt;30 ml/min) were excluded from the belzutifan clinical studies. Safety data is, therefore, only available for patients with mild to moderate renal impairment, i.e. with a CrCl &lt;60 ml/min. Patients with a CrCl &lt;60 ml/min (nr 181) had a similar rate of AEs compared to patients with a CrCl ≥60 ml/min (nr 395), but numerically more anaemia (90.1% vs. 80.0%, respectively). They also had numerically more grade 3-5 AEs (67.4% vs. 59.0%, respectively; primarily due to anaemia: 37.6% vs. 24.6%), and dose modifications due to an AE (56.9% vs. 46.8%, respectively; primarily due to anaemia: 18.2% vs. 7.3%) but not discontinuations (7.7% vs. 5.8%, respectively).

## Safety in patients with mild hepatic impairment

Based on the eligibility criteria, patients with moderate to severe hepatic impairment were excluded from the belzutifan clinical studies. Safety data is, therefore, only available for patients with mild hepatic impairment, i.e. with abnormal hepatic funct ion based on the used criteria (AST, ALT, or bilirubin Grade ≥1).

The safety in the 50 patients with abnormal hepatic function (AST, ALT, or bilirubin Grade ≥1) were

<div style=\"page-break-after: always\"></div>

compared to 526 patients with normal hepatic function. Both patient subgroups had similar rates of AEs across all AE categories.

## 2.6.8.5. Discontinuation due to adverse events

## AEs leading to discontinuation

The overall percentage of patients with AEs resulting in treatment discontinuation was 5.9% for the belzutifan group and 14.7% for the everolimus group; 6.6% in Study 004; and 6.4% in the CRSD.

AEs leading to treatment discontinuation reported in ≥1% of patients were pneumonitis none in the belzutifan group, (4.4%) in the everolimus group; toxicity due to various agents, dizziness, haemorrhage intracranial, and suicide attempt (1.6% each) in Study 004; and hypoxia (1.4%) in the CRSD.

The percentage of patients with drug-related AEs that led to treatment discontinuation was 2.7% for the belzutifan group and 10.6% for the everolimus group; 3.3% in Study 004; and 3.1% in the CSRD.

In Study 005, the most frequently reported (≥0.5% of patients) drug -related AE leading to discontinuation in the belzutifan group was hypoxia (0.8%); and in the everolimus group these AEs were pneumonitis (4.4%), blood creatinine increased (0.6%), and anaemia (0.6%).

In Study 004, the most frequently reported (≥0 .5% of patients) drug-related AE leading to discontinuation were dizziness (1.6%) and haemorrhage intracranial (1.6%).

In the CSRD, the most frequently reported (≥0.5% of patients) drug -related AE leading to discontinuation was hypoxia (1.4%).

## AEs leading to dose reduction

The overall percentage of patients with AEs leading to a dose reduction was 14.0% for the belzutifan group and 14.7% for the everolimus group, 16.4% in Study 004, and 15.5% in the CRSD. In Study 005, the most frequently reported (≥2.0% of patients) AEs leading to a dose reduction in the belzutifan group were hypoxia (5.6%) and anaemia (3.0%); and in the everolimus group stomatitis (2.8%).

In Study 004, the most frequently reported AEs (≥2 .0% of patients) leading to a dose reduction were fatigue (8.2%) and anaemia (3.3%).

In the CRSD, the most frequently reported AEs (≥2.0% of patients) leading to a dose reduction were hypoxia (6.3%) and anaemia (3.8%).

The overall percentage of patients with drug-related AEs leading to a dose reduction was 11.8% for the belzutifan group and 14.4% for the everolimus group, 13.1% in Study 004, and 13.4% in the CRSD. The most frequently reported drug-related AEs leading to a dose reduction (and their observed rates) across the safety datasets were very similar to as described above for the AEs regardless of causality leading to a dose reduction (data not shown).

## AEs leading to dose interruption

The overall percentage of patients with AEs leading to a dose interruption was 43.5% for the belzutifan group and 48.1% for the everolimus group, 42.6% in Study 004, and 40.8% in the CRSD).

In Study 005, the most frequently reported (≥5% of patients) AEs leading to a dose interruption in the belzutifan group were anaemia (8.6%) and hypoxia (5.6%); and in the everolimus group stomatitis (7.8%).

In Study 004, the mo st frequently reported (≥5% of patients) AEs leading to a dose interruption were fatigue (11.5%), nausea (9.8%), and headache (6.6%).

In the CRSD, the most frequently reported (≥5% of patients) AEs leading to a dose interruption were anaemia (6.9%) and hypoxia (5.4%).

<div style=\"page-break-after: always\"></div>

The overall percentage of patients with drug-related AEs leading to a dose interruption was 21.5% for the belzutifan group and 36.7% for the everolimus group, 21.3% in Study 004, and 20.0% in the CRSD. The most frequently reported drug-related AEs leading to a dose interruption (and their observed rates) across the safety datasets were very similar to as described above for the AEs regardless of causality leading to a dose reduction (data not shown).

Table 90 shows the most common drug-related AEs resulting in treatment modification, i.e., discontinuations, dose reductions, and dose interruptions combined) across the safety datasets.

Table 84: Patients With Drug-Related Adverse Events Resulting in Treatment Modification by Decreasing Incidence of Preferred Term (Incidence &gt; 1 Patient in CRSD) (APaT Population)

|                                      | MK-6482-005 Data for Belzutifan 120 mg QD   | MK-6482-005 Data for Belzutifan 120 mg QD   | MK-6482-005 Data for Everolimus 10 mg QD   | MK-6482-005 Data for Everolimus 10 mg QD   | MK-6482-004 Data for Belzutifan 120 mg QD   | MK-6482-004 Data for Belzutifan 120 mg QD   | Cumulative Running Safety Dataset for Belzutifan 120 mg QDi   | Cumulative Running Safety Dataset for Belzutifan 120 mg QDi   |
|--------------------------------------|---------------------------------------------|---------------------------------------------|--------------------------------------------|--------------------------------------------|---------------------------------------------|---------------------------------------------|---------------------------------------------------------------|---------------------------------------------------------------|
|                                      | n                                           | (%)                                         | n                                          | (%)                                        | n                                           | (%)                                         | n                                                             | (%)                                                           |
| Participants in population           | 372                                         |                                             | 360                                        |                                            | 61                                          |                                             | 576                                                           |                                                               |
| with one or more adverse events      | III                                         | (29.8)                                      | 182                                        | (50.6)                                     | 18                                          | (29.5)                                      | 170                                                           | (29.5)                                                        |
| with no adverse events               | 261                                         | (70.2)                                      | 178                                        | (49.4)                                     | 43                                          | (70.5)                                      | 406                                                           | (70.5)                                                        |
| Hypoxia                              | 34                                          | (9.1)                                       | 0                                          | (0.0)                                      |                                             | (1.6)                                       | 58                                                            | (10.1)                                                        |
| Anaemia                              | 36                                          | (9.7)                                       | 12                                         | (3.3)                                      | 4                                           | (6.6)                                       | 54                                                            | (9.4)                                                         |
| Fatigue                              | 9                                           | (2.4)                                       | 10                                         | (2.8)                                      | 9                                           | (14.8)                                      | 21                                                            | (3.6)                                                         |
| Nausea                               | 3                                           | (0.8)                                       | 1                                          | (0.3)                                      | 4                                           | (6.6)                                       | 10                                                            | (1.7)                                                         |
| Aspartate aminotransferase increased | 7                                           | (1.9)                                       | 3                                          | (0.8)                                      | 0                                           | (0.0)                                       | 9                                                             | (1.6)                                                         |
| Alanine aminotransferase increased   | 5                                           | (1.3)                                       | 4                                          | (1.1)                                      | 0                                           | (0.0)                                       | 8                                                             | (1.4)                                                         |
| Dyspnoea                             | 5                                           | (1.3)                                       | 4                                          | (1.1)                                      | 0                                           | (0.0)                                       | 8                                                             | (1.4)                                                         |
| Dizziness                            | 5                                           | (1.3)                                       | 0                                          | (0.0)                                      | 2                                           | (3.3)                                       | 7                                                             | (1.2)                                                         |
| Diarrhoea                            | 6                                           | (1.6)                                       | 7                                          | (1.9)                                      | 0                                           | (0.0)                                       | 6                                                             | (1.0)                                                         |
| Asthenia                             | 4                                           | (1.1)                                       | 7                                          | (1.9)                                      | 0                                           | (0.0)                                       | 4                                                             | (0.7)                                                         |
| Headache                             | 1                                           | (0.3)                                       | 0                                          | (0.0)                                      | 2                                           | (3.3)                                       | 4                                                             | (0.7)                                                         |
| Platelet count decreased             | 3                                           | (0.8)                                       | 6                                          | (1.7)                                      | 0                                           | (0.0)                                       | 3                                                             | (0.5)                                                         |
| Pleural effusion                     | 3                                           | (0.8)                                       | 1                                          | (0.3)                                      | 0                                           | (0.0)                                       | 3                                                             | (0.5)                                                         |
| Pneumonitis                          | 1                                           | (0.3)                                       | 33                                         | (9.2)                                      | 0                                           | (0.0)                                       | 3                                                             | (0.5)                                                         |
| Vomiting                             | 1                                           | (0.3)                                       | 4                                          | (1.1)                                      | 1                                           | (1.6)                                       | 3                                                             | (0.5)                                                         |
| Abdominal pain                       | 1                                           | (0.3)                                       | 1                                          | (0.3)                                      | 1                                           | (1.6)                                       | 2                                                             | (0.3)                                                         |
| Blood alkaline phosphatase increased | 1                                           | (0.3)                                       | 1                                          | (0.3)                                      | 0                                           | (0.0)                                       | 2                                                             | (0.3)                                                         |
| Blood creatinine increased           | 2                                           | (0.5)                                       | 7                                          | (1.9)                                      | 0                                           | (0.0)                                       | 2                                                             | (0.3)                                                         |
| Pyrexia                              | 一                                           | (0.3)                                       | 2                                          | (0.6)                                      | 0                                           | (0.0)                                       | 2                                                             | (0.3)                                                         |
| Rash                                 | 2                                           | (0.5)                                       | 11                                         | (3.1)                                      | 0                                           | (0.0)                                       | 2                                                             | (0.3)                                                         |
| Thrombocytopenia                     | 2                                           | (0.5)                                       | 4                                          | (1.1)                                      | 0                                           | (0.0)                                       | 2                                                             | (0.3)                                                         |

## 2.6.8.6. Post marketing experience

Belzutifan is not currently approved in the EU, thus post marketing experience in the EU is not applicable to the current MAA. Belzutifan is, however, approved in the US, Great Britain, and several other countries for the indication of VHL-associated RCC, CNS-HBs, and pNET in certain patients. As of the data cutoff date, there are no records of any belzutifan registration being revoked or withdrawn for safety reasons in any of the currently approved countries.

The most recent global Periodic Safety Update Report (PSUR) covered data from the reporting interval of 13FEB-2024 to 12-AUG-2024. During this reporting interval, safety (and efficacy) information that became available continued to support the previously established positive benefit-risk profile for belzutifan in the approved indications.

<div style=\"page-break-after: always\"></div>

## 2.6.9. Discussion on clinical safety

The analysis of safety of belzutifan is based on the pooled safety data in the cumulative running safety dataset (CRSD; n=576), which includes 372 patients with advanced RCC from Study 005 and 61 patients with VHL disease from Study 004, as well as 58 patients with advanced solid tumours from the phase 1 study MK-6482-001 (Study 001) and 76 patients with advanced RCC from the phase 2 study MK-6482-013 (Study 013). The CRSD, therefore, mainly includes patients with advanced RCC (88.9%) and only 61 patients (10.6%) with VHL disease. The impact of these relatively few patients with VHL disease on the overall safety profile will thus be limited.

The observed safety profile of belzutifan has been consistent between study populations and the pooling strategy in the form of the CRSD is, therefore, supported.

The majority of patients in the CRSD were male (76.6%) and White (82.5%); the median age was 61.0 years, with 35.8% and 8.5% ≥65 and ≥75 years old, respectively; 48.3% and 50.0% of patients had an ECOG PS of 0 and 1, respectively; and 39.2% and 38.4% of patients were from Western Europe and North America, respectively.

The median duration of exposure in the CSRD was 9.2 months. The number of patients who received study drug for ≥12 months and ≥24 months, respectively, was 254 and 115. In line with ICH/EMA guidance (CPMP/ICH/375/95), the CRSD (n=576) - with more than half of patients from a phase 3 randomized controlled trial - is considered of sufficient size for B/R assessment. The median duration of exposure in the CRSD - with &gt;250 patients treated ≥12 months - can generally be considered sufficient, certainly for the advanced RCC indication where both expected time on therapy and overall life expectancy are rather short. For the VHL indication, however, a relatively long treatment duration (many years) is expected. From that perspective, long-term safety data are rather scarce, with very few patients (n=2) who received belzutifan ≥42 months. It is therefore supported that long -term safety is included in the RMP as missing information.

The most common AEs of any grade in the CRSD were anaemia (84.2%), fatigue (42.7%), nausea (24.1%), dyspnoea (21.4%), headache (19.1%), constipation (18.2%), arthralgia (17.9%), dizziness (17.9%), peripheral oedema (17.7%) and hypoxia (16.3%). Particularly the frequencies of anaemia, dizziness and hypoxia were higher for belzutifan compared to everolimus in Study 005 (between-group difference of &gt;10%).

The most common any-grade drug-related AEs, as assessed by the investigator, were anaemia (74.3%), fatigue (32.3%), nausea (13.5), and hypoxia (13.4%). Dizziness was considered drug-related in 7.5% of cases in the CRSD. These AEs are all related to the mechanism of action of belzutifan.

Anaemia and hypoxia were also the most frequent grade 3-5 AEs, in 28.6% (assessed as drug-related by the investigator in 24.3%) and 12.2% (drug-related in 9.9%) of the CRSD, respectively.

Based on the provided summary of most common AEs (of any grade and grade 3 or higher), the causality assessment by the investigator, and the mechanism of action, the selection of anaemia, hypoxia, dyspnoea, fatigue, nausea and dizziness as ADRs is understood. Weight increased was added as an ADR based on a signal from Study 005 assessed in a recent PSUR. This is acknowledged.

Serious AEs occurred in 41.0% of the CRSD (drug-related in 12.3%), most commonly hypoxia (7.1%; drugrelated 5.4%) and anaemia (4.7%, drug-related 3.5%).

In the CRSD, there were 19 patients with an AE resulting in death (3.3%). There was one AE resulting in death that was considered drug-related by the investigator, which was a case of multi organ dysfunction

<div style=\"page-break-after: always\"></div>

syndrome. A contribution of belzutifan to the death of this patient cannot be excluded, however, other factors such as infectious complications appear to have also played a role. Anaemia and hypoxia caused by belzutifan might have contributed to the clinical deterioration of the patient. Progression of the underlying disease was likely the main cause of the fatal respiratory failure.

Anaemia and hypoxia were identified as the most important adverse drug reactions of special interest. They are the most common high-grade AEs and/or serious AEs and were the most frequent AEs leading to treatment modifications. Both relate to the mechanism of action of belzutifan.

Anaemia led to dose modifications in 10.9% of patients in the CRSD, while only two patients (0.3%) discontinued belzutifan because of anaemia. From the patients with anaemia, this ADR was handled with a dose reduction in (22/485) 4.5% of cases. Of the 485 patients with anaemia, 22.9% were treated with ESA only, 17.5% were treated with blood transfusion only, and 12.8% were treated with ESA and blood transfusion. Patients should be monitored for anaemia before initiation of and periodically throughout treatment with belzutifan. For patients who develop Grade 3 anaemia, belzutifan should be withheld and patients should be treated according to standard medical practice, including ESA administration until resolved to ≤ Grade 2. For recurrent Grade 3 anaemia, bel zutifan should be discontinued. For patients who develop Grade 4 anaemia, belzutifan should be withheld and permanently discontinued for recurrent Grade 4 anaemia (see sections 4.2, 4.4 and 4.8 of the SmPC).

Hypoxia was often managed by dose modifications (in 66/94 = 70.2% of patients with this ADR), i.e., in 11.5% of patients in the CRSD. Eight patients in the CRSD discontinued belzutifan because of hypoxia (1.4%). Of the 94 patients with hypoxia, 70.2% received oxygen therapy. Patients should be monitored for oxygen saturation with pulse oximetry before initiation of and periodically throughout treatment with belzutifan. For Grade 3 asymptomatic hypoxia, providing supplemental oxygen and continuing or withholding treatment should be considered. If withheld, belzutifan should be resumed at a reduced dose. For patients who have Grade 3 symptomatic hypoxia, belzutifan should be withheld, hypoxia should be treated, and belzutifan should be resumed at a reduced dose. If symptomatic hypoxia continues to recur, treatment should be discontinued. For Grade 4 hypoxia, treatment should be permanently discontinued (see sections 4.2, 4.4 and 4.8 of the SmPC).

In Study 004, there were two SAEs of intracranial haemorrhage in patients with CNS-HB, of which one was considered drug-related and led to treatment discontinuation. These two cases of CNS-bleeding are, however, less likely to be associated to belzutifan treatment, because the events occurred late in the treatment course in patients that were also on anticoagulant therapy. In the literature, there have been at least two other cases presented of patients experiencing a CNS bleeding after initiation of treatment with belzutifan (Saeed et al. JCO Precis Oncol. 2023 [fatal]; Trinh et al. Clin Cancer Res. 2023). In both case reports, the CNS bleeding was shortly after starting belzutifan treatment and confounding factors were described. A thorough review of all cases of CNS bleeding in patients with CNS haemangioblastoma from all sources, e.g., clinical studies, literature, and including cases from post-marketing sources (spontaneous and solicited sources) were provided during the assessment. An additional case of a serious CNS-bleed shortly after the start of belzutifan treatment was retrieved from a post-marketing source. For this case, no other confounding factors were described.

In conclusion, three cases of serious (one fatal) CNS bleeding have been reported in patients with VHL-associated CNS-HB shortly after starting belzutifan treatment, in which a causal relationship is likely. These bleedings could have been the result of tumour response upon belzutifan treatment and as such not related to the mechanism of action of belzutifan per se. This was included as an important potential risk in the RMP, and a warning was added in the SmPC that physicians should be cautious of symptoms or signs of

<div style=\"page-break-after: always\"></div>

CNS haemorrhage in patients with VHL disease-associated CNS-HB being treated with belzutifan (see sections 4.2, 4.4 and 4.8 of the SmPC).

Haemorrhagic events were reported in patients with advanced RCC in Study 005 in a similar frequency for belzutifan (47/372=12.6%; data not shown) and everolimus (45/360=12.5%; data not shown), with numerically more grade 3-5 events for belzutifan (3.8% vs 1.1%, respectively; data not shown). Taking into account that:

- -'haemorrhage' is a listed ADR for Afinitor (Afinitor SmPC section 4.8, frequency 'common'); and
- -according to the Welireg USPI in 3% of patients in Study 005 receiving belzutifan a serious adverse reactions of haemorrhage occurred, with a fatal adverse reaction in 0.5%, and clinically relevant adverse reactions included haemorrhage in 9%, including intracranial/cerebral haemorrhage in 0.8%;

A causal association between belzutifan and haemorrhage was further discussed. The provided summary of haemorrhagic events across the four belzutifan monotherapy studies in advanced RCC shows an overall rate of 14.6% (89/610) reported events within the Haemorrhages SMQ (data not shown).

No dose response for haemorrhagic events was evident in Study 013 (of 200 mg QD vs the proposed posology of 120 mg QD), but this also does not preclude haemorrhage being a belzutifan ADR.

Of note, the most reported haemorrhagic event in Study 005 with belzutifan was haematuria (3.2% vs 1.4 with everolimus). There were two events of 'Haemorrhage intracranial', i.e., one grade 2 and one grade 4, and a single event of grade 3 'Cerebral haemorrhage' (vs no cases with everolimus). In all three cases, an effect of belzutifan cannot be excluded.

That fact that the majority of cases of haemorrhagic events were grade 1-2 and did not lead to discontinuation of study treatment, does not preclude haemorrhage being a belzutifan ADR.

All in all, this warrants including in section 4.8 of the SmPC the ADR 'Haemorrhage', including different bleeding events from different sites not listed individually.

The percentage of patients in the CRSD requiring a dose modification (interruption in 20.0%; reduction in 13.4%) due to a drug-related AE is considered acceptable. Treatment only had to be discontinued due to a drug-related AE in 3.1% of patients in the CRSD.

The most frequently reported drug-related AEs leading to a dose interruption in the CRSD were anaemia (7.1%) and hypoxia (5.4%).

In the CRSD, the most frequently reported drug-related AEs leading to dose reduction were hypoxia (6.3%) and anaemia (3.8%).

In the CRSD, the most frequently reported drug-related AE leading to discontinuation was hypoxia (1.4%).

AE summaries by the intrinsic factors age, gender and ECOG-PS were provided.

Age - Of the 576 patients in the CRSD, 370 were &lt;65 (64.2%), 157 were aged 65-74 (27.2%), 45 were aged 7584 (7.8%) and 4 were aged ≥85 years (0.7%). Patients &gt;65 years had a higher percentage of grade 3 -5 drug-related AEs than patients &lt;65 years of age (49.0% vs 31.4%). This can be explained by the higher incidence of grade 3 anaemia and hypoxia in patients &gt;65 years of age, as there were no cases of grade 4 or 5 anaemia or hypoxia in these patients. Dose modifications (mainly interruptions) also appeared to be more frequent in the higher age categories. Regarding safety by age category in the CRSD, the frequency of AEs and SAEs reported in patients younger than 75 years of age compared to those ≥75 years of age were generally similar. However, given the difference in sample size across the different age categories (with small

<div style=\"page-break-after: always\"></div>

sample size in the 75 to 84 and ≥85 years of age categories), comparisons and interpretability of the data are limited. Therefore, no final conclusions can be made from the analysis of SAEs by age category in the CRSD.

Gender - In the CRSD, 23.4% of patients were female. All between-group differences in safety parameters were &lt;10%.

Race - No analysis of safety data per race category was provided for the CSRD. However, as most of the patients were White (82.5%), and the other race categories were very small (Asian 9.5%, all other categories &lt;2%), this is acceptable.

ECOG PS - In the CRSD, almost all patients had an ECOG PS of 0 (48.2%) or 1 (50%); there were 10 patients with an ECOG PS of 2 (1.7%). There were more drug-related grade 3-5 AEs and dose modifications due to an AE for patients with a worse ECOG PS. This is as expected.

Regarding safety data in patients with renal or hepatic impairment, (excluding the [very] limited safety data from the two small, single-dose PK studies [Study 020 and Study 021]) the incidences of AEs and SAEs reported were generally similar between patients enrolled in belzutifan clinical trials with and without renal and hepatic impairment. The percentages of patients with Grade 3 to 5 AEs of anaemia and AEs of anaemia leading to dose modification were higher in patients with abnormal renal function at baseline (CrCl &lt;60 mL/min) than in patients with normal renal function at baseline. These differences may have been influenced by the association between decreased kidney function and anaemia.

All in all, the applicant has sufficiently substantiated the dosing recommendations in the SmPC. There are no safety data on the use of belzutifan in pregnant women, lactating women, or patients younger than 18 years of age, as these patients' categories were excluded from the clinical studies. This is, however, adequately reflected in the SmPC section 4.6.

Assessment of laboratory parameters across the safety datasets did not reveal any unexpected findings.

To support the proposed ADRs in section 4.8 of the SmPC, the applicant presented the methodology used to define ADRs and calculate ADR frequencies based on a pooled analysis of the safety data reflecting the CRSD.

## Additional safety data needed in the context of a conditional MA

Long-term safety data is rather scarce, and this is relevant given the anticipated long-term use of belzutifan in VHL patients. Long term safety data will be provided subject to specific obligations laid down in the MA (SOB 1 and SOB 2).

## 2.6.10. Conclusions on the clinical safety

In the CRSD, 91.3% of patients treated with belzutifan experienced drug-related AEs, 37.7% drug-related grade 3-5 AEs, and 12.3% drug-related SAEs, the overall toxicity profile of belzutifan is considered nonnegligible. This toxicity seems, however, manageable with dose modifications, seeing the low and thus acceptable rate of drug-related AEs leading to discontinuation (3.1%) in the CRSD.

The most common significant toxicities from belzutifan treatment are anaemia and hypoxia, which can be explained by the mechanism of action. These AEs led to treatment modifications in only a small percentage of patients and sufficient information on the management of these AEs is included in the SmPC.

<div style=\"page-break-after: always\"></div>

Long-term safety data is rather scarce, and this is relevant given the anticipated long-term use of belzutifan in VHL patients.

The CHMP considers the following measures (SOBs) necessary to address the missing safety data in the context of a conditional MA:

- In order to confirm the efficacy and safety of belzutifan as monotherapy for the treatment of adult patients with von Hippel-Lindau disease who require therapy for associated, localised renal cell carcinoma (RCC), central nervous system (CNS) haemangioblastomas, or pancreatic neuroendocrine tumours (pNET), and for whom localised procedures are unsuitable, the MAH should submit the final results of the ongoing study MK6482-004, an open-label Phase II single-arm study to further investigate the long-term efficacy and safety of belzutifan for the treatment of von Hippel-Lindau disease-associated Renal Cell Carcinoma.
- In order to confirm the efficacy and safety of belzutifan as monotherapy for the treatment of adult patients with von Hippel-Lindau disease who require therapy for associated, localised RCC, CNS haemangioblastomas, or pNET, and for whom localised procedures are unsuitable, the MAH should submit efficacy and safety data from at least 64 patients with at least 24 months follow-up of cohort B1 for the ongoing study MK-6482-015, an uncontrolled Phase II study to evaluate the efficacy and safety of belzutifan in patients with von Hippel Lindau disease-associated tumours who have at least 1 measurable RCC, pNET, or pheochromocytoma/paraganglioma (PPGL) tumour.

## 2.7. Risk Management Plan

## Summary of Safety Concerns

The applicant proposes the following summary of safety concerns in the RMP:

| Summary of safety concerns   | Summary of safety concerns                                                       |
|------------------------------|----------------------------------------------------------------------------------|
| Important identified risks   | None                                                                             |
| Important potential risks    | CNS Haemorrhage in VHL patients with CNS haemangioblastoma Embryo-fetal toxicity |
| Missing information          | Long-term safety                                                                 |

## Pharmacovigilance plan

Table 85 Planned and on-going post-authorisation efficacy studies that are conditions of the marketing authorisation or that are specific obligations.

| CoStudy status                                                                                                                                                       | Summary of Objectives                                                                                                                                                | Efficacy uncertainties addressed                                                                                                                                     | Milestones                                                                                                                                                           | Due dates                                                                                                                                                            |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Efficacy studies which are Specific Obligations in the context of a conditional marketing authorisation or a marketing authorisation under exceptional circumstances | Efficacy studies which are Specific Obligations in the context of a conditional marketing authorisation or a marketing authorisation under exceptional circumstances | Efficacy studies which are Specific Obligations in the context of a conditional marketing authorisation or a marketing authorisation under exceptional circumstances | Efficacy studies which are Specific Obligations in the context of a conditional marketing authorisation or a marketing authorisation under exceptional circumstances | Efficacy studies which are Specific Obligations in the context of a conditional marketing authorisation or a marketing authorisation under exceptional circumstances |
| An open-label Phase 2 Study to Evaluate Belzutifan for the treatment of Von-                                                                                         | To confirm long term efficacy and safety of belzutifan in participants                                                                                               | Long- term efficacy and safety                                                                                                                                       | Final Analysis                                                                                                                                                       | 1Q 2027                                                                                                                                                              |

<div style=\"page-break-after: always\"></div>

| CoStudy status                                                                                                                                                     | Summary of Objectives                                                                                                                           | Efficacy uncertainties addressed   | Milestones     | Due dates   |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------|----------------|-------------|
| Hippel-Lindau (VHL) Disease-Associated Renal Cell Carcinoma (MK-6482-004) (ongoing)                                                                                | with VHL disease- associated tumours                                                                                                            |                                    |                |             |
| A Phase 2 Study to Evaluate the Efficacy and Safety of Belzutifan Monotherapy in Participants with VHL Disease-Associated Tumors (MK-6482-015 Cohort B1) (ongoing) | To confirm efficacy and safety of belzutifan in at least 64 participants with VHL disease-associated tumours, with at least 24 months follow-up | Additional efficacy and safety     | Interim report | 1Q 2027     |

## 3.4.4 Risk minimisation measures

## 3.4.3.1 Summary table of pharmacovigilance activities and risk minimisation activities by safety concern

## Table 86  Description of Routine Risk Minimisation Measures by Safety Concern

| Safety Concern                                             | Routine Risk Minimisation Activities                                    |
|------------------------------------------------------------|-------------------------------------------------------------------------|
| CNS Haemorrhage in VHL patients with CNS haemangioblastoma | Section 4.8 of the SmPC Section 4 of the Patient Leaflet                |
| Embryo-Fetal Toxicity                                      | Sections 4.3, 4.4, and 4.6 of the SmPC Section 2 of the Patient Leaflet |
| Long term safety                                           | No routine risk minimization measures have been proposed.               |

## 3.4.3.2 Additional risk minimisation measures

## Description of Additional Risk Minimisation Measures by Safety Concern

| Safety Concern        | Additional Risk Minimisation Activities                                                                                                                                                                           |
|-----------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Embryo-fetal toxicity | Proposed Actions: • Safety advice tools: o Patient card o Guide for healthcare professionals Objectives : To minimize the risk of embryo-fetal toxicity. Rationale for the Additional Risk Minimization Activity: |

<div style=\"page-break-after: always\"></div>

To inform patients and educate healthcare professionals of the important potential risk of embryo-fetal toxicity, the need for suitable contraception measures, and the need to discontinue treatment with belzutifan if a pregnancy is planned or a pregnancy is detected.

## Target audience and Planned Distribution Path:

- Female patients of childbearing potential
- Oncologists and other physicians who may prescribe belzutifan to treat female patients of childbearing potential within the approved indication(s)

A package containing a letter explaining the rationale for the educational materials and describing their intended use and a copy of the Guide for healthcare professionals will be distributed to oncologists and other physicians who may prescribe belzutifan to treat female patients of childbearing potential within the approved indication(s). The patient card is provided in the product package. The healthcare professional will be requested in the letter to provide contraceptive counselling to women of childbearing potential prior to the prescription of the product and inform them of the purpose of the patient card.

## Plans to Evaluate the Effectiveness of the Intervention and Criteria for Success:

Clinical features of all reports received describing exposure to belzutifan during pregnancy will be reviewed as part of routine pharmacovigilance processes. An analysis of these cases will be presented in the PSUR, in the context of the guidance within the SmPC, Package Leaflet and additional risk minimization measures, and appropriate measures will be considered if information is obtained that indicates that updates to the risk minimization measures are warranted.

Records will be retained of the distribution of the package containing the educational material to oncologists and other physicians who may prescribe belzutifan to treat female patients of childbearing potential within the approved indication(s).

## 2.7.1. Conclusion on the RMP

The CHMP considers that the risk management plan version 1.0 is acceptable.

## 2.8. Pharmacovigilance

## 2.8.1. Pharmacovigilance system

The CHMP considered that the pharmacovigilance system summary submitted by the applicant fulfils the requirements of Article 8(3) of Directive 2001/83/EC.

## 2.8.2. Periodic Safety Update Reports submission requirements

The requirements for submission of periodic safety update reports for this medicinal product are set out in the Annex II, Section C of the CHMP Opinion. The applicant did request alignment of the PSUR cycle with the international birth date (IBD). The IBD is 13.08.2021. The new EURD list entry will therefore use the IBD to determine the forthcoming Data Lock Points.

<div style=\"page-break-after: always\"></div>

## 2.9. Product information

## 2.9.1. User consultation

The results of the user consultation with target patient groups on the package leaflet submitted by the applicant show that the package leaflet meets the criteria for readability as set out in the Guideline on the readability of the label and package leaflet of medicinal products for human use.

## 2.9.2. Additional monitoring

Pursuant to Article 23(1) of Regulation No (EU) 726/2004, Welireg (Belzutifan) is included in the additional monitoring list as it is approved under a conditional marketing authorisation.

Therefore, the summary of product characteristics and the package leaflet includes a statement that this medicinal product is subject to additional monitoring and that this will allow quick identification of new safety information. The statement is preceded by an inverted equilateral black triangle.

## 3. Benefit-Risk Balance

## 3.1. Therapeutic Context

## 3.1.1. Disease or condition

The final agreed indications are:

## Renal cell carcinoma (RCC)

Welireg is indicated as monotherapy for the treatment of adult patients with advanced clear cell renal cell carcinoma that progressed following two or more lines of therapy that included a PD-(L)1 inhibitor and at least two VEGF-targeted therapies.

## Von Hippel-Lindau (VHL) disease-associated tumours

Welireg is indicated as monotherapy for the treatment of adult patients with von Hippel-Lindau disease who require therapy for associated, localised renal cell carcinoma (RCC), central nervous system (CNS) haemangioblastomas, or pancreatic neuroendocrine tumours (pNET), and for whom localised procedures are unsuitable.

## 3.1.2. Available therapies and unmet medical need

## Advanced RCC

The final agreed indication positions belzutifan in the treatment of advanced ccRCC from 2L+ to 3L+. For this 3L+ disease setting, the current clinical guidelines recommend either a VEGF-targeted therapy not previously administered, belzutifan, or everolimus (ESMO 2024).

## VHL disease

<div style=\"page-break-after: always\"></div>

In the EU, no systemic therapeutic options are approved for treating VHL disease-associated tumours for which localized procedures (such as surgery, radiation, or ablation) are unsuitable or undesirable. While these procedures temporarily address individual tumours, they are not curative, and new tumours continue to occur. There is, therefore, an unmet need for systemic treatment options that would reduce the size and/or reduce the growth rate of VHL tumours and/or delay or obviate the need for surgery, for select patients with VHL disease-associated neoplasms, including RCC, CNS HB, and pNET.

## 3.1.3. Main clinical studies

## Advanced RCC

Study MK-6482-005 (hereafter referred to as Study 005; LITESPARK-005; NCT04195750; EudraCT Number: 2019-003444-72; Choueiri et al. N Engl J Med. 2024) is an open-label, randomized phase 3 study comparing belzutifan vs everolimus in patients with unresectable, locally advanced or metastatic ccRCC that has progressed after prior PD-1/L1 and VEGF-targeted therapies (up to 3 prior treatment regimens).

## VHL disease

Study MK-6482-004 (hereafter referred to as Study 004; LITESPARK-004; NCT03401788; EudraCT Number: 2018-000125-30; Jonasch et al NEJM 2021, Jonasch et al JCO 2022 [abstract], Iliopolous et al JCO 2023 [abstract]) is an ongoing phase 2, single-arm, open-label study to evaluate the efficacy and safety of belzutifan in patients with at least one measurable VHL-RCC, though no greater than 3.0 cm which would require immediate surgery.

## 3.2. Favourable effects

## Advanced RCC - Study 005

In the approved indication of patients that received two or more lines of therapy that included a PD-(L)1 inhibitor and at least two VEGF-targeted therapies, at IA1 (data cut-off date 01-NOV-2022; median duration of follow-up 13.2 months) there was a gain in PFS 'HR' (by BICR per RECIST 1.1) for belzutifan over everolimus: PFS HR 0.73 (95% CI: 0.57, 0.94) with median PFS of 4.6 months (95% CI: 3.5, 7.3) vs 5.4 months (95% CI: 3.8, 6.5), respectively.

At FA (data cut-off date 15-APR-2024; median duration of follow-up 18.9 months) the OS analysis showed similar result for belzutifan and everolimus: OS HR 0.94 (95% CI: 0.74, 1.21) with median OS of 21.8 months (95% CI: 17.4, 25.8) vs 18.1 months (95% CI: 14.2, 23.9), respectively.

At IA1, the ORR was 24.1% (95% CI: 18.1, 30.8; 2.7% CR) in the belzutifan group vs 3.3% (95% CI: 1.2, 7.0; 0% CR) in the everolimus group.

## VHL Disease - Study 004

At the data cutoff date of 01-APR-2022, the median duration of follow-up was 37.7 months.

The ORR (per RECIST 1.1 by IRC) was 63.9% (95% CI: 50.6, 75.8), including 6.6% complete responses, 57.4% partial responses. Median DOR in the responder was not estimable. Based on the Kaplan-Meier curve, 29 patients (93.5%) had a duration of response of at least 18 months.

In the 50 patients with a measurable VHL-associated haemangioblastoma, the ORR was 44.0% (95% CI: 30, 58.7), with 4 complete responses (8%) and 18 partial responses (36%). Median DOR in the 22 responders

<div style=\"page-break-after: always\"></div>

was not estimable. Based on the Kaplan-Meier curve, 14 patients (90.2%) had a duration of response of at least 18 months.

In the 22 patients with a measurable VHL-associated pNET at baseline, the ORR was 90.9% (95% CI: 70.8, 98.9), with 7 complete responses (31.8%) and 13 partial responses (59.1%). Median DOR in the 20 responders was not estimable. Based on the Kaplan-Meier curve, 19 patients (100%) had a duration of response of at least 18 months.

Figures depicting the tumour response of different tumours (RCC, CNS-HB, and/or pNET) that co-manifested in individual patients indicated, in most cases, a concordant reduction in tumour diameter from baseline within a patient. For instance, based on the sum of diameter of target lesions by tumour type in individual patients, of the 41 patients that had more than one tumour type, most (35/41, 85.4%) had concordant responses. Based on measurements of individual lesions (for example two separate pNETs in a single patient), the concordance was 70.7% across different tumour types.

Updated Efficacy data with a median follow-up of 49.7 months (cut-off date 3 Apr 2023) showed an ORR (per RECIST 1.1 by ICR) for VHL-associated RCC of 67.2% (54.0, 78.7), including 11.5% complete responses and 55.7% partial responses. Median DOR in the 39 responders was not estimable. Based on the Kaplan-Meier curve, 32 patients (94.2%) had a duration of response of at least 18 months. Median time to response (TTR) in the 41 responders was 11.1 months.

## 3.3. Uncertainties and limitations about favourable effects

## Advanced RCC

There was no type I error control for the efficacy analyses in the approved indication of patients that received two or more lines of therapy that included a PD-(L)1 inhibitor and at least two VEGF-targeted therapies. The efficacy results in this subgroup are considered exploratory, nevertheless the results were consistent with the primary analysis and are considered reassuring.

Given patients were not followed up after receiving new anticancer therapy and the imbalance in informative censoring between the arms, there is uncertainty in the PFS results. Based on what has been provided with additional analyses, the EMA-preferred treatment effect for PFS (i.e., based on the treatment policy strategy) cannot be estimated but is likely to be weaker than the estimated effect in the primary analysis.

## VHL disease

The main limitations in relation to the efficacy of belzutifan in the VHL indication is the uncontrolled nature of the pivotal evidence (Study 004) which hampers the assessment of the time-to-event endpoint, and the limited number of patients included. Moreover, the efficacy for non-RCC tumours was only a secondary endpoint of Study 004 with data provided from an interim analysis of a small, single-arm study. These limitations will be addressed post authorisation with the submission of longer-term efficacy and safety data from Study 004, projected to be available by Q1 2027 together with the efficacy and safety data for at least 64 additional patients from Study 015 Cohort B1 (SOB).

<div style=\"page-break-after: always\"></div>

## 3.4. Unfavourable effects

The most common AEs of any grade in the CRSD were anaemia (83.2%), fatigue (42.7%), nausea (24.1%), dyspnoea (21.4%), headache (19.1%), constipation (18.2%), arthralgia (17.9%), dizziness (17.9%), peripheral oedema (17.7%) and hypoxia (16.3%).

The most common any-grade drug-related AEs, as assessed by the investigator, were anaemia (74.3%), fatigue (32.3%), nausea (13.5%), and hypoxia (13.4%). Dizziness was considered drug-related in 7.5% of cases in the CRSD. These AEs are all related to the mechanism of action of belzutifan.

Anaemia and hypoxia were also the most frequent grade 3-5 AEs, in 28.6% (assessed as drug-related by the investigator in 24.3%) and 12.2% (drug-related in 9.9%) of the CRSD, respectively.

Serious AEs occurred in 41.0% of the CRSD (drug-related in 12.3%), most commonly hypoxia (7.1%; drugrelated 5.4%) and anaemia (4.7%, drug-related 3.5%).

In Study 004, there were two SAEs of intracranial haemorrhage, one of which was considered drug-related and led to treatment discontinuation.

In the CRSD, there were 19 patients with an AE resulting in death (3.3%). One AE resulted in death that was considered drug-related by the investigator.

The percentage of patients in the CRSD requiring a dose modification due to a drug-related AE were dose interruption in 20.0%; dose reduction in 13.4%; and discontinuation in 3.1% of patients.

The most frequently reported drug-related AEs leading to a dose interruption were anaemia (5.6%) and hypoxia (4.0%).

The most frequently reported drug-related AEs leading to dose reduction were hypoxia (6.1%) and anaemia (3.8%).

The most frequently reported drug-related AE leading to discontinuation was hypoxia (1.4%).

Regarding the intrinsic factor age, patients &gt;65 years old in the CRSD had a higher percentage of grade 3-5 drug-related AEs than patients &lt;65 years of age (49.0% vs 31.4%, respectively). This can be explained by the higher incidence of grade 3 anaemia and hypoxia in patients &gt;65 years of age, as there were no cases of grade 4 or 5 anaemia or hypoxia in these patients.

Anaemia led to dose modifications in 10.9% of patients in the CRSD and the discontinuation of two patients (0.3%). Among the patients with anaemia in the CRSD, this ADR was handled with a dose reduction in 4.5% of cases.

In the CRSD, 22.9% of the patients with anaemia, were treated with ESA only, 17.5% were treated with blood transfusion only, and 12.8% were treated with ESA and blood transfusion.

Hypoxia led to dose modifications in 11.5% of patients in the CRSD and 8 patients (1.4%) discontinued belzutifan because of hypoxia. Among the patients with hypoxia in the CRSD, this ADR was handled with a dose reduction in 38.3% of cases.

In the CRSD, 70.2% of the patients with hypoxia received oxygen therapy.

Haemorrhagic events were reported in 14.6% (89/610) of patients across the four belzutifan monotherapy studies in advanced RCC.

<div style=\"page-break-after: always\"></div>

Three cases of serious (one fatal) CNS bleeding have been reported in patients with VHL-associated CNS-HB shortly after starting belzutifan treatment, in which a causal relationship is not excluded.

## 3.5. Uncertainties and limitations about unfavourable effects

Duration and extent of exposure are considered limited in the target population of patients with VHLassociated tumours. The safety data in this population comes from a single, small, uncontrolled study and long-term safety data is rather scarce. Longer-term safety data are expected to be submitted with the specific obligation imposed as post approval measures (Annex IIE).

The Study 004 population of patients with VHL-associated tumours consists of relatively fit patients (ECOG PS 0 or 1) with at least one measurable VHL-associated RCC, though no greater than 3 cm which would require immediate surgery. As the target population in the VHL indication is more advanced in the disease course, tolerability might be worse.

Safety data are not available in patients with severe hepatic impairment, as such patients were excluded from the belzutifan clinical studies. This is, however, adequately reflected in the SmPC. There are no safety data on the use of belzutifan in pregnant women, lactating women, or patients younger than 18 years of age. This is, however, adequately reflected in the SmPC.

## 3.6. Effects Table

Table 87: Effects Table for Welireg (belzutifan) as Monotherapy for the Treatment of Adult Patients with Advanced Clear Cell RCC that Progressed Following Two or More Prior Lines of Therapy that Included a PD-1/L1 Inhibitor and at Least Two VEGF-targeted Therapies (Data Cutoff for IA1: 01 NOV 2022; Data Cut-off for FA: 15 APR 2024).

| Effect                               | Short description                                 | Unit                                 | Treatment Belzutifan                           | Control Everolimus               | Uncertainties / Strength of evidence                                                                                    | References                       |
|--------------------------------------|---------------------------------------------------|--------------------------------------|------------------------------------------------|----------------------------------|-------------------------------------------------------------------------------------------------------------------------|----------------------------------|
| Favourable Effects                   | Favourable Effects                                | Favourable Effects                   | Favourable Effects                             | Favourable Effects               | Favourable Effects                                                                                                      | Favourable Effects               |
| Approved indication subgroup (n=369) | Approved indication subgroup (n=369)              | Approved indication subgroup (n=369) | N=187                                          | N=182                            |                                                                                                                         |                                  |
| Primary endpoint PFS IA1 results     | Progression- free survival by BICR per RECIST 1.1 | Median (95%CI) in months             | 4.6 (3.5, 7.3) PFS HR a =0.73 (95% CI: 0.57,   | 5.4 (3.8, 6.5) 0.94)             | Strength: - Derived from Phase 3, randomized study with active comparator Uncertainties/Limitatio ns: - No type I error |                                  |
| Primary endpoint OS FA results b     | Overall survival                                  | Median (95%CI) in months             | 21.8 (17.4, 25.8) OS HR a =0.94 (95% CI: 0.74, | 18.1 (14.2, 23.9) 1.21)          | control for efficacy analyses in approved indication subgroup                                                           |                                  |
| Secondary endpoint ORR               | Objective response rate by BICR per RECIST 1.1    | % (95% CI)                           | 24.1 (18.1, 30.8)                              | 3.3 (1.2, 7.0)                   |                                                                                                                         |                                  |
| IA1 results Unfavourable Effects     | IA1 results Unfavourable Effects                  | IA1 results Unfavourable Effects     | IA1 results Unfavourable Effects               | IA1 results Unfavourable Effects | IA1 results Unfavourable Effects                                                                                        | IA1 results Unfavourable Effects |
| APaT (n=732)                         |                                                   |                                      | N=372                                          | N=360                            |                                                                                                                         |                                  |
| Grade 3-5 AEs                        | All causality (drug-related)                      | %                                    | 61.8 (38.7)                                    | 62.5 (39.4)                      | Strength: - Derived from Phase                                                                                          |                                  |

<div style=\"page-break-after: always\"></div>

| Effect               | Short description            | Unit   | Treatment Belzutifan   | Control Everolimus   | Uncertainties / Strength of evidence   | References   |
|----------------------|------------------------------|--------|------------------------|----------------------|----------------------------------------|--------------|
| SAEs                 | All causality (drug-related) | %      | 42.2 (13.2)            | 38.1 (13.1)          | 3, randomized study                    |              |
| DC due to AE         | All causality (drug-related) | %      | 5.9 (2.7)              | 14.7 (10.6)          | Limitation: - Open-label study         |              |
| Death due to AE      | All causality (drug-related) | %      | 3.5 (0.3)              | 5.3 (0.6)            |                                        |              |
| Select AEs           |                              |        |                        |                      |                                        |              |
| Anaemia (all grades) | All causality (drug-related) | %      | 82.8 (71.8)            | 56.7 (34.2)          |                                        |              |
| Grade 3-5 anaemia    | All causality (drug-related) | %      | 32.5 (27.2)            | 18.1 (10.8)          |                                        |              |
| Hypoxia (all grades) | All causality (drug-related) | %      | 14.5 (11.8)            | 1.1 (0.0)            |                                        |              |
| Grade 3-5 hypoxia    | All causality (drug-related) | %      | 10.5 (8.6)             | 1.1 (0.0)            |                                        |              |

Abbreviations: AEs: adverse events; APaT: all-patients-as-treated; BICR: blinded independent central review; CI: confidence interval; DC: discontinuation; HR: hazard ratio; IA: interim analysis; RCC: renal cell carcinoma; RECIST 1.1: Response Evaluation Criteria In Solid Tumours version 1.1; SAEs: serious adverse events; VEGF: vascular endothelial growth factor.

Note: The above table shows the favourable effects of the approved indication subgroup (only) and the unfavourable effects of the (entire) APaT population. For the benefit-risk assessment, however, the toxicity profile in the continuous running safety database (CRSD) is considered, see the below table.

a  HR and 95% CI based on Cox regression model with Efron's method of tie handling.

b At FA, the number of belzutifan participants with ≥2 prior VEGF changed from 187 to 188 due to data update.

c  Difference estimate based on Miettinen &amp; Nurminen method.

Table 88: Effects Table for Welireg (belzutifan) for the Treatment of Adult Patients with VHL Disease (Study 004, Data Cut-off: 03-APR-2023.

| Effect                            | Short Description                              | Unit                         | Treatment belzutifan         | Uncertainties / Strength of evidence                                                                                      | References         |
|-----------------------------------|------------------------------------------------|------------------------------|------------------------------|---------------------------------------------------------------------------------------------------------------------------|--------------------|
| Favourable Effects                | Favourable Effects                             | Favourable Effects           | Favourable Effects           | Favourable Effects                                                                                                        | Favourable Effects |
| Efficacy analysis set (n=61)      | Efficacy analysis set (n=61)                   | Efficacy analysis set (n=61) | Efficacy analysis set (n=61) | Efficacy analysis set (n=61)                                                                                              |                    |
| Primary endpoint ORR in VHL-RCC   | Objective response rate by BICR per RECIST 1.1 | % (95% CI)                   | 67.2% (54.0, 78.7)           | Uncertainties/ limitations: - Data derived from interim analyses of single-arm study, without adjustment for multiplicity |                    |
| Secondary endpoint DOR in VHL-RCC | Duration of response                           | Median (range) in months     | NR (8.6+, 44.4+)             | Uncertainties/ limitations: - Data derived from interim analyses of single-arm study, without adjustment for multiplicity |                    |
| Patients with CNS-HB (n=50)       | Patients with CNS-HB (n=50)                    | Patients with CNS-HB (n=50)  | Patients with CNS-HB (n=50)  | Uncertainties/ limitations: - Data derived from interim analyses of single-arm study, without adjustment for multiplicity |                    |
| Secondary endpoint ORR in CNS-HB  | Objective response rate by BICR per RECIST 1.1 | % (95% CI)                   | 48% (33.7, 62.6)             | Uncertainties/ limitations: - Data derived from interim analyses of single-arm study, without adjustment for multiplicity |                    |
| Secondary endpoint DOR in CNS-HB  | Duration of response                           | Median (range) in months     | NE (0.0+, 47.5+)             | Uncertainties/ limitations: - Data derived from interim analyses of single-arm study, without adjustment for multiplicity |                    |
| Patients with pNET (n=22)         | Patients with pNET (n=22)                      | Patients with pNET (n=22)    | Patients with pNET (n=22)    | Uncertainties/ limitations: - Data derived from interim analyses of single-arm study, without adjustment for multiplicity |                    |

<div style=\"page-break-after: always\"></div>

| Secondary endpoint ORR in                                                                                          | Objective response rate by BICR per                                                                                | % (95% CI)                                                                                                         | 90.9 (70.8, 98.9)                                                                                                  | pNET DOR in pNET                                                                    |
|--------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------|
| RECIST 1.1 Secondary endpoint Duration of response Median (range) in months NE (11.0+, 48.3+) Unfavourable Effects | RECIST 1.1 Secondary endpoint Duration of response Median (range) in months NE (11.0+, 48.3+) Unfavourable Effects | RECIST 1.1 Secondary endpoint Duration of response Median (range) in months NE (11.0+, 48.3+) Unfavourable Effects | RECIST 1.1 Secondary endpoint Duration of response Median (range) in months NE (11.0+, 48.3+) Unfavourable Effects |                                                                                     |
|                                                                                                                    |                                                                                                                    |                                                                                                                    |                                                                                                                    | Strengths: - Pooled safety database of sufficient size. Uncertainties/ limitations: |
| CRSD (n=576) Grade 3-5 AEs SAEs                                                                                    | All causality (drug-related) All causality (drug-related)                                                          | % %                                                                                                                | 61.6 (37.7) 41.0 (12.3)                                                                                            | Strengths: - Pooled safety database of sufficient size. Uncertainties/ limitations: |
| DC due to AE                                                                                                       | All causality (drug-related)                                                                                       | %                                                                                                                  | 6.4 (3.1)                                                                                                          | - Exposure is limited in patients with VHL- disease.                                |
| Death due to AE                                                                                                    | All causality (drug-related)                                                                                       | %                                                                                                                  | 3.3 (0.2)                                                                                                          | - Exposure is limited in patients with VHL- disease.                                |
| Anaemia (all grades)                                                                                               | All causality (drug-related)                                                                                       | %                                                                                                                  | 83.2 (74.3)                                                                                                        | - Exposure is limited in patients with VHL- disease.                                |
| Grade 3-5 anaemia                                                                                                  | All causality (drug-related)                                                                                       | %                                                                                                                  | 28.6 (24.3)                                                                                                        | - Exposure is limited in patients with VHL- disease.                                |
| Hypoxia (all grades)                                                                                               | All causality (drug-related)                                                                                       | %                                                                                                                  | 16.3 (13.4)                                                                                                        | - Exposure is limited in patients with VHL- disease.                                |
| Grade 3-5 hypoxia                                                                                                  | All causality (drug-related)                                                                                       | %                                                                                                                  | 12.2 (9.9)                                                                                                         | - Exposure is limited in patients with VHL- disease.                                |

Abbreviations: AEs: adverse events; BICR: blinded independent central review; CI: confidence interval; CNS: central nervous system; CRSD: continuous running safety database; DC: discontinuation; HB: haemangioblastoma; HR: hazard ratio; IA: interim analysis; pNET: pancreatic neuro-endocrine tumour; RCC: renal cell carcinoma; RECIST 1.1: Response Evaluation Criteria In Solid Tumours version 1.1; SAEs: serious adverse events; VHL: von Hippel-Lindau.

Notes: the presented efficacy results are from IA2 with a DCO of 01 April 2022. Median duration of follow-up was 37.7 months.

## 3.7. Benefit-risk assessment and discussion

## 3.7.1. Importance of favourable and unfavourable effects

## Advanced RCC

In the indication of patients with advanced clear cell RCC that progressed following two or more prior lines of therapy that included a PD-1/L1 inhibitor and at least two VEGF-targeted therapies the efficacy of belzutifan - with similar OS, a PFS gain, and a numerically higher ORR - was at least equal to everolimus which is an approved medicinal product for treatment in this disease setting that is also recommended by current clinical guidelines. Moreover, belzutifan has a novel MoA that is different from the other medicinal products approved for the treatment of advanced RCC. Due to the different MoA, belzutifan has also a toxicity profile distinct from everolimus and other VEGF-targeted therapies and therefore could represent a relevant alternative therapeutic option in this population.

<div style=\"page-break-after: always\"></div>

## VHL disease

In the single-arm phase 2 Study 004, treatment with belzutifan resulted in an ORR of 63.9% for VHL-associated RCC. These responses were durable with 93.5% having a DOR of at least 18 months.

The ORR (44%) for VHL-associated CNS haemangioblastoma although lower than that reported for VHLassociated RCCs appears durable, and the clinical relevance of these efficacy estimates are viewed in light of the unmet medical need of patients with VHL-associated haemangioblastomas.

The reported ORR (90%) for patients with a pNET that was measurable at baseline is very high (as was the percentage of complete responses) and responses appear durable.

Even if efficacy data for different VHL-associated tumours can be taken together to support a positive B/R in the population of patients with VHL disease as a whole, the data are not considered comprehensive therefore eligible to a conditional marketing authorization.

The toxicity of belzutifan is non-negligible it is however manageable with dose modifications, considering the low and thus acceptable rate of drug-related AEs leading to discontinuation (3.1%) in the CRSD.

## 3.7.2. Balance of benefits and risks

## Advanced RCC

Benefits: In Study 005, in the subgroup of patients with advanced clear cell RCC who progressed following two or more prior lines of therapy that included a PD-1/L1 inhibitor and at least two VEGF-targeted therapies, the efficacy of belzutifan, with similar OS, a PFS gain, and a numerically higher ORR, is at least equal to everolimus.

Risks: In Study 005, the overall toxicity profile of belzutifan was manageable. Due to its novel and different MoA, the toxicity profile of belzutifan is distinct from that of everolimus. More patients receiving belzutifan reported AEs of anaemia and hypoxia, while more patients receiving everolimus discontinued due to AEs.

Balance of benefits and risks: For the subgroup of patients with advanced clear cell RCC that progressed following two or more prior lines of therapy that included a PD-1/L1 inhibitor and at least two VEGF-targeted therapies benefit -risk balance is considered positive.

## VHL disease

In Study 004, a high ORR with durable responses was observed in the study population which reflects the intended patient population. This high activity is expected to translate into clinical benefit for the patients. This data from an interim analysis of a small, single-arm trial, cannot be considered comprehensive and uncertainties are still present. The remaining uncertainties will be addressed by the studies imposed as specific obligations which will provide comprehensive data on both efficacy and safety aspects (see section 3.7.3).

The benefit -risk balance for belzutifan in the VHL indication is considered positive.

<div style=\"page-break-after: always\"></div>

## 3.7.3. Additional considerations on the benefit-risk balance

## VHL disease

## Conditional marketing authorisation

As comprehensive data on the product are not available, a conditional marketing authorisation or a marketing authorisation under exceptional circumstances was proposed by the CHMP during the assessment, after having consulted the applicant who requested consideration for its application for a conditional marketing authorisation.

The product falls within the scope of Article 14-a of Regulation (EC) No 726/2004 concerning conditional marketing authorisations, as it aims at the treatment of a seriously debilitating, life-threatening disease. Furthermore, the CHMP considers that the product fulfils the requirements for a conditional marketing authorisation

- o The benefit-risk balance is positive , as the result from Study 004 are expected to translate into a clinically relevant benefit in the final indication. ORR range from 44% to 90% with durable responses in the study population which reflects the intended patient population. From a safety point of view, a nonnegligible toxicity profile was observed but was manageable with dose modifications.
- o It is likely that the applicant will be able to provide comprehensive data.
- o Study 004 is an ongoing phase 2, single-arm, open-label study to evaluate the efficacy and safety of belzutifan in patients with at least one measurable VHL-RCC Study 004 was the pivotal study for the current procedure and the feasibility of the provision of further efficacy and safety data is not questioned. The study will provide further data on the primary and secondary endpoint (ORR and DOR) in all patients and in the subgroups of patients with CNS haemangioblastoma, and pNET and further characterize and determine the incidence and severity serious adverse events in patients receiving belzutifan. The long-term efficacy and safety data will be submitted by Q1 2027.
- o Study 015 (NCT04924075) is an ongoing, uncontrolled phase 2 study to evaluate the efficacy and safety of belzutifan 120 mg QD in 5 cohorts of patients: with advanced PPGL (Cohort A1), pNET (Cohort A2), advanced wtGIST (Cohort C), advanced solid tumours with HIF-2 α related genetic alterations (Cohort D), and VHL-associated tumours who have at least 1 measurable RCC, pNET, or PPGL tumour (Cohort B1).In Cohort B1, the planned maximum enrolment is 92 patients (32 with RCC, 30 with pNET, and 30 with PPGL). A patient with different VHL-associated tumours can count for all three tumour types, therefore the study could also be completed with 32 included patients. Interim results from 23 patients with VHL disease have already been submitted. The submission of at least 64 additional patients (China + Japan subgroups + patients with pNET and/or PPGL from other countries) with at least 24 months FU from Study MK-6482-015 (Study 015) Cohort B1 is considered feasible. The data will be submitted by Q1 2027.
- o Unmet medical need will be addressed , as there are currently no available systemic treatment options for the intended population, which are at lifelong risk for the development of tumours in several organs, including the kidneys, brain and spinal cord. Management often involves extensive lifelong surveillance and multiple local procedures/ surgeries in the same and/or different organs which are

<div style=\"page-break-after: always\"></div>

associated with significant morbidity and mortality, including long-term complications and / or organ function. Belzutifan targets the underlying pathophysiological driver of VHL-associated tumours and has a positive B/R balance in the target population.

- o The benefits to public health of the immediate availability outweigh the risks inherent in the fact that additional data are still required , since the safety profile has been shown to be manageable and the immediate availability would allow treatment of patients who do not have any other systemic or local therapeutic option available.

## 3.8. Conclusions

The overall benefit-risk balance of Welireg (belzutifan) is positive for the treatment of clear cell RCC and of the VHL disease indications.

## Recommendations

## Outcome

Based on the CHMP review of data on quality, safety and efficacy, the CHMP considers by consensus that the benefit-risk balance of Welireg is favourable in the following indications:

Welireg is indicated as monotherapy for the treatment of adult patients with advanced clear cell renal cell carcinoma that progressed following two or more lines of therapy that included a PD-(L)1 inhibitor and at least two VEGF-targeted therapies.

Welireg is indicated as monotherapy for the treatment of adult patients with von Hippel-Lindau disease who require therapy for associated, localised renal cell carcinoma (RCC), central nervous system (CNS) haemangioblastomas, or pancreatic neuroendocrine tumours (pNET), and for whom localised procedures are unsuitable.

The CHMP therefore recommends the granting of the conditional marketing authorisation subject to the following conditions:

## Conditions or restrictions regarding supply and use

Medicinal product subject to restricted medical prescription (see Annex I: Summary of Product Characteristics, section 4.2).

## Other conditions and requirements of the marketing authorisation

- Periodic Safety Update Reports

The requirements for submission of periodic safety update reports for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal.

<div style=\"page-break-after: always\"></div>

## Conditions or restrictions with regard to the safe and effective use of the medicinal product

- Risk Management Plan (RMP)

The marketing authorisation holder (MAH) shall perform the required pharmacovigilance activities and interventions detailed in the agreed RMP presented in Module 1.8.2 of the marketing authorisation and any agreed subsequent updates of the RMP.

An updated RMP should be submitted:

- At the request of the European Medicines Agency;
- Whenever the risk management system is modified, especially as the result of new information being received that may lead to a significant change to the benefit/risk profile or as the result of an important (pharmacovigilance or risk minimisation) milestone being reached.

## Additional risk minimisation measures

Prior to the launch of Welireg in each Member State the Marketing Authorisation Holder (MAH) must agree about the content and format of the guide for health care professionals, including communication media, distribution modalities, and any other aspects of the safety advice tool, with the National Competent Authority. The patient card is included in the pack.

The safety advice tools are aimed at informing about appropriate contraceptive measures to prevent pregnancies in female patients treated with belzutifan.

The MAH shall ensure that in each Member State where Welireg is marketed, all healthcare professionals and female patients of childbearing potential who are expected to prescribe or use Welireg, respectively, have access to/are provided with the following educational package:

- Guide for healthcare professionals
- Patient card

## Educational material for healthcare professionals :

- The Summary of Product Characteristics
- Guide for healthcare professionals

## Guide for healthcare professionals:

- Belzutifan may cause embryo-foetal harm, including foetal loss, when administered to a pregnant woman.
- Belzutifan is contraindicated in pregnant women treated for von Hippel-Lindau (VHL) diseaseassociated tumours.
- Belzutifan should not be used during pregnancy in women treated for renal cell carcinoma unless the clinical condition requires treatment with belzutifan.
- Details on how to reduce the potential risk of exposure during pregnancy for women of childbearing potential based on the following:

o A pregnancy test should be performed before start of treatment with belzutifan.

<div style=\"page-break-after: always\"></div>

o Women of childbearing potential have to use highly effective contraception method during treatment with belzutifan and up to at least 1 week after the last dose.

o Explain to patient that belzutifan may reduce the efficacy of hormonal contraceptives. Therefore, a non-hormonal contraceptive method should be used or have their male partner use a condom.

o The female patients of childbearing potential should be informed about the potential risk of embryo-foetal harm and appropriate contraceptive measures before start of treatment with belzutifan.

- Need to discontinue treatment with belzutifan if a pregnancy is planned or a pregnancy is detected.
- A patient card is included in the pack. Healthcare professionals should inform each female patient of childbearing potential prior to the start of treatment about the purpose of the patient card.

## Patient card:

- Belzutifan should not be used by pregnant women because the use of belzutifan can cause foetal harm, including foetal loss, when used during pregnancy.
- Language describing how to reduce the potential risk of exposure during pregnancy based on the following:

o A pregnancy test should be performed before start of treatment with belzutifan.

o Women of childbearing potential have to use highly effective contraception method during treatment with belzutifan and up to at least 1 week after the last dose.

o Belzutifan may reduce the efficacy of hormonal contraceptives. Therefore, a non-hormonal contraceptive method should be used or have their male partner use a condom.

o If a pregnancy occurs during treatment with belzutifan contact your treating physician immediately.

- Contact details of the belzutifan prescriber.
- Women of childbearing potential should be instructed to talk to their healthcare professional about contraception while taking belzutifan.
- Instruct patient to refer to PIL for additional information about the safety of belzutifan

## Specific obligation to complete post-authorisation measures for the conditional marketing authorisation

This being a conditional marketing authorisation and pursuant to Article 14-a of Regulation (EC) No 726/2004, the MAH shall complete, within the stated timeframe, the following measures:

| Description                                                                                                                                                                                                                                                                                                                                                                                                       | Due date   |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|
| In order to confirm the efficacy and safety of belzutifan as monotherapy for the treatment of adult patients with von Hippel- Lindau disease who require therapy for associated, localised renal cell carcinoma (RCC), central nervous system (CNS) haemangioblastomas, or pancreatic neuroendocrine tumours (pNET), and for whom localised procedures are unsuitable, the MAH should submit the final results of | Q1 2027    |

<div style=\"page-break-after: always\"></div>

| Description                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | Due date   |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|
| the ongoing study MK-6482-004, an open-label Phase II single-arm study to further investigate the long-term efficacy and safety of belzutifan for the treatment of von Hippel-Lindau disease-associated Renal Cell Carcinoma.                                                                                                                                                                                                                                                                                                                                                                                                                                                           |            |
| In order to confirm the efficacy and safety of belzutifan as monotherapy for the treatment of adult patients with von Hippel- Lindau disease who require therapy for associated, localised RCC, CNS haemangioblastomas, or pNET, and for whom localised procedures are unsuitable, the MAH should submit efficacy and safety data from at least 64 patients with at least 24 months follow-up of cohort B1 for the ongoing study MK-6482-015, an uncontrolled Phase II study to evaluate the efficacy and safety of belzutifan in patients with von Hippel Lindau disease-associated tumours who have at least 1 measurable RCC, pNET, or pheochromocytoma/paraganglioma (PPGL) tumour. | Q1 2027    |

## New active substance status

Based on the CHMP review of the available data, the CHMP considers that Belzutifan is to be qualified as a new active substance in itself as it is not a constituent of a medicinal product previously authorised within the European Union.